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Management of acute myocardial infarction has dramatically evolved over the last 
70 years. Advances in the understanding of the aetiologies of myocardial infarction 
coupled with development of the defibrillator, the introduction of the coronary care 
unit and the application of various pharmacological interventions that improved 
both survival and outcomes all represent significant milestones. Arguably though, 
the most important gains came from the appreciation that outcome is intimately 
related to the extent of myocardial injury, and that rapid reperfusion of the infarct- 
related artery offers striking benefits in terms of myocardial salvage and concomi-
tant reductions in morbidity and mortality.
Early attempts at pharmacological reperfusion were unpredictable and were 
associated with an increased risk of bleeding—an inherent pitfall of the need for 
systemic fibrinolysis to achieve a focal effect (reperfusion of the occluded coronary 
artery). With the introduction of coronary angioplasty in 1977, a new treatment 
paradigm emerged—targeted therapy direct at the focal culprit lesion. Indeed, semi-
nal trials of coronary angioplasty conducted just 15 years following the first proce-
dure demonstrated superior outcomes with the angioplasty approach compared with 
systemic fibrinolytic therapy. Consequently, the use of coronary angioplasty to 
achieve reperfusion for acute myocardial infarction, termed primary percutaneous 
coronary intervention (primary PCI), has represented a major focus for provision of 
acute cardiac care over the last 15 years. With vastly improved outcomes and lower 
complication rates as compared with fibrinolytic therapy, primary PCI has evolved 
to become the gold standard treatment and is increasingly available not only in ter-
tiary centres but also in smaller district hospitals, allowing rapid treatment upon first 
medical contact.
Adoption of primary PCI did not occur in isolation, but instead is best considered 
a component of a larger system of emergent healthcare. Partnerships between 
healthcare providers in the community, emergency department and cardiologists are 
required. Patient and community education programmes that emphasise early rec-
ognition and triage are also necessary. New funding streams for healthcare delivery 
must also be leveraged. In parallel, the medical device industry has driven rapid 
evolution in technology of the procedure itself improving outcomes and reducing 
risks.
Perhaps though, the most critical contribution to a successful primary PCI pro-
gramme has been emergence of a shared passion for education and teaching within 
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the cardiology community. Learning through our own successes and failures has 
provided an opportunity to reflect. Dedicated programmes such as the annual and 
hugely successful Asia Primary Angioplasty Congress offer important platforms to 
educate each other, and through such activity we have seen successful primary PCI 
programmes even in countries where healthcare resources are still limited.
This handbook is the result of our cumulative years of experience in the field of 
primary PCI. We have brought together some of the leading experts in the world and 
have aimed to make this handbook both practical and relevant to all those involved 
in delivering the benefit of primary PCI to our patients.
Kuala Lumpur, Malaysia Timothy J Watson
Singapore, Singapore  Paul JL Ong
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1Historical Perspectives on Management of Acute Myocardial Infarction
Zhen Vin Lee and Bashir Hanif
1.1  Introduction
In 1977, the first successful coronary angioplasty was performed by Andreas 
Gruentzig using a double-lumen balloon catheter. This pivotal event spurred major 
advances in the field of percutaneous coronary intervention (PCI) over the subse-
quent four decades, including in the setting of myocardial infarction (MI) where 
primary PCI is now the established gold standard therapy. Nonetheless, although 
reperfusion is the cornerstone of management of acute MI, the role of various 
adjunctive therapies also needs to be recognized as these have had a substantial 
influence in improving both morbidity and mortality. This chapter serves to revisit 
the key historical milestones that have helped shape the modern management of 
acute MI.
1.2  Angina Pectoris as a Clinical Entity
In 1772, the eminent English physician, William Heberden, described what would 
later become known as angina pectoris in the most apt manner [1]:
‘But there is a disorder of the breast marked with strong and peculiar symptoms, 
considerable for the kind of danger belonging to it, and not extremely rare, which 
deserves to be mentioned more at length. The seat of it, and sense of strangling, and 
anxiety with which it is attended, may make it not improperly be called angina pec-
toris. They who are afflicted with it, are seized while they are walking, (more espe-
cially if it be up hill, and soon after eating) with a painful and most disagreeable 
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sensation in the breast, which seems as if it would extinguish life, if it were to 
increase or continue; but the moment they stand still, all this uneasiness 
vanishes...’
As early as 1850, Richard Quain published a comprehensive review on fatty 
diseases of the heart, describing an observed association between coronary artery 
sclerosis and myocardial scars. Subsequently, the theory of ‘coagulation necrosis’ 
was coined by Cohnheim, who wrote in 1882, that ‘the occlusion of a coronary 
artery, in case it does not prove fatal, leads to the destruction of the contractile sub-
stance of that portion of the heart, which is fed by the affected artery, and afterwards 
to the formation of so-called myocarditic indurations’ [2].
Later, advances in imaging technology would make it possible to objectively 
identify narrowing (sclerosis) of the coronary arteries and actively demonstrate the 
presence of myocardial ischaemia allowing correlation between symptoms of the 
various ischaemic heart disease syndromes and the underlying anatomic and physi-
ologic abnormalities [2]. Thus was born our understanding that at least in simplistic 
terms, restriction of blood flow in the epicardial coronary arteries led to symptom-
atic onset of disease.
1.3  Development of the Electrocardiogram
Over the late 1800s to early 1900s, cardiology witnessed a great technological 
breakthrough that was to have a major effect on the understanding of arrhythmia: 
the electrocardiograph (ECG). Physiologist Augustus Desiré Waller working in St. 
Mary’s Hospital, London, recorded the first human surface ECG using the Lippmann 
capillary electrometer to deflect a light beam (Fig. 1.1). Waller had learnt that ‘each 
beat of the heart gives an electric charge, beginning at one end of the organ and end-
ing at the other’. He was convinced that he could measure these electromotive 
events from the skin surface and proceeded to do so with the electrometer connected 
between the left and right hands or between the front and back paws of his dog. The 
clinical significance of the electrocardiogram was not appreciated at the time. Waller 
himself said: ‘I do not imagine that electrocardiography is likely to find any very 
extensive use in the hospital. It can at most be of rare and occasional use to afford a 
record of some rare anomaly of cardiac action’ [3].
Another physiologist, Willem Einthoven, shares the honour with Waller of hav-
ing a pivotal role in founding this new diagnostic modality. Einthoven recorded the 
first human ECG in 1892 using the Lippmann capillary electrometer. He initially 
indicated the four observed deflections with the characters A, B, C and D but later 
instead adopted the middle characters of the alphabet: P, Q, R, S and T. In 1902, he 
made the first direct recording of the true human ECG using a modified string gal-
vanometer (Fig. 1.2) [4]. Although there was wide scepticism by the contemporary 
scientific community against his methods, Einthoven continued publishing, in 1913 
described the Einthoven triangle as the basis for calculations of ECGs and intro-
duced the bipolar electrode system. Classic rhythms were obtained and published. 
In 1924, he was awarded the Nobel Prize for Physiology and Medicine for his pio-
neering work in developing the string galvanometer [3].
Z. V. Lee and B. Hanif
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Fig. 1.1 Lippmann capillary electrometer (Source: Aquilina O. A brief history of cardiac pacing. 
Images Pardiatr Cardiol. 2006;8 (2): 17–81)
1.4  Evolving Concepts in Pathophysiology of Myocardial 
Infarction
Although, even in the nineteenth century, coronary thrombosis was recognized as a 
cause of death, it was predominantly regarded as a medical curiosity. On the basis 
of animal experiments involving ligation of a major coronary artery and of limited 
observations in human beings at necropsy, for many years the condition was consid-
ered to be immediately and universally fatal. However, in 1901, Krehl reported that 
coronary thrombosis did not always result in sudden death and that symptoms were 
more severe when arterial occlusion was sudden as opposed to progressive. He also 
recognized that MI may be complicated by ventricular aneurysm formation and 
myocardial rupture [4].
Once it became clear that survival from acute myocardial infarction (AMI) was 
possible, attention naturally began to be directed towards management. In his 1912 
paper, Herrick stated that after AMI, ‘the importance of absolute rest in bed for 
several days is clear’. This dictum would become the cornerstone of therapy for the 
1 Historical Perspectives on Management of Acute Myocardial Infarction
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next half-century. Herrick also recognized that hope for restoration of the integrity 
of the damaged myocardium was possible where collateral blood supply developed. 
In the course of his work, Herrick also reported ECG findings consistent with acute 
MI, enabling the ECG to become a powerful diagnostic test in the recognition of 
this condition [4].
In the early 1920s, Wearn described the first significant series of patients with 
AMI, in all 19 of whom clinical-pathological correlations had been made. He rec-
ommended that ‘every effort [be made] to spare the patient any bodily exertion’ to 
prevent sudden death from cardiac rupture. In patients with pulmonary rales, fluid 
intake was restricted and digitalis given. Caffeine and camphor, two stimulants 
(vasopressors) then available, were used to prevent hypotension, syncope and heart 
block. Later that decade, Samuel Levine described a series of his own patients with 
acute MI. He identified the frequency of, and risk posed by, various cardiac arrhyth-
mias. He recommended quinidine to treat ventricular tachycardia and intramuscular 
adrenaline to treat heart block and syncope [4].
By the 1930s and 1940s, as outcomes slowly started to improve, there was con-
siderable debate about when in the course of the illness patients could be permitted 
to sit in a chair, use a commode, ambulate, be discharged from the hospital and 
ultimately resume their normal activities. In 1952, when Levine and Lown proposed 
the ‘armchair treatment’ of AMI, this suggestion, quite radical at the time, provoked 
heated debate. However, by the mid-twentieth century, it had become clear that 
although MI was now the most common cause of death in the industrialized world, 
concepts for post MI care needed to evolve. Cardiac rupture, although almost 
Fig. 1.2 ECG recording using a modified string galvanometer (Source: AlGhatrif M, Lindsay J. A brief 
review: history to understand fundamentals of electrocardiography. Journal of Community Hospital 
Internal Medicine Perspectives. 2012;2(1). Available from: doi:https://doi.org/10.3402/jchimp.v2i1.14383)
Z. V. Lee and B. Hanif
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universally fatal, was relatively uncommon; absolute limitation of physical activity 
was not truly required; long-term bed rest might itself be associated with serious 
and occasionally fatal complications such as venous thromboembolism. As a conse-
quence, practice gradually changed. Ambulation was accelerated and convalescence 
shortened; post-infarction rehabilitation made possible a more rapid return to regu-
lar lifestyle [4].
1.5  Cardiopulmonary Resuscitation and External 
Defibrillation
Coupled with advances in understanding of natural history of CAD and MI, Beck 
and colleagues in 1947 had resuscitated, by electric shock, a 14-year-old boy in 
whom ventricular fibrillation developed during surgery. Beck’s group was also 
successful in correcting ventricular fibrillation, using open thoracotomy, in a 
65-year- old physician with a myocardial infarction [5]. Soon after, Zoll intro-
duced external defibrillation demonstrating that ‘ventricular tachycardia and 
fibrillation’ could be successfully terminated by externally applied electric coun-
tershock. This of course was not always successful, but it was recognized that 
early application of the shock was required to maximize efficacy and that cardiac 
monitoring provided opportunity for immediate recognition of cardiac arrest and 
identification of the arrhythmia [6]. A further advance observation was efficacy of 
mouth-to-mouth breathing, sternal compression and closed-chest electrical defi-
brillation in restoring normal cardiac function in some victims of ventricular 
fibrillation. It was this advance that triggered the interest in intensive care for 
myocardial infarction [7].
1.6  The Coronary Care Unit
The coronary care unit (CCU) is, perhaps, the single most important advancement 
in the treatment of MI and encompasses clinical application of four separate devel-
opments, namely, the appreciation of the importance of arrhythmias as the principal 
cause of early death in MI; ability to monitor the ECG continuously with the 
cathode- ray oscilloscope; development of closed-chest cardiac resuscitation; and 
delegation of the treatment of life-threatening arrhythmias, particularly ventricular 
fibrillation, to trained nurses in the absence of physicians [4].
Desmond Julian of the Royal Infirmary of Edinburgh is largely credited as the 
pioneer in the development of the CCU and wrote in his 1961 that ‘Many cases of 
cardiac arrest associated with acute myocardial ischaemia could be treated success-
fully if all medical, nursing and auxiliary staff were trained in closed chest cardiac 
massage and if the cardiac rhythm of patients with MI were monitored by an ECG 
linked to an alarm system… Such units should be staffed by suitably experienced 
people throughout the 24 hours’ [8]. Julian’s colleagues in Edinburgh were 
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unenthusiastic about his concept, and subsequently he moved to Australia where he 
launched a programme of continuous monitoring of patients who presented to 
Sydney Hospital with MI [9]. The first presentation of coronary care given to the 
British Cardiovascular Society was at the Autumn Meeting in 1964 when the Sydney 
experience was described [10].
It was clearly apparent that the new treatment technologies had to be used immedi-
ately to save lives. To achieve this goal, doctors had to abandon traditional notions of a 
nurse’s limited role in clinical decision-making and transition to a system where the 
CCU nurse was able to implement therapeutic measures by herself without specific 
orders, including sometimes the definitive treatment for ventricular fibrillation. The 
CCU-inspired empowerment of nurses represented a critical first step in the evolution of 
team-based care that is such a conspicuous part of current-day cardiology practice [9].
With improving survival from MI, Myocardial Infarction Research Units (MIRU) 
were created in the United States, and a large programme of research was initiated 
into the investigation of the haemodynamic effects of myocardial infarction. It was 
quickly shown that the commonly used right atrial and central venous pressures 
provided an unreliable index of left-sided function. The introduction of the Swan- 
Ganz flow-guided catheter was a major advancement in the evaluation of cardiac 
performance in the CCU, allowed more precise delineation of the various haemody-
namic subsets of patients with MI and facilitated their more rational treatment [10].
1.7  Concept of Reduction of Infarct Size
Left ventricular function emerged as a critical factor in the outcome in patients who 
were nursed in the CCU and in whom fatal primary arrhythmias were prevented. 
Infarct size became recognized as the major determinant of mortality and morbidity, 
and the concept was put forwards that even after the onset of infarction the quantity 
of damaged myocardium could be influenced by interventions designed to improve 
the balance between oxygen supply and demand in the jeopardized zone [4]. 
Preservation of left ventricular function became the major predictive factor of prog-
nosis. The size of the infarct was then defined as the major determinant of mortality 
and morbidity. The use of injectable and oral beta blockers not only to treat arrhyth-
mias but also to limit myocardial damage induced by the ischemic area arose as a 
therapeutic possibility. These drugs reduce oxygen consumption by the myocar-
dium and enhance blood redistribution from the epicardium to the myocardium, 
diminishing the area of infarct and increasing survival [11].
1.8  Advent of Thrombolysis and Role of Aspirin
In the 1950s and 1960s, Fletcher and Verstraete pioneered the experimental use of 
streptokinase for thrombolysis. By the 1970s, Chazov and Rentrop were driving 
what would become a revolution in cardiology, demonstrating that intracoronary 
infusion of streptokinase could dissolve intracoronary thrombi, thereby limiting the 
Z. V. Lee and B. Hanif
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infarct extension and size. This work was corroborated by the studies of De Wood 
et al. according to which 90% of patients with clinical findings of infarction and 
alterations in the ST segment had occlusive thrombi in the coronary arteries. The 
need for a direct intracoronary injection, however, was the major obstacle to its use. 
Intravenous infusion, which was easier and faster, quickly proved to be equivalent 
to the intracoronary infusion [11].
The ISIS-2 trial represented a significant milestone in rapid treatment of AMI 
with streptokinase and aspirin. This trial demonstrated that streptokinase and aspi-
rin alone each produced a significant reduction in 5-week vascular mortality. The 
combination of streptokinase and aspirin was synergistic and markedly better than 
either treatment alone. The differences in vascular and in all-cause mortality pro-
duced by streptokinase and aspirin remained highly significant, even after a median 
of 15 months of follow-up [12]. This trial was followed by the GISSI study, which 
again proved the benefits of streptokinase and indicated that earlier treatment led to 
greater benefit [13].
Streptokinase though was known to have limitations, including propensity to 
induce hypotension, high rates of allergy, prolonged anticoagulant effect and devel-
opment of neutralizing antibodies. It was clear that more efficacious and safer agents 
were needed. This paved the way for the GUSTO trial series which led to the intro-
duction of differing thrombolytic regimens including the use of accelerated tissue 
plasminogen activator (t-PA) with intravenous heparin. Although bleeding remained 
a concern, accelerated t-PA given with intravenous heparin seemed to confer a sur-
vival benefit [14, 15]. As agents were further refined, recombinant tissue- type plas-
minogen activator (rt-PA) was introduced and showed a significantly reduced 1-month 
mortality in a cohort of patients with suspected AMI who were randomized to receive 
either rt-PA plus heparin or placebo plus heparin. Whilst there was an excess of 
bleeding complications in the rt-PA group of patients, the incidence of stroke was 
similar [16]. The introduction of single-bolus injection of tenecteplase (a genetically 
engineered variant of alteplase with slower plasma clearance) would facilitate more 
rapid treatment of AMI both in hospital and in the community setting [17].
These results together with the low incidence of severe adverse effects made the 
use of thrombolytic agents unquestionable in the first hours of AMI. In addition to 
significantly reducing mortality, thrombolytic agents protect against associated mor-
bid events, such as cardiogenic shock and heart failure, in a direct relation to the speed 
with which they are administered. In regard to adverse effects, thrombolytic therapy 
is related to a small and significant increase in the occurrence of cerebral strokes [11].
1.9  Coronary Angiography and Percutaneous 
Revascularization
Accurate depictions of the epicardial coronary arteries are present in the historical 
works of Leonardo da Vinci and Andreas Vesalius; however, smaller intramural 
branches were difficult to be demonstrated by simple dissection. Later, post-mortem 
injection techniques facilitated in-depth study of coronary circulation [18].
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With the discovery of X-rays in 1895 by Wilhelm Röntgen, a new approach 
to the study of cardiac anatomy would, with time, become possible. These 
experiments were made possible by development of a technique for human right 
heart catheterization by the German physician Werner Forssmann who under-
took catheterization of his own heart in 1929. Forssmann soon extended his 
experiments to include the intracardiac injection of contrast material. 
Forssmann’s contributions together with the development of nontoxic contrast 
materials and steady advances in X-ray equipment and technique set the stage 
for the development of cardiac angiography and subsequently coronary arteriog-
raphy [18].
In the 1950s, Mason Sones developed more selective coronary imaging. 
Whilst performing aortographic examinations in patients with rheumatic valvu-
lar disease, Sones discovered that some injections would preferentially fill one 
coronary artery and that this caused no apparent harm to the patient. After his 
studies of semi- selective coronary arteriography, Sones began to perform true 
selective coronary arteriography in 1958. Sones combined anatomic and physi-
ologic considerations in developing his method of selective coronary arteriogra-
phy and designed a preformed catheter with a tapered tip permitted selective 
entry into the coronary ostia but avoided complete obstruction of the coronary 
artery—an event much feared by earlier physicians who were not using tapered 
catheters. Furthermore, Sones introduced continual pressure monitoring com-
bined with fluoroscopy to alert the operator to inadvertent complete obstruction 
of the coronary artery [18].
This has paved the way for the progressive advancement and modernization in 
the field of coronary angiography and angioplasty. Diagnostic catheters, guiding 
catheters, coronary guidewires, balloon catheters and coronary stents were invented 
and upgraded. Techniques of PCI were invented, modified and improved upon, 
details of which will be further elaborated in subsequent chapters of this 
handbook.
1.10  Progress of Adjunctive Pharmacotherapy
1.10.1  Beta Blockade
In 1984, the International Collaborative Study Group reported the benefits of timo-
lol. Given as a bolus followed by oral maintenance, this agent was shown to reduce 
myocardial ischaemia and infarct size as measured by an accelerated reduction of 
ST-vector magnitude, a significant reduction of maximal cumulative creatine kinase 
release and significantly smaller changes in QRS-vector variables. Timolol was also 
associated with significant reductions in pain and was well tolerated overall [19]. 
Further studies demonstrated efficacy for other beta blockers, notably metoprolol 
and atenolol, which proved to be even more effective with markedly improved 
longer- term outcomes through to 1 year [20, 21].
Z. V. Lee and B. Hanif
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1.10.2  ACE Inhibitors
The role of angiotensin converting enzyme (ACE) inhibitors was established in a 
number of studies. The AIRE study found that ramipril resulted in a significant 
reduction in all-cause mortality as well as a significant reduction in the first validated 
outcome, namely, death, severe or resistant heart failure, MI or stroke in patients 
with clinical heart failure. These benefits were seen as early as 30  days [22] . 
Similarly, administration of captopril after AMI was shown to attenuate the process 
of progressive ventricular enlargement and was able to confer improvement in left 
ventricular (LV) systolic function in those patients where LV dysfunction was most 
marked [23, 24]. Later, the HOPE study would report that ramipril significantly 
reduced the rates of death, myocardial infarction and stroke in a broad range of high-
risk patients who were not known to have a low ejection fraction or heart failure [25].
1.10.3  HMG Co-A Reductase Inhibitors
The 4S trial reported that in stable patients with angina or previous MI with elevated 
serum cholesterol, on a lipid-lowering diet, simvastatin significantly improved sur-
vival and reduced the risk of undergoing myocardial revascularization procedures 
and established the role of statins in management of coronary artery disease (CAD) 
[26]. Subsequent studies indicated similar advantage from other statins, even where 
serum cholesterol levels were in the normal or low range [27–29]. Later data would 
emerge indicating that early administration of statin may offer advantage in the 
early phase after onset of AMI.
1.10.4  Thienopyridines
Aggregating platelets have long been suspected of having an important role in the 
development of coronary thrombi, but it remained for the ISIS-2 trial to show 
unequivocally the enormous effectiveness of aspirin which is a simple, well- 
tolerated and inexpensive drug in reducing mortality in AMI [4].
The CAPRIE trial randomized 19,185 patients with atherosclerotic vascular dis-
ease manifested as either recent ischaemic stroke, recent MI or symptomatic periph-
eral arterial disease to either clopidogrel at dose of 75 mg once daily or aspirin at 
dose of 325 mg once daily. The authors reported that clopidogrel is more effective 
than aspirin in reducing the combined risk of ischaemic stroke, MI or vascular death 
and the overall safety profile of clopidogrel is at least as good as that of medium- 
dose aspirin [30].
In the PLATO trial, 18,624 patients who were admitted with an acute coronary 
syndrome (ACS), with or without ST-segment elevation, were randomized to 
receive either clopidogrel or ticagrelor, which is an oral, reversible, direct-acting 
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inhibitor of the adenosine diphosphate receptor, P2Y12, that has a more rapid 
onset and more pronounced platelet inhibition than clopidogrel. Ticagrelor was 
found in the trial to have significantly reduced the rate of death from vascular 
causes, MI or stroke without an increase in the rate of overall major bleeding but 
with an increase in the rate of non-procedure-related bleeding compared to clopi-
dogrel [31] .
In the TRITON-TIMI 38 trial, 13,608 patients with moderate- to high-risk ACS 
with scheduled PCI were randomized to receive a new thienopyridine and prasugrel 
or to receive clopidogrel. It was found that prasugrel therapy was associated with 
significantly reduced rates of ischemic events, including stent thrombosis, but with 
an increased risk of major bleeding, including fatal bleeding. Overall mortality did 
not differ significantly between treatment groups [32].
1.10.5  Glycoprotein IIb/IIIa Inhibitors
The EPIC trial randomized 2099 patients who were scheduled to undergo coronary 
angioplasty or atherectomy in high-risk clinical situations such as severe unstable 
angina, evolving AMI or high-risk coronary morphologic characteristics to either a 
bolus and an infusion of placebo, a bolus of a chimeric monoclonal-antibody Fab 
fragment (c7E3 Fab) directed against the platelet glycoprotein IIb/IIIa receptor and 
an infusion of placebo or a bolus and an infusion of c7E3 Fab. The investigators 
concluded that ischemic complications of coronary angioplasty and atherectomy 
were reduced with the usage of c7E3 Fab, although the bleeding complications were 
increased [33].
The RAPPORT trial demonstrated that in a cohort of patients suffering from 
AMI of less than 12 h duration, who underwent primary percutaneous translumi-
nal coronary angioplasty (PTCA), administration of abciximab resulted in a sig-
nificant reduction in the incidence of death, reinfarction or urgent target vessel 
revascularization at 30 days compared to placebo albeit at a cost of higher bleed-
ing rates. The 6-month primary end point however was the same for both treat-
ment groups [34].
The EPILOG trial on the contrary was terminated early as abciximab, together 
with both low-dose and standard-dose heparin, significantly reduced the risk of 
acute ischemic complications compared to placebo and standard-dose heparin in 
2792 patients who underwent either urgent or elective percutaneous coronary revas-
cularization [35].
 Conclusion
The last 120 years have witnessed considerable progress in our understanding 
and management of CAD and MI. Modern treatment algorithms have encom-
passed and refined techniques to achieve rapid reperfusion and salvage-threat-
ened myocardium and enhance prospects for patient stability and recovery.
Z. V. Lee and B. Hanif
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2.1  Introduction
The outcomes of patients suffering from acute myocardial infarction are contingent 
on the time taken to deliver definitive treatment. Evidence has shown that the extent 
of myocardial salvage is greatest if patients are reperfused in the first 3 h from the 
onset of symptoms [1]. For every 30-min delay in coronary reperfusion, the relative 
1-year mortality rate increases by 7.5% [2]. This has driven physicians and policy- 
makers to popularize phrases such as ‘time is myocardium’ and concepts such as 
‘door-to-balloon’ time—the latter representing the time to reperfusion with an intra-
coronary device from the arrival of the patient at hospital (Fig. 2.1). The biggest 
delays and challenges in reducing the time to reperfusion, however, are in fact 
mostly seen in the prehospital setting. This consists of the time from the onset of 
symptoms to first medical contact (FMC) and subsequently the time from FMC to 
diagnosis and then reperfusion treatment—termed ‘system delay’. Patient delay 
may be multifactorial and depends on a host of issues including socioeconomic fac-
tors and access to healthcare. The rapid patient assessment and field diagnosis of 
myocardial infarction has become a crucial factor in time to reperfusion as it dic-
tates the decision on the most appropriate form of reperfusion treatment accounting 
for geographical factors and available facilities. Importantly, the prehospital role in 
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the management of acute myocardial infarction also involves the initiation of ther-
apy, the upstream of the hospital-delivered treatment. This commonly involves the 
administration of antiplatelet and anticoagulant therapy in metropolitan areas, while 
in remote areas where patients cannot be transferred to hospital facilities in a rea-
sonable time, there are policies in place for administration of field thrombolytic 
agents. Other aspects of the management may involve intravenous access or, indeed 
in the cases of cardiac arrest, cardiopulmonary resuscitation. In this chapter we will 
discuss the management of patients presenting with acute myocardial infarction, in 
the crucial period ahead of their arrival at the heart attack centre.
2.2  Activation of Emergency Services
2.2.1  The Call for Help
The diagnosis and treatment of acute myocardial infarction (MI) in the community 
is dependent on the recognition of clinical symptoms. Awareness of potential warn-
ing signs is largely dependent on the patient, yet it is not uncommon for patients to 
wait 2 h or more after symptom onset before contacting emergency medical services 
(EMS) [3]. Reasons for delayed presentation include perception of the ‘Hollywood 
heart attack’ (despite up to one-third of patients presenting without angina), differ-
ing symptoms compared with previous experiences in patients with known isch-
aemic heart disease, fear of embarrassment or troubling others and persistent 
attempts at self-medication. Thus, community awareness and patient education 
remain a cornerstone of early diagnosis. Public health initiatives encompass identi-
fication of key warning signs such as chest discomfort radiating to relevant areas, 
light headedness or dyspnoea, as well as advocacy of contacting EMS within 5 min 
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individuals such as those with relevant cardiovascular comorbidities, alongside their 
families, are a fundamental aspect of primary and secondary prevention. However, 
systemic factors such as access to EMS, provision of health insurance and socioeco-
nomic background also influence the time to presentation, and policy-makers hold 
a substantial role in determining patient outcomes.
Following symptom recognition, prompt contact with EMS is necessary. Where 
previously prescribed, patients may be given a trial of nitroglycerine; however, the 
worsening or persistence of symptoms (usually beyond 5 min after administration) 
is indicative of non-response and mandates EMS contact. There is also the risk of 
systemic hypotension after repeated nitroglycerin administration which may pre-
cipitate cardiogenic shock in the context of acute myocardial infarction. Private 
transportation as opposed to EMS transfer is unsafe given the risk of cardiac arrest 
in the absence of any trained medical support. Other benefits of prompt EMS con-
tact include the opportunity to perform an ECG leading to earlier diagnosis, subse-
quent assessment of timely transfer to primary PCI centre and early fibrinolytic 
therapy by adequately trained healthcare providers.
2.2.2  First Medical Contact
First medical contact (FMC) is the time at which trained EMS providers who can 
obtain and interpret the ECG arrive at the patient’s side. The task faced by EMS 
providers upon initial patient contact should not be underestimated. An assessment 
of the patient’s need for immediate life support, attainment of key history from the 
patient and witnessing bystanders and focused clinical examination must be per-
formed efficiently and accurately for appropriate triage. This evaluation may be 
complicated by atypical but not uncommon presentations such as those in elderly, 
female, diabetic or cognitively impaired patients. The availability of a defibrillator 
is a mandatory part of EMS given the initial presentation may be cardiac arrest. 
Subsequently, a prehospital 12- or 18-lead ECG is crucial in the context of relevant 
symptoms and can be electronically transmitted to a hospital doctor or interpreted 
by EMS personnel with adequate training. A prehospital diagnosis of STEMI com-
bined with direct referral to a primary PCI centre reduces time to device interven-
tion and all-cause mortality [4]. In brief, significant ST-segment changes or left 
bundle branch block with sufficient clinical suspicion warrants exclusion of acute 
myocardial infarction. At this point and ideally less than 10 min from FMC, EMS 
providers should activate the ‘STEMI pathway’ in which patients may be trans-
ferred to a centre capable of primary PCI, a non-PCI centre for fibrinolysis, or 
receive prehospital fibrinolysis during transfer. While immediate transfer to a pri-
mary PCI centre is ideal, this is largely dependent on the presence of an established 
STEMI activation pathway, a coordinated hospital network and regional geography. 
Moreover, local protocols that facilitate prehospital registration may be in place to 
transfer patients directly to the catheterization lab, effectively bypassing the emer-
gency department and further reducing unnecessary delays. Current guidelines rec-
ommend a FMC to device intervention time of 120 min or less when considering 
2 Prehospital Diagnosis and Management of Acute Myocardial Infarction
18
primary PCI [5]; however, any system must ultimately focus on reducing total isch-
aemic time irrespective of the mode of reperfusion therapy (Fig.  2.2). Caution 
should be exercised concerning overdependence on primary PCI where facilities 
may not be within reasonable accessibility.
2.3  Diagnosis of Myocardial Infarction
The diagnosis of an acute myocardial infarction is made when a patient has elevated 
blood serum levels of cardiac enzymes (preferably cardiac troponin) and one or 
more of the following: (a) symptoms suggestive of myocardial ischaemia, (b) ECG 
demonstrating new significant ST-T changes or new left bundle branch block 
(LBBB), (c) new pathological Q waves on ECG, (d) imaging evidence of new loss 
of viable myocardium or new regional wall motion abnormality or finally (e) iden-
tification of intracoronary thrombus on angiography or autopsy [6]. The suspicion 
of myocardial infarction usually begins from the point at which a call is made to the 
emergency medical services (EMS). At the point of FMC, a working diagnosis of 
STEMI must be made as soon as possible, and therefore a focused history and 
12-lead electrocardiogram must be performed with a maximum target delay of 
10 min. The clinical history is a critical component of the diagnosis of STEMI, with 
particular emphasis on the nature of the chest pain. While other mimics of STEMI 
such as myopericarditis or aortic dissection would be important to consider at an 
early stage as they would affect the subsequent management, acute myocardial 
infarction should remain at the forefront of the differential diagnoses as it remains 
common and is time critical in its management.
2.3.1  History and Examination
A focused history and examination must be carried out promptly at FMC. Symptoms 
suggestive of myocardial ischaemia may include chest pain which can radiate to the 
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diaphoresis, nausea, vomiting, palpitations or even syncope. The early recognition 
of patients with decompensated heart failure may enable the early administration of 
diuretics. Pulse rate, blood pressure monitoring and oxygen pulse oximetry should 
be monitored. It is recommended that as soon as the suspicion of a diagnosis of 
acute myocardial infarction is made, that ECG monitoring (with defibrillator capac-
ity) is carried out as these patients are at high risk of malignant arrhythmias.
2.3.2  ECG Diagnosis
The 12-lead ECG should be calibrated at 10  mm/mV with a standard paper (or 
screen) speed of 25  mm/s. The interpretation of the ECG should be made by a 
trained medical professional; otherwise, field transmission of the ECG should be 
done for immediate diagnosis. An ECG diagnosis of STEMI is made with new 
ST-segment elevation at the J point in two contiguous leads at (a) ≥0.2  mV in 
≥40 years, ≥0.25 mV in men <40 years or ≥ 0.15 mV in women in leads V2–V3 and/
or (b) ≥0.1 mV in all other leads (Fig. 2.3). The presence of reciprocal ST depres-
sion helps confirm the diagnosis and differentiates myocardial ischaemia from other 
causes of ST-segment abnormalities, such as left ventricular aneurysm or even non-
cardiac causes such as subarachnoid haemorrhage. New LBBB in the context of a 
highly suggestive history should be treated as acute myocardial infarction. While 
LBBB is not specific for an MI, one which is related to an infarct is more likely to 
be inferred a larger infarct size with poorer prognosis. Associated features such as 
decompensated cardiac failure and cardiogenic shock should raise clinical suspi-
cion [7]. While various algorithms have been proposed to aid the diagnosis in the 
context of LBBB, they do not offer sufficient diagnostic certainty. Findings in the 
Fig. 2.3 Anterior ST-segment-elevation ECG.  More marked ST-segment elevation V1–V4 with 
reciprocal change in other leads
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context of LBBB which should raise clinical suspicion include (a) concordant 
ST-segment elevation ≥1 mm in leads with positive QRS complex, (b) concordant 
ST-segment depression ≥1 mm in V1–V3 and (c) discordant ST-segment elevation 
≥5 mm in leads with a negative QRS complex. Given that right bundle branch block 
(RBBB) in the context of a STEMI often has ambiguous ST segments and has also 
been associated with a poor prognosis, recent guidelines have advised a change in 
approach in the management of such patients. In the context of persistent ischaemic 
symptoms, they should be treated in a similar fashion to LBBB with emergent coro-
nary angiography and PCI if indicated. Likewise, patients with permanent pace-
maker devices that are set up for right ventricular pacing will exhibit ECG changes 
similar to that of left bundle branch block. Of note, a patient with an ECG demon-
strating ST-segment elevation in aVR and/or V1 with otherwise widespread 
ST-segment depression should raise the suspicion of left main coronary artery 
obstruction, particularly if coupled with haemodynamic compromise. The localiza-
tion of myocardial infarction can be also be deduced from the ECG as in table 
(Table 2.1).
While those with STEMI are at greatest risk from morbidity and mortality, 
patients presenting with non-ST elevation acute coronary syndromes (NSTEACS) 
also benefit from angiography and revascularization for prognostic advantage. It has 
become evident however that patients with NSTEACS and high-risk features benefit 
from early intervention, and as such, guidelines are now advocating angiography for 
this group within 24 h of presentation [8, 9]. In order to deliver this high standard of 
care, select ambulance services have recently adopted a direct access pathway 
which facilitates patients with certain high-risk clinical and ECG features to be 
brought directly to a heart attack centre. These protocols frequently include patients 
with (a) persistent ST depression >1 mm or transient ST elevation, (b) pathological 
T-wave inversion in V1–V4, (c) dynamic T-wave inversion >2 mm in two or more 
contiguous leads or (d) haemodynamic (e.g. sustained hypotension >15 min, pul-
monary oedema, heart failure) or electrical (e.g. sustained ventricular tachycardia or 
fibrillation) instability thought to be secondary to cardiac ischaemia.
2.3.3  Cardiac Biomarkers
Point-of-care cardiac biomarkers are well established and demonstrate excellent 
diagnostic performance compared with lab-based assays. Their use in the 
Table 2.1 Localizing of myocardial infarction on ECG
Infarct location ECG changes Affected coronary artery
Septal V1–V2 Septal LAD
Anterior V3–V4 LAD
Lateral I, aVL, V5, V6 LCx, diagonals
Inferior II, III, aVF LCx (15%), RCA (85%)
Posterior V7, V8, V9 (posteriorly placed) RCA
A. J. Brown et al.
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prehospital setting is still being evaluated, but use of these tests may provide some 
guidance in the appropriate triaging of patients with suspected acute myocardial 
infarction, especially in cases where there is diagnostic uncertainty, such as ambigu-
ous chest pain or in the unconscious patient. Some cardiologists have raised con-
cerns that serum levels of cardiac biomarkers may be undetectable or below 
reference range if they are measured very early in an evolving myocardial infarc-
tion, which may in turn provide false reassurance to the practitioner assessing the 
patient. Their use has therefore been limited to few ambulance services, and their 
benefit to patient care will continue to be appraised.
2.4  Prehospital Treatment of Myocardial Infarction
2.4.1  Principles of Prehospital Therapy
Prehospital therapy for acute MI focuses on reducing thrombus burden and coagula-
tion cascade hyperactivity prior to coronary reperfusion treatment. Potential thera-
pies include antiplatelets, anticoagulants and glycoprotein (GP) IIb/IIIa inhibitors; 
the combination in which they are used is often institution or even operator depen-
dent (Table 2.2). The evidence to support each type of therapy and specific drugs 
within each class varies, although current class 1 guideline recommendations are 
prompt dual antiplatelet therapy in the form of aspirin and a potent P2Y12 inhibitor 
and an appropriate anticoagulant after assessment of bleeding risk [5]. Total isch-
aemic time remains the priority, and administration of these adjunct agents should 
not delay EMS transfer. While the optimal coronary reperfusion is primary PCI, 
such facilities may not be readily available to all patients. In such cases, prehospital 
fibrinolytic therapy can be utilized for initial reperfusion.
2.4.2  Antiplatelet Therapy
The benefits of dual antiplatelet therapy (DAPT) in patients undergoing primary 
PCI are well established. While initially borne out in the context of reducing the 
ongoing and persistent risk of stent thrombosis, DAPT also reduces the risk of sub-
sequent spontaneous MI in non-stented coronary segments and all-cause mortality 
[10]. In the prehospital setting, aspirin should be administered as soon as possible. 
The dissolved or chewed oral form is preferable over swallowing a whole tablet due 
to more rapid absorption, with a recommended dose of 150–300 mg. There is a 
paucity of data evaluating intravenous aspirin therapy in the setting of STEMI 
although given its 50% oral bioavailability, a corresponding dose between 75 and 
150 mg is appropriate in patients unable to tolerate the oral route. In contrast, the 
timing for initiation of adjunct P2Y12 inhibition therapy, including ticagrelor, prasu-
grel or clopidogrel, is uncertain. The ATLANTIC trial aimed to evaluate the safety, 
ECG changes and pharmacodynamics based on timing of P2Y12 inhibition therapy 
in the form of ticagrelor in early-presenting STEMI patients [11]. In 1862 patients 
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randomized to prehospital or in-hospital ticagrelor with a median time difference 
between strategies of 31 min, there was no between-group difference in the co-pri-
mary end point of pre-PCI resolution of ST-segment elevation or absence of TIMI 
flow grade 3 in infarct-related artery on angiography. However, there was a trend 
favouring prehospital ticagrelor for the resolution of ST-segment elevation after PCI 
which is consistent with the pharmacokinetic data of drug onset time. As such, the 
current practice is prompt prehospital DAPT in STEMI patients undergoing primary 
PCI. Prasugrel and ticagrelor are superior to clopidogrel in patients with acute coro-
nary syndrome (ACS) across a range of cardiovascular outcomes including recur-
rent MI and stent thrombosis, while also having a faster onset of action [12–14]. An 
initial loading dose is needed to rapidly attain a therapeutic concentration; however, 
patients should be assessed for bleeding risk, exclusion of other possible diagnoses 
and drug-specific contraindications before administration. Cangrelor is another 
P2Y12 inhibitor administered intravenously with benefits including rapid onset and 
superiority over clopidogrel for the composite end point of death, MI, 





in primary PCI Evidence Notes
Aspirin +++ ISIS-2, 
collaborative 
meta-analysis
– Dissolved or chewed
– Loading dose (≥150 mg)
P2Y12 inhibitors
Clopidogrel ++ COMMIT, 
CURE
– Slower onset vs. prasugrel/ticagrelor
Prasugrel +++ Triton–TIMI 38, 
ETAMI
–  Avoid in patients with previous stroke/
TIA or high risk of bleeding (previous 
haemorrhagic stroke, oral 
anticoagulants, liver disease)
Ticagrelor +++ PLATO –  Avoid in patients at high risk of 
bleeding
Cangrelor ++ CHAMPION 
PHOENIX
– IV administration
– Rapid onset and offset
Anticoagulants
UFH +++ (Operator 
familiarity)
–  Can measure anticoagulation with 
ACT
Enoxaparin +++ ATOLL – Better clinical outcomes than UFH
Bivalirudin ++ MATRIX – More expensive than heparin
– Consider in patients with HIT
Fondaparinux − OASIS 6 –  No demonstrated benefit in primary 
PCI
GP IIb/IIIa inhibitors
Abciximab + FINESSE –  Consider as bailout therapy in 
angiographic evidence of no or slow 
reflow or large thrombus
Tirofiban + On-TIME 2
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ischaemic-driven revascularization or stent thrombosis in patients undergoing PCI 
[15]. It has yet to be compared with prasugrel or ticagrelor and its use limited to 
patients yet to receive oral P2Y12 inhibition therapy.
2.4.3  Anticoagulants
The use of prehospital anticoagulant therapy for primary PCI has been mostly 
derived from extensive experience and familiarity rather than established clinical 
evidence. Despite the lack of a placebo-controlled trial for anticoagulants in pri-
mary PCI, they are still frequently used in clinical practice. Unfractionated heparin 
(UFH) is the standard anticoagulant for primary PCI. Enoxaparin is an alternative 
and has been associated with a reduction in composite risk of death, recurrent ACS 
or urgent revascularization at 30 days (7% vs. 11%, respectively; p = 0.02) com-
pared with UFH in the ATOLL trial [16]. However, the ability to measure UFH 
anticoagulation through activated clotting time (ACT) has led to UFH remaining the 
standard of care for PCI. Bivalirudin may be considered with the MATRIX trial 
reporting lower mortality and bleeding at the expense of increased absolute stent 
thrombosis events compared with UFH in 7213 ACS patients [17]. Its compara-
tively higher cost and lack of prehospital data have limited its use, although it may 
be preferred in patients at greater risk of bleeding, especially when infused for lon-
ger durations (>4 h) post-PCI. Conversely, fondaparinux has shown no benefit in 
primary PCI and is not recommended in this setting. However it may be an attractive 
alternative in STEMI patients not suitable for primary PCI with reduced death and 
re-infarction compared with UFH at 3–6 months (hazard ratio 0.77, 95% CI 0.64–
0.93, p = 0.008) shown in the OASIS-6 trial [18].
2.4.4  GP IIb/IIIa Inhibitors
Prehospital glycoprotein (GP) IIb/IIIa inhibitors are proposed to reduce thrombus 
burden and improve reperfusion success in primary PCI given its rapid onset in 
intravenous administration. Examples include abciximab, eptifibatide and tirofiban. 
While they are generally associated with a greater reduction in ST-segment devia-
tion post-PCI, data are conflicting as to whether this translates to better clinical 
outcomes. The FINESSE trial is the largest trial to evaluate the use of upstream GP 
IIb/IIIa inhibition using abciximab or combination of abciximab-tenecteplase com-
pared with PCI alone in STEMI patients intended for primary PCI [19]. In 2452 
patients, there was no difference in mortality between any of the patient groups at 
90 days follow-up (between 4.5 and 5.5% for all three groups; p = 0.49). Conversely, 
in the On-TIME 2 trial, pre-PCI tirofiban was associated with fewer major adverse 
cardiovascular events at 30 days compared with placebo (5.8% and 8.6%, respec-
tively; p = 0.04) and a trend towards reduced mortality at 1 year (3.7% and 5.8%, 
respectively; 0.08) [20]. Given mortality is significantly reduced in patients who 
receive early compared with late GP IIb/IIIa inhibitors [21], it should be noted that 
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time from symptom onset to drug therapy was 165 min in the FINESSE trial which 
was much longer compared with ~75 min in On-TIME 2. Further to the conflicting 
evidence for clinical benefit, these agents are highly potent and could unnecessarily 
increase the risk of bleeding, particularly where the diagnosis of STEMI is not 
definitive. In view of these limitations, current guidelines do not recommend the use 
of GP IIb/IIIa inhibitors in the prehospital setting [5].
2.4.5  Fibrinolytic Therapy
Fibrinolytic therapy was previously the mainstay treatment for STEMI patients with 
early presentation from symptom onset. Its rapidly waning beneficial effects with 
ongoing myocardial injury highlight the importance of early administration; mortal-
ity is more than halved when given less than 2 h from symptom onset compared 
with later [22]. However, more than two decades ago, primary coronary angioplasty 
was shown to significantly reduce death, re-infarction and hospital readmission 
compared with thrombolysis [23]. While subsequent findings from the CAPTIM 
trial suggest fibrinolysis may be equivalent if administered early in intermediate- 
risk STEMI patients and where rescue angioplasty is readily available [24], the 
further development of stent technology has since established primary PCI as the 
optimal reperfusion strategy for STEMI patients presenting within 12 h of symptom 
onset. However, the success of any reperfusion strategy is still dependent on total 
ischaemic time. Patients should not be delayed with treatment where a primary PCI 
facility is not within reasonable proximity, either by EMS vehicle or air transporta-
tion. Where a predefined time threshold according to local protocols cannot be met, 
the role of fibrinolytic therapy remains a critical aspect of prehospital STEMI 
management.
Fibrinolytic therapy should be administered prehospital (preferably <10 min of 
STEMI diagnosis) and within 12 h of symptom onset in the absence of contrain-
dications if a primary PCI facility is logistically unavailable. Fibrin-specific 
agents are preferred (e.g. tenecteplase) over systemic lytic agents (e.g. streptoki-
nase) and should be co-administered with age-adjusted doses of dual antiplatelet 
and anticoagulation therapy. In the PCI-CLARITY study, adjunct clopidogrel sig-
nificantly reduced the rate of major adverse cardiovascular events compared with 
aspirin alone in STEMI patients receiving fibrinolytic therapy (relative risk reduc-
tion, 40%) [25]. At present, no studies have evaluated the adjunct use of ticagrelor 
or prasugrel with fibrinolytic therapy, and thus clopidogrel is the preferred choice 
in this setting. For adjunct anticoagulation, enoxaparin is the preferred treatment 
and is associated with fewer deaths, re-infarction or urgent revascularization com-
pared with UFH for STEMI patients scheduled for fibrinolysis [26]. When consid-
ering fibrinolytics in the context of optimal adjunct therapy, the risk of bleeding, 
particularly intracranial, must be weighed against the expected benefit. Absolute 
contraindications include previous intracranial haemorrhage, ischaemic stroke 
within the last 6 months, any central nervous system malformations, gastrointes-
tinal bleed within the last month, known bleeding disorders or possible aortic 
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dissection. Certain patient characteristics such as elderly, female gender or chronic 
kidney disease also increase bleeding risk, and risk prediction scores are available 
although should not unnecessarily delay reperfusion therapy [27]. In STEMI 
patients with cardiogenic shock, fibrinolysis does not improve clinical outcomes 
possibly due to decreased coronary perfusion, and in this setting, primary PCI is 
recommended.
2.4.6  Role of PCI After Fibrinolytic Therapy
The necessity and timing of PCI after administered fibrinolytic therapy has been an 
area of controversy since the advent of angioplasty. Several trials have sought to 
evaluate the role of immediate coronary angiographic assessment (i.e. facilitated 
PCI) compared with conservative, ischaemia-driven angiography after fibrinolysis. 
The GRACIA-1 trial randomized 500 patients with thrombolysed STEMI to either 
facilitated PCI or conservative, ischaemia-driven management with the primary end 
point being death, re-infarction or revascularization at 12 months [28]. Patients in 
the facilitated PCI group had lower frequency of the primary end point (9% vs. 
21%; p < 0.001): however, the time from symptom onset to fibrinolysis was 3 h. 
With such delay, the optimal benefit of fibrinolysis may have passed, thus favouring 
PCI. The ASSENT-4 PCI trial also evaluated facilitated PCI and reported higher 
rates of adverse cardiovascular events (19% vs. 13%, respectively; p = 0.005) and 
stroke (1.8% vs. 0%, respectively; p < 0.0001) compared with PCI alone in patients 
with an anticipated PCI delay [29]. Routine fibrinolytic therapy with immediate PCI 
in patients with anticipated PCI delay could heighten the risk of intracranial bleed-
ing in the context of adjunct DAPT and peri-procedural anticoagulants, which may 
in turn outweigh the benefits of thorough reperfusion.
Focus has since shifted towards a pharmaco-invasive strategy in which early- 
presenting STEMI patients receive prehospital fibrinolytic therapy and transfer to a 
PCI-capable facility for timely, but not necessarily immediate, angiographic assess-
ment. This approach carries the benefit of reducing early procedural risk from PCI, 
while enabling rapid emergency angiography (i.e. rescue PCI) in those with failed 
reperfusion after fibrinolysis (<50% ST-segment elevation resolution within 90 min) 
[30]. The STREAM trial confirmed the safety of this strategy, in which 1892 STEMI 
patients within 3 h of symptom onset and > 1 h of anticipated PCI delay were ran-
domized to either prehospital fibrinolysis and angiographic assessment within 24 h 
or primary PCI alone [31]. No difference in the primary end point of death, shock, 
heart failure or re-infarct at 30 days was detected, although fibrinolysis was still 
associated with increased risk of intracranial haemorrhage (1.6% vs. 0.5%; 
p = 0.03). Of note, the trial protocol mandated direct EMS transfer to a primary PCI 
facility which was critical to showing equivalence given more than one-third of 
patients required rescue PCI. Taken together, there remains a distinct role for early 
fibrinolytic therapy in STEMI patients with anticipated PCI delay and considered 
risk of bleeding, although it should be followed by transfer to a PCI-capable centre 
for routine early angiographic assessment.
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2.4.7  Safe Transfer to the Heart Attack Centre
Ensuring patient safety while minimizing total ischaemic time underlies optimal 
transfer of patients being managed for STEMI.  Following attainment of 12-lead 
ECG and transmission where possible, defibrillator pads should be routinely 
attached with continuous cardiac monitoring throughout transfer. Supplemental 
oxygen therapy in hypoxaemic patients (haemoglobin-oxygen saturation <90–94%) 
is part of routine initial management; however, its effect above this saturation level 
is currently uncertain (see next section). During immediate assessment and transfer, 
sublingual nitroglycerin can be administered where there is ongoing chest pain 
although regular non-invasive blood pressure monitoring for hypotension is needed. 
Intravenous morphine may also be administered where pain persists. An EMS 
checklist and transfer report regarding patient presentation, clinical assessment 
findings and received treatments, including dose, time and route of administration, 
is common and provides clear documentation and handover to the receiving hospital 
team. The ability to consistently perform these tasks while monitoring the patient’s 
clinical status is dependent on established regional STEMI protocols. The protocol 
should also incorporate specific key parameters for time thresholds such that EMS 
personnel can rapidly determine whether primary PCI is logistically achievable and 
to enable quantitative and regular assessment of local outcomes compared with per-
formance benchmarks.
2.4.8  Oxygen Therapy in Acute Myocardial Infarction
Oxygen therapy has historically been a part of routine initial management of STEMI 
patients regardless of haemoglobin-oxygen saturation. This was derived from the 
belief that increased oxygen delivery to an ischaemic myocardium would reduce 
myocardial injury. However, the AVOID trial which randomized 441 STEMI 
patients with ≥94% baseline oxygen saturation to either supplemental oxygen at 
8 L/min or no oxygen found that supplemental oxygen was associated with a signifi-
cant increase in peak creatine kinase [32]. Additionally, recurrent MI (5.5% vs. 
0.9%, p = 0.006) and cardiac arrhythmias (40.4% vs. 31.4%, p = 0.05) at 6 months 
follow-up were higher in patients receiving supplemental oxygen compared with 
none, although the study was not powered for clinical outcomes. Subsequently, the 
much larger DETO2X-AMI trial found no difference with or without supplemental 
oxygen in patients with suspected myocardial infarction for all-cause mortality 
(5.0% and 5.1%, respectively) and rehospitalization with MI (3.8% and 3.3%, 
respectively) [33]. Of note, less than one-half of patients in each arm had a final 
diagnosis of STEMI, and the lower threshold of oxygen saturation for inclusion was 
90%. While it remains unclear whether supplemental oxygen is harmful in patients 
with oxygen saturation in the normal range, the equivalent lack of benefit suggests 
that it should be reserved for patients with lower saturation (<90–94%) and we 
await further randomized data to elucidate this controversy.
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2.5  Summary
Patient outcomes following myocardial infarction are heavily dependent on the pre-
hospital phase. Prompt recognition and correct triage of patients suffering from 
chest pain are paramount, with healthcare networks continually evolving to deliver 
upfront pharmacological treatment and rapid access to therapies that allow for myo-
cardial reperfusion. As we move into the future, our focus as healthcare providers 
should remain on reducing the overall duration of myocardial ischaemia while also 
considering expansion of rapid reperfusion to patients with an acute coronary syn-
drome not currently served by existing pathways.
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3.1  Introduction
Internationally ischaemic heart disease (IHD) is the single most common cause of 
death, and its frequency is increasing. The relative incidences of ST-elevation myo-
cardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) 
are decreasing and increasing, respectively. In European countries, the incidence 
rate for STEMI ranges from 43 to 144 per 100,000 population per year. Similarly, 
the reported adjusted incidence rates from the USA decreased from 133 per 
100,000  in 1999 to 50 per 100,000  in 2008, whereas the incidence of NSTEMI 
remained constant or increased slightly. STEMI is more common in younger than in 
older people and is more common in men than in women.
Mortality in STEMI is associated with advanced age, Killip class, time delay to 
treatment, presence of emergency medical system (EMS)-based STEMI networks, 
treatment strategy, history of MI, diabetes mellitus, renal failure, number of dis-
eased coronary arteries and left ventricular ejection fraction (LVEF). Overall mor-
tality from STEMI remains substantial with the in-hospital mortality of unselected 
patients with STEMI in the national registries of the European Society of Cardiology 
(ESC) member countries varying between 4% and 12%. Whilst reported 1-year 
mortality among STEMI patients in other registries is approximately 10%.
Although IHD develops later in women compared with men, MI remains a lead-
ing cause of death in women. Acute coronary syndrome (ACS) occurs three to four 
times more often in men than in women below the age of 60 years, but after the age 
of 75, women represent the majority of patients. Women may present with atypical 
symptoms—seen in up to 30% in some registries. It is therefore important to be 
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vigilant when encountering a potential ACS presentation in a female. Women also 
have a higher bleeding risk peri- and post-PCI. Several studies have suggested a 
poorer outcome in females suffering MI, related to older age and more comorbidi-
ties. Some studies have indicated that women may undergo fewer interventions than 
men and receive reperfusion therapy less frequently. The guidelines stress the fact 
that women and men receive equal benefit from a reperfusion strategy and STEMI- 
related therapy and that both genders must be managed in a similar fashion.
3.2  Treatment of STEMI
Patients with chest pain suggestive of an ACS and having ECG evidence of an acute 
STEMI are candidates for reperfusion therapy with either primary percutaneous 
coronary intervention (PPCI) or fibrinolytic therapy. Patients with typical symp-
toms in the presence of a new left or right bundle branch block or a true posterior 
STEMI are also considered eligible.
Coronary reperfusion with PPCI or fibrinolytic therapy improves outcomes in 
patients with acute ST-elevation MI. However, PPCI is the reperfusion therapy of 
choice compared to fibrinolysis because it achieves a higher rate of TIMI 3 flow 
(more than 90%), does not carry the risk of intracranial haemorrhage and is associ-
ated with improved outcomes. The time to onset of reperfusion therapy is a critical 
determinant of outcome with both PPCI and fibrinolysis.
Definitions—The delay in treatment delivery between the onset of symptoms 
and primary percutaneous coronary intervention (PPCI) is termed the treatment 
delay and has the following components:
• Patient delay—This is the time between onset of symptoms and the call to the 
emergency medical system (EMS).
• Prehospital system delay—This is the time between the EMS call and the arrival 
at the PCI centre and is equivalent to the time of EMS evaluation, prehospital 
electrocardiogram obtainment (if any) and transportation to the hospital. For 
patients transferred from a local hospital to a PCI centre, this is sum of the time 
between the EMS call and arrival at the local hospital, the time at the local hos-
pital and the time between hospitals (second transfer time).
• Door-to-balloon delay (D2B)—This is the time between arrival at the PCI centre 
and PPCI. Time of PPCI refers to the time of coronary intervention with a bal-
loon, stent or other intervention, not to be confused with the time of arrival in the 
catheterization laboratory or the time of vascular access.
• First medical contact (FMC)—This concept is upgraded in the 2017 version of 
the ESC guidelines. This is the time point when the patient is initially assessed 
by a physician, paramedic or nurse who can obtain and interpret an ECG. This 
can be prehospital or in-hospital. Note if FMC is in the community and if the 
patient is transferred directly to the catheter laboratory, then the concept of door 
to balloon is dropped.
• System delay—This is the sum of the prehospital system and door-to-balloon 
delays.
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In this schema, patient delay is not easily corrected by the healthcare system, 
while strategies to shorten other delays are potentially modifiable. Such an effort 
will be useful if longer time intervals are associated with worse outcomes.
3.3  Fibrinolytic Therapy
Fibrinolytics are most effective when given within the first 2 h after the onset of 
symptoms. However, many patients with STEMI present late after the develop-
ment of symptoms. In different registries of patients, the time from symptom 
onset to hospital presentation was ≥4 h in 50%, more than 6 h in 40% and more 
than 12 h in 9–31%. Delay is greatest in women, older adults, low socioeconomic 
and ethnic minority groups and those with symptoms that occur between 6 P.M. 
and 6 A.M.
3.4  Late Presentation PPCI
In contrast to fibrinolysis, revascularization after 12 h with PCI may still be benefi-
cial in the 9–31% of patients with STEMI who present more than 12 h after the 
onset of symptoms. The randomized trials that have evaluated late PCI have included 
patients at different time periods after symptom onset, ranging from 12 h to up to 
28 days. Some have demonstrated an improvement in left ventricular function with 
PCI, but none have demonstrated a significant benefit on death.
The American College of Cardiology/American Heart Association (ACC/AHA) 
guidelines suggest that it is reasonable to perform PPCI for patients with onset of 
symptoms within the prior 12–24 h who have one or more of the following:
• Severe heart failure
• Haemodynamic or electrical instability
• Persistent ischaemic symptoms
In contrast, the task force did not recommend PPCI in stable, asymptomatic 
patients presenting more than 12 h after symptom onset.
3.5  Door-To-Balloon Time (D2B)
D2B is well studied and is predictive of in-hospital mortality. Longer D2B times 
result in poorer outcomes as evidenced by both observational studies and random-
ized trials:
• The NRMI-3 and NRMI-4 registries (1999–2002) reported 29,222 ST-elevation 
myocardial infarction (STEMI) patients who were treated with PCI within 6 h of 
presentation. Longer D2B times were significantly associated with increased in- 
hospital mortality (3.0%, 4.2%, 5.7% and 7.4% for D2B time of ≤90  min, 
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91–120 min, 121–150 min and >150 min, respectively). Patients with D2B times 
>90  min had a significant increase in mortality compared to those with D2B 
times ≤90 min (odds ratio 1.42).
• The CADILLAC and HORIZONS-AMI trials analysed 4548 patients; short D2B 
times (≤90  min) were associated with a significantly lower mortality rate at 
1  year compared to longer times (3.1% vs. 4.3%; hazard ratio 0.72, 95% CI 
0.52–0.99).
Despite the evidence that longer D2B times lead to worse outcomes, improve-
ment in D2B times has not lead to improvement in survival rates. In a study of 
nearly 100,000 STEMI patients in the US CathPCI Registry of the National 
Cardiovascular Data Registry who underwent primary PCI between July 2005 and 
June 2009, median D2B times fell from 83 to 67 min, comparing the first to the last 
12 months of the time period. Despite this significant improvement, there was no 
change in risk-adjusted in-hospital mortality (5.0% vs. 4.7%, respectively; 
p = 0.34).
Although there is a direct relationship between increasing mortality and longer 
D2B time, it may be difficult to demonstrate further improvements in survival with 
shorter D2B times, particularly if they are in the order of magnitude of minutes. 
This is in part related to the impact of total ischaemic time on mortality.
Outcomes in patient subgroups—The issue of whether the improvement in 
survival with short D2B times is delivered equally to all patients has been studied, 
and two subgroups of patients appear to benefit the most: those who present early 
after symptom onset and those at high risk.
Early versus late presentation—With regard to early versus late presentation, 
it appears that short D2B time is associated with improved outcome in early pre-
senters more than in late presenters:
• In a study of 2322 patients who underwent PPCI comparing short versus long 
D2B time (<2 vs. >2 h), there was a significant decrease in 7-year mortality in 
patients presenting ≤3 hours from symptom onset (15.0% vs. 24.7%), but not in 
patients presenting after 3 h (18.5% vs. 21.1%).
• Similarly in 4548 patients who underwent PPCI win the CADILLAC and 
HORIZONS- AMI trials, short (≤90  min) compared to long D2B times were 
associated with a significantly lower 1-year mortality rate in patients with early 
presentation (≤90 min vs. ≥90 min), but not those with later presentation (1.9% 
vs. 3.8%, HR = 0.86, 95% CI 0.26–0.93 and 4.0% vs. 4.6%, HR = 0.86, 95% CI 
0.58–1.28, respectively).
Patient risk category—High-risk patients (defined as one or more of Killip 
class 3 or 4, heart failure, age >70 years or anterior MI) appear to benefit more from 
short D2B time:
• In the study of 2322 patients discussed above, there was a significant decrease in 
7-year mortality with shorter D2B times (<2 vs. ≥2 h) in high-risk (21.5% vs. 
32.5%) but not low-risk patients (9.2% vs. 10.8%).
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• In the CADILLAC and HORIZONS-AMI trials, short compared to long D2B 
times showed a trend toward lower 1-year mortality in both high- and low-risk 
groups (5.7% vs. 7.4% and 1.1% vs. 1.6%, respectively). In patients presenting 
early (≤90 min), the hazard ratios for mortality rate in patients with short versus 
long D2B times were identical for high- versus low-risk patients, but the absolute 
mortality rate differences were greater in high-risk patients (3.3% vs. 0.7%). In 
patients presenting late (>90  min), mortality was similar with short and long 
D2B times in both high- and low-risk patients.
The findings above suggest that short D2B times are critically important in 
patients who present early, especially in high-risk patients.
3.6  Time from First Medical Contact with the Healthcare 
System (System Delay)
System delay is the sum of the prehospital system and door-to-balloon delays. For 
patients first brought to a hospital without PCI capability, the system delay has mul-
tiple components.
The associations between healthcare delays and mortality were evaluated in a 
study of 6209 patients with STEMI from 2002 to 2006 by Danish researchers. 
Approximately one-third of these patients were triaged in the field to a PCI centre, 
and two-thirds were admitted to a local hospital and then transferred to a PCI centre. 
The median follow-up time was 3.4 years, and the cumulative 1-year mortality was 
9.3%. The following findings were noted:
• In the univariate analysis of the components of delay (system, prehospital sys-
tem, door-to-balloon, treatment and patient), system delay had the strongest 
association with mortality (hazard ratios [HR] 1.22, 1.19, 1.13, 1.054 and 1.042, 
respectively). All HR were significant.
• For system delays of 0–60 min, 61–120 min, 121–180 min and 181–360 min, the 
long-term cumulative mortality was 15.4%, 23.3%, 28.1% and 30.8%, 
respectively.
• In the multivariate analysis, treatment delay and patient delay were not associ-
ated with mortality, but system delay was independently associated with mortal-
ity (HR 1.10, 95% CI 1.01–1.16 per 1-hour delay). The main components of 
system delay, prehospital system delay and door-to-balloon delay were similarly 
associated with mortality (HR 1.10, 95% CI 1.02–1.18 and 1.14, 95% CI 1.05–
1.24, respectively).
This study demonstrates the negative impact of increasing system delay on mor-
tality. It does not allow any firm conclusion regarding the time at which using a 
fibrinolytic agent would be preferable. Therefore, the earlier a patient presents (and 
thus a higher baseline risk), the less D2B delay that is acceptable. Thus, fibrinolytic 
therapy is an important option for patients who present within the first 3 h and who 
are at a low risk of bleeding.
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3.7  Direct Transfer from the Community
Mortality is improved with direct transfer from the community to a PCI hospital 
compared with evaluation and treatment at a closer hospital without PCI capability. 
The feasibility and impact of this strategy on D2B delay were evaluated in a nonran-
domized comparison of 344 patients with chest pain of less than 12 h duration and 
ST-segment elevation characteristic of acute MI in 2005 and 2006. In this study, 135 
patients were referred directly from the community by paramedics trained in ECG 
interpretation, and 209 patients were referred directly from regional emergency 
departments. The median D2B time, defined as the time between arrival at the first 
hospital to first balloon inflation, was significantly shorter in patients referred from 
the community (69 vs. 123 min), and the percent of patients with D2B times of less 
than 90 min was significantly higher (80 vs. 12).
For patients with STEMI diagnosed with a prehospital ECG who are transported 
to a PCI-capable hospital, one way to shorten the time to reperfusion is to bypass the 
emergency department (ED) and take the patient directly to the catheterization labo-
ratory. The efficacy of this approach was addressed in a study of 12,158 STEMI 
patients, 10.5% of whom bypassed the ED.  The time from first medical contact 
(FMC) to device activation was shorter in these individuals compared to those who 
went to the ED (68 vs. 88 min; p < 0.0001). There was a trend toward lower mortal-
ity (2.7% vs. 4.1%; adjusted odds ratio 0.69, 95% CI 0.45–1.03).
Therefore, the optimal strategy for STEMI patients diagnosed with a prehospital 
ECG should be to transfer the patient directly to the catheterization laboratory of a 
PCI-capable hospital (bypassing the ED) if the following two criteria are met:
 1. The patient is haemodynamically stable.
 2. The patient is received by personnel (including one physician) qualified to care 
for critically ill patients.
Transfer from a non-PCI centre—The poor outcomes seen in patients who are 
initially evaluated at hospitals without on-site PCI capability are of concern. The 
time spent at the first hospital, the subsequent transfer time and the time spent at the 
receiving hospital prior to arrival in the catheterization laboratory are sources of 
longer D2B. The frequency, magnitude and clinical impact of delays occurring at 
each of these time intervals were examined in a prospective study of 2034 patients 
referred to a PCI centre for primary PCI. The following findings were noted:
• Delays occurred most frequently in the ED at the referral hospital, with less 
delay seen at the PCI centre or in transport (64%, 16% and 13%, respectively).
• For the referral hospital, the most frequent reasons for delay were awaiting trans-
port and ED delays (26% and 14%, respectively).
Interestingly, diagnostic difficulties, including non-diagnostic initial ECGs, led 
to the greatest delay, but these had limited or no impact on mortality.
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3.8  The Door-In to Door-Out (DIDO) Time
This is defined as the duration of time from arrival to discharge at the first (non-PCI 
capable) hospital. The DIDO time is probably modifiable, as opposed to the non- 
modifiable delay caused by an additional ambulance ride. The optimum DIDO mea-
sure is<30  min, (AHA/ACC 2008). The relationship between DIDO time and 
outcomes was evaluated in in the Acute Coronary Treatment and Intervention 
Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) between 
2007 and 2010. The following results were reported:
• The median DIDO time was 68 min, with only 11% of patients having a goal 
DIDO time of less than 30 min.
• Predictors of longer DIDO times included older age, female sex, off-hours pre-
sentation and non-emergency medical services presentation to the first 
hospital.
• Patients with DIDO times less than 30  min had significantly shorter door-to- 
balloon times (85 vs. 127 min) and a lower in-hospital mortality rate (2.7% vs. 
5.9%).
AHA/ACC and ESC Recommendations—The 2013 American College of 
Cardiology Foundation/American Heart Association guideline for the management 
of ST-elevation myocardial infarction (STEMI) recommends the timely perfor-
mance of primary percutaneous coronary intervention (PCI) and sets the following 
time goals:
• For patients who initially arrive at or are transported to a non-PCI-capable hos-
pital, the first medical contact to device time should be 120 min or less.
• For patients who initially arrive at or are transported to a PCI-capable hospital, 
the first medical contact to device time should be 90 min or less.
• The 2012 European Society of Cardiology guideline on STEMI recommended 
shorter time intervals of 90 and 60 min, respectively.
ESC 2017 Summary of important time targets
Time 
targets
Maximum time from FMC to ECG and diagnosis ≤10 min
Maximum time delay from STEMI diagnosis to PPCI (wire crossing) to choose 
PPCI strategy over fibrinolysis (if this target cannot be met consider fibrinolysis)
≤120 min
Maximum time from STEMI diagnosis to wire crossing in patients presenting to 
PPCI hospitals
≤60 min
Maximum time from STEMI diagnosis to wire crossing in transferred patients ≤90 min
Maximum time from STEMI diagnosis to bolus or infusion of fibrinolysis in 
patients unable to meet PPCI target times
≤10 min
Time delay from start of fibrinolysis to evaluation of its efficacy 60–90 min
Time delay from start of fibrinolysis to angiography (if fibrinolysis successful) 2–24 h
Ref: academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehx393/4095042
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3.9  Non-system Factors Leading to Delay
In a study of nearly 83,000 patients with STEMI in the US PCI Registry (2009–
2011), non-system delays occurred in 14.7%. Typical reasons cited included delays 
in gaining consent, difficult vascular access and difficulty in crossing the lesion. As 
expected, and consistent with an increase in D2B time, the in-hospital mortality was 
greater in those with compared to those without non-system delay (15.1% vs. 2.5%; 
p < 0.01) even after PCI.
Prognosis after Primary PCI—In a registry study of 2804 patients, 30-day, 
1-year and 5-year all-cause (and cardiac) mortality rates were 7.9 (7.3)%, 11.4 
(8.4)% and 23.3 (13.8)%, respectively. In this study, the main causes of cardiac 
death within the first 30 days were cardiogenic shock and anoxic brain injury. After 
30 days, causes of death were predominantly noncardiac, with malignancies and 
pulmonary diseases dominating.
Other risk factors are discussed below:
TIMI flow grade—Patients with normal blood flow in the infarcted artery at the 
end of the procedure have a better prognosis than those who do not.
Electrocardiographic markers—Electrocardiographic markers can success-
fully predict outcome in the broad range of patients with ST-elevation myocardial 
infarction. The prognostic utility of six different methods for evaluating the extent 
of ST-segment elevation resolution after PCI was assessed in 4866 patients enrolled 
in the APEX-AMI trial. All six methods were successful in predicting outcomes of 
death or the composite of death, cardiogenic shock or heart failure at 90 days. One 
of these, the measurement of the residual, absolute ST elevation in the single, most 
affected (worst) lead 30  min after PCI, performed as well as the more complex 
methods.
Infarct size—Larger infarct size after PPCI is associated with worse outcomes. 
In a patient-level meta-analysis of ten randomized trials of primary PCI in which 
infarct size was assessed with cardiac magnetic resonance imaging or technetium-
 99 m sestaMIBI single-photon emission computed tomography within 1 month of 
STEMI, the following was noted:
• Median infarct size (percent of left ventricular myocardial mass) was 
17.9%.
• One-year estimates of all-cause mortality, re-infarction and heart failure hospi-
talization were 2.2%, 2.5% and 2.6%, respectively.
• There was a strong, graded response between infarct size and mortality and hos-
pitalization for heart failure at 1 year.
Other risk factors—Other risk factors including Killip class, age and the num-
ber of diseased vessels are also important. These parameters have been incorporated 
into three risk models that have been prospectively validated: the Zwolle risk index, 
the TIMI risk score and the CADILLAC risk score.
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3.10  What Is New in the ESC 2017 Guidelines on AMI-STEMI? 
New/Revised Concepts
Strategy Selection and Time Delays:
• Clear definition of first medical contact (FMC).
• Definition of “time 0” to choose reperfusion strategy (i.e. the strategy clock starts 
at the time of “STEMI diagnosis”).
• Selection of PCI over fibrinolysis: when anticipated delay from “STEMI diagno-
sis” to wire crossing is ≤120 min.
• Maximum delay time from “STEMI diagnosis” to bolus of fibrinolysis agent is 
set in 10 min.
• “Door-to-balloon” term eliminated from guidelines.
• See www.escardio.org/guidelines 2017 ESC Guidelines for the Management 
of AMI-STEMI (European Heart Journal 2017—doi:10.1093/eurheartj/
ehx095).
3.11  Summary
The following conclusions can be reached from the clinical trials and observational 
studies discussed above:
• Primary percutaneous coronary intervention (PPCI) with stenting, if performed 
in a timely manner, is associated with better outcomes than fibrinolysis.
• The time from symptom onset to PCI has not been shown to be an important 
determinant of outcome. At the least, the benefit from PPCI is less dependent 
upon the time from symptom onset than is fibrinolysis.
• The time from hospital arrival to PCI (D2B) is an important determinant of ben-
efit, with the best outcomes occurring when the time to PCI is 90 min or less. 
This measure is likely to be replaced with the greater use of FMC.
• Increasing system delay is associated with worse outcomes.
• Patients who are transferred to a PCI centre have better outcomes than those 
treated with fibrinolysis at the presenting hospital if PPCI is delivered according 
to guideline standards. Destination protocols for emergency medical system that 
bypass non-PPCI-capable hospitals and thereby shorten system delays to PPCI 
have been associated with improved outcomes in ST-elevation myocardial 
infarction.
• Hospitals should adapt strategies to reduce door-to-balloon times and thereby 
improve outcomes in STEMI patients treated with PPCI.
• Late PCI to open an occluded artery should be considered in patients with severe 
heart failure, hemodynamic or electrical instability or persistent ischemic 
symptoms.
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• PPCI should not be performed in hospitals without on-site cardiac surgery unless 
they meet specific criteria, including having a proven plan for rapid transport to 
a cardiac surgery operating room in a nearby hospital and having appropriate 
haemodynamic support capability for transfer.
 Conclusion
The acute ischaemia caused by SCAD in the left circumflex artery in this case 
acts as a physical and emotional stressor resulting in TC. Hence postischaemic 
myocardial stunning from SCAD may induce TC, and SCAD-induced MI may 
trigger rather than exclude TC.
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The facilities and expertise required for primary percutaneous coronary intervention 
(PPCI) of the infarct-related artery (IRA) in patients with ST-elevation myocardial 
infarction (STEMI) are only available at a limited number of hospitals. Fibrinolytic 
therapy, on the other hand, is more widely deliverable. This creates two distinct 
reperfusion choices: PPCI or a pharmacoinvasive strategy. The first option relies on 
immediate transfer to the closest PPCI-capable centre even if it means bypassing a 
closer non-PPCI centre. The second option is the “drip and ship” strategy. It involves 
delivery of fibrinolytic therapy by a non-PPCI facility with rapid transfer to a PPCI- 
capable centre.
In patients with ST-elevation myocardial infarction (STEMI), the primary thera-
peutic goal is the prompt restoration of coronary blood flow and myocardial perfu-
sion. This limits the total ischaemic time and, thereby, the extent of the myocardial 
injury. In patients presenting within 12 h of symptom onset, PPCI undertaken within 
120 min of diagnosis is the preferred reperfusion strategy. It leads to higher rates of 
IRA patency and thrombolysis in myocardial infarction (TIMI) 3 flow with lower 
rates of recurrent ischaemia, reinfarction, emergency repeat revascularisation, intra-
cranial haemorrhage and death. This superiority over fibrinolytic therapy was 
observed when the delay to treatment was short and when patients were treated in 
high-volume centres by high-volume operators.
The choice of reperfusion strategy depends mainly on the time delays to treat-
ment (Fig. 4.1), which can be categorised into patient- and system-related delays. 
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Patient delay accounts for the time taken from symptom onset to first medical con-
tact (FMC). The widely accepted definition of FMC is the time of first assessment 
by a healthcare professional who is able to obtain and interpret a 12-lead electrocar-
diogram (ECG) and deliver initial interventions. System delay refers to the time 
from FMC to reperfusion. The time of reperfusion is defined as the commencement 
of fibrinolytic administration or, in the case of primary PCI, initial wire crossing. 
The benefit of fibrinolytic therapy has not been established in the context of patient 
delay >12 h. It could be considered if there is no possibility of PPCI and the patient 
has ongoing symptoms, particularly when there is a large area of myocardium at 
risk or there is haemodynamic instability. When the patient delay is between 12 and 
48  h, a routine PPCI strategy is recommended. There is no role for PCI to an 
occluded IRA when the patient delay is >48 h and there are no ongoing symptoms. 
The task of minimising patient delay rests primarily with public health services. 
Steps to achieving the goal of reduced delay include increasing public awareness of 
common symptoms of myocardial ischaemia and the need for early recognition and 
activation of emergency medical services (EMS). In patients presenting within 12 h 
of symptom onset, anticipated system delay is the key determinant of reperfusion 
strategy (Fig. 4.2). If PPCI can be realistically achieved within 120 min of diagno-
sis, it is clearly preferred to fibrinolytic therapy. On the other hand, a pharmacoin-
vasive strategy should be adopted if the system delay associated with PPCI is 
expected to be >120 min.
The well-established relationship between system delay and mortality led to 
numerous efforts to accelerate the delivery of care. One of the most important 
advances in addressing system delay is the development of STEMI regional net-
works or systems of care, which are designed to enhance rapid recognition of 
STEMI and enable timely reperfusion therapy. Not all hospitals will have the capac-
ity to provide a 24-h PPCI service in any given region. The reasons for this are 
twofold. Firstly, it is neither practical nor cost-effective to have multiple PPCI ser-
vices operating within the same region. It leads to duplication of services, a reduc-













Fig. 4.1 Components of delay in management of patients with STEMI. FMC first medical con-
tact, STEMI ST-elevation myocardial infarction
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destination. In smaller hospitals, a 24-h PPCI roster may not be possible due to 
limited staffing. Secondly, there is a need to maintain high operator and institutional 
case volumes given the link between higher volume and better outcomes. These fac-
tors support a hub-and-spoke model of care. The hub is the PPCI-capable centre and 
the spokes are services that do not have PPCI capability. Each node of the network 
is linked by technology and by a prioritised and efficient EMS. It relies heavily on 
active multidisciplinary collaboration between cardiologists, emergency physicians 
and EMS. A well-organised regional network reduces system delay by using simple 
management algorithms that are locally developed, practical and acceptable to all 
stakeholders.
This chapter will describe the organisation and implementation of STEMI net-
works including the need for ongoing quality control initiatives. A case study is 
presented to highlight key ideas.
4.2  Organisation of a Regional ST-Elevation Myocardial 
Infarction Network
A successful STEMI network requires the close interaction of local services. They 
must be capable of responding to differences in patient presentation and geogra-
phy (Fig. 4.3). For instance, some patients will self-present to a nearby primary 
care service or emergency department (ED), while others will call the EMS. The 
management of these patients will also depend on patient delay and their proxim-













































Fig. 4.2 Reperfusion strategy selection and timing. PCI percutaneous coronary intervention, 
PPCI primary percutaneous coronary intervention, STEMI ST-elevation myocardial infarction
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components of a network are the EMS, primary care facility or non-PPCI-capable 
centre, ED at a PPCI-capable centre and the cardiac catheterisation laboratory 
(CCL).
4.3  Emergency Medical Service
The EMS has an important role in early management patients with STEMI, which 
has evolved from patient transportation to include expedited initial diagnosis, triage 
and initiation of treatment. Depending upon the geography of the network, transfer 
of patients to a CCL may require a combination of transport modalities including 
road ambulances, helicopters and fixed-wing aeroplanes. The EMS may be staffed 
by suitably trained physicians, nurses or paramedics who are capable of basic and 
advanced life support.
To facilitate early diagnosis, EMS need to be equipped with a 12-lead ECG 
recorder and have trained personnel to acquire and interpret a trace correctly. This 
involves the correct application of leads, operation of the ECG recorder and recog-
nition of different patterns consistent with STEMI or equivalent. Occasionally, 
paramedic interpretation of the ECG is not possible due to lack of training or experi-
ence. In this situation, the diagnosis may be based upon computer algorithm inter-
pretation or physician interpretation of a transmitted ECG.  While the computer 
algorithm output is easy to obtain, it is limited by a higher rate of erroneous inter-
pretations. Wireless transmission and physician interpretation, on the other hand, 
have the highest level of interpretation accuracy and afford the opportunity for early 
physician direction of management. Wireless transmission requires transmitting 
Symptom onset in a PPCI



















































Fig. 4.3 Modes of patient presentation and transfer for primary percutaneous coronary interven-
tion. ED emergency department, EMS emergency medical service, GP general practitioner, PPCI 
primary percutaneous coronary intervention
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and receiving technology at both ends as well as an available physician for interpre-
tation at the receiving centre. This system is vulnerable to network and technologic 
failures.
Once the diagnosis has been established, the EMS needs a clear destination pro-
tocol to guide transportation to the most appropriate facility. For example, such 
protocols may authorise EMS units to bypass closer non-PPCI centres and take 
patients directly to a CCL.
Patients with STEMI are at higher risk of fatal arrhythmias such as ventricular 
tachycardia (VT) or ventricular fibrillation (VF). Accordingly, EMS providers must 
have the ability to undertake continuous cardiac rhythm monitoring and administer 
shocks with an external defibrillator.
Even though PPCI is often the preferred reperfusion strategy, rural paramedics, 
in particular, should be qualified to administer fibrinolytic therapy. If the delay asso-
ciated with PPCI is expected to be >120 min, prehospital fibrinolysis is indicated.
4.4  Primary Care Service or Non-primary Percutaneous 
Coronary Intervention Centre
Sometimes patients with chest pain will transport themselves in a private vehicle to 
their local primary care service or the ED at a nearby non-PPCI hospital. These 
facilities are usually capable of recording and interpreting a 12-lead ECG. When a 
STEMI is diagnosed, the EMS should be activated and initial therapy commenced. 
This may include opioids and antithrombotic drugs including fibrinolysis. Yet, in 
comparison to a direct call to the EMS, self-presentation to a non-PPCI-capable 
facility is usually associated with a greater time delay to reperfusion. As such, 
patients with symptoms suggestive of a myocardial infarction should be discour-
aged from transporting themselves to a medical centre, by public health campaigns 
to raise awareness and understanding.
4.5  Emergency Department at a Primary Percutaneous 
Coronary Intervention Centre
The major tasks of an ED at a hospital that is PPCI-capable in patients with STEMI 
relate to diagnosis, initial therapy and immediate transfer to the CCL.
While there may be no doubt about the diagnosis in the majority of patients with 
STEMI brought into the ED by EMS, some may have an ambiguous clinical presen-
tation. In this scenario, the ED staff assess the patient and clarify the diagnosis, in 
consultation with the cardiology service. In others, an alternate diagnosis may be 
found, and the ED physicians redirect patient care accordingly. Infrequently, the ED 
discover significant comorbidities (e.g. terminal cancer) that warrant de-escalation 
of care and adoption of a conservative approach. There are patients who present 
directly to the ED with chest pain. The ED team makes the initial diagnosis of 
STEMI for such patients.
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The two main initial therapies delivered in the ED are symptom relief and anti-
thrombotic therapy. Pain relief is useful to minimise patient discomfort and reduce 
sympathetic activation. Intravenous opioids such as morphine are used for analge-
sia. Routine oxygen is no longer indicated although it should be administered in the 
context of hypoxia (SpO2 < 90%). Patients are loaded with dual antiplatelet therapy 
in the form of aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor). 
Depending on the local protocol, heparin or enoxaparin may also be given in the 
ED.
In the context of PPCI, the main role of the ED is to facilitate rapid patient trans-
fer to the CCL.  If the CCL is available and ready to receive, the patient should 
bypass ED altogether. However, this approach may not be achievable at all times. 
For instance, the CCL may be occupied by another patient or the on-call CCL team 
may not have arrived at the hospital. In this scenario, the ED performs the function 
of a holding bay until the patient can be transferred to the CCL. While the patient is 
waiting in ED, possible arterial access sites for coronary angiography should be 
prepared and initial blood samples sent to the laboratory for assessment. During this 
time, the patient is carefully observed with continuous cardiac monitoring and defi-
brillator nearby. The routine insertion of central venous or arterial access should be 
avoided as it often unnecessary and delays transfer to the CCL.
4.6  Cardiac Catheterisation Laboratory
The CCL is the final common destination for patients with STEMI within a regional 
network. Each region requires a CCL that is operational at all times even when the 
hospital is at maximum bed occupancy or the ED is closed due to overcapacity. It is 
recommended that each network has a single PPCI centre. There are a number of 
other more complex and less ideal models that may be employed. For instance, in 
some networks there are multiple PPCI centres or rotation of PPCI centre on a daily 
or weekly basis. The most recent European Society of Cardiology guidelines for the 
management of patients with STEMI recommend that any CCL that cannot offer 
24-h service should be discouraged from offering PPCI. It is argued that the pres-
ence of daytime-only PPCI services may lead to confusion of EMS, affect the qual-
ity of intervention and increase system delay. The exception should be for patients 
admitted to those hospitals for a different reason that develop a STEMI during their 
hospital stay. However, this model is refuted by those belonging to networks in 
which alternate arrangements work well. A designated CCL for PPCI within a net-
work should preferably be in a central geographic location within the region. Once 
the patient arrives on site, easy access to the CCL from the ambulance bay, helipad 
and ED enhances rapid transfer. Though patients with STEMI rarely require urgent 
surgical revascularisation, an on-site cardiac surgical facility is an advantage. The 
support provided by dedicated cardiac intensivists and cardiac anaesthetists at surgi-
cal centres is particularly useful when managing critically unwell patients in the 
CCL. The on-call CCL team usually comprises an interventional cardiologist, scrub 
nurse, circulating nurse, cardiac technologist and cardiac radiographer.
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4.7  Implementation of a Regional ST-elevation Myocardial 
Infarction Network
Over the last decade, there have been a number of initiatives around the world to 
develop and implement regional networks with the goal of improving the care of 
patients with STEMI in accordance with current guidelines. For example, in North 
America, the American Heart Association promoted Mission: Lifeline® and the 
American College of Cardiology ran the Door-to-Balloon (D2B): An Alliance for 
Quality campaign. Similarly, in Europe, the Stent for Life Initiative was a combined 
joint program by the European Society of Cardiology. To meet the tight guideline- 
based target times for reperfusion, these initiatives have outlined a number of help-
ful approaches.
Prior to the designing and implementing a regional network, the Stent for Life 
Initiative recommends understanding existing local practice with regard to patients 
with STEMI. This investigation should seek to accurately establish the following 
statistics:
• Rates of STEMI
• Total number of patients with STEMI per annum
• Number and location of PPCI centres
• Ratio of PPCI centres to overall population
• Time taken patients to arrive at a PPCI centre
• Geographic constraints
• Modes of patient transportation
• Existing transportation protocols
• Equipment available on ambulances
• Level of training EMS personnel
• Proportion of the population served by a PPCI centre within a 90-min travel 
window
• Variation in the quality of service within the region
• Number of participating interventional cardiologists
• Number of interventional cardiologists per capita
• Reperfusion rates
• Mortality rate
Using the accumulated data, barriers to the delivery of timely reperfusion ther-
apy can be identified. For instance, some of the commonly reported barriers 
include:
• Insufficient number of 24-h CCLs available for PPCI
• Lack of even geographic distribution of PPCI centres with overconcentration in 
urban areas
• Variation in the management of patients with STEMI throughout the region
• Delayed or inappropriate EMS response (such as non-adherence to the destina-
tion protocol)
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• Inadequately equipped or trained EMS
• Lack of EMS motivation to participate in network plans and protocols
• Commercial bias where there are too many CCL offering 24-h PPCI service
• Lack of quality control initiatives
• Poor public awareness of STEMI symptoms leading to delay in seeking medical 
attention
• Lack of a national registry
• Ineffectual communication and poor collaboration between key stakeholders 
within network
Once local barriers to timely care have been identified, the next step is to define 
realistic objectives and prioritise them. For example, the primary objective may be 
to initially develop a network focussed on a small region. Other possible objectives 
include setting up a quality control and feedback system or increasing public aware-
ness about the symptoms warranting immediate medical attention. With these 
objectives in place, a strategic plan should be developed to realise each of them. 
Such planning has to involve all stakeholders in the networks including medical, 
transportation, industry and political partners.
Over the last decade, as it has become clear that treatment delays are associated 
with worse outcome in patients with STEMI, a number of strategies to minimise 
system delay were examined. Some of the successful approaches that reduce door- 
to- balloon time and thereby system delay are detailed below.
 1. A careful and clear definition of geographic areas of responsibility reduces mis-
understanding between each of the stakeholders in a regional network.
 2. The use of a prehospital 12-lead ECG to activate the CCL while the patient is 
in route to the hospital allows time for the team to arrive and prepare to receive 
the patient in the CCL.
 3. Limiting the number of stops on the patient journey from the community to the 
CCL reduces system delay. At times this will require the EMS to bypass nearby 
non-PPCI hospitals when a diagnosis of STEMI has been made. Likewise, on 
arrival at the appropriate hospital, bypassing the ED and heading straight to the 
CCL saves time. If a prehospital diagnosis was not made, the EMS should await 
the diagnosis in ED and immediately transfer the patient to a PPCI-capable 
hospital if the diagnosis is STEMI.
 4. A discussion of the case and ECG findings by the ED physician with either a 
general cardiologist or interventional cardiologist prior to the activation of CCL 
incurs unnecessary delay. The ideal scenario is that the ED physician diagnoses 
the STEMI and activates the CCL immediately with consultation only when 
there is doubt.
 5. Current laboratory and radiographic results should not be a prerequisite for 
activation of the CCL. Waiting for these results to be available leads to a further 
avoidable delay.
 6. Using a single-call system to activate the CCL saves time. Typically, the call is 
to the hospital switchboard operator who then contacts each member of the 
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CCL team. A return call can be made by the operator to the activating individual 
to confirm that the whole team has been notified. An even better option, if avail-
able, would be a simultaneous automatic activation system. This bypasses the 
operator and delivers the activation message simultaneously to each team 
member.
 7. An expectation that the CCL team be available within 20 min of being paged 
and priority hospital parking during off-hours ensures that CCL staff-related 
delays are avoided. At some centres, the team is expected to be on site through-
out the duration of their on-call period.
 8. The initiation of patient transport from ED to CCL after a set time interval fol-
lowing activation rather than awaiting notification that the CCL team are ready 
was successful at reducing door-to-device time. Another approach is to trans-
port the patient to the CCL when a minimum number of the CCL team arrive. 
Someone must always available to transport patients from ED to CCL. Whatever 
the approach adopted, a direct wireless phone line between an ED staff member 
and a CCL staff member facilitates communication and efficiency of patient 
transfer.
 9. Each regional STEMI network is based on the collaboration of multiple organ-
isations including hospitals, EMS and primary care facilities. The overall suc-
cess of the network relies on the performance of each organisation. This, in 
turn, requires the support of senior management and an organisational culture 
that fosters and sustains change directed at minimising system delays. For those 
dealing with patients with STEMI directly, having a team-based approach from 
ambulance to device and a culture of continuous quality improvement is also 
very useful.
 10. A regular multidisciplinary team review of local data with prompt feedback to 
all involved staff (i.e. EMS, ED and CCL) helps to identify deficiencies in the 
network and prompts continuous quality improvement initiatives. When signifi-
cant delays occur in the care of individual patients, the use of a root cause 
analysis or similar approach helps to prevent recurrences.
4.8  Quality Control
Contemporary guidelines emphasise the importance of robust quality control 
measures within regional STEMI networks. A useful tool to monitor networks 
within a country is a national acute coronary syndrome registry. It can be used 
to ensure that simple quality of care indicators are met and maintained over 
time. The registry should record demographic data, relevant time points for the 
calculation of treatment delays, PPCI penetration, morbidity and mortality. Of 
these parameters, treatment delays are the most straightforward index of qual-
ity to audit. A simple comparison of practices and outcomes across different 
regions and within each region helps to identify outliers. If the continuously 
recorded quality of care indicators fall short of agreed benchmarks, then spe-
cific interventions addressing deficiencies should be devised and implemented 
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to improve the performance of system. The data should be reviewed on a regu-
lar basis (e.g. quarterly). All major stakeholders in the network should receive 
feedback.
4.9  Case Study
The Northern Regional STEMI Network in New Zealand (NZ) includes both the 
Auckland and Northland regions. The Auckland region has a land area of 4894 km2 
and a population of 1,657,200 in June 2017. This represents the highest population 
and second smallest land area of any region of NZ. It also has the largest economy 
in the country. The Northland region has land area of 13,789 km2 and a population 
of 175,500 in June 2017. The public hospitals and other health services in NZ are 
administered by district health boards (DHBs). There are 20 DHBs throughout the 
country and each is governed by a board of up to 11 members. They plan, manage, 
provide and purchase health services for the population of their district. The largely 
urban Auckland region has three DHBs: Auckland DHB (ADHB), Counties 
Manukau DHB (CMDHB) and Waitemata DHB (WDHB). The population of 
Northland is largely rural and is serviced by Northland DHB (NDHB). The 
Northern Regional STEMI Network is comprised of these four DHBs. Each is 
autonomous and has its own protocols for STEMI. The three urban DHBs (ADHB, 
CMDHB and WDHB) have CCLs that provide a PPCI service during standard 
working hours. However, ADHB has the only CCL in the network that offers a 
24-h PPCI service. It is also the only one of the four to have on-site cardiac surgery. 
The NDHB does not have a CCL, and contracts ADHB for all cardiac catheterisa-
tion services. Patients with STEMI residing within the Northland region are trans-
ported to ADHB via helicopter. Within the Auckland region, PPCI within 120 min 
of STEMI diagnosis is feasible in the vast majority of patients. As a result, the 
default reperfusion strategy throughout the region is PPCI. The STEMI protocols 
for patients residing in the Northland region are necessarily more complex. The 
much smaller population of Northland is more widely spread out across a larger 
area. Patients self- presenting to or brought in by EMS to Whangarei Hospital, 
NDHB’s base hospital, receive fibrinolytic therapy unless there is a contraindica-
tion. They are then transferred to ADHB for coronary angiography and PCI as 
indicated. At other smaller hospitals within the NDHB, the anticipated time delay 
to PPCI is considered and discussed with the on-call interventional cardiologist. If 
the delay to PPCI is expected to be over 120 min, fibrinolytic therapy is adminis-
tered, and the patient is transferred to ADHB soon after. Alternately, if the delay is 
calculated by the EMS to be less than 120 min, the local hospital is bypassed, and 
the patient is transferred urgently by helicopter to ADHB for PPCI. In the mean-
time, the on-call CCL team is activated to meet the patient in the CCL on arrival. 
All out-of-hours (5  p.m. to 8  a.m. and weekends; 73% of the week) PPCI for 
patients residing within the Auckland and Northland regions are undertaken in the 
CCL at ADHB.  In a unique collaboration, the four interventional cardiologists 
from WDHB and the three interventional cardiologists from CMDHB join the four 
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interventional cardiologists from ADHB in a network-wide on-call roster. Out-of-
hours there is always one interventional cardiologist on call. The on-call CCL team 
includes a scrub nurse, circulating nurse, cardiac technologist and cardiac radiog-
rapher who are all employed by ADHB and work there during standard working 
hours. The on-call interventional cardiologist can be contacted on a dedicated free 
call number that is diverted to his/her mobile phone. The on-call interventional 
cardiologist or ED physician at ADHB is able to activate the CCL by contacting the 
operator at ADHB. In turn, the operator contacts each individual team member and 
often confirms with the interventional cardiologist that every team member has 
been contacted. There is an expectation that every member of the team, including 
the interventional cardiologist, should arrive within 20 min of the call-out. The 
individual data for all patients treated within the network are entered electronically 
into a national registry known as the All NZ Acute Coronary Syndrome Quality 
Improvement (ANZACS-QI) registry. The data concerning patients with STEMI 
are analysed and presented to stakeholders on a quarterly basis. In addition, regular 
network meetings every 6 weeks provide a forum for the discussion of specific 
concerns as they arise.
4.10  Summary
The management of patients with STEMI is time critical. The choice of reperfusion 
strategy is contingent upon patient and system delay. Primary PCI is preferred over 
a pharmacoinvasive approach when the anticipated system delay is short. While 
public health initiatives help to reduce patient delay, system delay is minimised by 
well-designed effective regional networks or systems of care. These systems rely on 
the collaboration of a number of local services such as the EMS, non-PPCI facilities 
and PPCI hospitals. They lead to better patient outcomes by reducing the time to 
diagnosis and treatment. Within networks, continuous quality control initiatives 
with regular feedback to all stakeholders are vital to maintain standards and improve 
the service.
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It is estimated that there are 1.5 million hospitalizations with acute coronary syn-
dromes (ACS) per year in the United States, with 30–45% being a ST-segment ele-
vation myocardial infarction (STEMI) presentation [1, 2]. STEMI occurs due to an 
acute occlusion of an infarct-related artery (IRA) that can cause irreversible 
ischemia- induced myocardial necrosis within 20–60  min of onset. Untreated 
STEMI patients have higher mortality and poor clinical outcomes compared to 
those who receive a reperfusion strategy [3–10]. The mainstay of STEMI manage-
ment is rapid intervention aimed at relieving the IRA thrombotic obstruction and 
thus reducing infarct size, preserving left ventricular function, and decreasing mor-
bidity and mortality. In the 1980s, fibrinolysis became the standard means to achieve 
reperfusion. Subsequently, a number of randomized trials and meta-analyses showed 
that primary PCI (PPCI), when performed rapidly, was associated with improved 
clinical outcomes compared to fibrinolytic therapy [11–18]. However, the mortality 
benefit of primary PCI is reduced with treatment delays, with no benefit observed 
when the difference between time of fibrinolysis and time of PCI exceeds 115 min 
[19, 20]. Current guidelines recommend the use of fibrinolytic therapy when the 
time from first medical contact to PCI is anticipated to be greater than 120 min 
[17, 18]. Despite these recommendations, data from the US National Cardiovascular 
Data Registry showed that only 51% of STEMI patients transferred for primary PCI 
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achieved the recommended first door-to-balloon time of <120  min [21]. Similar 
European data show that 65% of transferred patients had a delay of >120 min, which 
was associated with increased mortality [22].
Many strategies have been developed to increase the number of patients who can 
undergo timely primary PCI, including prehospital identification of STEMI and 
establishment of networks that allow ambulances to bypass the closest hospital and 
take patients directly to PCI facilities [23–34]. Nevertheless, there will always be a 
cohort of patients who are too far from PCI centers, and fibrinolytic therapy remains 
the treatment of choice for these patients [35, 36]. Transporting patients to a PCI 
center for routine early PCI after fibrinolysis, the so-called pharmacoinvasive strat-
egy, has been shown to reduce the risks of reinfarction and recurrent ischemia with 
no increase in major bleeding. Within the literature, there exist examples of success-
ful implementation of a combined primary PCI and pharmacoinvasive strategies 
depending on patient distance from facilities [37], with regional systems proposed 
[38]. This chapter addresses the evidence for PCI after fibrinolytic therapy, illustrat-
ing how and when it should be used.
5.2  Fibrinolytic Therapy
The use of fibrinolytic therapy in STEMI is long established, with pioneering work 
in 1976 by Chazov et al. showing benefit [39]. Prior to the development of fibrino-
lytic therapy, treatment of STEMI was limited to analgesia, antiplatelets, anticoagu-
lants, and blood pressure management. The use of fibrinolytic therapy became the 
standard practice after the pivotal randomized clinical trials Gruppo Italiano per lo 
Studio della Streptochinasi nell’Infarto Miocardico (GISSI) and Second International 
Study of Infarct Survival (ISIS-2) [40, 41]. These two studies used intravenous 
streptokinase (SK) showing a mortality benefit when compared to placebo, espe-
cially in combination with aspirin. Based on these studies, SK became standard 
treatment for STEMI. However there remained concerns about bleeding and limited 
efficacy, leading to the development of fibrin-specific fibrinolytic agents. These 
included tissue plasminogen activator (alteplase) [42, 43], recombinant plasmino-
gen activator (reteplase) [44, 45], and tenecteplase [46]. Overall there have been 
over 40 trials comparing different fibrinolytic regimens. A recent meta-analysis 
indicated that the lowest mortality and bleeding rates were seen with the use of 
reteplase, alteplase, and tenecteplase in combination with parenteral anticoagulant 
therapy [47].
The main advantage of fibrinolytic therapy is the ease of administration, which 
includes the ability to be given in small rural hospitals and in the prehospital setting. 
It is most effective when administered early (especially within the first 2 h of symp-
tom onset). To help with appropriate administration, there are time recommenda-
tions for each step (Table  5.1). There are however substantial limitations of 
fibrinolytic therapy, and it is essential that its use is appropriate (Figs. 5.1 and 5.2). 
Firstly, there is risk of major bleed, including intracranial bleeding, with SK having 
the highest risk [47]. Secondly, only 40–50% of all patients treated with fibrinolytic 
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Table 5.1 Time targets for fibrinolytic therapy
Intervals Time targets
Maximum time from FMC to 1st ECG and STEMI diagnosis ≤10 min
Maximum time from STEMI diagnosis to fibrinolytic therapy ≤10 min
Time from fibrinolytic therapy to assessment of reperfusion efficacy 60–90 min
Time from fibrinolytic therapy to angiography (if fibrinolysis is successful) 2–24 h
FMC first medical contact. Adapted from 2017 ESC STEMI Guidelines [17]
Indications:
   •    Chest pain or other ischemic symptoms < 12 hours duration
   •    Persistent ST elevation in ≥ 2 contiguous leads
    - ≥ 2 mm in anterior leads (≥ 1.5mm in women)
    - ≥ 1 mm  in inferior leads
    - Absence of LBBB, LVH or other STEMI mimics
Absolute Contraindications:
   •    Any prior intracranial hemorrhage
   •    Intracranial vascular or malignant lesion (AVM, tumour)
   •    Ischemic stroke within 3 months
   •    Sustained Hypertension: SBP > 180 or DBP > 110 mm Hg
   •    Active bleeding or bleeding diathesis (not incl menses)
   •    Significant closed head or facial trauma within 3 months
Relative Contraindications:
   •    Cardiogenic Shock
   •    Traumatic or prolonged CPR
   •    Major surgery within past 3 weeks
   •    Internal bleeding within past 4 weeks
   •    Active peptic ulcer disease
   •    Non-compressible vascular puncture
   •    Pregnancy
   •    Current use of anticoagulants
Fig. 5.1 Indications and contraindications for fibrinolytic therapy
1.   Use Fibrin-specific Agent (Accelerated tPA, Reteplase, Tenecteplase)
2.   Administer ASA 160 mg chewed, Clopidogrel 300 mg (75 mg if patient > 75 years of age)
3.   Administer parenteral anticoagulant
          a.   UFH 60 U/kg bolus (max 4000 U) then 12 U/kg per hour (max 1000 U/hr)          
          b.   Enoxaparin 30 mg IV plus 1mg/kg sc (Avoid for elderly patients or renal insufficiency)
          c.   Fondaparinux IV bolus followed by 2.5 mg sc dose 24 hours later
4.   Transfer patient to PCI center immediately after fibrinolytic therapy for pharmacoinvasive
      protocol if possible
5.   If pharmacoinvasive strategy not possible, transfer to PCI hospital for hemodynamic
      instability or evidence of failed reperfusion (persistent chest  pain or ST elevation) at 60-90
      minutes after fibrinolysis
Fig. 5.2 Fibrinolysis checklist
5 Utilization of PCI After Fibrinolysis
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therapy achieve normal TIMI (Thrombolysis in Myocardial Infarction) grade 3 
flow, with this figure even lower in elderly patients or those with cardiogenic shock 
[48–51]. Even patients with TIMI grade 3 flow may have evidence of failed myocar-
dial perfusion [52]. Noninvasive identification of successful reperfusion after fibri-
nolytic therapy is challenging, with limited positive and negative predictive values 
for resolution of chest pain and ST-segment elevation. Furthermore, approximately 
5% of patients will reinfarct after initial successful reperfusion [53].
5.3  PCI-Based Approaches
Given these limitations of fibrinolytic therapy, and the time dependency of primary 
PCI, it has been questioned whether combining fibrinolytic therapy and PCI could 
be the ideal treatment strategy, particularly for patients who cannot undergo timely 
primary PCI. This combined strategy would minimize treatment delays using rapid 
administration of fibrinolytic therapy but also achieve complete and sustained reper-
fusion using PCI. The use of PCI after fibrinolytic therapy can be classified based 
on the timing and indications for PCI (Table 5.2).
5.3.1  Rescue PCI
Patients who have persistent chest pain and ST elevation after fibrinolytic therapy 
require urgent cardiac catheterization and rescue PCI to restore flow to the occluded 
infarct-related artery. Rescue PCI is indicated in the case of suspected failed fibrino-
lysis (i.e., ST-segment resolution <50% within 60–90 min of fibrinolytic adminis-
tration) or hemodynamic instability [18]. The landmark rescue PCI trials were 
Rescue Angioplasty versus Conservative Treatment or Repeat Thrombolysis 
(REACT) and the Middlesbrough Early Revascularization to Limit Infarction 
(MERLIN) [54, 55]. REACT compared rescue PCI, medical management, and 
Table 5.2 Reperfusion strategies combining fibrinolytic therapy and PCI
Strategy Definition
Rescue PCI Emergent PCI performed for failed reperfusion after fibrinolytic therapy
Facilitated PCI Administration of fibrinolytic therapy (and/or GP IIb/IIIa inhibitors) prior 




Administration of fibrinolytic therapy followed by immediate transfer to 
a PCI center; emergent PCI for patients with evidence of failed 
reperfusion, hemodynamic instability, or reinfarction; and PCI within 
24 h of fibrinolytic therapy for patients who are stable with successful 
reperfusion
P. McKavanagh et al.
57
repeat fibrinolytic therapy for patients with clinical evidence of failed reperfusion 
after fibrinolysis. Rescue PCI was associated with a reduction in reinfarction, with 
no mortality difference between treatments. The trial was terminated prematurely 
raising concerns about the true benefit. MERLIN compared rescue PCI and conser-
vative therapy but did not show significant reduction of the primary endpoint, all- 
cause mortality. In addition, in both trials, patients who underwent rescue PCI had 
increased bleeding. Meta-analyses have been performed to help guide practice. 
Patel et al. included five trials and found a 36% decrease in the risk of death with 
rescue PCI (RR 0.64, 95% confidence interval 0.41–1.00, p = 0.048) and a margin-
ally significant 28% decrease in the risk of heart failure (RR 0.72, 95% confidence 
interval 0.51–1.01, p  =  0.06) [56]. Wijeysundera et  al. analyzed eight trials and 
found that rescue PCI was not associated with a significant reduction in mortality 
but was associated with significant reductions in heart failure (RR 0.73, 95% CI 
0.54–1.00) and reinfarction (RR 0.58, 95% CI 0.35–0.97) when compared with con-
servative treatment [57]. Rescue PCI was also associated with an increased risk of 
stroke (RR 4.98, 95% CI 1.10–22.5) and minor bleeding. Another meta-analysis by 
Testa et al. had similar findings. Rescue PCI was associated with a 70% reduction 
in the risk of reinfarction [OR 0.32 (0.14–0.74), p = 0.008], with a number needed 
to treat of 17. On balance rescue PCI is superior to conservative therapy for patients 
with failed reperfusion after fibrinolytic therapy and has a Class I indication in the 
guidelines [17, 18].
5.3.2  Facilitated PCI
Initial attempts to routinely combine pharmacological reperfusion therapy and PCI 
focused on administering fibrinolytic agents and/or glycoprotein IIb/IIIa inhibitors 
to patients being transferred for immediate PCI to help bridge the treatment delay. 
This strategy was termed “facilitated PCI” and was assessed in two large random-
ized trials.
The Assessment of the Safety and Efficacy of a New Treatment Strategy with 
Percutaneous Coronary Intervention (ASSENT-4 PCI) randomized patients to either 
PPCI (n = 838) or facilitated PCI using full-dose tenecteplase (n = 829) [58]. The 
median time from tenecteplase to first balloon inflation was 104 min. The primary 
endpoint (death or congestive heart failure or shock within 90 days) was found in 
19% of patients assigned to facilitated PCI vs. 13% of those randomized to PPCI 
(relative risk 1.39, 95% CI 1.11–1.74, p = 0.0045). During hospital stay, signifi-
cantly more strokes (1.8% vs. 0, p < 0.0001) were reported in patients assigned to 
facilitated rather than standard PPCI. There were also more ischemic cardiac com-
plications, such as reinfarction (6% vs. 4%, p = 0.0279) or repeat target vessel revas-
cularization (7% vs. 3%, p = 0.0041) within 90 days.
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The Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events 
(FINESSE) study randomized 2452 patients to undergo facilitated PCI using a com-
bination of abciximab plus half-dose reteplase, facilitated PCI using abciximab 
alone, or primary PCI [59]. The primary endpoint was the composite of death from 
all causes, ventricular fibrillation occurring more than 48  h after randomization, 
cardiogenic shock, and congestive heart failure during the first 90 days after ran-
domization. The primary endpoint occurred in 9.8, 10.5, and 10.7% of the patients 
in the combination-facilitated PCI group, abciximab-facilitated PCI group, and pri-
mary PCI group, respectively (p = 0.55); 90-day mortality rates were 5.2, 5.5, and 
4.5%, respectively (p = 0.49).
A meta-analysis comparing facilitated and primary percutaneous coronary inter-
vention was published by Keeley et al.[60]. In this they identified 17 trials of patients 
with STEMI assigned to facilitated (n  =  2237) or primary (n  =  2267) PCI.  The 
facilitated PCI group had higher rates of death (5% vs. 3%; 1.38, 1.01–1.87), non-
fatal reinfarction rates (3% vs. 2%; 1.71, 1.16–2.51), and urgent target vessel revas-
cularization rates (4% vs. 1%; 2.39, 1.23–4.66). Facilitated PCI was associated with 
higher rates of major bleeding than PPCI (7% vs. 5%; 1.51, 1.10–2.08). Hemorrhagic 
stroke was also higher in fibrinolytic therapy facilitated regimens compared with 
primary PCI (hemorrhagic stroke 0.7% vs. 0.1%, p = 0.0014; total stroke 1.1% vs. 
0.3%, p = 0.0008). The overall conclusion was that facilitated PCI offers no benefit 
over PPCI and should be avoided.
There are several limitations of the facilitated PCI trials and meta-analysis. 
Firstly, FINESSE was not included in the meta-analysis, and thus more than half of 
the patients in the analysis came from the ASSENT-4 trial. Of the 17 trials, 9 used 
only glycoprotein IIb/IIIa inhibitors and no fibrinolytic, and of the remaining 8 fibri-
nolytic trials (except ASSENT-4), most of them were small and used balloon angio-
plasty without coronary stents. Another important limitation to these trials is the 
absence of up-front clopidogrel loading at the time of fibrinolysis. Fibrinolytic 
therapy increases platelet activation and aggregation, and without clopidogrel load-
ing, PCI performed early after fibrinolysis may be predisposed toward thrombotic 
complications [61].
Most patients enrolled in the facilitated PCI studies underwent PCI within 
120 min of fibrinolysis. Secondary analyses of the ASSENT-4 and FINESSE study 
suggested that there may be a subgroup of patients (such as high-risk patients who 
presented early to non-PCI hospitals) that could benefit from facilitated PCI 
[62, 63]. However there is no large dataset to support this, and facilitated PCI is not 
currently recommended in guidelines.
5.3.3  Pharmacoinvasive
The pharmacoinvasive strategy applies to STEMI patients who are treated with 
fibrinolysis at a non-PCI center. It involves transferring patients to a PCI center 
right after fibrinolysis (without waiting to see if reperfusion is successful), fol-
lowed by routine early PCI. For those patients who successfully reperfuse with 
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fibrinolytic therapy, early PCI prevents recurrent ischemia and reinfarction. In the 
case of failed reperfusion or clinical instability, the patient undergoes emergent 
PCI on arrival to the PCI center. Figure 5.3 is a checklist for the use of a pharma-
coinvasive strategy.
A number of studies have compared routine early PCI after fibrinolysis with an 
ischemia-driven conservative strategy or delayed PCI [64–68]. The initial studies 
Confirm that patient meets indication for
fibrinolysis with no contraindications 
Administer fibrinolytic therapy (fibrin-
specific agent), ASA, Clopidogrel,
Parenteral Anticoagulant
Transfer patient to PCI center as soon as
possible after fibrinolytic therapy (ideally
within first hour, not waiting to assess
reperfusion) 
On arrival to PCI center, if patient has
ongoing chest pain, persistent ST elevation
or hemodynamic instability, perform
emergent coronary angiography & PCI
If patient arrives to PCI center stable and 
painfree with clinical reperfusion, perform
coronary angiography & PCI within 24
hours
Fig. 5.3 Flow diagram for 
pharmacoinvasive strategy
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were done prior to the use of coronary stents and antiplatelet agents that help main-
tain infarct artery patency and showed increased rates of emergency bypass surgery 
and higher mortality when PCI was performed routinely within 24 h of fibrinolysis 
[69]. Studies that were performed using contemporary PCI techniques (including 
coronary stenting) and pharmacotherapy have shown improved outcomes with rou-
tine early PCI after fibrinolysis [70].
The largest such randomized trial, TRANSFER-AMI (Trial of Routine 
Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute 
Myocardial Infarction), randomized 1059 high-risk patients who received fibrino-
lytic therapy to either usual care (including rescue PCI for failed fibrinolytic ther-
apy) or urgent transfer to a PCI-capable hospital for a routine early PCI within 6 h 
after fibrinolytic therapy [71]. The primary endpoint—a composite of death, rein-
farction, recurrent ischemia, new or worsening heart failure, or cardiogenic shock 
within 30  days—was reached in 17.2% of patients in the usual care group and 
11.0% of patients assigned to an early invasive strategy (RR 0.64, 95% CI 0.47–
0.87, p = 0.004). A meta-analysis of seven contemporary trials comparing a pharma-
coinvasive strategy to ischemia-driven (or delayed) PCI after fibrinolytic therapy 
(Figure  5.1) demonstrated a significant reduction in death or MI at 6  months to 
1 year in the pharmacoinvasive group, with no difference in stroke or major bleed-
ing (Fig. 5.4) [72].
Real-world data from a prospective registry involving a rural population 
served by a large regional health network demonstrated the safety and efficacy of 
a pharmacoinvasive strategy. Two thousand six hundred twenty-four consecutive 
patients presenting with STEMI to a non-PCI-capable hospital, more than 
60 miles from the nearest PCI center, received aspirin, clopidogrel, unfraction-
ated heparin, and half- dose fibrinolysis and were transferred for PCI. When out-
comes were compared to STEMI patients presenting directly to PCI centers for 
primary PCI, there were no significant differences in 30-day mortality (5.5% vs. 
5.6%, p  =  0.94), stroke (1.1% vs. 1.3%, P  =  0.66), major bleeding (1.5% vs. 
1.8%, p = 0.65), or reinfarction (1.2% vs. 2.5%, p = 0.088) despite a longer door-
to-balloon time [73]. An analysis of the FAST-MI also showed no difference in 
Fig. 5.4 Clinical endpoints at 6–12 months when comparing early routine percutaneous coronary 
intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction. 
Taken from a meta-analysis by Borgia et al. [72]
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risk-adjusted mortality at 1 year with primary PCI compared to a pharmacoinva-
sive strategy [74].
The STREAM trial was an international, multicenter randomized trial compar-
ing a pharmacoinvasive strategy to primary PCI in 1892 STEMI patients presenting 
within 3 h from symptom onset but who were unable to undergo PPCI in less than 
1 h after first medical contact [75]. The primary outcome was a composite of death, 
reinfarction, shock, or congestive heart failure. There was no significant difference 
in the composite primary endpoint between the two groups, 12.4% in the fibrinoly-
sis group versus 14.3% in the primary PCI group (p = 0.21, 95% CI 0.68–1.09). 
There was a higher rate of intracranial hemorrhage in the fibrinolysis group (1.0% 
vs. 0.2%, p = 0.004). However, after a protocol amendment to decrease the fibrino-
lytic dose by half in patients ≥75 years of age, there was no longer any significant 
difference in rates of intracranial hemorrhage between groups (0.5% vs. 0.3%, 
p = 0.45). It is important to note that almost one third of patients experienced a PPCI 
delay of less than 1 h and the average time from first medical contact to balloon 
inflation was 117 min. As such, the results of the STREAM trial may not be appli-
cable to patients who cannot undergo primary PCI within 120 min of first medical 
contact.
Based on the results of contemporary pharmacoinvasive trials, current guidelines 
recommend transfer to a PCI-capable hospital after fibrinolysis “even when hemo-
dynamically stable and with clinical evidence of successful reperfusion,” to undergo 
coronary angiography and revascularization within 24 h after fibrinolysis (Class IIa, 
Level of Evidence B) [17, 18].
5.4  Antiplatelet Therapy as Adjunct to Fibrinolysis
Current guidelines recommend adjunctive antiplatelet therapy in the setting of fibri-
nolysis in the form of aspirin 162–325  mg as well as clopidogrel 300  mg (for 
patients <75 years of age) or 75 mg (for patients >75 years of age) (Class I, Level of 
Evidence A) [17, 18]. The largest trial studying the use of dual antiplatelet therapy 
was the CLARITY-TIMI 28 trial [53], published in 2005. In CLARITY, the authors 
randomized 3491 patients presenting within 12  h of onset of STEMI who were 
planned for fibrinolysis with adjunctive anticoagulant and aspirin to either clopido-
grel (300 mg loading dose followed by 75 mg daily) or placebo. The primary end-
point was a composite of occluded IRA on angiography, death prior to angiography, 
or recurrent MI prior to angiography. For patients who did not undergo angiogra-
phy, the primary endpoint was death or recurrent MI by day 8. The primary safety 
endpoint was TIMI major bleeding. The primary endpoint occurred in 21.7% of the 
placebo group versus 15.0% in the clopidogrel group (OR 0.64, 95% CI 0.53–0.76, 
p < 0.001), an absolute reduction of 6.7%. There was no difference in the rate of 
TIMI major bleeding.
In the modern era of primary PCI, two novel oral P2Y12 inhibitors have been 
studied for use in acute coronary syndrome in conjunction with aspirin as part of 
a dual antiplatelet strategy, namely, prasugrel and ticagrelor [76, 77]. The safety 
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of combining these more potent P2Y12 inhibitors with fibrinolytic therapy is not 
known. The TREAT trial randomized 3800 STEMI patients treated with fibrino-
lytic therapy to ticagrelor or clopidogrel. The primary endpoint is major bleed-
ing. Enrollment was recently completed, and the results of this trial are anticipated 
in 2018.
More recently, cangrelor, an intravenous, fast-acting, and rapidly reversible 
P2Y12 inhibitor, has become available for use in the setting of primary PCI, but has 
not been studied as part of a pharmacoinvasive or fibrinolytic strategy [78].
5.5  Optimal Timing of PCI After Fibrinolytic Therapy
While the current guidelines recommend coronary angiography within 24  h 
after fibrinolysis as part of a pharmacoinvasive strategy, they discourage per-
forming angiography less than 2–3  h after fibrinolysis, based in part on the 
adverse outcomes seen in the facilitated PCI trials. However, there remains 
uncertainty regarding the optimal timing of angiography after fibrinolysis. In 
TRANSFER-AMI, the median time from randomization to first balloon infla-
tion was 3.2 h, with an interquartile range of 2.5–4.2 h [71]. A meta-analysis 
evaluating the timing of PCI after fibrinolysis found higher rates of recurrent 
ischemia and a trend to higher reinfarction when angiography was performed 
>4 h after fibrinolysis [79].
 Conclusions
Fibrinolysis remains a mainstay of STEMI treatment throughout the world and is 
the initial reperfusion strategy of choice when primary PCI cannot be performed 
with a first medical contact to balloon time less than 120 min. Fibrin-specific 
fibrinolytic agents should be used, combined with clopidogrel and parenteral 
anticoagulant therapy. Patients should be transferred to PCI centers right after 
receiving fibrinolytic therapy and undergo coronary angiography and revascular-
ization within 24 h. Regional STEMI networks should provide both primary PCI 
and pharmacoinvasive strategy, based on anticipated first medical contact to bal-
loon times.
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6Catheter Laboratory Design, Staffing and Training
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6.1  Introduction
Treatment of acute myocardial infarction has improved dramatically in recent 
years. Primary percutaneous coronary intervention (PPCI) has now become the 
mainstay of treatment and is available to all but a few geographical catchment 
areas in the UK.  Annually over 24,000 primary PCIs are performed in the UK 
representing approximately a quarter of the total coronary intervention cases each 
year [1].
From national registry data in the UK, the reported mortality risk of patients with 
acute myocardial infarction receiving PPCI is of the order of 6%. Published litera-
ture demonstrates that this mortality risk may rise to 40–50% in patients who 
develop cardiogenic shock.
Patients undergoing primary angioplasty are therefore amongst the highest risk 
group of patients receiving coronary intervention. It is vital that we should seek to 
reduce that risk as much as possible by having well-trained teams who work in an 
optimum environment.
6.2  Personnel: The “Cath Laboratory Team”
The most valuable asset of any catheter laboratory is without doubt the catheter 
laboratory team. Without a good team, even a catheter laboratory in possession of 
the most abundant resources will not function as a safe and efficient clinical 
environment.
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The composition of the catheter laboratory team will vary between centres but, 
broadly speaking, will consist of the following team members:
• Consultant interventionist
• Interventional trainee (registrar or fellow)




• Management/catheter laboratory director
This list is by no means exhaustive. Additional teams may attend the catheter 
laboratory on a regular basis, for example, the anaesthetic team including anaesthe-
tist and emergency airway practitioner (EAP), who may be required to attend when 
patients have compromise of their conscious level and/or airway problems or are 
requiring critical care support. This is a common scenario in most centres, espe-
cially when treating patients who have return of spontaneous circulation (ROSC) 
after suffering an out-of-hospital cardiac arrest. This particular group of patients 
may deteriorate rapidly and thus require a very high level of clinical suspicion and 
hence very close supervision.
For procedures requiring conscious sedation (in the UK), the Association of 
Anaesthetists of Great Britain and Ireland (AAGBI) has issued specific guidance for 
how these patients should be monitored and managed in the peri-procedural envi-
ronment, including the need for capnography [2]. The catheter laboratory and 
recovery area must therefore possess the ability to monitor end-tidal CO2 to ensure 
these patients are appropriately monitored and managed.
The time-dependent nature of managing patients with acute STEMI means that 
catheter laboratory lists must have capacity to be flexible and allow for patients 
requiring emergency procedures, sometimes with only a few minutes notice. Local 
arrangements with ambulance services are key aspects in ensuring this is imple-
mented in an efficacious manner. Good working relationships, regular interaction 
and feedback to and from the ambulance teams are essential to improve and stream-
line processes. It is useful to have a member of staff allocated on a daily basis to 
co-ordination of catheter laboratory activity who can act as a contact point for 
ambulance activation and alter schedules to accommodate emergencies. This can be 
a complex and stressful role, so ideally this role should be rotated amongst experi-
enced staff to lessen the burden.
The catheter laboratory is an environment where team members may be exposed 
to situations which are potentially extremely stressful, and it is essential that they 
are provided with the appropriate training and skills to enable them to deal with this 
in a way that will protect them from burnout and post-traumatic stress, which are 
increasingly being recognised as occupational hazards amongst emergency medical 
teams.
It is important to ensure that the workforce is well supported in terms of educa-
tion and physical resources (equipment). Of at least equivalent importance is to 
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ensure that emotional support is available. These measures, in turn, will reap rewards 
in terms of the well-being and retention of staff.
6.2.1  Education
The role of ongoing education in maintaining the highest standards of care in the 
catheter laboratory cannot be underestimated. In an environment where standards 
are often updated and evidence rapidly developing, keeping staff up to date must be 
part of the ongoing catheter laboratory activity.
There are a variety of methods which may be employed in doing so—from teach-
ing during cases (including debrief) to separate educational sessions (which should 
be considered to be mandatory in maintaining skills and knowledge) with tradi-
tional classroom-style teaching and training in practical skills with manikins. 
Simulation is an extremely useful method of teaching and has obvious advantages 
in training staff to be familiar with a variety of both routine and emergency scenar-
ios. If using simulation, it is useful to poll the team beforehand to identify any obvi-
ous knowledge gaps in order to plan sessions in order of importance. The obvious 
disadvantage of simulation is that it is resource and personnel-heavy, and therefore 
it must be planned very carefully. Overall, simulation is felt to be one of the most 
valuable methods of training and education for the team, and it has the obvious 
advantage of enhancing communication and relationships between the team 
members.
There are a variety of simulation courses available for all team members, but 
there is no substitute for teams being familiar with one another’s skills, environ-
ment, local arrangements, policies and equipment. The workplace is therefore the 
ideal environment for simulation.
In addition to the above methods of learning, the role of debrief deserves to be 
considered separately as it is an important method for team members to discuss their 
performance (as part of routine clinical practice and after emergencies or simula-
tion) in a safe, noncritical environment. It is important that this is delivered in a 
supportive environment as participants may feel particularly vulnerable after an 
event, and early debrief can reduce stress levels and identify individuals requiring 
extra support early on.
6.2.2  The Workforce
Let us now consider the core (non-medical) members of the team in more detail.
6.2.2.1  Nursing Staff
Nursing staff will be registered with the Nursing and Midwifery Council (in the 
UK) or equivalent registration body in other countries. They will usually have to 
work for a minimum of 2 years post-qualification prior to working in the catheter 
laboratory environment, but this varies widely from centre to centre. Ideally two 
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nurses should be present during primary PCI—one scrubbed or administering drugs 
and one circulating nurse or “runner” to retrieve necessary drugs and/or equipment. 
They should be familiar with the administration of drugs required during primary 
PCI as well as pressors and those required during emergency intubation and 
resuscitation.
6.2.2.2  Allied Healthcare Professionals
The group of allied health professionals (AHPs) includes radiographers and physi-
ologists and may include operating department practitioners/physician associates. 
The roles of many of the AHPs and of the nursing team may overlap significantly, 
and it is very useful for each member of the team to be familiar with the processes 
which their colleagues must carry out during the procedure to facilitate efficient 
working. Some centres have also adopted a policy of training AHPs to be proficient 
in performing the skills of multiple AHP groups in order to improve flexibility and 
improve patient care. These roles may be named as catheter laboratory practitio-
ners, and training may be nationally by a postgraduate certificate or by local 
processes.
6.2.2.3  Radiographer
Radiographers in the catheter laboratory will be in possession of a degree in diag-
nostic radiography which (in the UK) has been approved by HCPC (Health and 
Care Professions Council) and will have to work post-qualification in imaging radi-
ology for a period of 1–2 years before working in the catheter laboratory environ-
ment. After this period, they will usually work in the catheter labs for 3–6 months in 
order to achieve competency in primary PCI procedures. In the UK, there is usually 
one radiographer for each catheter laboratory who operates the C-arm and moves 
the table, but this practice varies in other countries such as North America, where 
typically the interventionist will operate the C-arm and one radiographer may then 
be used to cover two labs (where there is a shared control room for two labs).
6.2.2.4  Physiologist
Specialised cardiac physiologists working in the catheter laboratory will possess a 
degree in physiology (or will have achieved satisfactory competence by local train-
ing) or healthcare sciences and will specialise in cardiology. They will be registered 
with HCPC (UK) and the equivalent body in Europe and beyond. They will usually 
work under supervision for a period in the catheter laboratory (varies from centre to 
centre) before being considered sufficiently experienced to participate in catheter 
laboratory on-call rotas. The role includes monitoring and identifying cardiac 
rhythm and pressures and in many labs extends to preparing and monitoring adjunc-
tive therapy with devices such as intra-aortic balloon pump or Impella. It is recog-
nised that in some surgical centres, insertion of these devices is supported by the 
perfusion team.
It is important for the team to work in a cohesive manner and identify as part of 
a team providing excellent care to patients. All members should remember that 
although they have been involved in many procedures, for the patient it may be their 
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first and perhaps only one. The impact of this on patients is not to be underesti-
mated, and all should invest their time to ensure patients are dealt with in a sensitive 
and dignified manner.
6.2.3  Structure and Location of the Catheter Laboratory
The environment of the catheter laboratory and its surroundings should enhance 
patient care and protect patient and staff from physical harm.
6.2.3.1  Location
Before stepping into the catheter laboratory, it is worth taking into consideration 
where the catheter laboratory would ideally be housed within a hospital. Ideally, 
this would be within a short distance from an ambulance entrance which does not 
require use of an elevator to provide access to the catheter laboratory in order to 
reduce the transit time for critically unwell patients and minimise delay to reperfu-
sion in ST segment elevation myocardial infarction. For centres receiving patients 
from helicopter transfers, proximity to the helipad should likewise be given 
consideration.
For those environments where there is direct access from the community medical 
services, the ambulance entrance to the cardiac catheter laboratory should be very 
clearly signposted to enable paramedics unfamiliar with the hospital to easily iden-
tify the access route, and additional signposting should make the remainder of the 
route equally visible. Patients will also frequently be admitted to the catheter labo-
ratory from the emergency department (ED); therefore co-location to the ED would 
be desirable, as would proximity to the cardiology wards (for inpatient transfers) 
and the cardiac operating theatres (in tertiary centres) for the rare occasion in which 
patients are required to be directly transferred from the catheter laboratory for emer-
gency surgery.
As many patients coming to the catheter laboratory are of an acute nature, a wait-
ing area for relatives should be provided. This should be shielded from the public 
eye and be comfortable with adequate seating provision for larger families. It should 
be easy for relatives to contact staff if they have any queries. It is advisable that the 
relatives’ room should be close to, but not directly connected to, the catheter labora-
tory and the catheter laboratory recovery area should not be directly visible to rela-
tives. This will potentially reduce unnecessary anxiety from watching members of 
staff conducting their duties and relatives overhearing conversations which may or 
may not apply to their family member.
6.2.3.2  Staff Facilities
Adjacent to the catheter laboratory, there should be adequate facilities for staff to 
change and securely store personal belongings as well as washing and showering 
facilities for decontamination purposes. Rest/break facilities should also be pro-
vided; again, this would be ideally located in close proximity to the catheter labora-
tory to avoid time lost by employees in transit and to facilitate contact with teams 
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should there be an emergency requiring support of additional colleagues. Rest facil-
ities should be clean and comfortable and have facilities for preparing and cooking 
meals.
6.2.4  The Catheter Laboratory
The catheter laboratory area will generally comprise of an access corridor and 
entrance to the laboratory with a separate entrance to a control room.
6.2.4.1  Entrance
As the catheter laboratory is a designated area where ionising radiation is used, it is 
mandatory for “X-ray on” illuminated safety warning sign to be placed in a promi-
nent position at each entrance and also at the entrance to the laboratory from the 
control room. These must be clearly visible and illuminate in red when they are 
energised. They must state “No Entry” clearly, visible only when illuminated. The 
lamps are automatically switched on when the X-rays are being utilised and as such 
are wired into the X-ray activation system. These signs should have power provided 
in the essential and emergency backup electricity supply.
6.2.4.2  Control Room
In most catheter laboratories, the physiologist will be located along with monitoring 
equipment and IT equipment. They are separated from the procedure room by lead 
glass to enable direct visualisation of the patient and equipment while being pro-
tected from unnecessary radiation exposure. There should be good vocal contact 
between the control room and the laboratory—for this reason, it is usual to have a 
microphone system installed to amplify both operator and physiologist. It is essen-
tial that the physiologist has a clear view of the patient table to detect a change in 
the patient’s condition. In some centres, a single control room will be shared 
between two laboratories. If a shared control room is used, then access to either 
laboratory should be unobstructed.
6.2.5  The Procedure Room
The recommended minimum dimension for a procedure room is stated to be 50 m2. 
This is noted to be sufficient to accommodate the necessary equipment and up to 
eight members of staff [3]. Sufficient dimensions are required to permit safe pas-
sage of staff into and out of the room and for a patient to be transferred in on a trol-
ley or bed with safe access to equipment as necessary.
Basic requirements include piped medicinal gases via adaptors—including pres-
surised air and oxygen. Traditional wall sources have the potential to get caught in 
the C-arm operation and must be placed in position to minimise both this and trip 
hazards. Options exist to pipe these via floor or ceiling. For rooms where implant-
able devices will be placed (e.g. pacing procedures, trans-catheter valve 
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replacements), air flow and ventilation systems must comply with the standards 
expected in operating theatres.
6.2.5.1  Safe Practice
An abbreviated form of the World Health Organization safe surgical checklist 
should be displayed in a prominent position on the wall, and this should be com-
pleted as a “team brief” before the patient enters the catheter laboratory. This facili-
tates safe handover when members of staff may enter or leave the room during a 
procedure.
Upon the patient entering the laboratory, a safe surgical checklist should be com-
pleted to minimise unnecessary risk to the patient and ensure the team are aware of 
any significant clinical issues which may affect the procedure. In PPCI the paramed-
ics should form part of the check-in as they may have administered drugs or may 
possess additional information.
6.2.5.2  Clinical Preparation Areas
A scrub trough and gloving-up area, which may be within the procedure room or in 
an adjacent room, will be required. Ideally this should be placed in a position to 
minimise the number of staff walking past to avoid de-sterilisation.
6.2.5.3  Radiation
At the time of writing, the legislation regulating the use of ionising radiation 
(UK) is the Ionising Radiation Regulations, commonly referred to as IRR 99, and 
these are enforced by the Health and Safety Executive. It is expected that these 
will be replaced by IRR 17 at the beginning of 2018, subject to parliamentary 
approval.
The guiding principle of radiation protection remains that of “as low as reason-
ably practicable” or ALARP as it is commonly described.
The catheter laboratory is defined as a designated area from a radiation protec-
tion viewpoint. Its boundaries must be clearly identified. There is a legal obligation 
to describe the nature of the radiation and the potential risks of exposure. All mem-
bers of staff working within the designated area must be issued with appropriate 
training, and this information must be recorded and retained.
Personal protective equipment is also mandatory in this environment to avoid 
unnecessary radiation exposure to personnel. This may involve traditional lead 
aprons, which can be issued in a variety of forms, i.e. one or two piece. Additionally, 
areas particularly sensitive to radiation exposure must be protected by means of lead 
thyroid collar, lead glasses and leg shields.
In addition to protective clothing, further radiation protection should be available 
in the form of ceiling-mounted eye shield and a hanging “skirt” which is suspended 
from the procedural table, and these should be positioned in each case to minimise 
exposure to operator and assistant.
Should anaesthetic or airway support be required, it is useful to have a mobile 
screen which can be wheeled into position between the radiation source and assist-
ing team members.
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6.3  Protective Equipment
6.3.1  Lead Gowns
Leaded aprons/thyroid/leg shields/leaded glasses should be provided and stored 
outside of the entrance to the catheter laboratory area. These should be hung on 
reinforced racks due to their weight. These should be carefully labelled, identifying 
the level of protection afforded by each.
6.4  Equipment
Each catheter laboratory should contain the necessary equipment in order to safely 
perform the angioplasty procedure while minimising hazards to staff.
6.4.1  X-Ray Equipment
6.4.1.1  Image Intensifier
The digital angiographic X-ray system may be single or biplane and is usually floor 
mounted although ceiling-mounted systems are available.
6.4.1.2  Examination Table
This should be fully adjustable capable of multidirectional movement and be placed 
in a position which allows access to the patient from both sides. When selecting a 
table, consideration should be given to the treatment of bariatric patients. The C-arm 
should be able to be moved without restriction. If biplane equipment is installed, the 
room should be longer along the axis of the table to allow space for movement of 
the second C-arm. The procedural table should be placed in an area where there is 
adequate space at the cranial end to allow an area for attending anaesthetist/airway 
practitioners to perform their duties safely should they be required. At the head end, 
an anaesthetic machine would be desirable in each catheter laboratory where use of 
sedation may be required—this allows for additional monitoring, in particular cap-
nography, and the facility to administer anaesthetic gases should they be required 
(see Fig. 6.1). A power injector system for contrast injections (usually ceiling or 
table mounted) should also available for use.
6.4.1.3  Monitors
Display equipment for angiographic, ECG and pressure data is commonly ceiling 
mounted and mobile via an overhead gantry to accommodate for positioning of the 
C-arm. The number of monitors required will vary from centre to centre—with a 
minimum of three (pressure and ECG data, current image and stored reference 
image). Additional screens may be installed for display of intravascular imaging 
(such as integrated intravascular ultrasound or optical coherence tomography) or 
pressure wire data. The monitor position should be adjustable to permit the operator 
to view images comfortably.
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6.4.1.4  Work Surfaces




In acute myocardial infarction, opiate analgesia is commonly required; thus the 
presence of a wall-mounted controlled drug cupboard within the procedure 
room is desirable to avoid the need for members of nursing staff to leave the 
operating environment during a procedure to retrieve medications. Similarly, 
there should be a locked cupboard to store other intravenous fluids and drugs, 
both injectable and oral, which may be required during the procedure. A heated 











Fig. 6.1 Potential arrangement of catheter laboratory equipment. 1. Transparent ceiling-mounted 
protective eye shield. 2. Leaded radiation—protective skirt mounted on catheter laboratory table. 
3. Anaesthetic machine. 4. Mobile cabinet containing cardiac catheters. 5. Mobile cabinet contain-
ing stents and balloons. 6. C-arm in stowed position. 7. Emergency equipment trolley-containing 
airway kit, pericardiocentesis set, etc. 8. Portable adjustable radiation protection screen with 
leaded glass upper section. 9. Ceiling-mounted operating light
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6.4.2.2  Consumables
Catheters are best stored in hanging racks to enable ease of identification and rapid 
retrieval for use. These may be housed in mobile units which may be moved to a 
variety of positions or between labs should this be required. Likewise, miscella-
neous equipment, such as for cannulation, vascular access sheaths, balloons and 
stents, etc. should be available in the procedure room—these may be stored in 
mobile cabinets or wall-mounted cupboards. Extra storage for additional stock will 
be required in a separate area (located nearby) to avoid cluttering the procedural 
room unnecessarily. Items used less frequently may be located in an adjacent stor-
age area.
6.4.2.3  IT Equipment
Computer workstations are required—the number of these will vary—but generally 
at least two of these will be required. The physiologist will be required to enter 
contemporaneous data and thus will require a workstation (usually located in the 
viewing “control” room)—ideally with three screens (one for inputting data, the 
other for viewing an uninterrupted rhythm and pressure strip and finally a screen for 
viewing the current fluoroscopic image). The nursing team will also require a com-
puter (ideally a portable workstation on wheels within the procedure room) to enter 
data and record drug administration, etc. The anaesthetic team may also require a 
workstation on wheels (ideally this will be incorporated into the anaesthetic 
machine) to enable data entry and recording of haemodynamic pressures/anaes-
thetic drug administration, etc. The majority of cables should either run underfloor 
or overhead to avoid trip hazards.
6.4.2.4  Emergency Equipment
Every laboratory should have an emergency trolley which houses the necessary 
equipment should there be a life-threatening emergency. This will include (but is 
not limited to) emergency airway equipment, emergency drug box and pericardio-
centesis set. This trolley should be clearly marked and visible. Access should be 
unimpeded by equipment or personnel. All staff should be familiar with its location 
and contents. A small stock of covered stents should also be readily available for 
rapid access in the event of a coronary perforation.
6.4.2.5  Defibrillator
Patients with acute myocardial infarction have a very high risk of arrhythmia, and a 
defibrillator should be positioned close to the patient to enable rapid defibrillation in 
the event of a compromising heart rhythm disturbance. All catheter laboratory staff 
should be familiar with the operation and functionality of the defibrillator. Centres 
may elect to attach the patient to the defibrillator to prevent delay in defibrillation 
due to time taken to attach pads to the chest. The capability of the defibrillator 
should include the ability to externally pace the myocardium should this be required, 
while more definitive management of bradycardia is arranged (i.e. temporary 
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pacing). Those defibrillators with adhesive pads may be preferable to use of paddles 
as this facilitates rapid and safe shock delivery while permitting continuation of the 
PCI procedure. This is particularly relevant for those cases where there are recur-
rent/frequent bouts of VF/VT.
6.4.2.6  Pacing Equipment
In acute myocardial infarction, particularly those affecting the inferior territory, 
patients are at high risk of bradycardia and complete heart block. Each laboratory 
should therefore possess the facility to perform temporary pacing—necessitating 
pacing box, a stock of temporary wires and batteries for the pacing boxes.
6.4.2.7  Mechanical Chest Compression Device
Provision of effective CPR during a PCI is extremely challenging due to physical 
factors such as the C-arm placement, table height and the risk of radiation expo-
sure to the person performing CPR.  The use of a mechanical device such as 
LUCAS® or AutoPulse® will enable good-quality CPR to be delivered, while the 
PCI procedure is continued. This has obvious advantages in any cath laboratory 
performing PCI.  It is suggested that the device would be stored in the catheter 
laboratory—or if more than one laboratory performing PPCI, in a place which is 
easily accessible and unobstructed. All staff should be familiar with the device, 
and it should be checked regularly to ensure all components are present and in 
good working order.
6.4.2.8  Intra-aortic Balloon Pump (IABP)
Although the IABP is much less commonly used as a result of the SHOCK II trial 
data, there is still a place for its use in patients with refractory ischaemia/those with 
post-MI mechanical complications. The pump should be stored near the PPCI cath-
eter laboratory, and its location should be familiar to the catheter laboratory staff. 
The operator and physiologist (perfusionist in some tertiary centres) ± other team 
members should be trained in its indications and use and be familiar with the model 
available.
6.4.2.9  Ventricular Support Devices
The use of ventricular support devices in treatment of patients with cardiogenic 
shock is increasing worldwide. At the time of writing, there is only one device 
(Impella®) available for clinical use in the UK, although other devices are in devel-
opment, both nationally and worldwide. The Impella® device consists of a mobile 
unit (controller) which is easily transportable via a stand on wheels and the implant-
able device which is attached by a series of cables. If available, the device and the 
corresponding consumables should be stored at a location close to the catheter labo-
ratory. This is not considered to be a mandatory device in management of cardio-
genic shock; nonetheless in selected cases, it may be extremely valuable and merits 
consideration.
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6.4.3  Adjunctive Devices
6.4.3.1  Rotational Atherectomy
This is less commonly required during primary PCI but is occasionally useful in this 
setting. Most tertiary centres perform rotational atherectomy, but there are some 
lower-volume interventional labs where rotablation is not available, and these 
patients would commonly be referred to the tertiary centre for the procedure. The 
consumable components to the equipment are usually stored in a shared store room 
for the catheter labs as they are large, and the console should be housed in a dry 
storage space which is known to all laboratory staff. If using portable cylinders of 
pressurised air, they should be housed in a safe location and should be checked 
regularly to ensure there is an adequate air supply.
6.4.3.2  Intravascular Imaging: Optical Coherence Tomography (OCT) 
and Intravascular Ultrasound (IVUS)
These widely used systems are both available as mobile console units, and with both 
technologies, it is possible now to purchase integrated units where the operational 
equipment is integrated into the catheter laboratory table and monitoring display 
equipment. There are obvious advantages and disadvantages of integrating the 
equipment—these being that it limits use of the device to a single procedure room 
and there is additional cost involved in installation. The advantage is that in doing 
so, it permits use of co-registration (which although not essential is clearly a desir-
able property in assessing the nature and extent of complex disease). Additionally, 
integration allows for more free space in the laboratory, and fewer trip hazards cre-
ated by free cables, which may be accidentally disconnected. If using mobile con-
soles, a dedicated storage space in close proximity to the coronary labs which is 
known to all labs is most useful. If only one of these pieces of equipment is to be 
purchased, then arguably the most useful device would be intravascular ultrasound, 
as there are no specific cases in which it cannot be used. OCT and IVUS are 
extremely useful in detection of malapposition, which is particularly useful as it is 
one of the main risk factors for stent thrombosis after PPCI. Notably though, neither 
modality has been definitively proven to alter acute outcomes following primary 
PCI.
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7Patient Preparation, Vascular Access, and Guiding Catheter Selection
Fuminobu Yoshimachi and Yuji Ikari
7.1  Patient Preparation
Before cardiac catheterization, patient preparation and checking of general condi-
tion and appropriateness for procedure should be done. This may not always be 
possible in emergency cases however.
7.1.1  Changing Clothes
For elective procedure, nurses or assistants help a patient change clothes into hospi-
tal gown. However, for emergency cases, patients will usually be taken directly to 
the catheter laboratory in their usual attire.
7.1.2  Medication
Ideally, it should be confirmed that daily oral medicine is taken by the patient cor-
rectly with particular attention to allergies.
7.1.2.1  Dual Antiplatelet Therapy
The use of dual antiplatelet therapy (DAPT) including aspirin and P2Y12 inhibitor 
must be checked. In case of emergency PCI, aspirin and prasugrel or ticagrelor 
should be given immediately.
84
7.1.2.2  Metformin
When daily oral medication includes metformin, this should be stopped 48 h after 
catheterization since it may cause lactic acidosis together with contrast medium. It 
is a well-known serious complication of contrast medium.
7.1.3  Contrast Medium Allergy
Although an idiosyncratic reaction, prior contrast allergy is important to note, and 
pre-procedural use of corticosteroids or antihistamine drugs should be considered if 
this has occurred previously. The presence of asthma does not predict risk of bron-
chospasm with contrast and does not need routine prophylaxis.
7.1.4  Chronic Kidney Disease
The association of contrast to contrast-induced nephropathy (CIN) and risk fac-
tors for this phenomenon are well documented; however, in the emergency set-
ting, knowledge of background renal function is not always available. Intravenous 
fluids are an important strategy to reduce risk of CIN, but this may be contrain-
dicated in some patients with STEMI or severe cardiac dysfunction. The maxi-
mal advisable dose of contrast medium is considered according to kidney 
function. Traditionally, body weight (kg) × 5/serum creatinine (mg/dL) is a max-
imum dose of contrast medium. Lower volumes of contrast reduce the likelihood 
of CIN.
7.1.5  Anemia
Anemia may be a sign of concealed gastrointestinal carcinoma. Since DAPT is 
required following PCI, gastrointestinal disease should be checked before elective 
PCI. This is not feasible in the emergency setting, although should blood results be 
available, the operator may wish to consider a stent where abbreviated DAPT is 
permissible or use a balloon angioplasty strategy.
7.1.6  Blood Pressure/Oxygen Saturation Monitor/Venous Route
Venous route is necessary for cardiac catheterization, but it should be selected not 
to disturb the approach site of PCI. Although one route is enough for most of the 
cases, two or three routes may be necessary for separate administration of continu-
ous catecholamine and others. Saline or Ringer’s solution is given as drip infusion. 
Be careful of volume overload in case of heart failure as less than 100 mL/h is rec-
ommended for these cases.
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Although arterial pressure monitoring is possible, it is suggested to put manch-
ette on arms or legs. In continuous monitoring of oxygen saturation, 12-lead elec-
tronic cardiogram should be put on.
7.1.7  Emergency Cases
Requisite minimum dose of oxygen should be given according to oxygen saturation 
and/or blood gas analysis [1]. For marked respiratory dysfunction, usually due to 
acute pulmonary edema which is refractory to immediate intravenous diuretics, 
intubation and ventilation may be required to facilitate the PCI procedure. Pressor 
support is sometimes required – usually where the patients have established or early 
cardiogenic shock. These patients require early comanagement with a cardiac inten-
sivist to ensure that hemodynamic stability is maintained and optimized.
Emergency cases should be connected to a defibrillator – preferably using adhe-
sive pads to allow rapid defibrillation during the PPCI procedure should VT or VF 
occur. This is particularly common at the reperfusion phase.
7.2  Vascular Access
7.2.1  Access site
Choice of access site is radial, femoral, or brachial arteries. Radial access is favor-
able because lower access site bleeding complications result in lower mortality rate 
in patients with acute coronary syndrome [2, 3]. The second choice is femoral artery 
when radial access is not possible. Brachial access should be avoided because 
median nerve injury is a critical complication.
7.2.2  Sheath Size
A larger catheter caliber accepts bigger size devices or facilitates complex proce-
dure such as simultaneous two-stent inflation. This has to be counterbalanced with 
increased chance of vascular complications – particularly bleeding. Recent studies 
have shown that bleeding complications have predict mortality rates; therefore slen-
der size sheath is suggested for optimal safety. We generally recommend 6F sheath 
and guide catheter which permit almost all types of complex PCI to be undertaken.
7.2.3  Femoral Artery Puncture
Puncture level proximal to the femoral bifurcation is suggested. However, the 
level of femoral bifurcation is widely varied in each patient. Femoral puncture 
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point should be carefully determined. One technique is angio-guide positioning 
using the caput femoris. The other is ultrasound-guided positioning. Front wall 
puncture must be performed. Penetration to the back wall induces serious bleed-
ing complication and is difficult to manage. It is important to ensure the guide-
wire correctly passes through the iliac artery and descending aorta under 
fluoroscopy because the external iliac artery takes a retroperitoneal course. 
Rarely the guidewire may cause branch perforation and serious bleeding compli-
cations, and therefore resistance to wire advancement needs careful and methodi-
cal evaluation.
Where there is femoral/iliac calcification, it is desirable to use a long sheath 
rather than a short sheath to facilitate catheter insertion and exchange and removal. 
Sometimes a very long sheath or a metallic coil or spring-type long sheath is 
required. However, we advise these be aspirated and flushed frequently as in situ 
thrombosis can occur, and this may be transported to the coronary circulation during 
catheter exchange.
7.2.4  Radial Artery Puncture
Radial artery puncture is often erroneously perceived to be difficult because it is 
smaller than femoral artery. Radial artery spasm and occlusion are not uncommon 
complications but can be managed effectively with meticulous attention to care. 
Notably though, radial artery access is safe because of straight anatomy, no signifi-
cant branches, or very rare vascular complications such as bleeding – the vessel is 
easy to tamponade due to its superficial course and bony support posteriorly. Due to 
the lower complication rate, radial artery is considered as favorable approach site, 
particularly for primary PCI.
The puncture level is suggested as 1 cm above the radial process, but it is no 
problem to puncture above or below this point. Extremely low puncture may make 
application of hemostasis devices such as TR Band more challenging.
The use of sufficient local anesthetic (usually 1% lidocaine) may prevent radial 
artery spasm, by allowing arterial cannulation without pain. However, large bolus of 
anesthetic may make palpation of the artery more challenging. We generally use 
1–1.5 mL of sc 1% lidocaine. Once the Seldinger wire is passed into the artery, 
additional sc lidocaine is delivered.
To overcome difficulty due to small caliber, the following techniques are consid-
ered to improve puncture efficiency:
7.2.4.1  Ultrasound-Guided Radial Puncture
Due to small caliber, radial artery spasm, or small size, radial puncture is sometimes 
challenging. Ultrasound-guided radial artery puncture is suggested with high prob-
ability of successful puncture [4] (Fig. 7.1). Checking the axis view of radial artery, 
the needle is advanced in the direction to push and crush the vessel. Even when 
spasm occurs or where radial palpation is not possible, the radial artery can almost 
always be detected and successfully punctured by ultrasound.
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7.2.4.2  Infrared Light-guided Puncture
A recent technology has been developed to visualize radial artery using infrared 
light, named Mill Sus (Fig. 7.2). A purpose-designed camera detects transmitted 
near-infrared rays from the back of the wrist. The cardiologist can then puncture the 
visualized radial artery on the monitor.
Fig. 7.1 Echo-guided 
radial artery puncture
Fig. 7.2 Infrared 
light-assisted device called 
Mill Sus
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7.2.5  Radial Artery Puncture in Cardiopulmonary Arrest
It is very difficult to perform successful radial puncture in pulseless radial arteries 
due to shock or cardiopulmonary arrest.
7.2.5.1  Angiography-guided Radial Artery Puncture
In case of cardiopulmonary arrest (CPA), femoral artery puncture is also required 
for intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation 
(ECMO) insertion. After femoral access has been achieved and before inserting the 
IABP, a diagnostic catheter is inserted from the femoral into the subclavian artery to 
perform angiography of the upper limb. Because of CPA, contrast stasis in the arm 
allows fluoroscopic puncture of the radial artery.
7.2.5.2  Kenzan Technique
“Kenzan” is a classical, effective, and simple technique (Fig. 7.3).
Because of pulseless artery, the first puncture is made blindly. If first puncture is 
failed, with no backflow from needle, the needle should be left in situ. A second 
needle is then advanced next to the first needle. If no backflow is observed, a third 
needle is advanced next to the second needle. As many needles are used until back-
flow is observed. A mountain of needles appear like the Kenzan tool designed for 
Japanese flower arrangements to stand flowers. Quite aptly we call this technique 
“Kenzan.”
Fig. 7.3 Kenzan radial puncture technique. It is difficult to puncture pulseless radial artery in 
patients with cardiopulmonary arrest. In that case, puncture using several needles to the area of 
radial artery. One of the needles may be inside the radial artery. A kenzan, also called spiky frog, 
is a specific device used in the Japanese art of flower arrangement ikebana for fixing the flowers in 
the container. It consists of a heavy lead plate with erected brass needles where the stipes are fixed
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7.2.6  Distal Radial Artery Puncture/Proximal  
Palm Artery Puncture
This new method of approach has been introduced since 2016. Interchangeable 
terms of distal radial approach “d-TRI” or proximal palm artery puncture “PPAPp” 
are used [5] (Fig. 7.4). Hemostasis may be easy, and patient seems to have no dis-
comfort after PCI.  Long-term safety, feasibility, complication, and contraindica-
tions are unknown.
7.3  Guiding Catheter Selection
An appropriately selected guiding catheter is important for successful PCI either in 
transfemoral intervention (TFI) or transradial intervention (TRI). The radial 
approach presents a new set of challenges for the guiding catheter. It is important to 
understand the basic principles behind guiding catheter selection and the require-
ments for backup support, coaxial engagement, and the resulting procedural success 
that can be achieved when using a catheter specifically designed for access from the 
radial approach.
7.4  Left Coronary Artery
Performance of a guiding catheter can be assessed based on three factors: (1) easy 
and rapid engagement without specific manipulation, (2) strong backup force, and 
(3) safety not causing complications such as coronary or aortic dissection. An ideal 
guiding catheter should be easy to manipulate, supportive, and safe.
 
Fig. 7.4 Left distal 
transradial artery puncture. 
This is also called as 
proximal palmar arch 
puncture (PPAP)
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7.4.1  Judkins Left
The Judkins left (JL) catheter is an excellent catheter because of its easy engage-
ment and high safety margin. However, the backup force of JL in TRI is poor, 
although it fairs moderately better in TFI. Why is backup force of the JL in TRI so 
weak? One study on the physics of backup force in a guide catheter can answer this 
question (Fig. 7.5) [6]. This showed that the angle between the catheter and the 
reverse side of the aorta is a key factor to determine the backup force. The JL loses 
its angle-generating backup force when utilized in TRI. Thus, aside from simple 
interventions, this catheter is far from ideal in most TRI.
7.4.2  Ikari Left
The Ikari left (IL) guiding catheter was invented in 1995, first applied to PCI in 
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Fig. 7.5 (a) Judkins left from right transradial approach. (b) Judkins left from femoral approach. 
(c) Force (F) is necessary to pass a stent through a tight lesion. The force comes on the contralateral 
side of the aorta from where the catheter engages. The vertical segment of F is F cosθ Τηε ϖερτιχαλ 
σεγμεντ οϕ Φ ισ Φ χοσντ τηρουγη α τιγητ λεσιον. Τηε ϕορχε χομεσ ον τηε ραλ αππροαχη. (Χ) 
εβανα ϕορ ϕιξινγ τηε ϕλοωερσ ιν τηε χονταινερ. Ιτ χονσιστσ οϕ α ηεαϖψ λεαδ πλατε ωιτη 
ερεχτεδ βρ (d). In vitro measurement of backup force of TRI and TFI using Judkins L
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the JL: (1) shorter length between the third and the forth angles, (2) longer length 
between the second and the first angles, and (3) a new primary curve that was added 
to fit the brachiocephalic artery (Fig. 7.6). This means IL is a modified JR catheter 
designed specifically for TRI. Backup force of the IL is greater than the JL in TRI 
because the angle between the catheter and the reverse side of the aorta is increased. 
Furthermore, IL in TRI is shown to be more supportive than a JL in TFI.
7.4.2.1  Engagement Maneuver of Ikari Left
The maneuver is basically the same as JL. Advance the catheter slowly into the left 
coronary cusp; almost always it can engage the left coronary artery without any 
other manipulation. There is only a small difference in the gradual angle at the 
reverse side of the aorta compared with JL. However, this difference enhances safety 
because of the motion of the engagement. Professor Ikari has trained many people 
how to use IL; however, for operators familiar with JL, handling the IL will come 
naturally.
7.4.2.2  Tips to Increase Backup Force in Ikari L (Power Position)
Occasionally, stronger backup force is necessary for an extremely complex lesion. 
There is an easy manipulation to increase backup force in IL. This technique is as 
easy as pushing the guiding catheter up to the reverse side angle of 90° (black arrow; 
Fig. 7.7). At this point the backup force becomes much more significant because the 
backup force has strong relation with the angle between the guiding catheter and 
reverse side of the aorta. The power position with IL is safe because the distal tip is 










Fig. 7.6 Ikari left has three modifications compared with Judkins left
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between normal position and power position (white arrow; Fig. 7.7). To date, no left 
main dissections with IL have been reported in our database (>1000 cases) and in 
the reports from Youssef et al. (>600 cases) [8] or other studies.
7.4.2.3  Size of Ikari L
The IL 3.5 is a regular size catheter. Most cases can be done successfully with the 
IL 3.5. If the aorta is elongated, IL 4.0 fits this type of aorta. The elongated aorta is 
found in severe atherosclerotic patients such as old hypertensive patients or patients 
with diffuse and complex coronary disease. In the power position, the IL 4.0 will 
offer even more support than the 3.5. However, we suggest IL 3.5 for your first 
experience.
7.4.3  Long-tip Catheters as Voda/EBU/XB Type
Guiding catheters can be divided into active or passive manipulation types. The 
EBU/XB-type guide catheters are passive type, and this may explain why they are 
utilized so extensively, whereas the IL or JL is an active-type catheter.
What is the benefit of the passive guide catheter? It is not necessary to continu-
ally manipulate the guide catheter during the procedure, allowing the operator to 
concentrate on manipulating other devices such as guidewires, balloon catheters, 
etc. What is the disadvantage of the passive-type guiding catheter? Common passive 
guide catheters are the EBU/XB type for the left coronary artery and the Amplatz L 
for the right coronary artery. Note that these catheters are long-tip catheters. 
Engagement of long-tip catheters is more difficult than a short-tip catheter. Deep 
insertion is inevitable with the long-tip catheters, which have higher risk for 
ba
Fig. 7.7 (a) Normal position of Ikari left via right transradial approach. A black arrow shows that 
the angle θ is small. (b) When strong backup force is necessary, push the guiding catheter, and 
make the angle 90° (black arrow). Note that the distal tip of the guiding catheter is not deep since 
the white arrows show the same distance from the vertebrate both in normal and in power 
positions
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coronary dissection. Careful engagement is necessary. However, after safe engage-
ment of the guide catheter, the long-tip catheter can safely advance deeper over the 
guidewire or during balloon catheter removal without any operator manipulation. 
Operators cannot perfectly control advancement of the catheter, especially during 
counteraction of pulling devices out from the coronary artery. That being the case, 
if there is significant plaque at the proximal coronary artery, there is no way to avoid 
coronary dissection except to avoid using long-tip catheters. The choice of catheter 
needs to be carefully balanced with regard to the amount of support required and the 
dangers of potential for pressure damping and dissection.
7.4.4  Right Coronary Artery
The Judkins R (JR) is a standard catheter for the right coronary artery in the trans-
femoral approach. Easy engagement and safety are benefits of JR. However, in TRI, 
the JR behaves differently because of different angles and sometimes difficult 
engagement. This catheter also has weak backup force when used for TRI. Thus, we 
need a catheter like the JR but more suitable for TRI.
7.4.4.1  Ikari L for Right Coronary Artery
The Ikari L (IL) was originally designed for the left coronary artery, but it is also 
good for the right coronary artery [9]. The shape of the catheter looks like the JR if 
a 0.035 inch guidewire is inserted (Fig. 7.8). Thus, catheter manipulation for engage-
ment is similar to the JR. Once the guidewire is removed, the catheter will engage 
the right coronary artery in a very stable position. When strong backup force is 
necessary, you can facilitate a power position using the Ikari L catheter with marked 
deep engagement. Thus, the Ikari L is a strong-type Judkins R for TRI.  In vitro 
experiments showed that the IL in the power position can generate a stronger backup 
force than JR, Amplatz L, and Ikari R (Fig. 7.9).
Note that Ikari L in the right coronary artery may naturally engage deeply in 
the power position. This does not happen in the left coronary artery, but you 
should take care for the right coronary artery. Importantly, you can still control the 
catheter position and engagement depth. This is markedly different from long-tip 
catheters.
7.4.4.2  Amplatz L for Right Coronary Artery
The Amplatz L is a passive-type catheter good for the right coronary artery. It is a 
long-tip catheter and can therefore be inserted deeply into the coronary artery. 
This can mean a higher risk for coronary dissection. The Ikari L has a similar 
shape to the JR (Fig. 7.10). When used in a passive way, engagement manipula-
tion of the Ikari L is like JR, but backup force is stronger. If greater backup force 
is necessary for severe lesions, it is easy to make the power position by pushing 
the catheter along the guidewire. An in vitro study showed that backup force of 
the Ikari L at power position was stronger than any other catheters including 
Amplatz L.
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Judkins R Ikari L
With 035 inch GW
Fig. 7.8 When a 0.035 
inch guidewire is inserted, 
the Ikari L looks like 
Judkins R



























Fig. 7.9 Backup force for the right coronary artery showed Ikari L has the greatest backup force
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7.5  Benefits of Universal Guiding Catheters
Ikari L is a universal catheter both for the left and right coronary arteries. One 
great benefit is lower cost because of using a single catheter in the procedure. 
Secondly, a shorter procedure time in TRI may be especially important in patients 
with ST-segment elevation myocardial infarction. A smart way to reduce door-to-
balloon time is to use Ikari L [10]. Only a single catheter is necessary to perform 
coronary angiography both for the left and right coronary arteries and PCI for the 
culprit lesion which is found in either the right or left coronary artery. Torii et al. 
reported puncture-to- reperfusion time was significantly shorter in Ikari L use 
compared with conventional primary PCI (median 15 min vs. 25 min, p = 0.001) 
[11]. Thus, Ikari L both for the left and right coronary arteries is an ideal catheter 
for STEMI.
7.6  Case Report: Primary PCI Using an Ikari Guide
Fuminobu Yoshimachi and Yuji Ikari
7.6.1  Introduction
Timely reperfusion is the goal in management of ST elevation myocardial infarc-
tion (STEMI). This is best achieved using primary PCI (PPCI) and ideally via a 
radial approach as this has been shown to reduce procedure-related complications. 
The Ikari left (IL) guide catheter is a useful adjunctive tool for PPCI and can pro-
vide substantial guide support in both the left and right coronary artery 
positions.
JR4IL3.5AL1
Shape of Guiding Catheters for RCA
Amplatz L Ikari L Judkins R
cba
Fig. 7.10 Engagement showed Ikari L looks like Judkins R
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7.6.2  Case Report
A 72-year-old male was admitted to a local hospital with chest pain due to an inferior 
ST-segment elevation myocardial infarction. An attempt was made to undertake 
PPCI to the right coronary artery (RCA) in the district hospital from a radial approach. 
The RCA though was a challenging vessel and due to tortuosity needed an Amplatz 
1 guide catheter to gain adequate support. Unfortunately though, the operator was 
able to engage the RCA, the catheter had weak backup force, and although a wire 
would cross, a balloon would not track (Fig. 7.11a). The procedure was abandoned, 





Fig. 7.11 (a) A case with inferior ST elevation myocardial infarction. Coronary angiography 
showed tortuous right coronary artery with total occlusion. An Amplatz left guiding catheter had 
insufficient backup force. A guidewire passed but no balloon passed. (b) A 7Fr guiding catheter 
with anchor balloon technique supported balloon pass. However, a stent could not pass the lesion 
due to insufficient backup force of the guiding catheter. (c) A 6Fr Ikari L 3.5 with power position 
engaged well into right coronary artery. (d) Final angiographic result after delivery of the stent 
which had passed easily due to the high backup force of the power position
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In our center, a young operator tried PPCI using 7Fr Ikari L with an anchor bal-
loon technique (Fig. 7.11b) used to further engage the guide catheter more deeply. 
The balloon passed the lesion, and TIMI3 flow was achieved. The thrombus was 
allowed to dissolve over a few days, and he was brought back for relook angiogra-
phy and stenting. This time the procedure was performed using a 6Fr Ikari L guide. 
In the normal position, it was not possible to pass the lesion with a stent. However, 
in the power position (Fig. 7.11c), a stent easily passed the lesion because of the 
strong backup force with excellent final result (Fig. 7.11d).
7.6.3  Summary
The Ikari left guide is a useful time-saving measure for patients undergoing 
PPCI. Moreover, in expert hands, the power position can offer greater support than 
possible with conventional guides, especially in the RCA.
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8.1  Introduction
Platelet inhibition remains the core pharmacotherapy component in patients under-
going emergency or primary percutaneous coronary interventions (PCI). This can 
be achieved using a number of intravenous and oral preparations. Intravenous (iv) 
antiplatelets include various glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and the 
only available intravenous P2Y12 inhibitor, cangrelor. Available oral agents include 
aspirin and various P2Y12 inhibitors or their analogues. These are usually used in 
combination with the intention to maintain dual antiplatelet therapy (DAPT) for a 
period of time (generally up to 12 months) after the index PCI procedure.
Understanding and appropriate use of antiplatelet agents are vital in optimizing 
clinical outcomes of patients with acute coronary syndromes, particularly in the 
emergency setting where the patient may be naïve to all pharmacological agents. In 
this review, an overview on antiplatelet therapy for patient needing emergency PCI 
is described, including evidence from important clinical trials and suggested anti-
platelet therapy regimens by published clinical practice guidelines.
8.2  Aspirin
Aspirin (acetylsalicylic acid) (≥75  mg daily) permanently inhibits platelet- 
dependent cyclooxygenase 1 (COX-1) enzyme and consequently preventing synthe-
sis of and thromboxane A2 (TXA2), which is a powerful promoter of platelet 
aggregation [1]. At higher doses, aspirin inhibits COX-2 which offers analgesic and 
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antipyretic effects by blocking production of prostaglandin. Aspirin in a broad range 
of patients has been shown to offer clinically important benefits on protection from 
coronary artery disease (CAD). This predominantly appears related to antiplatelet 
effects, although the drug may also play a role in reducing atherosclerosis by block-
ing COX-dependent vasoconstrictors and prevent oxidation of low density lipopro-
tein. Importantly, aspirin has become a central component of the antiplatelet regimen 
both for patients with established CAD and those undergoing PCI procedures.
8.2.1  Evidence of Aspirin in Myocardial Infarction and PCI
Major studies indicating a central role for aspirin in patients with acute MI and 
undergoing emergency revascularization include:
• International Study of Infarct Survival (ISIS-2) [2]
• This study was performed in the thrombolysis era but demonstrated a headline 
23% reduction of mortality rate among patients with MI with a near to 50% 
reduction of nonfatal reinfarction or stroke.
• Meta-analysis of aspirin usage for prevention of stroke, myocardial infarction, 
and death among high-risk patients [3]
• This study from the Antithrombotic Trialists’ Collaboration showed a 53% reduc-
tion of death and vascular events in those underwent coronary angioplasty.
• Aspirin in prevention of restenosis after PCI [4]
This study showed that in addition to protection from stent thrombosis, aspirin 
offered a significant reduction of stent restenosis rate after PCI.
8.2.2  Aspirin Dosing
Consensus with regard to dosing of aspirin before and after PCI (including primary 
PCI) has been established and recommended as follows [5]:
• Loading (prior to PCI)
Tablet 300–325  mg stat dose—if not on chronic aspirin therapy, at least 2  h 
before PCI
Tablet 81–325 mg stat dose—if already on chronic aspirin therapy
• Maintenance therapy (post PCI)
Tablet 75–162 mg OD—to continue indefinitely
8.3  P2Y12 Inhibitors
The P2Y12 receptor plays a key role in the platelet activation process. Adenosine 
diphosphate (ADP) interacts with the platelet P2Y12 receptor stimulating activation 
of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. In turn, activation of the GP2b3a 
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receptor results in enhanced platelet degranulation and thromboxane production, 
driving platelet aggregation [6].
Various P2Y12 inhibitors are available. Clopidogrel and prasugrel are thienopyri-
dine prodrugs that must undergo cytochrome P450-mediated conversion to the 
active metabolite which then covalently bond to the P2Y12 receptor, thus inhibiting 
platelet activation. In contrast, ticagrelor and cangrelor are direct-acting platelet 
inhibitors which do not need activation. These agents are thus more potent and have 
more rapid onset of action.
8.3.1  Evidence for P2Y12 Inhibitor in MI and PCI
• CURE (PCI-CURE) [7]
• This trial showed a significant reduction of cardiovascular death and myocardial 
infarction post PCI using clopidogrel.
• TRITON-TIMI 38 [8]
• This trial showed a significant reduction of cardiovascular death, nonfatal myo-
cardial infarction, and stroke using prasugrel among patients with high-risk ACS 
undergoing PCI. Of note, patients with prior stroke, transient ischemic attack 
(TIA), age > 75, and weight < 60 kg had no net benefit.
• PLATO [9]
• This trial showed a reduction of composite death from vascular causes, MI, and 
stroke with use of ticagrelor. Of note, patients with prior stroke, TIA which led 
to net harm, age > 75, and weight < 60 kg had no net benefit.
8.3.2  P2Y12 Inhibitor Dosing
• Clopidogrel
Loading (prior to PCI)




Loading (prior to PCI)
Tablet 60 mg stat dose
Maintenance therapy
Tablet 10 mg OD
Tablet 5 mg OD (if body weight < 60 kg)
• Ticagrelor
Loading (prior to PCI).
Tablet 180 mg stat dose
Maintenance therapy
Tablet 90 mg BD
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8.4  Glycoprotein IIb/IIIa Inhibitors
GPIIb/IIIa inhibitors directly target the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) 
receptor. This receptor is the most abundant integrin found on the surface of plate-
lets and is composed of two separate subunits, αIIb (GPIIb) and β3 (GPIIIa). GPIIb/
IIIa inhibitors prevent binding of primarily fibrinogen, but various other ligands 
also, hence, inhibit the aggregation of platelets [10]. Various agents are available: 
Abciximab is a monoclonal antibody. Eptifibatide is a synthetic cyclic heptapeptide. 
Tirofiban is a nonpeptidal antagonist to glycoprotein IIb/IIIa receptor.
8.4.1  Evidence for GPIIb/IIIa Inhibitors in MI and PCI
 – Guidance on the Use of Glycoprotein IIb/IIIa Inhibitors in the Treatment of 
Acute Coronary Syndrome [10]
Review of multiple trials showed statistically significant benefit in GPIIb/IIIa 
treatment groups in terms of composite outcome of death, subsequent MI, and 
revascularization.
 – Evaluation of 7e3 for Prevention of Ischemic Complication (EPIC) [11]
Usage of abciximab during coronary angioplasty after presentation with high- 
risk unstable angina showed significant reduction in composite death, nonfatal MI, 
repeat coronary artery bypass grafting (CABG), repeat PCI for recurrent ischemia, 
or requirement for a coronary stent after balloon angioplasty.
 – Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression 
Using Integrilin Therapy (PURSUIT) [12]
Usage of eptifibatide in patient with ST changes and MI (but not persistent ST 
elevation) together with aspirin and intravenous heparin, via infusion for up to 96 h, 
significantly reduces composite of death and nonfatal myocardial infarction within 
30 days from index event.
 – The Platelet Receptor Inhibition in Ischemic Syndrome Management in 
Patients Limited by Unstable Signs and Symptoms (PRISM PLUS) [13]
Usage of tirofiban with heparin infusion in patient with acute myocardial infarc-




Bolus of 0.25 mg/kg intravenous
Infusion at 0.125 μg/kg/min (maximum 10ug/min) for 12 h
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• Eptifibatide
Double bolus of 180 μg/kg intravenous (given at 10-min interval)
Infusion 2.0 μg/kg/min for up to 18 h
• Tirofiban
Bolus of 25 μg/kg over 3 min
Infusion at 0.15 μg/kg/min for up to 18 h
DAPT and glycoprotein IIb/IIIa inhibitor in emergency PCI
8.5  Recommended Treatment Algorithms from Consensus 
Guidelines [14, 15]
 1. A potent, faster onset and superior clinical efficacy P2Y12 inhibitor (prasugrel or 
ticagrelor) is recommended ideally prior to (or at least at the time of) PCI.
 2. Ticagrelor is recommended as P2Y12 inhibitor of choice on top of aspirin in 
patients with ACS.
 3. Ticagrelor should not be used in patient with previous intracranial hemorrhage 
or ongoing bleeds or on oral anticoagulants.
 4. Prasugrel should not be used in patient with previous intracranial hemorrhage, 
previous ischemic stroke or transient ischemic attack, or ongoing bleeds or on 
oral anticoagulants. Prasugrel is generally not recommended in patient 
>75 years old or weighing <60 kg.
 5. In cases prasugrel is used for patient >75 years old or weighing <60 kg, a dose 
of 5 mg OD should be used.
 6. When none of the ticagrelor or prasugrel can be used, clopidogrel can be the 
choice of P2Y12 inhibitor.
 7. Switching from clopidogrel to either ticagrelor or prasugrel in acute setting 
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Fig. 8.1 Switching of P2Y12 inhibitor product in acute setting [13]
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 8. Switching in between ticagrelor and prasugrel or from either one to clopidogrel 
in acute setting requires 24-h lapse since the last dose (Fig. 8.1).
 9. Bleeding risk can be assessed using risk model, e.g., PRECISE-DAPT and 
DAPT score. Bleeding risk decides duration of DAPT (Fig. 8.2).
 10. Suggested duration of DAPT (Fig. 8.3):
 (a) Acute coronary syndrome receiving PCI
• At least 12  months of DAPT (aspirin and a P2Y12 inhibitor) is 
recommended.
• Six months of DAPT should be considered if there is high bleeding risk; 
with emerging data for abbreviated DAPT with certain stents, even ear-
lier cessation may be possible.
• Extension of DAPT >12 months may be considered if no bleeding com-
plication during initial treatment.
Treatment
indication




















































= Aspirin = Clopidogrel = Prasugrel = Ticagrelor
Fig. 8.2 Bleeding risk assessment before deciding duration of dual antiplatelet therapy [14]
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 (b) Benefits and risks of extended DAPT (18–36 months)
• Absolute decrease in risk of instent thrombosis, myocardial infarction, 
and major adverse cardiac events by 1–2%.
• Absolute increase in bleeding complications by 1%.
• More benefits are seen in patient with ACS rather stable IHD.
 11. Types of stent and its duration:
 (a) Shorter duration (3–6 months) may be reasonable in patients treated with 
newer-generation stents as compared to first generation. Emerging data 
may permit even shorter duration; trials are awaited.
 12. DAPT dose in chronic kidney disease:
 (a) Stages 1–3
• EGFR >30 mL/min/1.73 m2
Aspirin: Loading at 150–300  mg orally, followed by maintenance 
75 mg–100 mg/day
Clopidogrel: Loading at 300–600 mg orally, followed by 75 mg/day
Ticagrelor: Loading at 180 mg orally, followed by 90 mg BD/day
Prasugrel: Loading at 60 mg orally, followed by 10 mg/day
 (b) Stage 4
• EGFR 15–30 mL/min/1.73 m2
No dose adjustment
 (c) Stage 5
• EGFR <15 mL/min/1.73 m2
Aspirin: No dose adjustment
Clopidogrel: No information available




























































Prasugrel LD (60 mg)
24h after last Ticagrelor dose
Ticagrelor LD (180 mg)
24h after last Prasugrel dose
Ticagrelor LD (180 m
g)
irrespective of prior Clopidogrel
timing and dosing
Clopidogrel LD (600 m
g)
24h after last Ticagrelor dose
Fig. 8.3 Recommended duration of DAPT in patient undergoing PCI [14]
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 13. Glycoprotein IIb/IIIa inhibitor usage in prehospital or upstream settings has not 
shown extra benefits on efficacy of treatment.
 14. Selective downstream usage of GPIIb/IIIa inhibitors reduces cost of treatment 
and bleeding risk [15].
 15. Usage of glycoprotein IIb/IIIa inhibitor during coronary catheterization as a 
bailout therapy can be considered. This includes large thrombus, slow or no 
reflow, or other findings of thrombotic complications during coronary 
 angiogram [16].
 16. Special patient subgroup.
In patients on oral anticoagulation who present with STEMI and are undergoing 
emergency PCI, these patients should:
 (a) Loading of aspirin and clopidogrel (the P2Y12 inhibitor of choice, 600 mg load-
ing dose) should be done.
 (b) Also receive additional parenteral anticoagulation.
 (c) Chronic oral anticoagulation therapy should not be stopped during 
admission.
 (d) Gastric protection with a proton pump inhibitor is recommended.
 (e) Triple therapy (oral anticoagulation, aspirin, and clopidogrel) should be consid-
ered for 6 months after STEMI.
 (f) Oral anticoagulation plus aspirin or clopidogrel should be considered for an 
additional 6  months; after which, it is then indicated to maintain oral 
anticoagulation.
 (g) For patients with atrial fibrillation as the indication for anticoagulation, rivar-
oxaban in combination with clopidogrel and without aspirin may be a reason-
able choice.
 (h) The use of ticagrelor or prasugrel is not recommended as part of a triple therapy 
regimen with aspirin and oral anticoagulation.
8.6  Summary
• DAPT is an important periprocedural pharmacotherapy in patient receiving 
PCI.
• DAPT, aspirin, and a P2Y12 inhibitor are to be loaded orally as soon as diagnosis 
of ACS was made.
• Choice of P2Y12 inhibitor includes prasugrel, ticagrelor, and clopidogrel.
• Duration of DAPT treatment after emergency PCI depends on bleeding risk 
assessment and types of stents used.
• Extra attention in cases with bioresorbable vascular scaffold, which requires at 
least 12 months of DAPT regardless of bleeding risk.
• Glycoprotein IIb/IIIa inhibitor usage depends on treating physician justification 
as no conclusive evidence of its routine use in emergency PCI.
A. Y. Y. Fong and H. S. Ling
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Percutaneous coronary interventions (PCI) mandate usage of anticoagulants to 
facilitate a successful and safe procedure. This chapter reviews commonly used 
anticoagulant regimens used for PCI with tailored guidance for the acute setting, in 
particular primary PCI for ST-elevation myocardial infarction (STEMI).
9.2  Rationale for the Use of Anticoagulant Therapy
PCI involves a variety of events that cumulatively increase the risk of intra and post 
procedure thrombosis. These include balloon-induced injury and dissection with 
exposure of the subendothelial tissue to blood, activation of platelets and the coagu-
lation cascade and implantation of a potentially thrombogenic foreign body (stent) 
in the coronary circulation. These effects are, of course, more pronounced during 
PCI for acute coronary syndromes (ACS) where the thrombotic milieu is already 
“hot” at the outset. Therefore, anticoagulation with antiplatelet and antithrombotic 
therapy during PCI is considered obligatory. Of note, no placebo-controlled trials of 
antithrombotic therapy in PCI have ever been conducted, nor will there ever be such 
a trial. Indeed, the 2017 European Society of Cardiology (ESC) guidelines [1] give 
anticoagulation (antithrombotic therapy) a class I indication for routine use during 
STEMI PCI.
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9.3  Classes of Anticoagulant
Several classes of anticoagulant regimens are available. Each of these is discussed 
in detail below.
9.3.1  Unfractionated Heparin and STEMI
Unfractionated heparin (UFH) has been available since the 1930s, and there is, 
therefore, an extensive generational physician experience with this drug in a vari-
ety of clinical settings. Derived from porcine intestine, a bag of UFH contains a 
heterogeneous mix of polysaccharides with a wide variety of molecular weights 
(Table 9.1). Only a third of the UFH molecules are biologically active as a result of 
possessing a key pentasaccharide sequence that is able to bind to antithrombin 
(AT) [2]. UFH attaches to AT to form a tertiary complex that binds to and inhibits 
Table 9.1 Comparative chart of characteristics of various anticoagulants used in the primary PCI 
setting
Drug UFH LMWH Fondaparinux Bivalirudin
Molecular 
weight (kDa)
3–30 (mean 15) 2–10 1.7 2.2
Action Binds to AT, inhibits IIa and 
Xa
Binds to AT, 
inhibits Xa








T ½ after dose Variable (dose dependent)a 25 min
PCI dose 70–100 U/kg (no GPI 
planned)
50–70 U/kg IV (GPI 










+++ + − −
HIT 0.5% <0.1% Negligible Negligible
Monitoring ACTb Anti Xa levels
?ACT
Anti Xa levelsc ACTd
Reversal Protamine Protamine 
(partial)
None None
AT antithrombin, ACT activated clotting time, HIT heparin-induced thrombocytopenia
aHalf-life increases with dose
bACT reflects therapeutic effect
cNo point-of-care options
dACT does not reflect therapeutic effect, only reflects delivery of drug
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both factor Xa and as IIa (thrombin), thereby inhibiting production and action of 
thrombin. As UFH inhibits both molecules, its anti Xa:IIa activity ratio is 1:1. In 
contrast, low molecular weight heparins (LMWH) by virtue of their predominantly 
shorter chains are only able to bind to AT and hence have primarily anti-Xa activity 
(Table 9.1).
Some well-known limitations of UFH include its inability to penetrate and bind 
to clot-bound thrombin, extensive binding by plasma proteins which limit bioavail-
ability, an inherent platelet-activating effect of heparin and complex pharmacokinet-
ics which make the anticoagulation response to a given dose somewhat unpredictable 
[2]. Despite these limitations unfractionated heparin remains the most widely used 
antithrombotic agent during PCI, and both the ACCF/AHA [3] and ESC [1] guide-
lines give UFH a class I recommendation in primary PCI.
There are no comparative dosing trials of UFH in primary PCI and dosing rec-
ommendations are somewhat arbitrary. The 2017 ESC guidelines [1] recommend an 
UFH dose of 70–100 IU/kg intravenous bolus when no glycoprotein IIb/IIIa inhibi-
tor is planned and 50–70 IU/kg bolus with planned glycoprotein IIb/IIIa inhibitor 
use. It remains unclear whether STEMI patients, given the ongoing thrombotic 
milieu, should receive the higher end of the dose spectrum of UFH.
9.3.2  Low-molecular Weight Heparins and STEMI
Unlike UFH, LMWH consist of a relatively more homogeneous mix of molecules 
and have better bioavailability and longer half-life. As a result, LMWH have the 
advantage of more predictable and consistent anticoagulation compared to 
UFH. Although extensively studied in the ACS population, there is limited data in 
the context of STEMI. In the randomized ATOLL trial [4], 910 STEMI patients 
were randomized to an intravenous bolus of 0.5 mg/kg enoxaparin or standard dose 
UFH. Although the trial had a strong trend towards benefit favouring enoxaparin 
(17% relative risk reduction; p = 0.068), it failed to meet the primary endpoint. 
Moreover, it should be recognized that this was an open label trial, and while a 
per- protocol analysis that excluded 13% of the study group (for protocol viola-
tions) suggested that enoxaparin was statistically superior to UFH, this can be 
regarded as hypothesis generating at best. Furthermore, > 70% of the study popula-
tion received a glycoprotein IIb/IIIa inhibitor; therefore it is difficult to extrapolate 
the data to patients not receiving additional glycoprotein IIb/IIIa inhibitor therapy. 
Nevertheless, these results do imply that enoxaparin is at least as safe as UFH in 
the primary PCI setting. The ACCF/AHA guidelines make no recommendations on 
enoxaparin, but the 2017 ESC guidelines [1] give it a class IIa recommendation 
(level of evidence A) (Table 9.2). Both the ACCF/AHA [3] and ESC guidelines 
recommend against the use of fondaparinux, a synthetic pentasaccharide LMWH, 
during primary PCI given a higher risk of ischemic events and catheter thrombosis 
in the OASIS-6 trial [5].
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9.3.3  Direct Thrombin Inhibitors and STEMI
The most widely studied and used direct thrombin inhibitor (DTI) is bivalirudin. 
Bivalirudin binds reversibly to the catalytic site of thrombin and acts as a competi-
tive inhibitor. Unlike heparins, bivalirudin can bind to clot-bound thrombin, is not 
bound by plasma proteins and, therefore, has excellent bioavailability. Bivalirudin 
also blocks thrombin-induced platelet aggregation. The dosing schedule of bivaliru-
din for STEMI patients undergoing PCI is outlined in Table 9.1. Despite its numer-
ous theoretical advantages, recent randomized trials have failed consistently to 
demonstrate unequivocal superiority of bivalirudin over unfractionated heparin in 
the STEMI setting (Table 9.3). The studies do suggest a lowered risk of major bleed-
ing, driven at least partially by reduced access site bleeding. Of note, several trials 
suggested an increased risk of early stent thrombosis (possibly ameliorated by pro-
longing the bivalirudin infusion post PCI).
Table 9.2 Summary of major societal guidelines on the use of various antithrombotic agents in 
primary PCI
Drug ACCF/AHA ESC
Rec. LOA: Rec. LOA
UFH I C I C
Enoxaparin No recommendation IIa A
Fondaparinux III B III B




ACCF/AHA American College of Cardiology Foundation/American Heart Association, ESC 
European Society of Cardiology, Rec recommendation, LOA level of evidence
aIn patients with heparin-induced thrombocytopenia
Table 9.3 Summary of randomized trials of bivalirudin vs. heparin in primary PCI







6% ↓ ↓ ↑
EUROMAX[14] 2013 Bivala Heparin ~50% ↓ ↓ ↑
HEAT-PPCI [15] 2014 Bival Heparin 80% ↑ No diff ↑
BRIGHT [16] 2015 Bivala Heparin or 
heparin + 
GPI
78% No diff ↓ No diff
VALIDATE- 
SWEDEHEART[17]
2017 Bivala Heparin 90% No diff No diff No diff
Bival bivalirudin, pGPI provisional GP IIb/IIIa inhibitor, MACE major adverse cardiac events, ST 
stent thrombosis
aBivalirudin infusion continued post PCI
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Given the lack of superiority and significantly higher costs, the role of bivaliru-
din in STEMI remains questionable. This is of particular importance in the current 
era of using more potent P2Y12 inhibitors (e.g. ticagrelor and prasugrel) and tran-
sradial access (which all but eliminates access site bleeding). Society guidelines are 
somewhat discordant, with the ACCF/AHA guidelines [3] awarding bivalirudin a 
class IB recommendation in STEMI, while the more updated 2017 ESC guidelines 
[1] give it a IIa recommendation unless there is a history of heparin-induced throm-
bocytopenia (class Ib).
9.4  Monitoring of Intensity of Anticoagulation 
in the Cardiac Catheterization Laboratory
9.4.1  Unfractionated Heparin
The anticoagulation response of UFH is variable and unreliable. Therefore, moni-
toring the level of anticoagulation using a point-of-care testing device is inherently 
attractive. The most widely used test to measure the anticoagulant effect of high 
doses of heparin (levels at which the aPTT would be “immeasurable”) is the acti-
vated clotting time (ACT) which has a linear dose-response to heparin concentra-
tions in the very high 1–5 U/mL range and is available as a point-of-care assay. That 
said, there is lack of robust data to suggest that ACT testing and monitoring is neces-
sary and beneficial. Several studies have questioned the relationship between ACT 
levels achieved and ischemic complications [6, 7]. Despite its limitations, ACT 
remains widely used in the cardiac catheterization laboratory to gauge the intensity 
of heparinization. Indeed, the ACCF/AHA guidelines [3] give monitoring ACT lev-
els and titrating UFH dosing during primary PCI a class I recommendation, though 
the ESC guidelines are silent on the subject. The ACCF/AHA/SCAI PCI guidelines 
[8] recommend titrating UFH dosing to target ACT levels (Table 9.4) although these 
“targets” are largely based on consensus and experience rather than systematic 
study.
Table 9.4 Effect of various antithrombotic drugs on activated clotting time
Drug Xa:IIa activity Effect on ACT Target ACT (s)
UFH 1:1 Linear ↑ GPI, 300–350 (Hemochron), 250–300 
(HemoTech)
No GPI, 200–250 (any device)
Enoxaparin 4:1 Modest ↑ None defineda
Fondaparinux Pure Xa No effect No recommendation
Bivalirudin Pure IIa Disproportionate ↑ No recommendationb
UFH unfractionated heparin, ACT activated clotting time, GPI glycoprotein IIb/IIIa inhibitor
aSee text for recommendations
bACT levels do not correlate with therapeutic efficacy; only an indicator of drug delivery
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9.4.2  Low Molecular Weight Heparin
Monitoring anticoagulation with enoxaparin is difficult because the ACT does not 
follow a linear dose-response unlike with UFH. The most definitive assay of enoxa-
parin’s anticoagulant effect (measuring anti factor Xa activity) is not a readily avail-
able laboratory or point-of-care assay. Nevertheless, enoxaparin does moderately 
prolong the ACT, and several authors have suggested a role of ACT testing to guide 
enoxaparin therapy in the cardiac catheterization laboratory. One group has pro-
posed a target ACT of 175 s for PCI performed with and 200 s for PCI performed 
without a glycoprotein IIb/IIIa inhibitor [9]. They also propose that every additional 
0.1 mg/kg bolus of intravenous enoxaparin may be expected to increase the ACT by 
10 s [10]. Of note, this has not been systematically studied for outcomes and remains 
a rough guide at most.
9.4.3  Bivalirudin
Bivalirudin raises the ACT usually in the “super therapeutic” range (often >300 s). 
However, studies with bivalirudin have reproducibly demonstrated no relationship 
between ACT levels and either bleeding or ischemic complications, quite in contrast 
to heparin. Thus, it may be reasonable to check an ACT once following the bolus of 
bivalirudin to confirm that the drug was delivered, thereby avoiding inadvertent 
failure of drug administration (e.g. intravenous line occlusion and other errors 
which may easily occur in the emergency setting). However, there is no role of 
sequentially testing ACT for the above-mentioned reasons. It is important to note, 
though, that the pivotal bivalirudin trials gave an additional dose of 0.3 mg/kg bolus 
if the post bolus ACT was <225 s. However, the ACCF/AHA or ESC guidelines do 
not specifically recommend this practice.
9.5  Approach to the Patient Who Has Received 
Anticoagulation Prior to Primary PCI
Although relatively unusual for a patient to receive parental anticoagulation prior to 
arrival to the cardiac catheterization laboratory for primary PCI, historically, some 
emergency room (ER) physicians have routinely administered UFH in the ER to 
STEMI patients. Also, in a “rescue” or “salvage” PCI setting, a patient may have 
received full-dose thrombolytic therapy prior to arriving to the laboratory. 
Furthermore, a situation may arise in which a patient admitted with an acute coro-
nary syndrome “heats up” and progresses to STEMI despite receiving some sort of 
anticoagulation therapy. Table 9.5 shows the therapeutic options for the patient who 
arrives to the cardiac catheterization laboratory with anticoagulant therapy on board. 




As a rule of thumb, if a patient has been on therapy, then a “booster” dose of 
the anticoagulant is recommended. On the other hand, if a patient has received no 
prior therapy, then the full dose of the anticoagulant should be administered. It is 
important to note that “on therapy” for these purposes assumes a steady state of 
the drug. For enoxaparin, which is commonly used in the acute coronary syn-
drome setting, this means at least two doses have been administered. Hence if a 
patient arrives to the cardiac catheterization laboratory after receiving one dose of 
enoxaparin in the ward, it is safer to administer an additional dose of enoxaparin 
(Table 9.6). Note that no good “formula” exists to switch previous therapy with 
UFH to enoxaparin and vice versa when a patient arrives to the cardiac catheter-
ization laboratory.
Table 9.5 Therapeutic options for anticoagulation during primary PCI based on pretreatment 
status








GPI UFH—check ACT and adjust dose (see Table 9.1)
Thrombolyticb UFH—check ACT and adjust dose
UFH unfractionated heparin, GPI glycoprotein IIb/IIIa inhibitors
aNo good “formula” to convert dosing of UFH to enoxaparin and vice versa
bSalvage” PCI setting
Table 9.6 Dosing of anticoagulation therapy in the cardiac catheterization laboratory in patients 
receiving anticoagulation prior to arrival
Drug On treatment Not on treatment
UFH Check ACT on arrival
“Top-up” UFH according to ACT
70–100 U/kg (no GPI planned)
50–70 U/kg IV (GPI planned). Target 
to therapeutic ACT
Enoxaparin Last SC dose <8 h—no additionala
Last SC dose >8 h—additional bolus 
0.3 mg/kg IV bolus
0.5 mg/kg IV bolus
Fondaparinux 70–100 U/kg (no GPI planned)
50–70 U/kg IV (GPI planned)
Target to therapeutic ACT [18]
Bivalirudin 0.5 mg/kg bolus; ↑ drip to 1.75 mg/
kg/h
0.75 mg/kg bolus; 1.75 mg/kg/h drip
ACT activated clotting time, UFH unfractionated heparin, SC subcutaneous, GPI glycoprotein IIb/
IIIa inhibitor
aIf patient received <2 doses, assume no steady state and administer additional bolus
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9.6  Role of Anticoagulation Following Successful PCI
By and large, anticoagulation should be stopped after a successful procedure. Data 
suggests that extending the anticoagulation with post procedure UFH or LMWH 
does not reduce ischemic complications but does increase bleeding risks [11, 12]. 
Therefore barring some compelling indication (very high thrombus burden or left 
ventricular thrombus) UFH or LMWH should not be continued after primary 
PCI. Similarly routine ACT check post procedure likely has little cumulative value 
other than to determine when the access sheath may be removed in the case of femo-
ral access. In the case of bivalirudin, trials have suggested an increased risk of acute 
stent thrombosis following drug cessation at the end of the procedure (Table 9.3). 
This may be related to the very short half-life of the drug with a rapid wash-out. 
Prolonging the infusion may help mitigate that risk, although the data shows mixed 
results.
9.7  Summary
Anticoagulation with an antithrombotic drug is considered mandatory during 
PCI. UFH remains the most widely used antithrombotic agent during primary PCI 
and ideally should be dosed to a target therapeutic ACT. Enoxaparin may be a rea-
sonable alternative in primary PCI, although advantage for this over heparin is 
debatable. Bivalirudin has many theoretical advantages over the heparins; however, 
trials in the primary PCI setting have failed to show superiority of bivalirudin for 
ischemic events, although bleeding events (driven partially by access site bleeding) 
are reduced. Furthermore, acute stent thrombotic events may be increased with 
bivalirudin, and consequently use of this drug is less widespread. Anticoagulation 
dosing in the cardiac catheterization laboratory needs to be tailored according to 
prior therapy and titrated (at least in the case of UFH) either empirically or to a 
therapeutic ACT where monitoring is available.
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10.1  Introduction
Partial or complete occlusion of the infarct-related artery (IRA) with intracoronary 
thrombus (ICT) is the pathognomonic hallmark of patients presenting with 
ST-elevation myocardial infarction (STEMI). Thrombus burden can be highly vari-
able, but its presence is associated with worse outcomes, including lower procedural 
success, increased abrupt vessel closure and an increased frequency of major in- 
hospital complications including death and recurrent myocardial infarction (MI). 
ICT poses a unique series of challenges, but appropriate management is an essential 
prerequisite for successful primary percutaneous coronary intervention (PPCI). 
This can largely be achieved using a combination of pharmacological and mechani-
cal approaches prior to coronary stent insertion.
In this chapter, we discuss the causes, sequelae and treatment of intracoronary 
thrombus specific to patients presenting with STEMI.
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10.2  Pathophysiology of Intracoronary Thrombus Formation
In the majority of cases, the nidus for thrombogenesis is erosion of an underlying 
atherosclerotic plaque and subsequent exposure of thrombogenic subendothelial 
matrix and plaque to circulating platelets [1]. Plaque rupture initiates the coagula-
tion cascade in one of two distinct but ultimately synergistic pathways (Fig. 10.1). 
In the first pathway, platelet glycoprotein VI binds directly with collagen exposed 
by the denuded endothelium. Concurrently platelet glycoprotein Ib-V-IX interacts 
with collagen-bound von Willebrand factor (vWf). This process triggers platelet 
activation, adherence and accumulation to the vessel wall leading to formation of 
‘white’ thrombi. In contrast, the second pathway leads to formation of ‘red’ 
thrombi where tissue factor initiates a proteolytic cascade which leads to genera-
tion of thrombin which in turn converts fibrinogen to fibrin while also triggering 
activation and accumulation of platelets through release of various agonists 
including adenosine, thromboxane A2 and serotonin. These agents activate other 
platelets, thereby amplifying the thrombogenic process. Coronary thrombus con-
sists of platelets, erythrocytes, inflammatory cells and fibrin. The thrombin-gener-
ating process leads to denser, more fibrin-rich thrombus which becomes 











Platelet aggregates+ Fibrin network
Activation of coagulation cascade
Fig. 10.1 Intracoronary effects of coagulation cascade. [Courtesy of Miss Christina YS Wong]
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The more friable the thrombus burden is at the time of PCI, the more susceptible 
it is to mechanical intervention. However, particularly with late presentations, 
thrombus can also be resistant to coronary devices, including balloons and aspira-
tion catheters. Thrombus variability relates to the two types of fibrin fibres that are 
deposited at the time of thrombogenesis, including thin dense fibres (which are 
poorly dissolved by thrombolytic agents and mechanical devices) and thick fibrin 
fibres (which are more susceptible to treatment).
10.2.1  Grading Coronary Thrombus
Grading tools are useful to quantify the thrombus burden in patients presenting with 
STEMI. The TIMI (thrombolysis in myocardial infarction) thrombus grading scale 
(Fig. 10.2) is commonly used and is a simple numerical scale ranging from grade 0 
(no thrombus) to grade 5 (very large thrombus that completely occludes vessel flow) 
[6, 7]. The scale is subject to variability in interpretation and can be simplified to a 
binary system: low-grade thrombus (TIMI 1–3) and high-grade thrombus (TIMI 
4–5) [8]. Visual grading tools also tend to underestimate thrombus size compared to 
other tools such as intracoronary imaging.
TIMI Thrombus Grade
0. No cine-angiographic characteristics of thrombus
    present
1. Possible thrombus present. Angiography shows
    characteristics such as reduced contrast density, 
    haziness, irregular lesion contour, or a smooth
    convex meniscus at the site of total occlusion
    suggestive but not diagnostic of thrombus
2. Thrombus present, small size: definite thrombus
    with greatest dimensions less than or equal to half
    vessel diameter
3. Thrombus present, moderate size: definite
    thrombus but with greatest linear dimension
    greater than half but less than 2 vessel diameters
4. Thrombus present, large size: as in grade 3 but
    with the largest dimension greater than or equal to
    2 vessel diameters
5. Total occlusion
Fig. 10.2 TIMI thrombus 
grade
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10.2.2  Intracoronary Thrombus and Clinical Outcomes
The presence of ICT during acute coronary syndromes often results in suboptimal 
coronary reperfusion and worse clinical outcomes [7, 9, 10]. The effect of thrombus 
on the microvascular circulation can be quantified using degree of ST-segment reso-
lution or the myocardial blush grade [11]. The myocardial blush grade is used as a 
marker of a perfusion in the capillary level at the tissue level. Both the degree of 
ST-segment resolution and myocardial blush grade have been shown to be indepen-
dent markers of mortality [12].
Use of a grading tool allows a consistent method for thrombus assessment and 
correlation to clinical outcomes. Importantly they can also aid in management deci-
sions prior to and during PCI. The presence of ICT and distal embolization to the 
microcirculation can lead to persistent chest pain, electrocardiogram changes and 
distal vessel occlusion. Even if normal epicardial flow is achieved, distal emboliza-
tion and microvascular obstruction are associated with increased infarct size, 
reduced ventricular function and worse survival. Due to the negative clinical conse-
quences of incomplete thrombus resolution, it is essential that interventional cardi-
ologists consider strategies to prevent and treat ICT during STEMI.
10.3  Management
The extent of ICT observed during PPCI correlates strongly with both procedural 
success and clinical outcome. Due to the complex nature of intracoronary thrombo-
genesis, a multi-faceted and systematic approach is required to achieve successful 
thrombus dissolution. This includes arrest of the coagulation cascade (usually 
achieved using pharmacotherapy), flow restoration (usually through mechanical 
techniques) and occasionally with the use of thrombus extraction tools. Thrombus 
extraction may theoretically limit distal embolization of thrombus, thereby prevent-
ing microvascular obstruction and incomplete microvascular reperfusion.
10.3.1  Pharmacological Interventions
Comprehensive review of pharmacological interventions utilized during PPCI is 
available in Chaps. 8 and 9. Due to the self-propagating nature of thrombogenesis, 
early and effective pharmacological interventions to inhibit this process are key. At 
point of initial STEMI diagnosis, patients should receive a loading dose of aspirin 
(e.g. 300  mg or institutional practice) and a P2Y12 antagonist (e.g. clopidogrel 
600 mg, prasugrel 60 mg or ticagrelor 180 mg) [13–15]. In some healthcare sys-
tems, community STEMI diagnosis may occur, and early administration of these 
oral antiplatelet agents may be feasible [16]. More commonly, administration occurs 
in the emergency department; with shorter transfer times to the cardiac catheteriza-
tion laboratory, this could lead to suboptimal platelet inhibition during the PPCI 
procedure [17]. Such considerations are important, particularly for the immediate 
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peri-PCI period in a freshly stented patient who is naïve to antiplatelet therapy and 
in cases where thrombus burden is significant. This has led to development of rapid- 
onset intravenous P2Y12 antagonists (e.g. cangrelor), which may prove useful as a 
bridge until the maximal antiplatelet effect of oral agents is realized [18]. An intra-
venous P2Y12 agent may also be advantageous in STEMI patients that are intubated 
or unable to have oral agents. However, these agents are not broadly available.
Peri-procedural anticoagulation is generally achieved using unfractionated hep-
arin or in some catheter laboratories using low-molecular weight heparin (e.g. 
enoxaparin), factor Xa inhibition (e.g. fondaparinux) or a reversible direct throm-
bin inhibitor (bivalirudin) [19, 20]. Each strategy has individual merit and choice 
is therefore largely determined by operator/unit preference or cost. The progressive 
shift from transfemoral to transradial intervention amongst patients with STEMI 
has vastly reduced vascular access complications such as bleeding and improved 
procedural safety [21, 22]. Consequently, the purported advantage of agents such 
as bivalirudin that reduce bleeding to improve clinical outcomes may be less 
marked [23].
In our opinion, peri-procedural anticoagulation is best achieved in keeping with 
the standard protocol each laboratory uses for PCI in stable patients without need 
for modified protocols. In most instances, this is likely to be adjusted dose heparin 
(70–100 international units/Kg) titrated to maintain an activated coagulation time 
(ACT) of >300 s. There is variability between catheterization laboratories regarding 
routine ACT assessment during PCI. We recommend that in cases with high burden 
of ICT, assessment of ACT may be useful to ensure that patients have had a thera-
peutic response to anticoagulation and may need additional heparin as required. 
Additionally, given the concern regarding efficacy of oral antiplatelet agents in 
pharmacologically naïve patients, a repeat ACT check at intervals and at procedure 
completion (with top-up heparin if required) may be prudent, although this strategy 
has not been proven in published trials to date.
Various ancillary pharmacological therapies have been utilized to treat distal 
embolization as a consequence of intracoronary thrombus formation. These agents 
include calcium channel blockers, adenosine, nicorandil, glycoprotein IIb/IIIa 
inhibitors, vasodilators and nitroprusside. Calcium channel blockers may inhibit 
platelet aggregation and have a direct effect on calcium flux through the sarcolem-
mal membrane that could protect injured myocytes [24, 25]. Adenosine affects 
intracellular calcium and inhibits neutrophil accumulation, superoxide generation 
[26, 27]. Nicorandil, an ATP-dependent potassium channel opener, can prevent 
reperfusion injury and protect cardiac myocytes [28–30]. Glycoprotein IIB/IIIA 
inhibitors have also been used in cases of no reflow and inhibit platelet aggregation 
[31, 32]. Each of these agents has variable success and none has been proven to be 
superior to another. Additionally, whether to administer these agents, pre- or post- 
stent deployment is also undetermined. The clinical benefit of each of these indi-
vidual agents on epicardial flow and myocardial salvage continues to be limited.
Intracoronary thrombolytic prior to aspiration thrombectomy could also be con-
sidered in selective cases. The DISSOLUTION trial compared intracoronary throm-
bolytic delivered via microcatheter and aspiration thrombectomy with aspiration 
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thrombectomy alone. Patients treated with upfront thrombolytic had high rate of 
TIMI 3 flow and higher proportion of patients with myocardial blush grade of 2/3. 
Patients also had greater volume of aspirate compared to aspiration thrombectomy 
alone [33]. Further study is needed with larger clinical trials.
10.4  Thrombectomy
Although PPCI has been established as the dominant reperfusion strategy for the 
treatment of STEMI, the benefit of this approach can sometimes be limited. 
Mechanisms that may explain this limited benefit have included delays in time from 
symptom onset to reperfusion, reperfusion injury following vessel recanalization 
and distal embolization of thrombus. This lead to the development of thrombus 
removal with the concept that prevention of distal embolization might improve out-
comes of primary PCI.
10.4.1  Thrombectomy Systems
Thrombectomy catheters while bulky confer benefits of better thrombus aspiration. 
Various systems exist that have different mechanisms of action which include rheo-
lytic, fragmentation and manual thrombectomy. Rheolytic involves using high- 
velocity jets of saline which creates negative pressure through a Venturi effect. The 
AnjioJet is an example of a rheolytic system [34]. This device has lost its appeal 
after trials demonstrated an increased mortality with no difference in infarct size or 
resolution of ST segments [35, 36]. Manual or ‘aspiration’ thrombectomy has been 
studied in large randomized controlled trials and emerged as the preferred method 
of thrombus removal primary due to its simplicity and ease of use.
Aspiration thrombectomy initially showed promise with benefit seen from 
early smaller randomized trials. These studies demonstrated the feasibility and 
potential benefit of thrombus extraction on indices of myocardial perfusion and 
ST segment resolution at time of PPCI. Infarct size was found to be less in patients 
undergoing thrombectomy before stenting compared with controls undergoing 
stenting without prior thrombectomy [37, 38]. These initial favourable studies 
lead to considerable uptake of routine manual thrombectomy during primary 
PCI. The advantages cited were improved reperfusion with less need for predilata-
tion and arguably improved myocardial blush. Mechanistically, the postulated 
benefits of aspiration thrombectomy were less distal embolization and prevention 
of reperfusion injury. However, the large randomized TOTAL trial did not show 
any benefit for use of routine thrombectomy, and of concern there was a signal for 
harm with increased risk of stroke in the thrombectomy arm of the study [39–41]. 
The mechanism of stroke is likely due to aspiration back of clot and subsequent 
embolization to the brain.
In patient presenting with acute coronary syndrome and preexisting thrombus as 
a consequence of plaque rupture, routine thrombectomy is not recommended. While 
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manual thrombectomy has a theoretical and intuitive basis for incremental value, 
results from pivotal trials and “real-world” registries of manual thrombectomy have 
not consistently demonstrated benefit over standard PCI [42]. Current European 
Society of Cardiology guidelines do not recommend routine use of thrombus aspira-
tion. There may potentially be a benefit of selective thrombectomy. Patients who 
have very large thrombus may benefit, but this has not been robustly proven with 
randomized controlled evidence [43]. A recent meta-analysis of the three random-
ized trials showed a trend towards less cardiovascular death with aspiration throm-
bectomy compared to PCI. Of concern, there was also increased stroke or transient 
ischaemic attack despite a benefit in mortality. The pathophysiology is likely multi-
factorial and more complex, warranting further study. Additionally, thrombectomy 
may be helpful in cases where thrombus develops during PCI and after post-stent 
deployment. Aspiration thrombectomy may aid restoration of flow and help guide 
subsequent PCI.
10.4.2  Suggested Technique for Manual Thrombectomy
While routine aspiration thrombectomy is not advocated, there may be some patients 
that may benefit. In selected cases where a decision is made to proceed with throm-
bectomy, we suggest the following technique using the commonly available aspira-
tion thrombectomy catheter.
 – Ensure the guiding catheter is well engaged at all times.
 – Start aspiration in the guiding catheter and make multiple passes until syringe is 
full.
 – Continue to switch syringes as needed.
 – Ensure a new syringe is placed with full negative pressure at time of removal of 
aspiration catheter. Prior to removal of the aspiration catheter, a small contrast 
test injection is advised to check that the guide is engaged.
 – After removal of the aspiration catheter, we suggest allowing the guide catheter 
to bleed back or to aspirate through the side port of the manifold or autoinjector 
to ensure any clots that remain in the guide catheter are cleared prior to taking 
any further angiographic images.
Fastidious technique may reduce the likelihood of any subsequent stroke 
occurring.
10.5  Other Causes of Intracoronary Thrombus Formation 
in STEMI Patients
It is important to appreciate other causes of ICT that can occur in patients presenting 
with STEMI. While most patients present with ICT due to plaque rupture, patients 
can also present with STEMI and ICT due to embolism, vasospasm, spontaneous 
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coronary artery dissection, coagulation disorders, trauma and endothelial dysfunc-
tion. In some cases, the underlying coronary artery is normal.
In cases where there is suspicion of another cause of STEMI other than plaque 
rupture, intracoronary imaging can be very helpful. In some cases, such as embolism, 
aspiration thrombectomy can aid restoration of vessel flow. Use of intravascular 
imaging with IVUS or OCT is very important to exclude underlying coronary artery 
disease. If the underlying vessel is normal, then stenting may not be required. In 
some causes such as spontaneous coronary artery dissection, diagnostic angiography 
and medical treatment only may be the optimal therapy for most cases. While intra-
coronary imaging can be used in cases of SCAD, routine use is not advocated as 
there is a risk of acute vessel closure with any further manipulation of the vessel.
10.6  Stenting Strategy
Large thrombus burden at time of primary PCI can lead to challenges with stent siz-
ing, stent apposition and final TIMI flow, which can in turn increase the risk of stent 
thrombosis. While not recommended routinely, aspiration thrombectomy can be 
useful in cases of large thrombus burden to allow visualization of the vessel and 
appropriate stent sizing [43]. During PPCI judicious use of nitroglycerin is recom-
mended to limit vasoconstriction which is common during STEMI due to inflamma-
tion and higher circulating catecholamines. Drug-eluting stents are recommended 
for PPCI.  Some novel mesh-covered stents such as the MGuard stent which by 
design aim to prevent thrombus distal embolization have been trialled in small trials 
but have not been proven beneficial for routine use [44, 45].
10.6.1  Deferred Stenting
Primary PCI and stenting is the current recommended treatment for patients pre-
senting with STEMI. This allows restoration of flow in the infarct artery and reduces 
reocclusion and restenosis. Implantation of a stent in a highly thrombotic milieu at 
the time of initial presentation with STEMI can be associated with risk of distal 
embolization and increased peri-procedural events. Furthermore, despite appropri-
ate administration of antiplatelet agents, patients are often taken to the catheteriza-
tion laboratory before these agents have achieved their desired therapeutic effect. 
One strategy to overcome this issue is ‘deferred stenting’, a practice that is not rec-
ommended routinely for all STEMI patients [46]. In selected cases, with high 
thrombus burden that are haemodynamically stable, deferred stenting may offer a 
therapeutic option. All patients should proceed urgently to the catheterization labo-
ratory, and flow may need to be restored with a wire or gentle predilatation with a 
balloon. If high burden of thrombus is seen, deferred stenting with an interim period 
of adjunctive antiplatelet/anti thrombotic therapy may be useful to reduce the 
thrombus load and minimize complications (such as no-reflow) at time of stenting 
[47, 48].
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10.7  Conclusion
Intracoronary thrombus during STEMI is common and can lead to worse clinical 
outcomes. While there is no gold-standard therapy to deal with ICT, there are a 
combination of both pharmacological and mechanical therapies that can be utilized. 
Importantly, aspiration thrombectomy should not be used routinely in STEMI cases 
but may be helpful in selected cases at the discretion of the operator. The manage-
ment of intracoronary thrombus at time of STEMI continues to remain a therapeutic 
challenge, but an awareness and aggressive management of ICT can lead to 
improved outcomes.
10.8  Case Report: Heavy Thrombus Load in Primary PCI
Janarthanan Sathananthan, Dale Murdoch,  and Christopher Overgaard
10.8.1  History
A 42-year-old man with risk factors of type 2 diabetes and hypertension presented 
with a 6-h history of central chest pain and inferior ST segment elevation to a non- 
PCI capable hospital. He was loaded with aspirin 325 mg and ticagrelor 180 mg and 
transferred to a hospital capable of primary PCI.  At time of presentation to the 
catheterization laboratory, he had ongoing chest discomfort and was bradycardic 
but haemodynamically stable.
10.8.2  Management
Arterial access was obtained via the transradial route. Intravenous heparin was 
administered at a dose of 100 IU/kg. Diagnostic coronary angiography showed a 
critical occlusion in the right coronary artery with a significant ICT burden and 
TIMI 1 flow. Using a Judkins right guiding catheter, the right coronary artery was 
wired with a Balance Middle Weight coronary wire. Given the significant burden of 
ICT, a bolus dose and infusion of glycoprotein IIb/IIIa inhibitor were then adminis-
tered. Following this, aspiration thrombectomy was performed to aid in restoration 
of vessel flow to prevent the need for balloon predilatation. Aspiration thrombec-
tomy restored flow in the right coronary artery, but there was distal embolization of 
thrombus to the posterolateral vessel. Further aspiration thrombectomy was per-
formed restoring flow and the culprit lesion was stented with a long drug-eluting 
stent. After stent deployment, there was evidence of no-reflow phenomenon. 
Repeated doses of intracoronary nitroglycerin and adenosine were administered. 
Subsequent angiographic pictures showed restoration of TIMI 3 flow and normal 
myocardial blush grade (Fig. 10.3). A left ventriculogram showed normal left ven-
tricular function.
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10.8.3  Outcome
Following PPCI the patient’s chest pain resolved. He had an uncomplicated recov-
ery on the coronary care unit. Transthoracic echocardiography also showed normal 
left ventricular function. This case highlights that with judicious attention to the 
management of ICT, use of both pharmacological and percutaneous techniques can 
be used to successfully deal with ICT.
10.9  Acute STEMI with Extensive Thrombus:  
An Illustrative Case
Deborah Lee, Deanna Khoo, and Paul JL Ong
10.9.1  Introduction
Intracoronary thrombus poses a considerable challenge during percutaneous coro-
nary intervention (PCI) and is associated with risk of no reflow, less intra-procedural 
success and increased in-hospital complications including myocardial infarction 
(MI) and death [49]. Many of these events are a direct result of distal embolization 
and microvascular obstruction. Consequently, various strategies to reduce thrombus 
burden have been explored. These include pharmacological thrombolysis, covered 
stents and thrombectomy—performed by manual aspiration or mechanical throm-
bus disruption. However, these strategies become a great challenge in the setting of 
large thrombus load. The use of stent retrievers for thrombus removal in acute 
a b c
Fig. 10.3 Case example of intracoronary thrombus management during an inferior STEMI. (a) 
Initial diagnostic angiogram showing critical right coronary lesion with large thrombus (white 
arrow) at lesion. (b) Angiographic picture following aspiration thrombectomy with evidence of 
distal thrombus embolization to the posterolateral branch. (c) Angiographic picture following fur-
ther thrombectomy and dose of glycoprotein IIb/IIIa inhibitor. (d) Final angiographic picture fol-
lowing stent deployment and doses of intracoronary adenosine and nitroglycerin to treat no reflow
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ischaemic stroke has been shown to be safe and effective [39]. We describe the use 
of the Solitaire thrombus retrieval system (Medtronic MN, USA) in a patient with 
MI and heavy thrombus burden which was refractory to treatment by conventional 
means.
10.9.2  Case Report
A 54-year-old male smoker presented to the emergency department with a 2-day 
history of intermittent chest pain and anterior ST depression. He was loaded with 
aspirin 300  mg and ticagrelor 180  mg and referred for emergent cardiac 
catheterization.
Coronary angiography demonstrated the culprit to be an occluded distal left cir-
cumflex (LCx) artery (Fig. 10.4). During the procedure, he received enoxaparin and 
two boluses of intravenous eptifibatide. The occlusion was crossed easily with a 
Sion Blue wire (Asahi Intecc, JP) following which balloon angioplasty was per-
formed with a 1.25 mm and then 2.0 mm compliant balloons inflated to nominal 
pressure. Although flow improved, a large intracoronary thrombus was now evident. 
Manual aspiration thrombectomy was performed with multiple runs of a 6F 
Eliminate catheter (Terumo, JP) which only managed to retrieve small fragments of 
thrombus. As flow in the LCx had been restored, we opted for a strategy of deferred 
stenting 48 h later after completion of an eptifibatide infusion and ongoing thera-
peutic enoxaparin.
At repeat angiography, the thrombus burden was largely unchanged (Fig. 10.5). 
Having failed both aspiration thrombectomy and pharmacological thrombolysis, 
thrombectomy was attempted with a 2–4 mm × 20 mm Solitaire thrombus retrieval 
Fig. 10.4 Coronary 
angiogram of left coronary 
system. Note occlusion of 
the left circumflex artery
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device. The left main was engaged with a 6F BL 3.5 guide catheter (Terumo), and a 
Sion Blue wire was advanced into the distal LCx, across the thrombus. A microcath-
eter was advanced through the wire and positioned distal to the thrombus. The self- 
expanding Solitaire was then loaded inside the microcatheter and deployed across 
the thrombus (Fig. 10.6). The device was left expanded for 5 min, following which 
it was carefully retrieved together with the microcatheter under continuous 
Fig. 10.5 Coronary 
angiogram after 
eptifibatide infusion. Note 
presence of large organized 
thrombus (arrow)
Fig. 10.6 Deployment of 
Solitaire device. Note the 
three dots visible at distal 
tip of Solitaire device. The 
microcatheter is still 
visible and will be used to 
partially collapse the 
proximal OD of the 
Solitaire and permit safe 
withdrawal
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aspiration through the guide catheter. Device inspection showed successful retrieval 
of a large thrombus (Fig.  10.7). A TIMI three distal flow was accomplished 
(Fig.  10.8). The procedure was completed with a BioMatrix 3.5  ×  33  mm stent 
(Biosensor) being deployed across the culprit lesion. The patient was discharged 
stable 2 days later and has remained symptom-free ever since.
10.9.3  Discussion
Aspiration thrombectomy for ST-elevation MI is no longer considered routine due 
to no effect on clinical outcomes and association with stroke [39], thus in favour of 
a balloon strategy to restore coronary flow. However, in cases of persistent coronary 
Fig. 10.7 Removal of 
Solitaire device. Note large 
thrombus entrapped within 
the struts of the device
Fig. 10.8 Coronary 
angiogram post thrombus 
retrieval. Note that the 
thrombus has largely been 
retrieved and the entirety 
of the circumflex artery is 
now widely patent
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thrombus—particularly when organized often leads to adverse sequelae and requires 
a tailored management approach.
In contrast to STEMI, manual thrombectomy in acute ischaemic stroke has been 
shown to be safe and is associated with improved recanalization rates and better 
functional outcomes [50]. Thrombus retrieval systems such as the Solitaire appear 
to be effective and are now class I guideline recommendation [51]. This device is 
easy to deliver even through tortuous cerebral vasculature; nonetheless reported 
complications include vessel dissection and thrombus embolization [52]. This case 
illustrates the potential use of this device to successfully retrieve the thrombus from 
the coronary circulation and further exploration of this strategy is warranted in a 
clinical trial.
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Early attempts at percutaneous coronary intervention (PCI) using balloon angio-
plasty were largely hampered by technical limitations. Although balloon angio-
plasty was moderately successful at relieving an obstruction, the procedure 
frequently resulted in dissections which, if uncontrolled, often led to abrupt vessel 
closure. Furthermore, while acute luminal gain could be impressive, a combination 
of elastic recoil and smooth muscle hyper-proliferation often negated the benefits of 
an acceptable immediate angiographic result. Elastic recoil could occur minutes to 
hours post-procedure resulting in acute myocardial infarction (AMI) and need for 
emergent coronary artery bypass grafting (CABG). This led to a pivotal develop-
ment in the history of PCI with introduction of the metallic stent, which drove rapid 
improvements in short- and long-term procedural safety and efficacy. Stent design 
has been a remarkable area of technological advances with pivotal milestones 
including evolution of metallic architecture and introduction of the drug-eluting 
stent (DES). Although DES is now considered the default option for most PCI, bare- 
metal stents (BMS) still represent a sizeable proportion of stent procedures in some 
countries and in some settings may have arguable advantage. In this chapter we aim 
to review contemporary evidence for the use of BMS in modern interventional 
practice.
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11.2  Bare-Metal Stents
The introduction of BMS in the mid-1980s allowed PCI procedures to rapidly enter 
mainstream clinical practice. Early BMS were crude, being largely constructed of 
relatively thick 316 L stainless steel and needed to be cut to length, and then crimped 
onto the delivery balloon catheter. However, once successfully in situ, these devices 
were able to effectively maintain vessel patency and thereby largely prevent the 
abrupt vessel closure and elastic recoil which had hampered balloon only proce-
dures. Consequently, PCI was to become safer and more efficacious. As technology 
improved further, particularly with pre-cut and pre-crimped stents delivered using a 
monorail system, PCI was to rapidly evolve into the preferred mode of revascular-
ization for selected patients due to the minimal invasive nature of the procedure 
coupled with rapid recovery.
Early BMS had important limitations, related to both device design and to bio-
compatibility. This led to the emergence of neo-intimal hyperplasia and neo- 
atherosclerosis as factors which could preclude optimal long-term outcomes and 
result in in-stent restenosis (ISR). With time, it was learned that reduced strut thick-
ness lessened the localized inflammatory responses that may both hinder endotheli-
alization and drive ISR. This led to improved stent architecture and a shift from 
316 L stainless steel to cobalt chromium, thereby permitting a marked reduction in 
strut thickness without loss of radial strength, while also facilitating improved deliv-
ery and conformability. Clinical studies demonstrated that the reduction in stent 
strut thickness resulted in improved delivery, conformability and reduced incidence 
of ISR.
11.3  Drug-Eluting Stents
One the most important milestones in interventional cardiology in recent decades 
was development of the DES. Initially these were developed by coating standard 
BMS with an anti-proliferative agent (e.g. sirolimus) which was bonded to the stent 
using a polymer which also served to regulate drug release. The anti-proliferative 
agent effectively led to localized arrest of the smooth muscle cell proliferation cycle 
around the implanted device and thereby limited propensity to ISR. With cardiolo-
gists eager to avoid ISR, DES technology rapidly entered mainstream practice and 
quickly became the default stent choice, with device implants both on and off label.
However an important downside to first-generation DES rapidly emerged related 
to delayed and incomplete neo-endothelialization around the stent struts. In early- 
generation DES, this led to observations of increased rates of stent thrombosis as 
compared to BMS. This resulted in the Food and Drug Administration (FDA) issu-
ing an advisory warning regarding the risk of late stent thrombosis after 
DES. Consequently, this led to an immediate decline in DES usage. Progress to 
tackle these deficiencies was rapidly developed. Pharmacologically, more potent 
antiplatelet agents were brought to market with increased duration of dual antiplate-
let therapy (DAPT). Meanwhile stent technological advances included thinner 
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struts, improvements in anti-proliferative drugs, use of new polymers with increased 
biocompatibility or biodegradability and more recently polymer-free stents and the 
concept of a bioresorbable vascular scaffold (BVS) which over time is completely 
reabsorbed. Although in theory BVS offer advantage over both BMS and DES due 
to lack of permanent metallic structure, initial results have not met expectations 
with higher stent thrombosis and target-vessel MI rates resulting in some early plat-
forms being withdrawn from clinical use. Research and development is ongoing, 
but currently BVS cannot be recommended for use during primary PCI and will not 
be discussed further in this chapter.
11.3.1  Anti-proliferative Drugs
Once the issues of ISR and stent thrombosis associated with use of stents were iden-
tified, several agents including gold, carbon and heparin were coated onto stents to 
try and improve biocompatibility, reduce inflammation and prevent thrombosis. 
None of these agents were shown to have any significant beneficial effects, and thus 
other solutions were clearly required.
The use of the anti-proliferative agents sirolimus and paclitaxel showed signifi-
cant reductions in ISR compared to BMS and was utilized in first-generation 
DES. Sirolimus is an immunosuppressive compound that acts by receptor inhibition 
of the mammalian target of rapamycin (mTOR) resulting in the cell-cycle progres-
sion and consequently inhibits cell proliferation. Paclitaxel is an oncological agent 
that inhibits cell proliferation by disturbing cellular microtubule organization. The 
use of the ‘limus’ drugs has been shown to be superior to other anti-proliferative 
agents, and newer agents such as zotarolimus, everolimus and the more lipophilic 
biolimus are used in most current-generation DES with similar efficacy.
11.3.2  Polymers
Initial DES technology required the incorporation of anti-proliferative drugs into 
permanent synthetic polymers. These polymers however increase local inflamma-
tory response and reduced endothelialization and were thought to be a key flaw in 
early designs driving propensity to stent thrombosis and mandating longer duration 
of DAPT. More biocompatible and even biodegradable polymers have now been 
developed. These cause less inflammation and hence permit more rapid and com-
plete endothelial coverage. More recently, polymer-free DES have also been devel-
oped. These use the concept of drug storage ‘wells’ or surface etching to load the 
drug but allow rapid dissolution of the anti-proliferative agent without use of a poly-
mer giving the benefits of the pharmacology with the early endothelialization 
offered by BMS.
Current-generation DES have reduced ISR rates to incredibly low levels while 
improving the safety profile of the devices and thus have become the ‘gold standard’ 
for definitive PCI in the majority of patients. This is supported by numerous 
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randomized controlled trials, meta-analyses and real-world data showing improved 
safety and efficacy with new-generation DES. Nonetheless, some still argue that 
there remains a role for BMS in contemporary clinical practice. A number of impor-
tant issues remain and in the context of primary PCI for STEMI.
11.4  DES vs. BMS for Primary PCI
Primary PCI is established as the optimal treatment strategy for STEMI patients 
with the use of coronary stenting achieving far superior reperfusion at lower risk 
compared to fibrinolysis. The use of BMS has been shown to be superior to balloon 
angioplasty alone, and several studies have subsequently shown advantage of DES 
over BMS. However, the supposed advantage of DES is predominantly driven by 
reduced need for long-term revascularization rather than immediate post-infarct 
survival. Newer-generation DES have largely been shown to be superior to first- 
generation stents for a broad range of indications with similar outcomes between 
most contemporary devices.
The EXAMINATION (everolimus-eluting stents versus bare-metal stents in 
ST-segment elevation myocardial infarction) trial investigated the use of everolimus- 
eluting stents (Xience V, Abbott Vascular) versus BMS (Multi-Link Vision, Abbott 
Vascular) in an all-comer STEMI population. 1498 patients were randomized in a 
1:1 fashion, and 2-year analysis found that EES had a trend towards a reduction in 
the primary endpoint, namely, the combined endpoint of all-cause death, recurrent 
MI and any revascularization from 17.3% in BMS to 14.4% (p = 0.11). Rate of 
target lesion revascularization (TLR) was significantly lower in the EES group at 
2.9% vs. 5.6% (p = 0.009) as was definite or probable stent thrombosis (0.8% vs. 
2.1%; p = 0.03 and 1.35 vs. 2.8%; p = 0.04, respectively). Recently published 5-year 
follow-up results showed a significant reduction in the primary endpoint (21% vs. 
26%; p = 0.033) with use of EES, mainly driven by the reduction of all-cause mor-
tality by EES as compared to BMS (9% vs. 12%; p = 0.047). TLR was also signifi-
cantly reduced although there was no difference in rates of stent thrombosis at 
5 years.
COMFORTABLE AMI (the effect of biolimus-eluting stents with biodegradable 
polymer vs. bare-metal stents on cardiovascular events among patients with AMI) 
compared a biolimus DES (BioMatrix, Biosensors) with a biodegradable polymer 
Potential Advantages of BMS
• More rapid endothelialization allowing abbreviated DAPT
 – Safety in high bleeding risk patients
 – Safety in elderly patients
 – Safe with concomitant need for anticoagulation (e.g. atrial fibrillation)
• Reduced cost
 – Price sensitive healthcare models
M. Hensey et al.
141
(BES) with BMS in 1161 patients presenting with STEMI. Major adverse cardiac 
events (MACE) were reduced in BES (4.3%) vs. BMS (8.7%) at 1 year (p = 0.004). 
This reduction was driven by a reduction in target-vessel-related re-infarction (0.5% 
vs. 2.7%, p = 0.01) and ischaemia-driven TLR (1.6% vs. 5.7%, p < 0.001) in BES 
as compared to BMS. At 2-year follow-up, TLR continued to be reduced in the BES 
group (3.1% vs. 8.2%; p < 0.001) and cardiac death or target-vessel MI was also 
reduced (4.2% vs. 7.2%, p = 0.036). A combined analysis of EXAMINATION and 
COMFORTABLE AMI demonstrated a reduction in both stent thrombosis and 
target- vessel MI with the use of DES over BMS.
The Norwegian coronary stent trial (NORSTENT) examined the use of DES 
versus BMS in 9013 patients undergoing PCI (26.3% with STEMI) over a 3-year 
period. Patients were randomized in a 1:1 fashion to BMS or DES (82.9% 
everolimus- eluting stents and 13.1% zotarolimus-eluting stents). The primary out-
come was a composite of death from any cause and nonfatal MI. After 6 years of 
follow-up, there was no difference found in the primary outcome between the 
groups (16.6% in the DES group vs. 17.1% in the BMS group; p = 0.66), which is 
reassuring given the ongoing use of BMS. There was however, in line with previous 
studies, a reduction in repeat revascularization (16.5% in DES vs. 19.8% in BMS; 
p < 0.001). There was also a reduction in the rate of definite stent thrombosis with 
DES (0.8% vs. 1.2%; p = 0.0498).
In light of these and other studies, it can be said that in the general STEMI popu-
lation, the use of current-generation DES is preferable to BMS. This is driven by the 
reduction in target-vessel revascularization and myocardial infarction. There are 
some special specific issues however, which require review.
11.4.1  Stent Thrombosis
Although an infrequent occurrence, stent thrombosis (ST) is the most feared com-
plication of stent implantation. ST can present immediately after stent implant or 
sometimes even many years later. Mode of presentation is highly variable but can 
include sudden (cardiac) death and STEMI. Worryingly ST has an extremely high 
mortality rate of up to 50% in some series—far in excess of that seen with STEMI 
due to de novo lesions. The explanation for the disparate mortality rate remains 
unclear. Nonetheless, avoidance of ST is of paramount importance, and the inter-
ventional cardiologist must always be mindful of the various factors that may pre-
dispose to this malignant process during any PCI procedure.
Purported mechanisms for ST are predominantly considered either mechanical, 
related to platelet activity, or a combination of both. The former includes stent mal- 
apposition, stent under-expansion, stent edge dissection, longer stent length and 
small stent calibre. In contrast, factors related to platelet function are represented by 
failure to adequately inhibit platelet adhesion/aggregation. This may include aspirin 
or thienopyridine ‘non-responders’ and, when these drugs have been erroneously 
omitted or withheld due to prescribing error, poor compliance, bleeding complica-
tions or need for emergent surgical interventions. Acute coronary syndrome (ACS) 
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as a clinical entity at the time of the index procedure is also frequently cited as an 
independent predictor of stent thrombosis.
The timing of stent thrombosis differs between the types of stents. During the 
first months, it may occur after both BMS and DES implantation. However, beyond 
1 year, it is more frequently observed after first-generation DES implantation. It was 
long assumed that this related to suboptimal endothelialization due to presence of 
the antimitotic agent or localized inflammation from ongoing presence of non- 
biocompatible polymers. Although autopsy and experimental studies have shown 
delayed healing to be more common with DES, new-generation DES have consis-
tently shown a reduction in ST as compared to BMS, both short and long term. 
Therefore the risk of stent thrombosis is no longer a reason to advocate the use of 
BMS over DES.
11.4.2  DAPT Duration
The most common convincing reason for the use of BMS is to allow shorter dura-
tions of DAPT. This may be because of concerns of a high bleeding risk, poor com-
pliance or the need for urgent/semi-urgent surgery. In a recent survey looking at the 
reasons for the decision to use BMS over DES at 31 European centres, concerns 
with patient DAPT compliance were the main reason for using BMS (39%). 
Concerns regarding compliance should be dealt with in a multidisciplinary fashion 
with assessment of a patient’s psychosocial status and patient education being of 
utmost importance. In high-risk anatomy, despite likely technical success of PCI, 
plain balloon angioplasty as a temporary reperfusion measure followed by coronary 
artery bypass may need to be considered.
The addition of more potent antiplatelet agents (e.g. prasugrel, ticagrelor) and 
studies demonstrating cardiovascular benefits of longer DAPT duration have 
resulted in the need for individualized DAPT decision-making with bleeding risk 
having to be balanced against the risk of further cardiovascular events. Tools such 
as the DAPT and PRECISE-DAPT scores can be used to guide the decision-making 
process. One study has shown safety of a <15  days of DAPT post PCI with 
BMS. However, in general, a minimum of 1-month DAPT is advised post BMS and 
6 months post DES (for elective PCI).
Current guidelines advise the use of DAPT for 12 months post PCI for acute 
coronary syndromes, independent of the type of stent used. These guidelines how-
ever are largely based on the results of old studies with use of first-generation stents, 
and a number of recent studies have challenged these guidelines. The recent DAPT- 
STEMI trial assessed the efficacy of 6 vs. 12 months of DAPT in STEMI with the 
use of a zotarolimus-eluting stent in 1496 patients with the 6-month strategy reach-
ing non-inferiority. Shorter DAPT regimes have also been investigated with several 
trials demonstrating safety of DES use with a 3-month DAPT regimen. Two studies 
have specifically examined very short DAPT strategies.
The ZEUS trial investigated the use of a zotarolimus-eluting stent (Endeavor, 
Medtronic) versus BMS with a short DAPT duration strategy in 1606 patients who 
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were deemed uncertain for DES use on the basis of bleeding, thrombotic or reste-
nosis risk criteria. 19% of the patients in the study were treated for STEMI and the 
median DAPT duration was 32 days. There was a reduction in the primary end-
point of MACE in the ZES group (17.5% vs. 22.1%; HR 0.76; 95% CI 0.61–0.95; 
p = 0.011) with lower MI (2.9% vs. 8.1% p < 0.001) and target-vessel revascular-
ization (TVR) rates (5.9% vs. 10.7%; p = 0.001). Definite or probable stent throm-
bosis was also significantly reduced (2.0% vs. 4.1%; p = 0.019). The Endeavor 
stent has now been replaced by the newer-generation Resolute stent which has 
thinner struts and a more biocompatible polymer which theoretically should offer 
additional protection, although this has not been demonstrated in a randomized 
controlled trial.
A polymer-free and carrier-free drug-coated stent (DCS) that transfers umiro-
limus (biolimus A9) (BioFreedom, Biosensors) was compared to BMS (Gazelle, 
Biosensors) with a 1-month DAPT strategy in the LEADERS-FREE trial in 2466 
high bleeding risk patients. 22.8% of the study population was treated for STEMI. 
2-year follow-up demonstrated superiority of DCS over BMS with a reduction of 
a combined endpoint of cardiac death, MI or stent thrombosis (12.6% vs. 15.3%; 
HR 0.80; CI 0.64–0.99; p = 0.039). Clinically driven TLR was also significantly 
lower in the DCS (5.6% vs. 10.3%; p < 0.001). Recently published 2-year out-
comes showed sustained benefits of DCS vs. BMS with a lower rates of the pri-
mary endpoint (13% vs. 21.5%, HR 0.57; 95% CI 0.39–0.85; p = 0.005) and TLR 
(7.4% vs. 10.4%; HR 0.45; 95% CI 0.24–0.83; p = 0.009). Stent thrombosis rates 
also tended to be lower with DCS (1.2% vs. 3.2%, HR 0.39; 95% CI 0.12–1.25; 
p = 0.1).
In summary, the requirement for a shortened duration of DAPT is no longer a 
robust reason to justify the use of BMS over DES with growing evidence that the 
use of DES is in fact superior (Fig. 11.1). Future trials are likely to add to the current 
evidence base.
11.4.3  Atrial Fibrillation
Atrial fibrillation (AF) is a common comorbidity in the setting of STEMI, estimated 
to occur in up to 20% of patients, and it is associated with a significant increase in 
mortality. The most important management issue in AF is the prevention of embolic 
events with anticoagulation. Traditionally this was achieved by the use of warfarin; 
however, the use of non-vitamin K antagonist oral anticoagulants (NOACs) is now 
recommended as first-line treatment for anticoagulation for AF.  The addition of 
antiplatelet agents for the treatment of STEMI in patients with AF, or conversely the 
addition of anticoagulation for the treatment of AF in patients post-STEMI, signifi-
cantly increases the risk of major bleeding. As part of a strategy to reduce duration 
of triple therapy with DAPT and an anticoagulant, the use of BMS for PCI in the 
setting of AF has been advocated; however this is no longer the accepted strategy 
due to evidence of the safety of shorter or indeed absence of the so-called triple 
therapy.
11 Is There a Role for Bare-Metal Stents in Current STEMI Care?
144
The WOEST (what is the optimal antiplatelet and anticoagulant therapy in 
patients with oral anticoagulation and coronary stenting) trial investigated the use of 
triple therapy (aspirin, clopidogrel and warfarin) versus double therapy (plavix and 
warfarin) in 573 patients undergoing PCI. Among the patient population, 28% had 
PCI for ACS and 31% of patients received BMS. The rate of bleeding episodes was 
significantly reduced in patients who received double therapy without any increase 
in thrombotic or cerebrovascular complications. In fact a composite endpoint of 
death, MI, stroke, TVR and stent thrombosis was lower in the double-therapy group 
(11.1% vs. 17.6%; HR 0.6; 95% CI 0.38–0.94; p = 0.025).
The use of NOACs in post-PCI regimens was examined in depth in the 
PIONEER-AF trial. Patients undergoing PCI with AF (either BMS or DES) were 
randomized to one of three pharmacological strategies; rivaroxaban 15  mg o.d. 
plus single P2Y12 inhibitor, low-dose rivaroxaban (2.5  mg b.d.) plus DAPT or 
warfarin and DAPT. 12% of the population included presented with STEMI and 
31.8% received BMS.  Both of the rivaroxaban regimens were associated with 
lower risk of clinically significant bleeding than the warfarin arm with no increase 
in cardiovascular or thromboembolic events. The use of other NOACs with similar 
shortened or less aggressive regimens is currently under investigation with results 
expected soon.
The evidence supporting the safety of shortened, or absence of, triple therapy in 




















Fig. 11.1 Simplified flow 
chart for choice of stent 
with shortened DAPT
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patients with AF and with broader indications for anticoagulation (paired with 
development of safer agents), combination of NOAC with a P2Y12 inhibitor is 
likely to be the favoured strategy.
11.4.4  Elderly Patients
For many of the reasons previously outlined (high bleeding risk, concerns regarding 
compliance, AF and other comorbidities), elderly patients have been traditionally 
seen as a population more suited to BMS use. In addition, they are often excluded 
from clinical trials. Elderly patients were not excluded in EXAMINATION or 
COMFORTABLE AMI, but the average age in both studies was approximately 
60 years old.
The XIMA (Xience or vision stents for the management of angina in the elderly) 
trial compared the use of EES and BMS in 800 patients ≥80 years of age undergo-
ing PCI for angina or ACS, and patients with STEMI were excluded. Results dem-
onstrated that for the primary composite endpoint of death, MI, stroke, TVR or 
major haemorrhage, DES was non-inferior to BMS. Rates of haemorrhage were not 
increased in the DES group despite the longer use of DAPT (94% on DAPT at 
1 year in DES group vs. 32.2% in BMS group). MI (8.7% vs. 4.3%; p = 0.01) and 
TVR (7.0% vs. 2.0%; p = 0.001) occurred more often in the BMS group. Although 
a STEMI population was not included, the data is reassuring in regard to similar 
advantages gained by the use of DES in elderly patients as seen in trials with a 
younger cohort.
The SENIOR (drug-eluting stents in elderly patients with coronary artery dis-
ease) trial investigated the use of DES vs. BMS in 1200 patients over the age of 75 
undergoing PCI; 10.6% were treated for STEMI and DAPT duration was short-
ened—1 month in stable patients and 6 months in those presenting with ACS. The 
use of a bioabsorbable polymer DES (Synergy, Boston Scientific) was associated 
with a 29% reduction in the composite primary endpoint of all-cause mortality, MI 
stroke and revascularization at 1 year. Consistent with other studies, the benefit was 
driven by a 71% reduction in ischaemia-driven TLR. Bleeding and stent thrombosis 
rates in both groups were low.
As demonstrated there is growing evidence that the use of BMS in elderly 
patients, including in the setting of STEMI, is no longer a recommended strategy.
11.4.5  Cost
Reduced cost is a common reason cited for the use of BMS over DES in 
PCI. Although upfront costs may be reduced, the increase in use of DES has reduced 
this gap. A number of studies on the cost-effectiveness of using DES as opposed to 
BMS have shown that although periprocedural costs are higher, long-term cost- 
effectiveness is achieved due to the lower rates of future cardiovascular events with 
the use of new-generation DES. However cost-benefit analyses are not universally 
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applicable to every healthcare environment, but we believe that in general stent cost 
cannot be used to justify use of BMS in STEMI.
11.5  Summary and Recommendations
In the present era, given generally excellent clinical outcomes, it is widely accepted 
that current-generation DES should be the default consideration for all patients 
undergoing PCI including primary PCI. Although theoretical advantages of BMS 
are often cited, current-generation DES not only appear to be more efficacious but 
also safer than BMS in a broad range of patients and clinical presentations. This 
likely now includes patients at high bleeding risk or where DAPT may need to be 
prematurely discontinued. However BMS use is likely to be continued in certain 
healthcare systems predominantly due to cost analyses. Recent data has shown that 
modern BMS have good long-term outcomes in regard to mortality and nonfatal MI 
but at the expense of increased revascularization.




A 66-year-old male came to the hospital with continuing central chest pain of 3-h 
duration, accompanied by diaphoresis and dyspnoea. His risk factors were hyper-
tension and dyslipidaemia. The ECG showed an inferior ST-elevation myocardial 
infarction (STEMI) with complete heart block (Fig. 11.2). His blood pressure was 
Recommendations
• New-generation DES should be the stent of choice for PCI including in 
STEMI presentations.
• If a shortened DAPT regime is required, the use of DES is still preferable 
with safety of a 3-month strategy established.
• If very short DAPT duration is required (1  month), then the use of a 
polymer- free biolimus A9-coated stent, if available, is preferable to BMS, 
although other contemporary platforms are currently under investigation in 
this setting.
• BMS should not be used for complex anatomical subsets with higher rates 
of ISR.
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80/60 mmHg. He was loaded with Aspirin 300 mg and clopidogrel 300 mg, given 
fluid boluses to support his BP and brought to the catheter laboratory for primary 
PCI (PPCI).
A temporary pacemaker wire was delivered to the right ventricle through the 
right femoral vein. Primary PCI was performed through right radial approach. A 
diagnostic TIG catheter was engaged to left coronary artery, and images were taken 
demonstrating that this was unobstructed (Fig. 11.3).
A JR 3.5 guide catheter was then delivered to right coronary artery but failed 
to engage adequately. The patient had VF requiring defibrillation two times at 
200 joules with successful restoration of circulation. The guide was switched to 
an AL 0.75 which engaged well. Angiography revealed a 99% stenosis in the 
mid-right coronary artery (RCA), which was somewhat ectatic (Fig.  11.4). A 
Sion Blue was used to cross the lesion. Direct stenting was then done with a 
Promus Element Plus 3.5 × 20 mm, inflated at 14 ATM for 13 s (Fig. 11.5). Post 
dilatation was performed with a non-compliant 4 mm balloon up to 16 ATM. The 
final angiogram showed no dissection, TIMI flow III, residual stenosis 0% 
(Fig. 11.6).
Our patient was transferred to the coronary care unit for observation and dis-
charged after 4 days. He remains well at subsequent outpatient review.
Fig. 11.2 12-lead ECG. Note complete heart block and inferior ST elevation
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This case illustrates the utility of contemporary DES platforms. Coronary artery 
calibre can easily be misjudged, particularly in primary PCI; however many con-
temporary platforms allow for significant oversizing without disruption of stent 
architecture, polymer or drug release kinetics. Moreover, even in a large-calibre 
vessel, the benefit of a DES in terms of reduction of ISR and improving long-term 
outcomes particularly among diabetic patients cannot be disregarded.
Fig. 11.4 AL 0.75 
engaged to RCA. Coronary 
angiogram of right 
coronary artery. Note 99% 
lesion in mid RCA
Fig. 11.3 Coronary 
angiogram of left coronary 
artery which was 
unobstructed. Note 
temporary pacing wire in 
situ
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12Drug-Coated Balloons in STEMI
Upul Wickramarachchi, Hee Hwa Ho, and Simon Eccleshall
12.1  Introduction
The management of ST-elevation myocardial infarction (STEMI) has evolved sig-
nificantly with the introduction of new pharmacological therapies as well as inter-
ventional procedures and devices. The GISSI and ISIS-2 studies showed a mortality 
benefit of streptokinase over standard therapy (heparin ± oral anticoagulation)/pla-
cebo which lead to the widespread use of streptokinase in the late 1980s [1, 2]. The 
use of recombinant tissue plasminogen activator (rt-PA) was shown to be more ben-
eficial than streptokinase in the TIMI and GUSTO trials [3, 4]. Results of other 
studies such as CLARITY and COMMIT paved the way for addition of clopidogrel 
to the drug regime which further reduced mortality [5, 6].
Primary percutaneous coronary intervention (PPCI) became the preferred choice 
of treatment for acute STEMI, with balloon angioplasty (BA) showing an improve-
ment in mortality (or the combined endpoint of mortality and MI) over thrombolysis 
in a number of studies [7, 8]. Subsequently, bare-metal stent (BMS) implantation in 
STEMI showed a reduction in target vessel revascularizations (TVR) in comparison 
with BA but without a reduction in death or MI in the Stent PAMI and CADILLAC 
trials [9, 10]. The percentage of vessels with TIMI III flow was numerically higher 
in the BA group as compared to the BMS group, while mortality and MI rates were 
numerically but not statistically lower [9]. When stenting (BMS) was compared 
with thrombolysis as in the STAT study, the results were similar with stenting show-
ing a reduction in TVR but no reduction in death or MI [11]. When both first- and 
second-generation drug-eluting stents (DES) were compared to BMS in the setting 
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of an acute STEMI, target vessel/lesion revascularization rates were shown to be 
lower with DES, but yet again no reduction in death or MI was shown [12–15]. 
Brodie et al. in a single-center study of 2195 patients over a follow-up period of 
16 years showed long-term target vessel MI, and stent or lesion thrombosis was 
significantly higher with both BMS and DES as compared to BA (after landmark 
analysis at 1 year) [16]. Thus, although stent implant is often considered as defini-
tive treatment for PPCI by securing the vessel lumen, this may not always provide 
optimal longer-term outcomes.
12.2  Drug-coated Balloons
There has been great interest recently in the concept of angioplasty with minimal or 
no permanent implant, by way of using either absorbable polymer DES or scaffolds. 
Drug-coated balloon-only (DCB-only) PCI has emerged as an alternative therapeutic 
option to treat coronary artery disease (CAD) and has the additional benefit of implant-
ing no material with the exception of the necessary anti-restenotic drug. DCBs are 
semi-compliant balloons with a chemotherapeutic drug (commonly paclitaxel) incor-
porated with an excipient to facilitate the drug transfer upon inflation of the balloon. 
Paclitaxel is the drug of choice in most commonly available DCBs because of its 
highly lipophilic properties allowing rapid delivery into the vessel wall and sustained 
antiproliferative effect despite its short contact time with the vessel wall [17].
The SeQuent Please (B Braun, Melsungen AG, Germany), Pantera Lux (Biotronik, 
Berlin, Germany), and In.Pact Falcon (Medtronic, CA, USA) have the most published 
data supporting their efficacy and safety. The best long-term results of DCB are 
achieved with a DCB-only approach as compared to DCB plus BMS. DCB-only PCI 
is associated with a lower late lumen loss and lower target vessel revascularization.
12.3  Evidence for DCB Angioplasty in PPCI
Several studies have reported their experience of using DCB without stenting in the 
PPCI setting. Vos et al. carried out a pilot study involving 100 patients presenting 
with acute STEMI using the paclitaxel-coated Pantera Lux™. Cardiogenic shock 
and intubated out of hospital arrests were excluded. 59% had DCB-only PCI, with 
the rest requiring BMS implantation due to dissections of type C or greater (National 
Heart, Lung, and Blood Institute (NHLBI) classification). A 12-month follow-up 
revealed cardiac death in 2%, MI 0%, and target lesion revascularization rate of 3% 
in this selected group. TIMI III flow was achieved in 96% of patients [18].
Ho et  al. reported their preliminary experience with paclitaxel-coated balloon 
(SeQuent Please) in the PPCI setting for 89 patients. 70% had TIMI 0 flow pre- 
procedure, and TIMI III flow was achieved in 98% patients. Glycoprotein IIb/IIIa 
inhibitors were used in 80%, and thrombus aspiration was carried out in 56%. DCB- 
only PCI was carried out in 96%, while the other 4% had bail out stenting for sig-
nificant acute recoil or dissections. They reported a death rate of 4.5%, MI 0%, and 
TLR/TVR of 0% at 30 days [19].
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Nijhoff et al. in a subgroup analysis from the DEBAMI trial showed that there 
was no difference in major adverse cardiac events in 40 patients treated with DCB- 
only PPCI in comparison with BMS only, BMS + DCB, and paclitaxel-eluting stent 
implantation at 6 months follow-up [20].
Wickramarachchi et  al. in an abstract published at EuroPCR, 2017  in Paris, 
reported their experience in the use of DCB-only PPCI in an all-comer cohort of 
253 patients. 4% of patients were in cardiogenic shock, and 6.7% were out of hos-
pital cardiac arrests. 91% had DCB-only PCI. A 30-day mortality was only 2.4% 
and mortality for 379 days was 6.3%. For a mean follow-up period of 261 days, MI 
and TLR rates were 2.6% and 3.3%, respectively [21].
These publications suggest that DCB-only PPCI is a safe alternative to standard 
stent implantation in this high-risk group. We advocate this approach for several 
compelling reasons:
12.3.1  No Mortality Benefit with Stents
The use of BA in PPCI has been superseded by routine stenting in the contemporary 
era due to the reduction of TVR as mentioned before. However, DCB therapy 
addresses the issue of restenosis with its drug delivery reducing neointimal hyper-
plasia. An improvement of the quality in angiography and the use of potent anti-
platelet therapy have reduced acute vessel closure rates. Currently, there are no 
studies showing a mortality benefit of stent implantation over balloon-only angio-
plasty or, in a majority of studies, a reduction of recurrent MI in this setting.
12.3.2  Risk of Stent Thrombosis
Studies have shown that the cumulative frequency of stent thrombosis (ST) follow-
ing stenting with both BMS and DES for STEMI continues to increase beyond 
1 year and that the frequency of very late ST may be higher with early-generation 
DES [16]. Moreover, the rate of stent thrombosis in patients undergoing PPCI can 
be high (ranging from 1 to 3% in contemporary trials). Patients with AMI have 
higher rates of stent-specific adverse events when compared to those with stable 
CAD. This could be related to coronary vasoconstriction and the presence of throm-
bus at culprit lesion site leading to suboptimal stent sizing and subsequent stent 
mal-apposition.
12.3.3  Inadequate Time to Know Patient’s History
Time pressure to open the occluded artery promptly in PPCI (shorter door-to- 
balloon times) may result in inadequate time to know patient’s full medical history. 
Routine stenting as per guidelines may therefore not be appropriate in some patients.
It remains a challenge to decide whether the patient is a candidate for a pro-
longed course of DAPT at the time of the PPCI.  DES should be avoided in the 
12 Drug-Coated Balloons in STEMI
154
presence of elevated bleeding risk, need for invasive or surgical procedures in the 
near future, and financial/social barriers that may limit patient compliance.
12.3.4  Avoidance of Long Stents in PPCI
DCB maybe a good alternative to treat diffuse lesions in PPCI as outcomes remain 
relatively unfavorable for stent-based coronary intervention especially those with de 
novo long CAD. Even in the DES era, studies have shown that the TLR rates can 
range from 6 to 28% for such lesion subsets with higher rates of instent restenosis 
for paclitaxel DES. Longer stent length is also recognized as predisposing factor for 
ST.
12.4  Technical Tips and Tricks with DCB-Only Angioplasty 
in Primary PCI
We recommend following the German consensus guidelines but with additional 
steps when successfully performing DCB-only PPCI [22].
12.4.1  Lesion Preparation
We recommend aspiration thrombectomy when faced with a high thrombus burden, 
i.e., TIMI thrombus grade 3 or more, aiming to reduce the thrombus burden to TIMI 
thrombus grade of 2 or less. A thrombus-laden lesion is more likely to hamper effec-
tive drug delivery to the vessel wall.
This should be followed by mandatory pre-dilatation of the lesion using semi- or 
non-compliant balloons with a balloon to vessel ratio of 0.8 to 1.0. This should be 
done carefully and slowly with enough pressure only to fully inflate the balloon 
(usually 6–8  atm). Liberal use of intracoronary nitrates is recommended as this 
helps accurate vessel sizing. We have a low threshold for the use of glycoprotein IIb/
IIIa inhibitors in treating lesions with high thrombus burden. Also, acquisition runs 
after pre-dilatation should be of a slightly longer duration to carefully look for evi-
dence of vessel-threatening dissections, in particular any contrast hang-up or accu-
mulation within a dissection plane indicating a NHLBI type C dissection and 
possible early vessel closure due to intramural hematoma formation.
Coronary dissections are an inevitable result of BA, but most are microdissec-
tions that cannot be seen on angiography and are of no clinical significance. 
However, abrupt vessel closure remains one of the most fearful complications of BA 
usually associated with NHLBI dissection grades of type C and above. With a good 
knowledge of the different NHLBI grades of coronary dissection, careful selection 
of those patients suitable for DCB-only angioplasty is possible [23]. Ho et al. in 
their study reported no abrupt closure of the culprit artery. Only 4% of patients 
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required bailout stenting for significant recoil/dissections of type C and above. 
Wickramarachchi U et  al. reported acute vessel closure rate of 0.75% requiring 
bailout stenting and an overall bailout stenting rate of only 9%. The incidence of 
abrupt closure is also significantly reduced in the current era of more potent anti-
platelet use.
12.4.2  Drug Delivery
If there are no dissections of more than NHLBI type C, TIMI III flow, and not more 
than 30% residual stenosis, drug delivery should be considered with the deployment 
of the DCB. DCB diameter should be the diameter of the largest balloon used to 
pre-dilate the lesion. The DCB should be used only for drug delivery and not for 
further angioplasty. It is good practice to check the guide catheter and wire position 
and ensure the O-ring is fully open before start delivering the DCB. Care should be 
taken not to touch the DCB prior to introduction. We recommend following manu-
facturer’s instructions for use to ensure adequate drug delivery. This will include 
maximum transit time to the lesion and balloon inflation times. In the case of a coro-
nary dissection of type C or above after DCB use, we recommend bailout stenting 
with a second-generation DES rather than a BMS [24]. Figure 12.1 summarizes the 
key steps.
Dissection Type A-B TIMI-3 flow Residual stenosis
≤ 30% TIMI thrombus grade 1-2
DCB
Aspirate + Predilate
Fig. 12.1 Proposed protocol for optimal use of DCB
The lesion should be aspirated if there is presence of intracoronary thrombus. The lesion should 
then be carefully pre-dilated. After check angiography, where there is TIMI-3 flow, dissection of 
grades A to B, residual stenosis of less than 30%, and TIMI thrombus grade no worse than grade 
1–2, it is reasonable to proceed with DCB therapy. Alternatively, insertion of an intracoronary stent 
is likely to be required
12 Drug-Coated Balloons in STEMI
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12.5  Conclusion
In conclusion, the use of DCB as primary therapy in primary PCI represents a novel 
approach in treating STEMI patients. This approach is possible with appropriate 
patient selection and by performing two key preconditioning steps, namely, aspira-
tion thrombectomy for lesions with high thrombus burden and careful lesion prepa-
ration. A randomized controlled trial (REVELATION) is underway to assess the 
safety and efficacy of a DCB-only strategy versus DES in primary PCI [25]. 
However, we would recommend performing DCB-only angioplasty in stable 
patients first, preferably with proctoring before treating such high-risk patient 
groups.
12.6  Primary PCI of RCA with Drug-Coated Balloon 
Angioplasty
Upul Wickramarachchi, Hee Hwa Ho, and Simon Eccleshall
12.6.1  History
A 47-year-old male smoker presented with inferior ST-elevation myocardial infarc-
tion (STEMI).
12.6.2  Baseline Coronary Angiography
The right coronary artery (RCA) showed 95% stenosis in mid-segment (culprit 
lesion site) and 70% diffuse stenosis in distal segment (Fig. 12.2).
12.6.3  Procedure
A 6 Fr sheath was inserted into the right radial artery, and the RCA was engaged 
with a 6 Fr Ikari left 3.5 guiding catheter.
A Runthrough NS guidewire was advanced into the right posterior descending 
artery. As there was minimal thrombus, aspiration thrombectomy was not performed. 
The mid- and distal RCA lesions were pre-dilated with a 2.5 × 15 mm balloon.
As POBA results were satisfactory (Fig. 12.3) and RCA lesions were diffuse in 
nature, we decided to treat these segments with drug-coated balloon (DCB).
Distal RCA was treated with a SeQuent Please Neo DCB 2.5 × 30 mm (inflated 
at 12 atm for 50 s) (Fig. 12.4).
Mid-RCA was treated with a SeQuent Please Neo DCB 2.75 × 30 mm (inflated 
at 12 atm for 45 s) (Fig. 12.5).
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Final angiographic results were satisfactory (Fig. 12.6) with TIMI 3 flow restored 
at the end of the procedure. There was residual stenosis of 30% with no obvious 
dissection.
12.6.4  Restudy Angiogram
Restudy angiogram (Fig.  12.7) 9  months later showed widely patent RCA with 
positive remodeling observed in mid-RCA.
Fig. 12.2 Baseline RCA 
angiography
Fig. 12.3 RCA after 
balloon angioplasty
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Fig. 12.4 Distal RCA 
treated with a DCB 2.5 × 
30 mm
Fig. 12.5 Mid-RCA 
treated with a DCB 2.75 × 
30 mm
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Fig. 12.6 Final RCA 
angiography after DCB 
angioplasty
Fig. 12.7 Restudy RCA 
angiography
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Optical coherence tomographic (OCT) imaging study (Fig.  12.8) showed a 
nicely healed plaque at mid-RCA (culprit lesion site).
Case illustration 2: Pre-, immediate-, and post-DCB-only PCI and follow-up 
angiography at 22 months of a 60-year-old male presenting with an anterior STEMI
 
Fig. 12.8 OCT image of 
mid RCA
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Case illustration 3: A 53-year-old female presenting with a lateral STEMI. Pre-, 
immediate-, post-DCB-only PCI (showing a type b dissection) and follow-up 
images at 17 months showing a nicely healed dissection and an excellent result
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13Culprit-Only Artery Versus Multivessel Disease
Valeria Paradies and Pieter C. Smits
13.1  Introduction
Primary percutaneous coronary intervention (pPCI) is the treatment of choice in 
patients presenting with ST-segment elevation myocardial infarction (STEMI). In 
contemporary practice, among patients who present to the hospital with STEMI, 
between 40 and 65% have concurrent multi-vessel (MV) coronary artery disease 
(CAD), a combination of a thrombotic culprit lesion and one or more significant 
(50% or more diameter stenosis) non-culprit lesions in other coronary artery territo-
ries on coronary angiography. Optimal management of these non-culprit lesions in 
this setting is still a matter of debate. STEMI patients with MV CAD are at higher 
risk of recurrent cardiovascular events. However, PCI of bystander lesions during 
pPCI can bring potential complications. The presence of MV CAD in STEMI 
patients often poses therapeutic dilemma for interventional cardiologists as there 
are multiple possible strategies and controversial data. Besides clinical relevance, as 
the burden of cardiovascular disease affects hospital systems around the world, 
there is growing interest to examine and improve the various treatment strategies 
involved in the management of STEMI with MV CAD.
13.1.1  Revascularization Strategies for STEMI Patients 
with MV CAD
Revascularization strategies for non-culprit lesions in haemodynamically stable 
patients after pPCI currently vary from an aggressive approach with the PCI of all 
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significant non-culprit lesions during the index intervention to a very conservative 
approach with culprit lesion-only treatment and only symptom-driven or ischaemia- 
driven non-culprit PCI during index hospitalization or after discharge (Table 13.1).
In general three PCI strategies can be identified:
 1. Culprit vessel-only pPCI with optimal medical therapy for bystander lesions and 
PCI of the non-culprit arteries only for spontaneous angina or myocardial isch-
aemia on stress testing
 2. MV PCI at the time of pPCI, guided by angiography or FFR
 3. Culprit vessel-only pPCI, followed by angiography or FFR-driven staged PCI of 
non-culprit arteries during the index hospitalization or after hospital discharge
Incomplete revascularization of STEMI patients presenting with MV CAD has 
been associated with worse early and late prognosis. The culprit vessel-only PCI 
strategy may reduce the contrast volume and risk of PCI complications but has been 
associated with increased risk of repeat revascularization and potential reduction in 
left ventricle ejection fraction (LVEF) recovery. There are several potential advan-
tages of performing single-stage MV PCI. Firstly, the complete restoration of myo-
cardial blood supply in the acute phase may increase myocardial salvage in 
hibernating myocardium, therefore improving LVEF.  Secondly, this strategy 
decreases the risk of access site vascular complications associated with repeat vas-
cular punctures. Thirdly, single-stage MV PCI reduces hospitalization with a rele-
vant impact on the healthcare costs. Finally, complete revascularization has been 
associated with an improved prognosis after PCI: achieving complete revasculariza-
tion decreases the risk of a future acute coronary syndrome (ACS) or revasculariza-
tion procedures and improves prognosis. Naturally, there are safety concerns 
associated with this strategy including prolongation of the interventional procedure, 
contrast overload and increased radiation exposure. Moreover, the occurrence of 
procedural complications during non-culprit lesion PCI may further depress LV 
function which is already compromised from the initial STEMI event. Furthermore, 
the risk of abrupt vessel closure and stent thrombosis may be increased in this set-
ting due to pro-thrombotic and pro-inflammatory state, while the risk of jeopardiz-
ing remote viable myocardium (distal embolization, no reflow, side branch 
occlusion, loss of collateral circulation) may result in haemodynamic instability.
Despite the additional risks related to PCI access site and additional costs, the 
staged PCI strategy allows more time to appropriately investigate and weigh on the 
risks and benefits of non-culprit lesion intervention.
Table 13.1 Factors influencing management of STEMI patients with MV CAD undergoing pPCI











Number of vessel disease
LM involvement
CTO calcifications
V. Paradies and P. C. Smits
169
13.1.2  Randomized Trials
There are a number of key clinical trials which provide the wealth of guidance with 
regard to timing of non-culprit lesion intervention in the setting of STEMI.
13.1.2.1  PRAMI
In the Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial, a total 
of 465 patients were randomly assigned to culprit-only revascularization (n = 231) 
and complete revascularization during the index procedure (n = 234). The study 
defined the presence of MV CAD as a non-infarcted-related artery lesion of ≥50% 
by angiography. Staged revascularization in the asymptomatic patients was discour-
aged. Patients in cardiogenic shock, unable to provide consent, with previous CABG 
or non-infarct stenosis of ≥50% in the left main or the ostia of both the left anterior 
descending and circumflex arteries, or if the only non-culprit stenosis was a chronic 
total occlusion (CTO), were excluded. After a mean follow-up of 23 months, this 
study reported a 65% reduction in the primary endpoint (cardiovascular death, new 
myocardial infarction (MI) and refractory angina defined as angina despite medical 
therapy supported by evidence of objective ischaemia) in complete revasculariza-
tion group compared to the culprit-only revascularization group. The study was dis-
continued early by the data safety monitoring board, due to a significant difference 
in primary endpoint in favour of complete revascularization which was mainly 
driven a significant reduction in refractory angina and non-fatal MI; however, no 
significant reduction in mortality was shown.
Although the study reported convincingly positive study results in favour of 
single- stage MV PCI, the study had little impact on clinical practice. Several con-
cerns have been raised: the randomization process was not stratified for timing of 
intervention in relation to symptom onset, nor for site of infarction; the study 
enrolment included less than 50% of screened patients with possible selection 
bias; no more information were provided on the non-culprit lesions (i.e. QCA, 
TIMI flow or lesion characteristics). Moreover, the infarct-related artery (IRA) 
only revascularization group in this study demonstrated a higher proportion of 
diabetic patients and anterior MI, which might have influenced the worse progno-
sis in this group. Finally, this study compared only the most aggressive to the most 
conservative strategy.
13.1.2.2  CvLPRIT
The Complete versus Lesion-only Primary PCI (CvLPRIT) trial randomized 296 
STEMI patients presenting with MV CAD to culprit-only strategy (n  =  146) or 
complete revascularization (n  =  150). Patients were excluded in case of 
age < 18 years, clear contraindication to MV pPCI according to operator judgement, 
prior MI or CABG, cardiogenic shock, ventricular septal rupture or  moderate/severe 
mitral regurgitation, chronic kidney disease, thrombosis of a previously stented 
artery and chronic total occlusion of the only non-culprit.
This study reported a 55% reduction of the primary composite endpoint of all- 
cause mortality, recurrent MI, heart failure and ischaemia-driven revascularization 
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by PCI or CABG within 12 months in the complete revascularization group as com-
pared to the culprit-only group. The investigators found also lower incidence of 
individual components of the primary endpoint in the complete revascularization 
group, though not statistically significant. Complete revascularization was per-
formed either at the time of index procedure (64%) or before hospital discharge 
(36%). The former group showed a trend of greater benefit in terms of MACE inci-
dence as compared to the latter. There was no increase in stroke, major bleeding or 
contrast-induced nephropathy with complete versus culprit-only revascularization. 
A pooled analysis of PRAMI and CULPRIT showed a significant reduction in indi-
vidual endpoints of CV death, recurrent MI and repeat revascularization associated 
with complete revascularization approach.
13.1.2.3  DANAMI-3 PRIMULTI
In The Third Danish Study of Optimal Acute Treatment of Patients with STEMI: 
Primary PCI in Multivessel Disease (DANAMI-3 PRIMULTI), 627 patients were 
randomized to receive culprit lesion-only treatment (n = 314) versus fractional flow 
reserved (FFR)-guided complete revascularization (n = 312). Patients with an angi-
ographic diameter stenosis >50% in one or more non-IRA were enrolled and ran-
domized after successful PCI of the culprit lesion. Patients intolerant to contrast 
media, relevant anticoagulant or antithrombotic drugs, in cardiogenic shock, with 
stent thrombosis, increased bleeding risk or indication for CABG were excluded 
from the trial. The FFR-guided staged revascularization was performed 2 days after 
the index procedure and during the index hospitalization.
One-third of patients within the complete revascularization group had FFR val-
ues >0.80 and did not receive PCI. The investigators demonstrated a significant 44% 
reduction in the composite primary endpoint of death, MI or ischaemia-driven 
revascularization within 12 months in the FFR-guided complete revascularization 
group, which was largely driven by a 69% reduction of ischaemia-driven revascu-
larization of the non-IRAs. There were no significant differences in the all-cause 
mortality or non-fatal MI rates between the two groups. This trial was not powered 
to evaluate an impact on hard outcomes (such as death and MI).
13.1.2.4  COMPARE-ACUTE Trial
The Comparison Between FFR-Guided Revascularization Versus Conventional 
Strategy in Acute STEMI Patients with MVD ̂ ^(COMPARE-ACUTE) trial enrolled 
885 STEMI patients with MV CAD. After successful revascularization of the cul-
prit artery, patients were randomly assigned in a ratio of 1:2 to FFR-guided com-
plete revascularization (n = 295) and culprit-only revascularization (n = 590). The 
most important exclusion criteria were left main CAD, chronic total occlusion, 
severe stenosis with a Thrombolysis in Myocardial Infarction (TIMI) flow grade of 
2 or less in the non-IRA, a suboptimal result or complication after treatment of IRA, 
severe valve dysfunction and Killip class III or IV. Complete revascularization was 
performed in lesions with FFR ≤0.80, preferably during the index procedure, but 
could be delayed within 72 h (complete PCI was performed during index procedure 
in 83.4% patients). Primary endpoint of the study was the composite of all-cause 
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mortality, non-fatal MI, any revascularization and cerebrovascular events (MACCE) 
at 12 months. FFR-guided revascularization treatment was associated with lower 
rate of MACCE compared to culprit-only revascularization, which seems to be 
driven mainly by the need for repeat revascularization. Similar to previous studies, 
COMPARE-ACUTE trial was not powered to detect differences in low-frequency 
events, such as death, re-infarction and stroke. However, in contrast with DANAMI- 
3PRIMULTI, this study investigated the role of FFR-guided revascularizations dur-
ing the index procedure, supporting this strategy as safe and cost-saving, from both 
a patient and economic perspective.
One main criticism of the trial was potential operator bias concerning the deci-
sion process about staging the revascularization of non-IRAs beyond the 45 days. In 
the IRA-only group, urgent revascularizations performed within this time window 
but after the index procedure or further revascularizations performed thereafter 
were indeed counted as events. Moreover, in the same treatment group, the indica-
tion to treat the non-culprit lesions was heterogeneous and based on detection of 
ischaemia, symptoms or clinical judgement. However, the rate of MACCE at 1 year 
remained significantly lower with the complete revascularization strategy even 
extending the treatment window from 45 to 60 or 90 days and excluding nonurgent 
revascularizations.
13.1.3  Safety of Complete Revascularization
The recommendation against PCI of non-culprit lesions was largely driven by 
results of non-randomized observational studies with conflicting results. These rec-
ommendations arose from historical safety concerns that included an increased 
potential risk for procedural complications. However, more complete acute revascu-
larization in patients with STEMI may be safer in the current era due to advances in 
stent technology and antiplatelet therapy. Recent evidences suggest that potential 
longer procedural time or increased use of contrast in complete revascularization 
does not translate into an increased risk of adverse events. A pooled analysis of 
PRAMI, CULPRIT and the trial by Politi et al. found no increase in cerebrovascular 
(CVA) events, bleeding or contrast-induced nephropathy associated with PCI of 
non-culprit lesions performed at the time of index procedure. DANAMI3- 
PRIMULTI study demonstrated similar rates of peri-procedural MI, stroke, contrast- 
induced nephropathy or bleeding between IRA-only and complete revascularization 
treatment. In a similar way, the recent COMPARE-ACUTE found no differences in 
terms of peri-procedural MI and bleeding between the two strategies.
13.1.4  Timing of Revascularization
The optimal timing for revascularization of the non-culprit lesions remains 
extremely debated. Potential options include performing complete revascularization 
during index procedure or as planned elective procedure during index 
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hospitalization or after discharge. To date there are no RCTs investigating both 
staged and immediate complete revascularization and analysing them separately. 
PRAMI specifically compared single-stage MV PCI to culprit-only strategy, while 
DANAMI3- PRIMULTI analysed only staged versus culprit-only revascularization. 
The two RCTs CvLPRIT and COMPARE-ACUTE were designed to perform com-
plete revascularization in the acute phase, but allowed staged revascularization, 
which happened in a minority of the cases. Although all RCT trials show an advan-
tage of immediate or early staged complete revascularization guided by angiogra-
phy or FFR in comparison to culprit-only treatment, still uncertainties exist about 
when the complete revascularization should be performed. Looking at the time to 
event curves in all the above-mentioned trials, we can observe that the event curves 
start to diverge from the outset, presumably indicating that an immediate or very 
early revascularization strategy is likely to be beneficial. This assumption is com-
plemented by a meta- analysis by Wang et al. comparing complete revascularization 
during the index procedure with staged revascularization that found a significantly 
lower incidence of MACE, all-cause death and/or MI, non-fatal MI and repeat 
revascularization associated with the former strategy.
Interestingly, the benefit of the immediate complete revascularization strategy 
has not been confirmed in other meta-analyses and in the various published obser-
vational studies. In the post hoc analysis of HORIZONS-AMI trial, MV PCI during 
index procedure was associated with an increased all-cause and cardiovascular mor-
tality compared to the staged MV PCI in a total of 668 STEMI patients. Similarly, 
a recent meta-analysis by Tarantini et al. demonstrated that a staged MV revascular-
ization strategy may improve both early and late survival. Moreover, a propensity- 
matched analysis of 3984 patients presenting with STEMI and MV disease suggested 
an improved survival and improved MACE with culprit-only PCI during the index 
procedure. The confusion is compounded by a paired and network meta-analysis of 
14 studies including 40,280 patients and compared three timing strategies in STEMI 
patients with MV disease: staged PCI (defined as separate procedure during index 
admission or within 1 month of the primary PCI), immediate complete revascular-
ization during index pPCI procedure and culprit-only PCI. This analysis found low-
est short- and long-term mortality rates in patients undergoing staged complete 
revascularization.
Overall, the above studies suggest staged revascularization as the best option. 
Nevertheless, these data are from prior observational studies and meta-analyses of 
revascularization strategies derived from an extremely heterogeneous set of inclu-
sion criteria, study protocols, PCI techniques, timing of MV PCI and comparator 
groups. Also with divergent analytical methods and variable endpoints, definite con-
clusions are difficult to draw.
13.1.5  Trials on the Horizon
The large ongoing randomized, Complete versus Culprit-only Revascularization to 
Treat Multivessel Disease After Primary PCI for STEMI (COMPLETE) trial will 
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enrol a total of 3900 STEMI patients with MV disease and is estimated to be com-
pleted in December 2018. Patients are randomized to receive either staged revascu-
larization or culprit-only revascularization, on top of optimal medical therapy 
(including low-dose aspirin and ticagrelor in both arms and FFR guidance in inter-
mediate lesions (50–70% diameter stenosis)) in the complete revascularization arm. 
The FULL REVASC trial from Sweden is another large-scale trial randomizing 
4052 MV-STEMI or high-risk MV-NSTEMI patients between FFR-guided com-
plete revascularization in the acute or staged phase and angiography-guided. The 
primary endpoint of both trials are the combination of recurrent myocardial infarc-
tion and all death (FULL REVASC) or cardiovascular death (COMPLETE) and will 
provide final answers with hard endpoints as to whether staged revascularization is 
better than culprit-only revascularization or FFR guidance is better compared to 
angiography in acute MI patients with MV disease.
13.2  State of the Art: Current Recommendations
Both the 2014 European Society of Cardiology guidelines and 2013 American College 
of Cardiology/American Heart Association guidelines did not recommend revascular-
ization of non-culprit lesions in the setting of STEMI unless complicated by cardio-
genic shock. These recommendations were influenced strongly by safety concerns 
based on observational studies. The publication of larger scale RCTs has prompted 
ACC/AHA to change the recommendation for complete revascularization to class IIb 
in the recent 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous 
Intervention for Patients with ST-Elevation Myocardial Infarction. These guidelines 
specifically allow consideration of single-stage MV PCI in selected patients, either at 
the time of pPCI or as a delayed, staged procedure. Similarly, 2017 ESC guidelines for 
the management of acute myocardial infarction in patients presenting with STEMI 
recommend that revascularization of non-IRA should be considered in STEMI 
patients with MV CAD at index or before hospital discharge (class IIa). The optimal 
timing of revascularization (immediate vs. staged) has not been adequately investi-
gated; therefore, no recommendation is provided in these guidelines.
13.3  Role of Fractional Flow Reserve
Most of the observational and randomized studies have so far used angiographic 
diameter stenosis severity to determine non-culprit lesions requiring PCI. Fractional 
flow reserve (FFR) has historically not been utilized in ACS due to concern that 
acute microvascular dysfunction might influence these results. It has been suggested 
that non-IRA stenosis severity may be acutely exaggerated as the result of circulat-
ing catecholamine-mediated vasoconstriction. Moreover, virtual histology intravas-
cular ultrasound (VH-IVUS) analysis of non-culprit lesions in ACS patients has 
shown a greater prevalence of vulnerable plaques, with greater necrotic core and 
thin-cap fibroatheroma as compared with stable coronary lesions.
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Nevertheless, reliability of FFR of non-culprit lesions in the acute phase of 
STEMI has been extensively demonstrated. Ntalianis et al. reported the reproduc-
ibility of FFR measurements in 75 STEMI patients undergoing PCI when repeated 
at a mean of 35 ± 4 days post initial procedure. The same was observed by a similar 
study performed by Musto et  al. when similar FFR and instantaneous wave-free 
ratio (iFR) values were obtained in the acute phase and 7 days later in 60 MV-STEMI 
patients undergoing pPCI. Moreover, the COMPARE-ACUTE trial demonstrated a 
discrepancy between angiographic and haemodynamically significant lesions in 
STEMI patients; approximately half of non-culprit lesions that were considered to 
be critical on coronary angiography were found to have an FFR value >0.80 and 
therefore not physiologically relevant.
Both DANAMI3-PRIMULTI and COMPARE-ACUTE trial showed that FFR- 
guided PCI decreased acute and repeat revascularization rates, though did not impact 
mortality or re-infarction rates. However, performing FFR during index procedure, 
as investigated in COMPARE-ACUTE trial, was found to be safe and to reduce cost 
and risk associated with a delayed procedure, justifies a selective anatomically 
incomplete revascularization, expedites post-STEMI care and discharge, facilitates 
decision-making in the heart team and may offer reassurance to the patient.
13.4  Prognostic Value of Complete Revascularization
Although recent RCTs showed a benefit of composite MACE endpoints associated 
with complete revascularization as compared to culprit-only strategy, this was 
mainly driven by a reduction in ischaemia-driven revascularization. Of note, none 
of these trials was powered to evaluate prognostic clinical endpoints such as death 
and myocardial infarction. Interestingly, a meta-analysis of four RCTs including 
CvLPRIT, PRAMI, Politi and HELP-AMI for a total of 1044 patients that compared 
complete revascularization and culprit-only demonstrated significant reduction in 
long-term (≥1  year) all-cause mortality, cardiovascular death and MI associated 
with the former treatment. A low degree of heterogeneity between the studies was 
reported for this meta-analysis. Despite all the limits related to differences of indi-
vidual studies, these findings suggest a trend towards improved death and MI with 
complete revascularization. Further clarification is expected from the COMPLETE 
trial which will investigate the benefit of complete revascularization in terms of 
composite of cardiovascular death and MI as primary endpoint.
13.5  STEMI with Multivessel Coronary Artery Disease 
Complicated by Cardiogenic Shock
Cardiogenic shock is present in 6–12% of cases with acute myocardial infarction, 
varying according to the population analysed and definition of cardiogenic shock. 
The presence of MV CAD has been reported in up to 60–70% of STEMI patients 
complicated by cardiogenic shock. In the Should We Emergently Revascularize 
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Occluded Coronaries for Cardiogenic Shock (SHOCK) trial, three-vessel CAD was 
found in 60% of patients undergoing PCI. MV CAD in STEMI patients complicated 
by cardiogenic shock has been found to be an independent predictor of in-hospital 
mortality.
Most of the current available data regarding the management of MV CAD in the 
context of cardiogenic shock are based on retrospective analysis of registries, there-
fore producing heterogeneous and conflicting results.
In the milestone SHOCK trial, 352 patients with acute myocardial infarction 
complicated by cardiogenic shock were randomized to receive either emergency 
revascularization with either PCI or CABG (n = 152) or initial medical stabilization 
(n = 150). Despite the high rate of intra-aortic balloon pump used in both groups, 
the investigators found no differences in terms of 30-day mortality and lower 
6-month mortality rates in the complete revascularization group as compared to 
culprit-only treatment. This study showed that a strategy of early revascularization 
resulted in 6-year higher survival rates compared with initial medical stabilization. 
Retrospective sub-analysis of KAMIR registry evaluating 510 STEMI patients with 
cardiogenic shock and evidence of MV CAD at angiography revealed reduction of 
early mortality with complete revascularization. Similarly, a prospective observa-
tional study of 266 STEMI patients with cardiogenic shock showed improved 
6-month survival associated with single-stage MV PCI strategy.
Results of the CULPRIT-SHOCK (Culprit Lesion-Only PCI Versus MV PCI in 
Cardiogenic Shock) trial have been recently published. This multicentre, open-label 
trial randomized 706 patients with cardiogenic shock and evidence of MV CAD at 
index angiography to receive either culprit vessel revascularization (during index 
procedure with possible staged revascularization) or single-stage MV PCI. The use 
of intra-aortic balloon pump and mechanical support device use was left at opera-
tor’s discretion. The 30-day risk of a composite of death or severe renal failure lead-
ing to renal replacement therapy was lower among those who initially underwent 
PCI of the culprit lesion-only than among those who underwent immediate MV 
PCI. One potential limitation of this study is advocating attempts at CTO revascu-
larization in the acute setting, which is usually performed only with evidence of 
ischaemia and viability demonstrated in the CTO territory.
Current ESC guidelines recommend that non-IRA PCI during the index procedure 
should be considered in STEMI patients with cardiogenic shock (Class IIA, Level of 
evidence C). The ACC/AHA/SCAI guidelines recommend emergency revasculariza-
tion with either PCI or CABG irrespective of the time delay from myocardial infarc-
tion onset in STEMI patients complicated by cardiogenic shock (Class I, Level of 
evidence B). The rationale behind complete revascularization is to improve perfusion 
to non-IRA territories in order to reverse the spiral of decline that characterizes this 
status. In the context of myocardial ischaemia, a pan-myocardial inflammatory pro-
cess as well as systemic hypotension might impact on the entire coronary circulation 
and exacerbate ischaemia in non-IRA lesions, leading to further coronary hypoperfu-
sion and impaired myocardial function. However, despite current recommendations, 
multiple registries have shown that only one-fourth to one-third of STEMI patients 
with cardiogenic shock and evidence of MV CAD undergo immediate MV PCI.
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13.6  Clinical Practice
The recently reported RCTs have shown potential benefit of complete revasculariza-
tion strategy which have led to guideline updates. These studies reflect more con-
temporary clinical practice where the use of DES, radial access and more effective 
P2Y12 inhibitors has improved clinical outcomes and reduced procedure-related 
complications. These findings have shed new light on the potential management of 
such patients. The use of FFR in this context has been proposed as a safe tool able 
to guide a functionally complete revascularization.
However, there are still unsolved issues with regard to the optimal timing of 
intervention as the current data present conflicting evidence. Moreover, the recent 
RCTs have shown improved MACE outcomes with complete revascularization 
mostly driven by need for repeat revascularization but are underpowered to deter-
mine hard clinical endpoints of death and MI. Furthermore, whether the goal of 
complete revascularization should be the treatment of ischaemia-related lesions or 
vulnerable plaques prone to thrombosis has yet to be determined.
Despite the available evidence and ongoing trials, defining a common strategy 
for all STEMI patients with MVD remains challenging. These patients are extremely 
heterogeneous, and any revascularization strategy should be individualized based 
on patient and lesion characteristics. Physiological evaluation of non-culprit lesions 
should be encouraged in order to define appropriate revascularization strategy.
13.7  Case Report
Valeria Paradies and Peter C. Smits
A 58-year-old man, without cardiac history, was admitted to our hospital for acute 
onset of chest pain and diagnosis of inferior STEMI. The ECG showed clear ST eleva-
tion in inferior leads, and the coronary angiography confirmed occlusion of RCA 
(Fig.  13.1a). However, a clear image of thrombus was detected in the mid- LAD 
involving the ostium of a diagonal branch (Fig. 13.1b). Our strategy began with PCI 
of RCA with a drug-eluting stent (DES) 4.0 × 12 mm (Fig. 13.2a). Due to plaque shift, 
a second 4.0 × 18 mm DES was implanted proximal to the previous one (Fig. 13.2b). 
No reflow occurred but rapidly improved with i.c. verapamil injection. Despite the 
culprit lesion having been identified and successfully treated, a clear image of throm-
bus that was evident in the mid-LAD was concerning, although not immediately com-
promising flow or generating apparent rest ischaemia. As the culprit lesion was 
successfully treated in a relatively short time and the patient remained haemodynami-
cally stable despite transient no reflow, we considered the option to proceed with 
immediate PCI of LAD and diagonal branch, both of which were non-culprit lesions 
(despite the presence of obvious but non- occlusive thrombus)
A provisional approach was taken, and predilatation of the LAD with a 2.5 × 10 mm 
balloon followed by DES 3.5 × 23 mm implantation in mid-LAD was performed 
(Fig.  13.3a). After LAD stenting, plaque shift occurred towards the ostium of the 
diagonal (Fig.  13.3b). At this point, our decision-making process considered the 
V. Paradies and P. C. Smits
177
potentially complicated issue of leading to a two-stent bifurcation PCI of a non-culprit 
vessel in a STEMI setting. However, given the degree of stenosis at ostium of the 
diagonal and calibre of this vessel, we decided to complete the procedure with a TAP 
stenting technique. A DES 2.75 × 8 mm was implanted in the diagonal branch and 
final kissing balloon dilatation performed using oversized NC balloons (Fig. 13.3c). 
The patient remained haemodynamically stable and was discharged home a few days 
later. Although there is currently a vivid debate on complete revascularization during 
a b
Fig. 13.1 (a) Left coronary angiography showed images of non-occlusive thrombus in the mid- 
LAD involving the origin of a relevant diagonal branch. (b) Right coronary angiography showed 
complete thrombotic occlusion of the right coronary artery in line with ECG findings of inferior 
STEMI
a b
Fig. 13.2 (a) Proximal plaque shift after DES 4.0 × 12 implantation on mid-RCA. (b) Final result 
after second stent implantation, i.c. verapamil administration and postdilatation of RCA lesion
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pPCI, this case highlights how the risk/safety balance of non-culprit PCI was steered 
by the angiographic findings of high thrombus burden in mid-LAD, which if left 
untreated may have had severe consequences.
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14Role of Intravascular Imaging in Primary PCI
William K. T. Hau and Bryan P. Y. Yan
14.1  Introduction
Acute ST-segment elevation myocardial infarction (STEMI) usually results from 
acute thrombotic occlusion of a major epicardial coronary artery. Primary percuta-
neous coronary intervention (PPCI) is the reperfusion strategy of choice if it can be 
done in a timely manner, its aim being to rapidly achieve complete myocardial 
reperfusion. Overwhelming evidence has shown that prompt reperfusion reduces 
infarct size, preserves left ventricular function, and improves survival [1, 2].
Studies have demonstrated the benefits of drug-eluting stents (DESs) in patients 
with acute myocardial infarction (MI) undergoing primary stent implantation. The 
HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in 
Acute Myocardial Infarction) trial demonstrated that the use of DESs in patients 
with STEMI is safe and effective compared with bare metal stents (BMSs) at 1-year 
follow-up. The use of DESs definitively reduces the need for repeat revasculariza-
tion without additional risk of death or MI [3]. Besides, a meta-analysis of 13 ran-
domized trials, which compared the outcomes of DES and BMS in 7352 randomized 
patients, suggested that DES use significantly decreases restenosis compared with 
BMS use in patients with STEMI. DES use yields a relative and absolute reduction 
in target vessel revascularization (TVR) of 56% and −7%, respectively (p < 0.001). 
The meta-analysis also suggested that this benefit does not come at the expense of 
stent thrombosis, reinfarction, or increased death within 2 years of the PCI [4].
Even though DES use has proven to be safe in the setting of primary PCI, stent 
thrombosis remains a serious complication associated with increased morbidity 
and mortality [5, 6]. Thus, careful attention must be paid to ensure complete stent 
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coverage of the culprit lesion in terms of diameter and stenosis. In STEMI 
patients, rapid reperfusion is the most crucial issue, so primary PCI is always 
targeted on the angiographically identified culprit lesion. However, the actual 
culprit lesion may not be lumen-compromising and could be located proximally 
or distally to the angiographic target lesion. As a result, the risk of incomplete 
lesion coverage could be high when the primary PCI is guided solely by angiog-
raphy. Furthermore, stent implantation must be optimized, as incomplete apposi-
tion and/or edge dissection may result in in-stent restenosis or thrombosis. Thus, 
invasive coronary imaging (Fig. 14.1) using intravascular ultrasound (IVUS) or 
optical coherence tomography (OCT) is useful for guiding the PCI procedure in 
the primary setting by locating the true culprit lesion and may lead to better stent 
coverage of the lesion. Besides, invasive imaging also helps to resolve diagnostic 
uncertainty and to identify the mechanism underlying the acute event. Thin-cap 
OCT IVUS
Resolution 15 µm 150 µm
Penetration 2 mm 10 mm
Field of View 10 mm 10 mm
Frame Rate 100 FPS 15-30 FPS
Pullback Speed 75 mm/sec 0.5/1.0 mm/sec
Catheter Size Sub 3F 3.2 F
Fig. 14.1 A comparison table of OCT and IVUS
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fibroatheroma (TCFA) is the most common type of vulnerable plaque and is 
defined as a lesion with a fibrous cap thickness ≤ 65 μm containing a large lipid 
pool with a necrotic core and infiltrated by macrophages. It is believed to be the 
precursor of thrombotic plaque rupture [7]. Autopsy studies have shown that 
TCFA is more commonly found in coronary segments with positive remodeling 
[8], and due to its better penetration power than OCT (Fig. 14.2), IVUS is very 
useful in identifying coronary vessels with positive remodeling [9]. However, the 
high resolution of OCT is able to provide accurate quantification of fibrous cap 
thicknesses ≤65 μm (Fig. 14.3). Other than coronary plaque rupture, plaque ero-
sion and calcified nodules are frequent pathophysiological mechanisms respon-
sible for acute coronary syndrome (ACS) [7], and OCT enables differentiation of 
all three features in  vivo [10]. Other rare causes of acute coronary symptoms 
such as spontaneous coronary artery dissection [11], myocardial bridging [12], 
or mechanical problems due to stent underexpansion [13] and/or stent fracture 
[14] can also be identified by invasive imaging. However, the impact of intravas-
cular imaging in terms of clinical outcomes in the setting of acute MI remains a 
matter of controversy.
Comparing OCT to IVUS
OCT can visualize 1-2mm
for seeing the lumen and
structures near the lumen
IVUS can penetrate deep
into tissue allowing
visualization of lumen,
stents, entire plaque and
vessel wall
Vessel Wall
Fig. 14.2 IVUS can penetrate deep into tissue allowing visualization of the lumen, entire plaque, 
and vessel wall. However, the high resolution of OCT provides superior delineation of the superfi-
cial structures
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14.2  Role of Invasive Imaging in the Management of STEMI 
and Non-STEMI
14.2.1  Intravascular Ultrasound
IVUS uses reflected high-frequency (10–60  MHz) sound waves to visualize the 
arterial wall in a two-dimensional tomographic format. IVUS permits not only a 
greater understanding of the characteristics of the coronary plaque and its response 
to interventional coronary procedures but also allows more precise quantification of 
the coronary luminal dimensions and atherosclerotic plaque burden [15–17]. In the 
setting of elective PCI, randomized trials and meta-analyses indicate that IVUS- 
guided PCI is associated with a lower incidence of TVR and fewer major adverse 
cardiac events (MACEs), MI, and stent thromboses than angiography-guided PCI 
[18, 19]. IVUS provides useful information about the morphology of the coronary 
lesion, as well as helping stent size selection, optimization of stent expansion, and 
detection of incomplete apposition and/or edge dissection, resulting in reduced 
restenosis or stent thrombosis. IVUS- measured minimal stent cross-sectional area 
(CSA) is the best IVUS predictor of DES failure. The results from the IVUS sub- 
study of the HORIZONS-AMI trial showed that mechanical problems such as a 
smaller final stent CSA (<5 mm2) and inflow/outflow disease (residual stenosis or 
dissection) but not acute mal-apposition were associated with early stent thrombosis 
after intervention for acute MI. The minimal stent CSA measured by IVUS and the 
degree of stent expansion were significantly smaller in patients with early stent 
thrombosis than in the control group. The finding that the minimal stent CSA was 
significantly smaller in acute MI patients with early stent thrombosis could be either 
because of tissue protrusion (plaque and/or thrombus) or stent underexpansion or 
Cap < 65 µm
TCFA
Fig. 14.3 Thin-cap 
fibroatheroma (TCFA) is 
the most common type of 
vulnerable plaque and is 
defined as a lesion with a 
fibrous cap thickness 
≤65 μm containing a large 
lipid pool with a necrotic 
core and infiltrated by 
macrophages. The high 
resolution of OCT is able 
to provide accurate 
quantification of fibrous 
cap thicknesses ≤65 μm
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both, as the culprit lesions in acute MI patients are presumed to be thrombus- 
containing, and thus tissue protrusion into the lumen through stent struts is common 
[20]. Besides, another IVUS sub-study of the HORIZONS-AMI trial also suggested 
that the final post-procedure minimal stent CSA in patients with STEMI after pri-
mary stent implantation was the only independent IVUS predictor of angiographic 
binary restenosis, similar to patients with stable coronary disease as previously 
reported. Angiographic restenosis rates were 26.7% in lesions with a CSA <4 mm2, 
22.2% in lesions with a CSA <5 mm2, and 20.5% in lesions with a CSA <6 mm2 
[21]. Therefore, a well-expanded stent with a final minimal stent CSA ≥5 mm2 by 
IVUS is needed in patients undergoing primary PCI to prevent stent thrombosis as 
well as restenosis at follow-up.
However, it is still controversial whether routine IVUS guidance improves out-
comes in patients receiving primary PCI treatment. The Assessment of Dual 
Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) trial reported that 
IVUS-guided PCI with DESs was associated with significantly lower rates of 
stent thrombosis, MI, and MACEs. In this particular trial, 813 STEMI patients 
were enrolled, and it was found that IVUS use was associated with substantially 
improved outcomes in these patients [22]. Besides, studies by Singh et al. have 
shown that the use of IVUS in patients with acute MI was associated with reduced 
in-hospital mortality but at the expense of increased cost of care and vascular 
complications, compared with angiography-guided PCI [23]. On the contrary, a 
few other studies did not support the routine use of IVUS for patients who present 
with an acute MI and undergoing primary PCI. A study by Maluenda et al. showed 
no clear clinical benefit of routine use of IVUS-guided stenting in 905 patients 
with acute MI undergoing primary PCI. The overall rates of the composite pri-
mary outcome were similar, as were the rates of stent thrombosis in the IVUS-
guided and the non-IVUS-guided groups. However, the number of treated lesions 
and the number of stents used were higher in the IVUS-guided group, with a 
longer procedural time as well [24]. Consistently, two studies from Korea reported 
similar findings; IVUS guidance during primary PCI did not provide a better clini-
cal outcome and prevent stent thrombotic events. Although the stent size and the 
final minimal stented CSA were larger in the IVUS-guided group, the use of IVUS 
was also associated with a longer stent length and higher number of stents used 
[25, 26]. Traditionally, longer and more stents used are associated with much 
worse clinical outcomes and thus may minimize the potential benefits of IVUS 
use in acute MI patients undergoing primary PCI. Supporting this notion, a recent 
study from Japan, the CREDO (Coronary Revascularization Demonstrating 
Outcome)-Kyoto AMI registry sub-analysis, evaluated the outcomes of 932 
patients undergoing IVUS-guided PCI among the 3028 STEMI patients enrolled 
in the registry and also found no apparent benefit of IVUS for reducing TVR and 
stent thrombosis as well as mortality in STEMI patients undergoing primary PCI 
[27]. Despite the fact that, in the setting of elective PCI, IVUS use has been dem-
onstrated to reduce the MACE rate and improve clinical outcomes, in the setting 
of primary PCI, it seems that IVUS use can be a two-edged sword; it may help in 
stent implantation guidance—and in terms of proper stent size selection and 
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postimplantation stent optimization, it may result in reduction of restenosis or 
stent thrombosis. On the other hand though, it may also be associated with a 
higher rate of coronary complications, and this could be because of poor IVUS 
interpretation due to a large thrombus burden in the culprit lesions of STEMI 
patients (Fig. 14.4), making it rather difficult to determine proper stent sizing and 
optimization of stent deployment, resulting in under- or oversize stent selection, 
and this may lead to disastrous consequences like perforation and stent thrombo-
sis. In addition, the underlying pathological process in acute settings is very dif-
ferent from that in elective settings. The culprit lesions responsible for causing the 
acute events are very soft with less calcification and naturally contain a large 
thrombus burden; thus post- dilatation to optimize stent deployment with high-
pressure ballooning in acute MI patients may potentially cause thrombus protru-
sion or tissue prolapse through the stent strut and increase the likelihood of distal 
embolization. Besides, acute MI patients might have a higher chance of late-
acquired stent mal-apposition due to the thrombus resolving over time, and that 
may lead to thrombotic events as well. It has been shown on IVUS that at the time 




Fig. 14.4 (a) Coronary angiography suggestive of thrombus formation at the mid-right coronary 
artery. (b) IVUS image of the normal reference distal to the culprit site. (c) IVUS image at the 
culprit site with positive remodeling contains a large thrombus (F) burden
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incomplete stent apposition, as this could result from either thrombus dissolution 
and/or positive vessel wall remodeling [28]. Thus, it is possible that IVUS use in 
the setting of primary PCI may increase the overall procedural time and cost with-
out providing additional clinical outcome benefits.
14.2.2  Optical Coherence Tomography
OCT generates real-time high-resolution cross-sectional images of the vascular wall 
from backscattered reflections of infrared light. The greatest advantage of this infra-
red light-based imaging technology is its significantly higher resolution (tenfold 
higher) than that of the sound-based technology, but at the cost of having to inject 
contrast medium to flush blood from the vessel, as the OCT signal is attenuated by 
the presence of red blood cells. Current commercially available intravascular OCT 
technologies have an axial resolution of 10–20  μm and a lateral resolution of 
20–25 μm. The higher resolution of OCT provides superior delineation of the super-
ficial structures and is able to visualize calcium (Fig. 14.5) without acoustic shad-
owing [29], as seen with IVUS. However, signal penetration through the diseased 
vessel is more limited due to its lower penetration power, making it difficult to 
quantify the plaque burden or to investigate large vessels. Besides, since OCT 
requires the injection of a contrast medium during image acquisition in order to cre-
ate a blood-free environment, OCT cannot be performed in scenarios such as totally 
occluded vessels or coronary arteries with massive dissection. The results from the 
CLI-OPCI (Centro per la Lotta contro l’Infarto-Optimisation of Percutaneous 
Coronary Intervention) registry suggested that the use of OCT in patients undergo-




Fig. 14.5 (a) The higher resolution of OCT is able to visualize calcium (Ca) without acoustic 
shadowing. (b) The IVUS image shows superficial calcium (Ca) from 4 o’clock to 8 o’clock with 
acoustic shadowing
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point of cardiac death or MI was found in patients undergoing OCT-guided PCI 
compared with patients treated with angiographic guidance alone [30]. Suboptimal 
stent deployment was associated with an increased risk of MACEs during follow-
 up. More recently, a randomized controlled trial reported that OCT-guided PCI pro-
cedures using a specific reference segment external elastic lamina-based stent 
optimization strategy resulted in clinical outcomes equivalent to those with IVUS-
guided PCI [31]. Due to the ultra-high resolution, OCT is more sensitive in detect-
ing mal-apposition, tissue prolapse, small edge dissection, and intra-stent thrombus 
than IVUS. However, studies have also shown that small dissections and tissue pro-
trusion detected by OCT tend to resolve over a 6-month follow-up period [32], so 
all these small details detected by OCT may be clinically irrelevant and could poten-
tially lead to unnecessary interventions and might eventually cause more 
complications.
Most acute coronary events, including MI, occur in relation to subsequent cor-
onary thrombus formation. Due to its high resolution, OCT can identify a throm-
bus better than IVUS and is able to discriminate two types of thrombi (Fig. 14.6): 
red thrombus (red blood cell-rich), which has high backscatter and high attenua-
tion, and white thrombus (platelet-rich) characterized by signal-rich low back-
scatter and low attenuation [33]. However, the impact of characterization of these 
two types of thrombi in clinical decision-making is still unclear, and further stud-
ies are needed. Furthermore, in the ACS setting, OCT has been shown to identify 
plaque morphologies associated with a worse prognosis. Plaque erosion and 
plaque rupture (Fig. 14.7) are the two most frequent pathophysiological mecha-
nisms responsible for ACS and contribute to almost 95% of the acute coronary 
events; OCT enables the differentiation of these two plaque features in vivo. At 
OCT, plaque erosion appears as a plaque covered by thrombus (typically a white, 
platelet-rich thrombus) without signs of fibrous cap disruption. This occurs at 
sites with impaired endothelium, rich in smooth muscle cells and proteoglycans. 




Fig. 14.6 (a) IVUS image of a vessel contains a large thrombus burden. OCT is able to discrimi-
nate two types of thrombi: (b) red thrombus, which has high backscatter and high attenuation, and 
(c) white thrombus characterized by signal-rich low backscatter and low attenuation. T thrombus, 
RT red thrombus, WT white thrombus
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discontinuity, creating communication between a cavity within the plaque and the 
arterial lumen. Calcified nodules contribute to ≤5% of acute coronary events, and 
these are characterized by fibrous cap disruption due to protrusion of calcium [34, 
35]. Differentiation of these three plaque features can be useful in the choice of 
therapeutic strategy. The recent EROSION (Effective Antithrombotic Therapy 
Without Stenting: Intravascular OCT-Based Management in Plaque Erosion) trial 
suggested that patients with ACS caused by plaque erosion may be stabilized by 
antithrombotic therapy alone, without stenting, and thereby potentially have fewer 
stent-related early and late complications [36].
The high resolution of OCT clearly enables a better understanding of the athero-
sclerotic plaque and helps to identify the mechanism underlying the acute event. 
Studies aiming to investigate an association between OCT and improvement in 
clinical outcomes may further strengthen the evidence in favor of using OCT to 
guide PCI in ACS patients. The DOCTORS (Does Optical Coherence Tomography 
Optimize Results of Stenting) trial is the first randomized, prospective, multicenter 
trial to investigate the use of OCT in optimizing the results of PCI for non-ST- 
segment elevation ACS. The results showed that OCT findings led to a change in 
procedural strategy in 50% of the patients in the OCT-guided group, mainly driven 
by the optimization of stent expansion, and were associated with higher fractional 
flow reserve values at the end of the procedure than angiography-guided PCI alone. 
However, this benefit was obtained at the cost of longer fluoroscopy and procedural 
times, as well as a greater volume of contrast medium and a higher dose of radia-





Fig. 14.7 OCT enables the differentiation of plaque erosion (PE) and plaque rupture (PR) in vivo. 
(a) PE appears as a plaque covered by thrombus (typically a white, platelet-rich thrombus) without 
signs of fibrous cap disruption. (b) PR is identified by the presence of a fibrous cap discontinuity, 
creating communication between a cavity within the plaque and the arterial lumen
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14.3  Role of Invasive Imaging in the Management 
of Spontaneous Coronary Artery Dissection
14.3.1  Pathogenesis of Spontaneous Coronary Artery Dissection
The usual pathogenesis of acute MI involves unstable plaque rupture or plaque ero-
sion that is distinct from spontaneous coronary artery dissection (SCAD). SCAD is 
a rare cause of acute MI, and is due to hemorrhage within the arterial wall, resulting 
in separation of the intimal-medial layers rather than atherosclerotic plaque rupture 
or erosion. The presence of true arterial lumen compression by the hematoma in the 
intimal-medial layers can subsequently result in myocardial ischemia or acute 
MI. Early recognition and precise diagnosis of SCAD is very important in order to 
implement the appropriate medical treatment; otherwise it will lead to disastrous 
consequences. Two potential mechanisms for the cause of SCAD have been pro-
posed. The first is that an intimal tear creates an entry point that promotes intramural 
bleeding inside the false lumen, leading to separation of the intimal-medial layers. 
The second is that rupture of the vasa vasorum leads to an intramural hematoma, 
which increases the pressure and potentially causes an intimal rupture into the true 
lumen. Thus SCAD caused by the latter mechanism can occur with or without a 
distinct intimal rupture [38]. SCAD is not uncommon in young females presenting 
with acute MI in the absence of traditional cardiovascular risk factors [39] and is the 
most frequent cause of acute MI among pregnant women [40].
The symptoms of SCAD usually do not differ from those of ACS, as SCAD 
impairs myocardial perfusion by reducing the vessel lumen in a manner very similar 
to atherosclerotic stenosis, and thus accurate recognition and management of SCAD 
may improve both short- and long-term outcomes. However, SCAD is mainly 
caused by spontaneous dissection of the coronary artery wall. As a matter of fact, it 
is very difficult to correctly diagnose based on angiography alone as angiography is 
only a two-dimensional luminogram and is not able to visualize the vessel wall, 
explaining why SCAD is frequently underdiagnosed. The angiographic appearance 
of SCAD consists of extraluminal contrast staining, spiral dissection, an intralumi-
nal filling defect, and smooth narrowing of varying length and severity which 
depends on the amount of blood accumulation within the false lumen. Based on the 
angiographic appearance, Saw proposed a classification of SCAD (Fig. 14.8) to aid 
its diagnosis [41]. Type 1 angiographic SCAD describes the pathognomonic appear-
ance of arterial wall contrast staining with multiple radiolucent lumens. Type 2 
angiographic SCAD describes long diffuse stenosis of varying severity (typically 
>20 mm), but often subtle, abrupt changes in arterial caliber from the normal diam-
eter to diffuse smooth narrowing, and often extends to the distal ends of the arteries. 
Type 3 angiographic SCAD describes focal tubular (typically <20 mm) stenosis that 
mimics atherosclerotic lesions. Invasive coronary imaging techniques like IVUS 
and OCT that can image the arterial wall improve SCAD diagnosis and are also very 
useful in guiding coronary intervention when revascularization is needed. However, 
they are not available in some catheterization laboratories and are also associated 
with additional risks and cost. Thus, angiography remains the frontline imaging 
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technology for the diagnosis of SCAD. However, when it comes to SCAD patient 
management, coronary revascularization is only indicated for those with ongoing or 
recurrent ischemia with favorable anatomy but is associated with high complication 
rates [42]. On the other hand, patients without evidence of ongoing ischemia can be 
treated medically, and most have an uneventful clinical course [43]. Medical man-
agement consists of blood pressure control with dual antiplatelet and 
beta-blockers.
14.3.2  Intravascular Ultrasound
As noted above, in both elective and acute settings, IVUS is very useful in the 
determination of the severity and characteristics of atherosclerotic plaques and 
has played a vital role in PCI guidance in terms of vessel sizing and the optimiza-
tion of stent implantation. In patients suspected of having SCAD, the diagnosis of 
SCAD requires visualization of the intramural hematoma and separation of the 
intimal- medial layers creating double true and false lumens. Thus, due to its better 
tissue penetration power, IVUS allows a more complete and deeper vessel visual-
ization of the extent of the intramural hematoma, as well as the dissected layers, 
while the true and false lumens can be clearly identified. Also, the distribution of 
the false lumen and the compromise of the true lumen can also be clearly visual-
ized on IVUS [44]. An intramural hematoma on IVUS appears homogeneous and 
hyperechoic, with a crescent-shaped area of blood accumulation (Fig.  14.9). 
However, due to its relatively poor image resolution, IVUS is not able to identify 
the intimal rupture site. On the other hand, IVUS is able to confirm the guide-wire 
position within the true lumen (Fig. 14.10), and IVUS findings have also been 
used to optimize the results of stent implantation in patients with SCAD requiring 
coronary intervention [45].
a b c
Fig. 14.8 Saw proposed an angiographic classification of SCAD to aid its diagnosis. (a) Type 1 
angiographic SCAD describes the pathognomonic appearance of arterial wall contrast staining 
with multiple radiolucent lumens. (b) Type 2 angiographic SCAD describes long diffuse stenosis 
of varying severity (typically >20 mm), but often subtle, abrupt changes in arterial caliber from the 
normal diameter to diffuse smooth narrowing, and often extends to the distal ends of the arteries. 
(c) Type 3 angiographic SCAD describes focal tubular (typically <20 mm) stenosis that mimics 
atherosclerotic lesions
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14.3.3  Optical Coherence Tomography
Coronary angiography is unable to establish a definitive diagnosis of 
SCAD. Conversely, OCT allows accurate visualization of the coronary artery wall 
with unprecedented resolution and thus is very useful to rule out this diagnosis in 
patients with images mimicking SCAD. OCT provides unique insights by visualiz-
ing most of the morphological features of the condition including intimal tears, intra-
luminal thrombi, double-lumen morphology, and intramural hematoma. However, 
inadequate optical penetration may impede full visualization of the circumferential 
extent of an intramural hematoma. Like IVUS, the distribution of the false lumen and 
the compromise of the true lumen can also be very clearly visualized on OCT. An 




Fig. 14.9 (a) and (b) Coronary angiography suggesting a type 2 SCAD. (c) IVUS revealing the 




Fig. 14.10 IVUS 
confirms the guide-wire 
(GW) is in the true (T) 
lumen, not the false (F) 
lumen
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In addition, due to its superb near-field resolution compared with IVUS, OCT is 
superior in identifying the precise location of the intimal rupture tear and readily 
depicts the length of the dissecting membrane [46]. However, IVUS provides deeper 
penetration of the vessel wall and is therefore able to fully visualize large hematomas 
(Fig. 14.12). On the other hand, caution must be exercised when performing OCT 




Fig. 14.11 (a) Coronary angiography suggesting a type 3 SCAD. (b) OCT revealing the presence 




Fig. 14.12 (a) Intramural hematoma on IVUS appears homogeneous and hyperechoic, with a 
crescent-shaped area of blood accumulation. The distribution of the false lumen (F) and the com-
promise of the true lumen (T) are clearly visualized. (b) Intramural hematoma has a dark appear-
ance on OCT. The distribution of the false lumen (F) and the compromise of the true lumen (T) can 
also be very clearly visualized on OCT. However, IVUS provides deeper penetration of the vessel 
wall and is therefore able to fully visualize large hematomas
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create a blood-free environment during image acquisition in order to obtain good 
images. This may cause the hematoma to extend distally. Also, abnormalities such as 
an extramural vessel hematoma or perivascular hematoma can be detected on IVUS, 
but not on OCT. Finally, for patients undergoing coronary intervention, OCT imag-
ing is also able to help to confirm the guide-wire position within the true lumen, as 
well as helping in vessel sizing and stent optimization [47].
14.4  Summary
Even though angiography is the gold standard to guide procedural decision-making 
during primary PCI, it has various well-known limitations. Angiography is only a 
luminology without providing any information on the vessel wall and atheroscle-
rotic plaque characteristics. Besides, it is suboptimal in detecting stent underexpan-
sion, stent edge dissection, plaque protrusion, or thrombi. Invasive imaging 
techniques like IVUS and OCT provide complementary details to help primary PCI 
guidance, such as to ensure stent coverage of the culprit lesion and optimization of 
stent implantation. OCT is superior in the visualization of superficial structures, 
such as stent edge dissection, intimal tear, tissue protrusion, and intraluminal 
thrombi, whereas IVUS is better for deep vessel imaging, vessel sizing, and identi-
fying positive remodeling. However, it remains controversial as to whether routine 
invasive imaging guidance improves outcomes in patients receiving primary PCI.
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Although coronary artery disease (CAD), the most common cause of morbidity and 
mortality in the USA, is identified principally by coronary angiography, the rela-
tionship between the degrees of angiographic narrowing (% stenosis) is poorly cor-
related to its functional response (e.g., stress testing or intracoronary physiology). 
Over the past two decades, the use of in-lab coronary physiology has demonstrated 
that angiography alone is not accurate in determining ischemia for intermediate 
lesions. Compared with angiographically guided percutaneous coronary interven-
tion (PCI), physiology-guided PCI is associated with improved clinical outcomes 
and cost-effectiveness. The most commonly used invasive physiologic indices 
include fractional flow reserve (FFR), coronary flow reserve (CFR), and instanta-
neous wave-free ratio (iFR). Understanding applied coronary physiology and the 
tools for measuring it in the cath lab is paramount to best clinical decision-making 
in interventional cardiology.
While FFR has been well validated in patients with chronic stable coronary 
artery disease, in ACS, physiological assessment of the culprit coronary artery is not 
performed because reduced flow to the myocardial bed can lead to false negatives. 
However, FFR can be measured in the non-culprit vessels because theoretically it is 
presumed that flow is not reduced to myocardial regions remote for the culprit 
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infarct vessel territory. This chapter will be to review the different methods of inva-
sive physiological assessment of coronary stenoses and their outcomes with a focus 
on their practical applications in patients with ST-elevation myocardial infarction 
(STEMI) and other ACS.
15.2  ACS and FFR Case
A 58-year-old man presented with 1 day of intermittent chest pain. His medical his-
tory was significant for hypertension and hyperlipidemia. The ECG showed anterior 
T wave inversions and his troponin was 4. Urgent cardiac catheterization revealed a 
95% stenosis in the proximal left circumflex (LCX) artery and a 60% stenosis in the 
proximal left anterior descending (LAD) artery (Figs. 15.1 and 15.2). The presumed 
culprit vessel, the left circumflex artery, was stented (Fig.  15.3). Turning to the 
LAD, should we proceed to stent, defer and treat medically, or measure FFR and 
treat based on the ischemic potential of the lesion? Based on the evidence (see 
below), FFR of the non-infarct LAD artery is not only reasonable but favored to 
reduce operator uncertainty and shorten the current and future hospitalizations. As 
the lesion was fairly remote from the injured lateral wall myocardial zone, FFR 
should be valid (especially if positive). FFR of the proximal LAD lesion was 0.78 
(Fig. 15.4) and stented (Fig. 15.5) in the same procedure. The patient was discharged 
uneventfully.
Fig. 15.1 Cineangiogram from ACS and FFR case (LAO cranial and RAO projections) showing 
95% circumflex and 60% LAD lesions
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Fig. 15.2 Cineangiogram 
from ACS and FFR case 
(LAO Caudal) showing 
95% circumflex and 60% 
LAD lesions
Fig. 15.3 Cineangiogram 
frame after circumflex 
stenting
15 Physiological Lesion Assessment in STEMI and Other Acute Coronary Syndromes
200
15.3  Fractional Flow Reserve Foundations
FFR is the ratio of the mean coronary pressure distal (Pd) to a stenosis to the mean 
aortic pressure (Pa) at maximal hyperemia when myocardial resistance is at its pre-
sumed absolute minimum. This condition permits pressure and flow to be linearly 
related, and thus the ratio represents the fraction of normal coronary blood flow 
across a stenosis with a normal value being 1 (i.e., Pd  =  Pa). FFR requires the 
Fig. 15.4 LAD FFR (Pd/Pa) is 0.78
Fig. 15.5 Cineangiogram frame after LAD stenting
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induction of maximal hyperemia, most commonly with an intravenous infusion or 
intracoronary bolus of adenosine. Initial validation studies in stable angina patients 
have shown that an FFR <0.75, a reduction in coronary perfusion pressure by 25% 
of normal, was indicative of ischemia on stress testing. Additional investigations 
comparing FFR to different types of stress tests found that nearly all were negative 
when FFR > 0.80 and positive with FFR < 0.75, thereby establishing a gray zone of 
uncertainty. Clinical trials opted to use the upper end of the gray zone, 0.80 as the 
clinical threshold for outcome decision-making. This threshold is endorsed by the 
American College of Cardiology (ACC), American Heart Association (AHA), 
Society for Cardiovascular Angiography and Interventions (SCAI), and European 
Society of Cardiology (ESC) in their guidelines for PCI.
The outcomes of patients within the gray zone of 0.75–0.80 have been studied by 
Adjedj J et al. [1] who found that among 238 patients with gray-zone FFR, revascu-
larization was associated with a significantly reduced risk of major adverse cardio-
vascular events (MACE) compared with medical therapy alone (Fig. 15.6) [1, 2]. 
On the other hand, the risk of MACE was not significantly different between 
deferred and revascularized lesions for FFR ≥0.76 (including the gray zone) in the 
large, prospective, multicenter Interventional Cardiology Research Incooperation 
Society Fractional Flow Reserve (IRIS-FFR) registry [3]. For patients with an FFR 
between 0.75 and 0.8, the decision to revascularize requires the operators’ synthesis 
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Fig. 15.6 MACE-free 
survival (%) in patients of 
the medical therapy group 
stratified by FFR strata 
(log-rank, 15; P < 0.001). 
FFR fractional flow 
reserve, MACE major 
adverse cardiovascular 
event. Source: Adjedj J, 
et al. Circulation. 
2016;133:502–508 [1]
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15.4  Fundamentals of Fractional Flow Reserve in STEMI 
and Other ACS
The utility of FFR to guide revascularization of intermediate lesions in patients with 
chronic stable multivessel coronary artery disease has been validated in several land-
mark clinical trials including the Fractional Flow Reserve to Determine the 
Appropriateness of Angioplasty in Moderate Coronary Stenosis (DEFER), FFR 
Versus Angiography for Multivessel Evaluation (FAME 1), and FFR-Guided 
Percutaneous Coronary Intervention Plus Medical Treatment Versus Medical 
Treatment Alone in Patients with Stable Coronary Artery Disease (FAME 2) trials 
[4–6]. The utility of FFR in acute coronary syndrome (ACS) has been controversial.
During a STEMI, the degree of damage to the infarct-related or culprit myo-
cardial bed in the first hours of the injury makes the accuracy of FFR in the 
culprit artery highly questionable when >0.80. Since microcirculatory injury 
reduces flow, a low flow across a stenosis can produce a high FFR. Depending 
on the severity of the infarct, flow may recover in the days following the infarct, 
and hence the prior negative FFR may become positive, i.e., <0.80. To recap, a 
sub-hyperemic response to adenosine would result in an underestimation of ste-
nosis severity so that an FFR >0.80 at the time of STEMI may initially be con-
sidered nonsignificant, but it may decrease several days later as the injured 
myocardial bed recovers and flow increases to the area. In other words, it may 











Fig. 15.7 STEMI and FFR cartoon on influence of myocardial bed size. The upper image shows 
a 50% stenosis supplying a large myocardial bed. Because flow to the bed is large, the FFR is 0.75. 
After a myocardial infarction of this bed, the injured myocardium has lower flow, and despite a 
more severe stenosis of 85%, the FFR is now higher 0.83
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In the case of the non-culprit ACS artery, the flow to the myocardium supplied by 
non-infarct-related arteries should not be as affected as the culprit artery. The micro-
circulation should be normal, and FFR should accurately reflect the functional sig-
nificance of a lesion in a non-culprit artery. All studies investigating the utility of 
FFR in STEMI or other ACS have assessed the non-culprit arteries. There are sev-
eral studies that have found the microcirculation of the remote region can be abnor-
mal [7], and the closer the non-culprit vessel is to the STEMI territory, the higher 
the potential for a false negative (due to impaired border zone microcirculatory 
function and less inducible hyperemia).
15.5  Fractional Flow Reserve and STEMI Revascularization 
Guidance
Traditionally, treating only the culprit vessel during STEMI has been considered 
superior to treating all lesions supported in part by several meta-analyses, and non- 
randomized registry studies showed that treating all vessels at the same time as the 
STEMI culprit was associated with more adverse events. Even the 2015 update of 
the 2013 ACC/AHA/SCAI STEMI guidelines gave a class III (do not do) recom-
mendation to intervening on a non-infarct-related artery at the time of primary PCI 
in patients who are hemodynamically stable [8].
However, several recent studies have shown FFR is accurate in ACS, including 
the Fractional Flow Reserve Versus Angiography in Guiding Management to 
Optimize Outcomes in Non-ST-Elevation Myocardial Infarction Cardiac Magnetic 
Resonance (FAMOUS NSTEMI CMR) substudy that showed an excellent accuracy 
of FFR <0.80 for predicting perfusion defects on cardiac magnetic resonance [9]. 
Furthermore, multiple trials including the Preventive Angioplasty in Acute 
Myocardial Infarction (PRAMI), Complete Versus Lesion-Only Primary PCI Trial 
(CvLPRIT), and Third Danish Study of Optimal Acute Treatment of Patients With 
STEMI: Primary PCI in Multivessel Disease (DANAMI3-PRIMULTI) have shown 
that revascularizing non-culprit arteries in a STEMI, either at the time of primary 
PCI or later in a staged manner, reduce risk of MACE by a relative 44–65% com-
pared with culprit-only PCI (Fig. 15.8) [10–12].
The PRAMI trial looked at 435 patients with acute STEMI and multivessel coro-
nary artery disease. Patients were randomized to receive immediate preventive PCI 
in non-infarct arteries with stenosis >50% or no further PCI procedures. Recruitment 
was stopped early due to a highly significant between-group difference in the inci-
dence of primary outcome favoring preventive PCI.  Preventive PCI reduced the 
combined rate of cardiac death, nonfatal MI, or refractory angina by 65%, an abso-
lute risk reduction of 14% over 23 months. Of note, revascularization was not 
included as a primary outcome. In this study, the severity of disease in non-infarct 
arteries was determined by angiographic assessment alone [10]. The effect of using 
FFR to determine the significance of disease in non-infarct arteries in STEMI 
patients was subsequently studied in DANAMI3-PRIMULTI and COMPARE- 
ACUTE trials.
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DANAMI3-PRIMULTI was an open-label, randomized controlled trial that 
enrolled 627 patients with STEMI who had ≥1 clinically significant coronary steno-
sis in addition to the culprit lesion. After successful PCI to the culprit lesion, patients 
were randomized into no further invasive treatment or complete FFR-guided revas-
cularization before discharge. A threshold of FFR <0.80 was used, and FFR was 
performed 2 days after primary PCI to avoid the risk of invalid FFR measurements 
inferred from acute changes in macrovascular tone or microvascular flow obstruc-
tion. The primary endpoint of a composite of all-cause mortality, nonfatal reinfarc-
tion, and ischemia-driven revascularization of lesions in non-infarct-related arteries 
was significantly lower in the complete revascularization group (13%) compared 
with the infarct-related-only group (22%). The favorable effect was driven by sig-
nificantly fewer revascularizations. A substudy of the DANAMI3-PRIMULTI trial 
found that the benefit of staged FFR-guided complete revascularization was 
observed primarily in patients with three-vessel disease and at least one non-infarct- 
related stenosis with a ≥ 90% diameter (Fig. 15.9) [13].
In the Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial 
Infarction, COMPARE-ACUTE trial, 885 patients with STEMI and multivessel dis-
ease who had undergone primary PCI of the infarct-related artery were randomized 
to undergo FFR-guided complete revascularization of non-infarct-related coronary 
arteries or no revascularization of non-infarct-related arteries. Unlike DANAMI3- 
PRIMULTI, FFR of the non-infarct-related artery was done in the acute STEMI 
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Fig. 15.8 Kaplan-Meier curves of PRAMI, CvLPRIT, and DANAMI3-PRIMULTI.  Source: 
Wald, et al., 2013; Gershlick, et al., 2015; Engstrom, et al., 2015 [10–12]
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setting, during the time of primary PCI. At 1 year those who underwent FFR-guided 
complete revascularization of non-infarct-related arteries had a lower risk of death 
(1.4 vs. 1.7%), MI (2.4 vs. 4.7%), revascularization (6.1 vs. 17.5%), and cerebrovas-
cular events (0.0 vs. 0.7%) compared with those who were treated for the infarct- 
related artery only [14]. Approximately half of the non-infarct-related artery lesions 
that were angiographically significant were not physiologically significant by FFR 
(≥0.80).
15.6  FFR in Other Acute Coronary Syndrome
FFR also plays a role in patients with non-STEMI ACS. This population may be 
more difficult to study than patients with STEMI because the culprit vessel is 
not always clear in NSTEMI or unstable angina (USA) group. The Impact of 
Routine Fractional Flow Reserve on Management Decision and 1-Year Clinical 
Outcome of Patients with Acute Coronary Syndrome (PRIME-FFR) pooled the 
results of the French FFR Registry (R3F) and the Portuguese Study on the 
Evaluation of FFR- Guided Treatment of Coronary Disease (POST-IT). A total 
of 1983 patients with NSTEMI or unstable angina (USA) were included in the 
large, international prospective study. They found that the use of FFR was asso-
ciated with a high rate of reclassification of treatment. The percent of patients 
with ACS who were reclassified by FFR was similar to those with non-ACS (38 
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p = 0.2) or symptoms (92.3 vs. 94.8%, p = 0.25) in patients reclassified based on 
FFR compared to those who were not reclassified. Fewer patients with ACS 
were reclassified from revascularization to medical treatment compared with 
those with non-ACS (P  =  0.01). Furthermore, deferral to medical treatment 
based on FFR was as safe in ACS as it was in non-ACS patients. Patients with 
disregarded FFR had higher rates of MACE [15].
The ideal threshold for FFR in the ACS population has been debated. The FFR 
threshold of 0.80, which is used to determine functional significance in the stable 
ischemic heart disease (SIHD) population, was applied to the ACS population in the 
above studies. The accuracy of this threshold for ACS patients has been challenged. 
Hakeem et  al. found that using the standard FFR threshold of 0.80 for clinical 
decision- making in ACS patients was associated with a threefold increase in the risk 
of subsequent MI and target vessel failure compared with SIHD patients and advised 
caution in using FFR-derived values for clinical decision-making in patients with 
ACS. They found that ACS patients had a higher FFR threshold of functional sig-
nificance, and those with an FFR <0.85 had significantly higher event rates than 
those with FFR >0.85 [16].
Lee et al. found that regardless of the FFR value (FFR = 0.8–1.0), non-culprit 
lesions of ACS had a more than twofold higher rate of MACE that that of SIHD. The 
clinical outcomes of 449 non-culprit lesions in 301 patients with ACS were com-
pared with the outcomes of lesions in patients with SIHD. The primary outcome of 
MACE (a composite of cardiac death, target vessel-related MI, and ischemia-driven 
revascularization) was higher in the ACS population (3.8 vs. 1.6%, HRadj 2.97, 95% 
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CI: 1.23–7.17, p = 0.016) after 2 years and was mainly driven by a higher rate of 
ischemia-driven revascularization [17]. Table 15.1 summarizes the key trials of FFR 
in STEMI and other ACS.
15.7  Coronary Flow Reserve and the Index of Microvascular 
Resistance
Coronary flow reserve measures flow through both the epicardial resistance conduit 
and the microcirculation. It represents the vasodilator capacity of the coronary vas-
cular bed during hyperemia and is another validated index of the functional signifi-
cance of a coronary stenosis. Since most resistance occurs in the microcirculation, 
it is a primary method to measure microvascular flow. It is well-established that the 
failure to achieve myocardial reperfusion in a STEMI results in myocardial hemor-
rhage and infarct. Despite timely reperfusion therapy with PPCI, microvascular 
obstruction still occurs in up to 25–50% of STEMI patients who go on to have a 
higher degree of MACE. Therefore, measuring microvascular function may be a 
useful way to risk stratify STEMI patients.
In a STEMI, the microvasculature of the myocardium supplied by the non-
infarct coronary arteries, in addition to the infarct-related artery, is abnormal. 
Cheng et al. evaluated 18 patients with acute MI and found that the CFR in the 
remote region (i.e., the region supplied by the non-infarct artery) was linked to 
CFR in the infarcted region and correlated with infarct size and severity. Even 
after successful PCI, the CFR in the myocardium supplied by the infarct-related 
artery was lower than normal [18]. A CFR  >  2.0 is generally considered 
normal.
The index of microvascular resistance (IMR) is a direct invasive measure of 
microvascular resistance. It is defined as the distal coronary pressure multi-
plied by the mean transit time of a 3 mL bolus of saline at room temperature 
during maximal coronary hyperemia. It has been less well studied compared to 
FFR, but it may be a useful tool in evaluating the microcirculation during pri-
mary PCI.  An IMR  >  40 is considered abnormal and has been found to be 
associated with microvascular pathology, changes in LV function and EDV, and 
all-cause death and heart failure [19]. In a meta-analysis of six studies, a 
median IMR > 40 was an independent predictor of death [20]. In some studies, 
the combination of a high IMR and reduced CFR enhances the detection of 
microvascular obstruction, but in other studies, the combination did not have 
any prognostic value [21, 22].
An invasive measurement of the coronary microcirculation at the end of primary 
PCI may be a more sensitive measure of successful reperfusion compared with stan-
dard tests such as angiography or ECG. This could help identify high-risk patients 
who may benefit from continued treatment such as with glycoprotein IIb/IIIa inhibi-
tors or intracoronary thrombolysis.
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15.8  Instant Wave-Free Ratio
iFR is a resting index used to assess the severity of an intracoronary stenosis. It 
measures the ratio of the Pd to the Pa during an isolated period of diastole (i.e., the 
“wave-free period”). It is an attractive alternative to FFR because it does not require 
hyperemia and therefore has a lower incidence of patient discomfort, side effects, 
and a shorter procedural time. iFR has been shown to be non-inferior compared to 
FFR in two large, multicenter, randomized controlled trials: the Instantaneous 
Wave-Free Ratio Versus Fractional Flow Reserve in Patients with Stable Angina 
Pectoris or Acute Coronary Syndrome (iFR-SWEDEHEART) trial and the 
Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization 
(DEFINE-FLAIR) trial. Both included patients with NSTEMI ACS, while DEFINE- 
FLAIR also included STEMI patients. The iFR-SWEDEHEART trial included 
2037 patients with stable angina, unstable angina, or NSTEMI and randomly 
assigned them to undergo either iFR- or FFR-guided revascularization. For patients 
with unstable angina or NSTEMI, only non-culprit lesions were evaluated, and the 
culprit lesions were managed as clinically indicated. The rate of primary endpoint 
(composite of death from any cause, nonfatal MI, or unplanned revascularization 
within 12 months after the procedure) was not significantly different between the 
iFR and FFR groups [23].
In the DEFINE-FLAIR trial, 2492 patients with CAD were randomized to have 
iFR-guided or FFR-guided coronary revascularization. Patients with ACS were 
included but only non-culprit vessels and outside of primary intervention during 
acute STEMI. The primary endpoint of a composite of death from any cause, non-
fatal MI, or unplanned revascularization did not differ significantly between groups. 
Additionally, the number of patients in the iFR group had lower rates of adverse side 
effects from the procedure (3.1 vs. 30.8%) and a shorter median procedural time 
(40.5 vs. 45.0 min) compared with the FFR group [24].
 Conclusion
The physiological assessment of coronary stenoses is an integral part of the 
decision- making process for interventional cardiologists. Functional assessment 
in the STEMI and other ACS situation should consider the altered milieu of the 
microvasculature in an infarcted territory. While FFR is not valid in the infarct-
related artery until recovery of the injured myocardium, the microcirculation in 
the non-infarct- related artery is not generally affected to reduce the accuracy of 
FFR and iFR.  Future applications of translesional physiologic indices will 
expand the use of these methods into unique clinical scenarios to improve out-
comes and prognosis.
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16Role of Coronary Artery Bypass Surgery in Acute Myocardial Infarction
William Y. Shi and Julian A. Smith
16.1  Introduction
Coronary artery bypass grafting (CABG) is one of the most commonly performed 
procedures worldwide. Its place in the treatment of coronary artery disease has been 
established for decades with the benefits of CABG versus percutaneous coronary 
intervention (PCI) in various scenarios being extensively investigated. Recent major 
landmark randomised clinical trials such as SYNTAX,1 EXCEL2 and NOBLE3 have 
helped to define the patients in which each approach is likely to be most successful. 
Indeed, the last decade has seen most centres embrace the “Heart Team” concept, 
whereby a collaborative approach helps to optimise patients’ outcomes.
The benefit of timely revascularisation in acute myocardial infarction (MI) is 
well established. The role of PCI and thrombolysis is discussed elsewhere; however, 
the former has now become the preferred strategy worldwide and is associated with 
1 Mohr FW et al., Lancet 2013.
2 Stone GW et al., N Eng J Med 2016
3 Makikallio T et al., Lancet 2016
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good outcomes. In general, PCI and thrombolysis can restore blood flow to the 
myocardium in the timeliest manner, whereas CABG is generally associated with a 
time delay and as such, is utilised in only around 5% of acute MI cases in today’s 
practice.
Historically, large multicentre randomised trials were designed to assess the effi-
cacy of thrombolysis and PCI. CABG was never investigated as a primary treatment 
modality for STEMI in major randomised trials. Thus, high-level evidence for its place 
in the management of acute MI has never been firmly established. Practical, logistic 
and economic restraints mean that surgery remains, in most cases, a third option 
behind PCI and thrombolysis in the management acute MI.  Nevertheless—as this 
chapter will discuss—CABG serves an important role in a select subgroup of patients.
16.2  Indications for CABG in Acute MI
16.2.1  Unsuccessful PCI and Incomplete Revascularisation
Patients with unsuccessful PCI, or those in which a less than satisfactory result has been 
achieved with PCI, should be referred for surgery if the coronary anatomy and patient 
factors are suitable. A substantial portion of patients with acute MI have multi-vessel 
coronary disease which may be long-standing and difficult to manage percutaneously.
Despite effective management of the culprit lesion via PCI, CABG may be 
required once the patient is stabilised in order to complete revascularisation of 
 diseased territories not amenable to PCI. Studies have suggested reasonable early 
and late outcomes for those undergoing emergent CABG after failed angioplasty. 
Even in patients with cardiogenic shock post PCI, CABG may be associated with 
improved survival compared to post-PCI medical therapy alone.
Although uncommon, complications encountered during PCI for STEMI may 
necessitate emergency CABG. These include failed stent deployment, stent frac-
ture, coronary artery dissection, coronary artery perforation or recurrent acute 
thrombosis. In these scenarios, patients with ongoing ischaemia will benefit from 
CABG so as to minimise further myocardial damage.
In general, restoration of blood flow should be a priority, and patients who con-
tinue to have clinical evidence of ongoing ischaemia post-PCI should be offered 
CABG if no further percutaneous options are available. The appropriateness of sur-
gery differs on a case-by-case basis, and co-operation between cardiologists and 
cardiac surgeons is crucial.
16.2.2  Mechanical Complications of Acute Myocardial Infarction
Common mechanical complications of myocardial infarction are acute mitral regurgi-
tation, rupture of the interventricular septum and rupture of the left ventricular (LV) 
free wall. These patients almost always require emergency surgery to repair the defect.
While a culprit lesion may be addressed via PCI, the restoration of blood flow will 
not reduce the haemodynamic burden of the mechanical defect. In select cases, it may 
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be appropriate to perform PCI to the culprit lesion—if it can be done so in a timely 
manner—and then subsequently transfer the patient to the operating theatre for repair 
of the mechanical defect and grafting of other diseased vessels not addressed via PCI. In 
general, this approach is unsuitable in patients with rupture of the LV or ventricular 
septal defect as in these cases, the infarcted area cannot be salvaged with PCI and repair 
of the defect and restoration of normal haemodynamics is of higher priority. In the 
operating theatre, grafting of the culprit vessel in those with LV rupture or ventricular 
septal defect (VSD) is generally not performed due to absence of viable myocardium.
Surgery for mechanical complications of myocardial infarction is associated 
with a high early mortality risk, ranging between 30 and 50%. Predictors of death 
are older age, worsening renal function, emergency surgery and higher filling pres-
sures. Infero-posterior ventricular septal rupture is associated with the worst prog-
nosis, owing to a more technically challenging repair and a higher rate of right 
ventricular dysfunction. Five-year survival ranges between 40 and 60%.
16.2.3  CABG as the Primary Revascularisation Strategy in STEMI
There are no randomised trials directly comparing CABG with PCI in the setting of acute 
MI. In the acute setting, PCI is most often the appropriate approach if there is a clear 
culprit lesion, the distal flow is poor, and a stent can be deployed safely and more rapidly 
than performing CABG. However, approximately 50% of patients presenting with acute 
MI will have multivessel disease, and in stabe patients with complex coronary anatomy 
and higher SYNTAX scores, CABG may be preferable to PCI given its superior long-
term clinical results, as demonstrated from observational and randomised studies.
There are cases in acute MI where CABG may be preferable. Patients who no 
longer have signs of active ischaemia but exhibit complex coronary anatomy may be 
better suited for CABG. Clinical factors such as diabetes and poor ventricular func-
tion also represent indications for CABG over PCI, even in the acute setting. The 
decision on which modality to pursue should be individualised and may also relate 
to whether surgical facilities are available in the local setting.
The advantage of CABG—even in the acute scenario—is that complete revascu-
larisation can be achieved, rather than only targeting the culprit lesion. Complete 
revascularisation restores myocardial perfusion and provides the best opportunity 
for myocardial salvage. The importance of complete revascularisation is even more 
pronounced in patients with multivessel disease, as myocardium may continue to be 
compromised even after a culprit lesion is addressed via PCI.
16.3  Timing of CABG After Acute Myocardial Infarction
The optimal timing of CABG after acute MI is controversial. In many cases, there 
are clear indications for emergency surgery. In situations of ongoing ischaemia, 
mechanical complications or severe cardiogenic shock, patients should be trans-
ferred directly to the operating theatre. However, in the absence of these, the ideal 
timing of surgery is less well established.
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While early surgical revascularisation may limit the size of the infarct and reduce 
the potential for mechanical sequelae, there is the risk of reperfusion injury associ-
ated with early restoration of blood flow. This may lead to haemorrhagic infarction, 
extension of the infarct and greater scar development. It has been postulated that 
early CABG—either with or without cardiopulmonary bypass—after MI may aug-
ment the systemic inflammatory response seen after STEMI.
In a multicentre study of 32,099 cases, Lee and colleagues4 showed that for 
transmural myocardial infarction, in-hospital mortality decreased with increasing 
time interval between myocardial infarct and surgery. Mortality was 14.2% for 
those undergoing surgery within 6 h, and 2.7% for those having surgery beyond 
15 days after presentation. Revascularisation within 3 days of MI was an indepen-
dent predictor of in-hospital mortality on multivariable regression analyses.
Similarly, Thielmann et al.5 reported their results of 138 cases of CABG in acute 
MI and found an overall mortality rate of 8.7%. The mortality rate however varied 
between 23.8% for those operated on between 7 and 24 h after presentation and 
2.4% for those receiving surgery at 8–14 days post-presentation.
At our centre, we generally avoid CABG on patients presenting with an acute 
STEMI and prefer to wait a period of 3–5 days until surgery in the absence of abso-
lute indications for emergent CABG.  Indeed, in cases where early surgery is an 
absolute necessity, we are usually prepared to offer post-operative mechanical cir-
culatory support if the patient had reasonable premorbid function, as mortality is 
likely to result from pump failure.
In addition to timing of surgery, risk factors for mortality in surgery for MI are increas-
ing age, renal impairment, number of previous MIs, hypertension, re- operative surgery, 
cardiogenic shock, reduced left ventricular ejection fraction, the need for cardiopulmo-
nary resuscitation, left main stem coronary disease and the need for intra-aortic counter-
pulsation. On the other hand, preserved left ventricular function, younger age, male 
gender and non-transmural MI are associated with more favourable outcomes.
Some have advocated the use of mechanical circulatory support to stabilise patients 
presenting with MI and shock. Dang and colleagues,6 in an analysis of 74 patients 
undergoing left ventricular assist device implantation for post-MI shock, showed that 
1-year survival was higher in patients undergoing direct left ventricular assist device 
(LVAD) placement rather than revascularisation followed by LVAD implantation.
16.4  CABG in Cardiogenic Shock
In patients with acute MI complicated by cardiogenic shock, CABG has been shown 
to result in a reasonable survival rate. Earlier reports from the 1980s and 1990s sug-
gested in-hospital mortality of approximately 10–30% for those with cardiogenic 
shock undergoing CABG.
4 Lee DC et al., J Thorac Cardiovasc Surg 2003.
5 Thielmann et al., Ann Thorac Surg 2007.
6 Dang NC et al., J Thorac Cardiovasc Surg 2005
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More recently, the SHOCK trial7 randomised 302 patients with acute MI and 
cardiogenic shock to medical therapy versus early revascularisation. Of the early 
revascularisation group, 38% underwent CABG and 55% PCI. One-year survival 
was improved for those receiving early revascularisation compared to medical ther-
apy. However, the design of the trial meant that patients could receive PCI or CABG 
up to 54  h after symptom onset and still be considered to have received early 
 revascularisation. Nevertheless, for patients with cardiogenic shock, CABG repre-
sents a reasonable strategy, despite the higher risk of post-operative low cardiac 
output and end-organ dysfunction.
16.5  Peri-operative and Operative Considerations
Compared to elective CABG, surgery in the context of AMI presents unique chal-
lenges for cardiac surgeons. The heightened risk of mortality and morbidity of 
emergency surgery compared to more conventional elective surgery must be care-
fully considered by surgeons and cardiologists when deciding upon the best mode 
of therapy.
16.5.1  Antiplatelet Therapy
Antiplatelet agents such as clopidogrel and ticagrelor are now commonly adminis-
tered to patients in combination with aspirin as dual antiplatelet therapy (DAPT) at 
presentation with an acute coronary syndrome, or around the time of angiography 
and stent implantation to reduce the risk of stent thrombosis.
In urgent scenarios, or those in whom a stent has been placed to treat a culprit 
lesion, patients often require surgery while on dual antiplatelet therapy. The risk of 
peri-operative bleeding after CABG in patients receiving DAPT is substantially 
increased, with the risk of reoperation for ongoing bleeding being reported as being 
up to 6 times higher. A meta-analysis investigating timing of surgery in patients on 
clopidogrel found that patients on DAPT were more likely to have ongoing bleed-
ing, require reoperation and experience adverse outcomes compared to those in 
whom a washout period of >5 days was observed. However, patients in whom a 
washout period of >5 days was observed, use of clopidogrel was associated with 
lower rates of mortality and myocardial infarction compared to those not on clopi-
dogrel, suggesting a valuable role for DAPT in those presenting with an acute MI.
The American Heart Association/American College of Cardiology (AHA/ACC) 
and European Society of Cardiology/European Association of Cardiothoracic 
Surgery (ESC/EACTS) guidelines suggest cessation of clopidogrel or ticagrelor for 
at least 5 days prior to nonurgent CABG (Table 16.1). For urgent cases, clopidogrel 
or ticagrelor should be discontinued for at least 24 h. At our centre, we generally 
cease clopidogrel or ticagrelor 3–5 days prior to CABG.
7 Hochman et al., N Eng J Med 1999
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16.6  Intra-aortic Balloon Pump (IABP)
For patients who are haemodynamically unstable, the IABP is a useful adjunct 
when performing CABG in the context of acute MI. The IABP has been shown 
to decrease myocardial oxygen requirements. Earlier studies suggested a reduc-
tion in early mortality associated with IABP use. However, the IABP-SHOCK 
II trial,8 which randomised 600 patients with cardiogenic shock complicating 
acute MI to IABP or no IABP, showed that IABP therapy did not significantly 
reduce early mortality. The ACC/AHA guidelines have also changed the recom-
mendation for IABP use in cardiogenic shock from a class I down to a class IIa 
recommendation.
At our centre, we generally insert an IABP for acute MI in patients with cardio-
genic shock in preparation for transfer to the operating theatre so as to provide 
temporary stabilisation until cardiopulmonary bypass can be established.
8 Thiele H et al., Lancet 2013.






Urgent CABG is indicated in patients with STEMI and coronary 
anatomy not amenable to PCI who have ongoing or recurrent ischaemia, 
cardiogenic shock, severe HF or other high-risk features
Class I
Immediate PCI is indicated for patients with cardiogenic shock if 
coronary anatomy is suitable. If coronary anatomy is not suitable for 
PCI, or PCI has failed, emergency CABG is recommended
Class I
CABG should be considered in patients with ongoing ischaemia and 
large areas of jeopardised myocardium if PCI of the ischaemia-related 
artery cannot be performed
Class IIa
CABG is recommended in patients with STEMI at time of operative 
repair of mechanical defects
Class I
The use of mechanical circulatory support is reasonable in patients with 




Emergency CABG within 6 h of symptom onset may be considered in 
patients with STEMI who do not have cardiogenic shock and are not 
candidates for PCI or fibrinolytic therapy
Class 
IIa
For nonurgent CABG, discontinue clopidogrel and ticagrelor for at least 
5 days before surgery and prasugrel for at least 7 days
Class I Class I 
(2014)c
Clopidogrel or ticagrelor should be discontinued at least 24 h before 
urgent on-pump CABG, if possible
Class I Class I 
(2014)
The use of intra-aortic balloon pump (IABP) counter-pulsation can be 




aO’Gara P et al., Circulation 2013
bIbanez et al., Eur Heart J 2017
cWindecker S, Eur Heart J 2014
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16.7  Intra-operative Considerations
In the last decade, observational and randomised studies have suggested a benefit in 
using additional arterial conduits (radial artery, right internal thoracic artery) to 
revascularise the myocardium in addition to the standard left internal thoracic artery 
to left anterior descending artery configuration. Indeed, the ACC/AHA guidelines 
give class II indications to the use of additional arterial conduits.
In general, the selection of conduits is similar to that of elective CABG cases. 
Unless patients are haemodynamically unstable, a LITA should still be harvested 
for revascularising the LAD territory, with additional supplemental conduits such as 
the long saphenous vein or radial artery.
Where patients are unstable with cardiogenic shock, it may be more prudent to 
cannulate the heart and establish cardiopulmonary bypass immediately following 
sternotomy, thus avoiding the 20–30  min delay associated with LITA harvest. 
Cardiopulmonary bypass with decompression of the heart substantially reduces 
wall tension and metabolic requirements. The LITA can then be harvested while on 
cardiopulmonary bypass. With unstable cases, we will generally harvest a LITA on 
cardiopulmonary bypass in younger patients with few comorbidities, while in older 
patients, we will use only peripheral conduits (radial artery, saphenous vein).
Both on-pump and off-pump CABG are acceptable techniques for surgery in 
acute MI. Fattouch et al. randomised 128 patients with STEMI to either on- or off- 
pump CABG and found off-pump surgery to be associated with low mortality 
(1.6%). Off-pump CABG was associated with lower rates of low cardiac output 
syndrome, mechanical ventilation, inotrope use and reoperation for bleeding. In our 
centre, on-pump CABG is our preferred technique; as such off- pump CABG in the 
acute setting is reserved for those cases where significant aortic calcification renders 
aortic cannulation and cross-clamping unsafe.
Some surgeons prefer to perform on-pump surgery without cardioplegic arrest (on-
pump beating heart CABG) in the acute setting, as this has the potential to reduce the 
impact of ischaemic-reperfusion injury associated with aortic cross- clamping. The 
beating heart technique has been shown to achieve similar results compared to con-
ventional CABG with comparable rates of early mortality and morbidity.9
16.8  Results of CABG in Acute MI
Earlier reports of CABG in acute MI showed mortality rates of 5–10%. As throm-
bolysis and PCI have evolved to become first-line the therapies, the spectrum of 
patients presenting for surgery has changed significantly compared to patients 
included in those earlier reports. Contemporary reports of surgery in acute MI show 
early mortality rates of 5–20%, with cardiogenic shock being a major predictor of 
early mortality. Long-term survival after emergency CABG is influenced chiefly by 
patient comorbidities and ventricular function.
9 Chaudhry UA et al., Ann Thorac Surg 2015
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16.9  Conclusions
Bypass surgery, despite not being first-line, remains an important modality in the 
management of patients unsuccessful acute MI. It is reserved for cases where PCI is 
not feasible, or has been unsuccessful, and in those where revascularisation cannot 
be completed with PCI alone. The optimal time to operate on patients can be diffi-
cult to determine. In those with ongoing ischaemia, emergency surgery is indicated. 
However, in stable patients, delayed surgery is associated with improved outcomes. 
For cardiac surgeons, surgery for acute MI presents additional challenges including 
bleeding risk, conduit selection and the decision to utilise mechanical support. A 
collaborative “Heart Team” approach ensures the management approach is tailored 
specifically to the patient.
16.10  Coronary Artery Bypass Surgery for STEMI
William Y. Shi and Julian A. Smith
16.11  Illustrative Cases
When managing patients with acute MI, cardiologists and cardiac surgeons may be 
faced with a number of difficult clinical decisions. The two cases below represent 
“real-life” clinical cases from our institution and illustrate the key themes discussed 
in this chapter.
16.11.1  Case 1: Delayed Surgery After PCI for Acute MI
A 54-year-old man presented with an acute STEMI. He had experienced intermit-
tent chest pain for several months. ECG revealed ST elevation in the inferior leads 
with ST depression in the anterolateral leads. He was loaded with 300 mg aspirin 
and 180 mg ticagrelor. He had no other past medical history. Coronary angiography 
revealed chronic total occlusion of the left anterior descending and left circumflex 
systems. The right coronary system was dominant. There was occlusion of the prox-
imal segment with TIMI I flow due to acute plaque rupture. The right coronary 
artery was providing retrograde collateral blood supply to the left coronary system. 
The right coronary occlusion was deemed to be the culprit lesion, and this was 
stented using a drug-eluting stent (Fig. 16.1).
The patient was subsequently referred for consideration of surgery given the left 
coronary system was not suitable for PCI.  Subsequent transthoracic echocardio-
gram demonstrated severe left ventricular dysfunction (LV ejection fraction 30%). 
Troponin I peaked at 7500ng/L.
The patient experienced short episodes of chest pain upon return to the ward; as 
such he was commenced on heparin and glyceryl trinitrate infusion and thereafter 
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remained pain-free. Given his haemodynamically stable state, poor ventricular 
function and substantial infarct size, the decision was made to delay surgery due to 
the high mortality risk associated with early surgery for acute MI. Due to recent 
PCI, dual antiplatelet therapy could not be ceased prior to surgery, and as such aspi-
rin 100 mg daily and ticagrelor 90 mg twice daily were administered up until the 
day of surgery.
The patient subsequently underwent surgery for CABG 7 days later and 
received a left internal thoracic artery to his left anterior descending artery and a 
radial artery to an obtuse marginal branch of the circumflex. An epicardial left 
ventricular lead was placed to facilitate cardiac resynchronisation therapy should 
the patient require it in the future. An intra-aortic balloon pump was considered 
but ultimately not used as the patient was weaned off cardiopulmonary bypass on 
Fig. 16.1 Coronary angiogram demonstrating chronic occlusions of the LAD and circumflex ves-
sels and acute occlusion of the proximal right coronary artery. Post-PCI result is demonstrated on 
the bottom right
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low-dose inotropes. Thromboelastography demonstrated abnormal platelet func-
tion, and platelet transfusion was required to obtain satisfactory haemostasis prior 
to surgical closure.
The patient was extubated on day 1 post-surgery. Aspirin was commenced on 
post-operative day 1, and ticagrelor was recommenced on post-operative day 2. 
Recovery was complicated by post-operative atrial fibrillation for which he received 
amiodarone. The patient was ultimately discharged home on post-operative day 11.
16.11.2  Case 2: Emergency CABG for Ongoing Ischaemia
A 72-year-old man presented with an inferior ST-elevation myocardial infarction. 
He had a past history of type 2 diabetes mellitus, hypercholesterolaemia, chronic 
obstructive pulmonary disease, obesity and chronic renal impairment. He presented 
with several hours of chest pain with inferior ST elevation. He developed cardio-
genic shock and acute pulmonary oedema requiring an adrenaline infusion and 
mechanical ventilation before transfer to the cardiac catheterisation laboratory.
Coronary angiography demonstrated an occluded distal right coronary artery with 
evidence of thrombus. His left anterior descending artery also showed severe disease 
with mid-segment occlusion (Fig. 16.2). Attempted PCI to the right coronary lesion 
was unsuccessful due to inability to pass the guidewire beyond the lesion. There was 
ongoing inferior ST elevation and hypotension. The patient was referred for emer-
gency CABG. Given the patient’s haemodynamic instability, an IABP was inserted in 
the catheterisation laboratory prior to transfer to the operating theatre. Transthoracic 
echocardiography demonstrated severe left ventricular impairment (EF 15%).
In the operating theatre, after sternotomy, cardiopulmonary bypass was immediately 
established. Simultaneously, the long saphenous vein was harvested. The LITA was not 
harvested. Saphenous vein was used to revascularise the LAD and the PDA. The patient 
was weaned off cardiopulmonary bypass using the IABP as an adjunct.
Fig. 16.2 Coronary angiogram of case 2, demonstrating occluded LAD and RCA. The RCA had 
evidence of thrombus formation, suggesting its role as the culprit lesion
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Post-operatively, the patient was supported on adrenaline infusion. The IABP 
was weaned and removed on post-operative day 2. The patient’s recovery was com-
plicated by prolonged ventilation, requiring tracheostomy and renal failure, requir-
ing temporary dialysis. The patient was discharged after 1 month to a rehabilitation 
facility and then subsequently discharged home.
Further Readings
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myo-
cardial infarction in patients presenting with ST-segment elevation: The Task Force for the 
management of acute myocardial infarction in patients presenting with ST-segment elevation 
of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–77. https://doi.
org/10.1093/eurheartj/ehx393.
Lee DC, Oz MC, Weinberg AD, Ting W. Appropriate timing of surgical intervention after transmu-
ral acute myocardial infarction. J Thorac Cardiovasc Surg. 2003;125:115–9.
Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutane-
ous coronary intervention in patients with three-vessel disease and left main coronary disease: 
5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381:629–38.
O’Gara PT, Kushner FG, Ascheim DD, et  al. 2013 ACCF/AHA guideline for the management 
of ST-elevation myocardial infarction: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 
2013;127:e362–425.
Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial 
infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a 
randomised, open-label trial. Lancet. 2013;382:1638–45.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter’s Creative Commons license and your intended use is not permitted by 
 statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
16 Role of Coronary Artery Bypass Surgery in Acute Myocardial Infarction
223© The Author(s) 2018
T. J. Watson et al. (eds.), Primary Angioplasty, 
https://doi.org/10.1007/978-981-13-1114-7_17
J. Adjedj · O. Muller · E. Eeckhout (*) 
CHUV, Cardiology Department, Lausanne University Hospital, Lausanne, Switzerland
e-mail: eric.eeckhout@chuv.ch
17A Handbook of Primary PCI: No-Reflow Management
Julien Adjedj, Olivier Muller, and Eric Eeckhout
17.1  Introduction
Although substantial progress has been made in recent decades in reducing mortal-
ity and performing optimal revascularization in patients with acute coronary syn-
drome (ACS) and stable coronary artery disease (CAD), one of the remaining 
challenges is to better prevent and treat extended myocardial damage despite 
“apparent” angiographic optimal percutaneous coronary intervention (PCI). The 
presence of no-reflow is related to higher risk of major adverse cardiac events 
(MACE) due to the poor healing of the infarct, adverse left ventricular remodelling, 
congestive heart failure occurrence and death. Despite optimal epicardial coronary 
artery reperfusion performed by PCI, distal microembolization into the coronary 
microcirculation limits myocardial salvage especially during ACS. No-reflow repre-
sents the ultimate stage of extended myocardial damage after PCI with absence of 
contrast medium progression in the coronary artery. This complication occurs 
mainly during ACS or during PCI of rotational atherectomy and venous graft in 
stable patients. The objective of this chapter is to describe how to manage a no- 
reflow phenomenon from the pathophysiology to the management in order to help 
physician to prevent this complication and if no-reflow occurs adapt therapeutics to 
limit myocardial damage and reduce poor outcomes.
17.2  Definition
The no-reflow phenomenon is defined as inadequate myocardial perfusion through 




Understanding the pathophysiology of the no-reflow phenomenon is the key to 
manage this phenomenon and prevent poor outcome. After prolonged coronary 
occlusion and restoration of coronary blood flow, structural damage to the micro-
vasculature reduces the amount of blood flow to the cardiac myocytes. This may 
lead to inadequate healing of the cardiac scar.
17.4  Aetiology
No-reflow phenomenon is commonly the consequence of distal embolization and 
reperfusion injury such as:
• Thrombus containing lesions (ACS)
• Oxygen free radical or cellular-mediated endothelial injury (ACS)
• Loss of microvascular compartment due to completed myocardial infarction
• Cellular and interstitial oedema
• Atherosclerotic debris (venous bypass graft or rotational atherectomy)
• Microvascular constriction of vasospasm (drugs, choc)
No-reflow generally occurs immediately after PCI between 1 and 3% of PCI and 
can arise in different clinical settings [2–8]:
 – Late presentation ACS
 – Large thrombus burden
 – Venous bypass graft PCI
 – Rotational atherectomy
 – Cardiogenic shock
17.5  Diagnosis
17.5.1  Clinical Presentation
Generally during ACS, revascularization is associated with relief of symptoms such 
as chest pain and regression of the ST-segment elevation in the electrocardiogram 
(ECG) in absence of no-reflow. In the presence of no-reflow, in the catheterization 
laboratory, the clinical presentation of no-reflow is often sudden and tragic. Control 
of coronary angiography confirms contrast medium staining in the coronary artery; 
the patient might complain of chest pain and symptoms persistence with a residual 
or increase elevation of the ST segment generally followed by haemodynamic 
instability.
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17.5.2  Coronary Angiography
Contrast medium progression speed into the coronary artery is preserved in the 
absence of sub occlusive coronary stenosis (<90%) and in the absence of microcircu-
lation damage. Therefore, after successful revascularization of an epicardial coronary 
stenosis, contrast medium progression impairment could reflect microcirculation 
damage. From the Thrombolysis in Myocardial Infarction (TIMI) study group, two 
indices were described: TIMI flow grade 0–3 is a semi-quantitative variable that 
ranges from no contrast medium progression (0) to normal progression (3); TIMI 
frame count is a quantitative index calculating the number of frames between two 
landmarks proximal and distal to the interrogated coronary artery [9]. In patients with 
ACS and preserved TIMI grade flow after revascularization, microcirculation can also 
be evaluated with myocardial blush, which corresponds to a densitometric method, 
assessing maximum intensity of contrast medium in the microcirculation. In practice, 
coronary microvascular obstruction is defined as TIMI grade flow ≤3 with myocardial 
blush stagnation (grade 0 or 1) [10] and no-reflow as the absence of contrast progres-
sion in the coronary vessel of interest in his most evident form. However, this may be 
subtle with preserved TIMI flow and absence of myocardial blush.
17.6  Management of No-Reflow
17.6.1  No-Reflow Prevention: Before the Procedure
No-reflow phenomenon is rare among overall PCI (1–3%) although some situations 
are associated with higher rate of no-reflow; therefore, management of some factors 
could help to prevent its occurrence according to the aetiology. Traditional cardiovas-
cular risk factors are associated with poor outcome and no-reflow increase rate. In 
patients with diabetes, optimal blood sugar control before the procedure could reduce 
the occurrence of no-reflow [11, 12]. An animal study suggests that hypertension 
might be associated with increased risk of no-reflow [13]. Meta-analysis showed that 
pre-procedural use of statins was associated with significant reduction rate of no-
reflow by 4.2% in all PCI patients (risk ratio (RR) 0.56, 95% confidence interval (CI) 
0.35–0.90, P = 0.016) and attenuated by 5.0% in non-STEMI patients (RR 0.41, 95% 
CI 0.18–0.94, P = 0.035). This benefit was mainly observed in the early or acute inten-
sive statin therapy populations (RR 0.43, 95% CI 0.26–0.71, P = 0.001) [14]. Active 
double antiplatelet therapy will prevent PCI complications such as acute stent throm-
bosis, periprocedural myocardial infarction (MI) and no- reflow (Fig. 17.1).
17.6.2  No-Reflow Prevention: During the Procedure
General good practice of PCI could limit the no-reflow occurrence. Anticoagulation 
should be performed at the early phase of the procedure with unfractionated heparin 
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(70–100 UI/Kg) and monitored with the activated clotting time (ACT) (200–250). 
Intracoronary nitrates should be administered (100–200 mcg) as well at the early 
phase, i.e. second angiographic view of diagnostic procedure. Optimal catheter 
selection is key to avoid damping intracoronary pressures, which can reduce coro-
nary flow due to catheter induced obstruction and thereby lead to thrombus forma-
tion. Regular and systematic flushing of catheters can avoid thrombus and air 
emboli. Because new microthrombus composed of platelet and fibrin is an impor-
tant contributor to the pathogenesis of the no-reflow phenomenon, glycoprotein IIb/
IIIa platelet receptor inhibitor (anti-GPIIb/IIIa) may be beneficial in prevention dur-
ing PCI. Studies suggest that anti-GPIIb/IIIa is beneficial in reducing rates of death, 
reinfarction and urgent revascularization when used in conjunction with PCI par-
ticularly as a rescue strategy [15] (Fig. 17.1).
17.6.2.1  Rotational Atherectomy
Balloon angioplasty exerts beneficial effects by enlarging the weakest part of coro-
nary artery wall thereby producing intimal splits and medial dissections in calcified 
lesions. In contrast, rotational atherectomy aims to weaken calcified lesions, erode 
calcium spicule protrusion and thereby obtains a relatively smooth luminal surface. 
Rotational atherectomy use a burr rotation with high speed which generate friction 
(microembolization) and heat (platelet activation) between the burr and calcify plaque.
In experimental modelling, heat varies with technique from 2.6 °C using inter-
mittent ablation and permitting minimal decelerations (5000 rpm) to 13.9 °C using 
continuous ablation allowing excessive decelerations (16,000 rpm) [16]. Along with 
microembolization of debris associated with thrombi, thermal injury may contribute 
to microvascular obstruction and no-reflow. To prevent these phenomena, medical 
therapy includes effective dual antiplatelet therapy, vasodilators and proper use of 
rotablational atherectomy. The benefit of antiplatelet therapy was established with 
the use of anti-GPIIb/IIIa reducing procedural morbidity and CK-MB elevation 
[17]. Preventive vasodilators are used for the purpose of reducing slow-flow and 
no- reflow, combining nitrates with calcium inhibitors and sometimes adenosine in 
the flush solution associated with heparin. Nicardipine may be effective when 
administered in a flush solution with other drugs during rotational atherectomy [18]. 





















Venous graft PCI protocol
No-Reflow
Fig. 17.1 No-reflow prevention and treatment
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complications is to perform short runs (15 s) with a pecking motion to preserve flow 
at a speed rate of 140,000 rpm and avoid deceleration >5000 rpm with maintained 
patient haemodynamics [19].
17.6.2.2  Venous Graft PCI
Venous graft intervention is associated with higher rates of periprocedural MI and 
in-hospital mortality compared with PCI of native coronary arteries due to highly 
friable atherothrombotic debris of venous graft lesion. Therefore, distal emboliza-
tion may result in slow or no-reflow phenomenon in more than 10% of cases. To 
prevent this distal embolization, it is recommended (IA) [20] to use distal protection 
device during stent implantation. In practice an American national registry showed 
that this protection device was used only in less than 25% of venous graft PCI, but 
still, the use of protection device was independently associated with a lower inci-
dence of no-reflow but not in-hospital mortality [21]. It is interesting to notice this 
study evaluated the use of intragraft infusion of adenosine during peri procedure 
venous graft PCI. The study showed a significant reduction of no-reflow rate and 
increase average peak velocity compared to control group [22]. Nicardipine may be 
effective when administered before PCI in vein grafts to prevent no-reflow with 
minimal systemic depressant effect [18].
17.6.3  No-Reflow Confirmation
Priority is to exclude other mechanical aetiology which could occur after PCI and 
limit the contrast progression (Fig. 17.2). After PCI other causes such as coronary 
spasm, diffusion of coronary haematoma, coronary dissection, intracoronary occlu-
sive thrombus or distal coronary stenosis could have similar angiographic and clini-
cal presentation. Therefore, the easiest way to confirm this diagnosis is to perform, 
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TIMI Grade ≤ 3
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after nitrates administration, distal coronary opacification using extension of guid-
ing catheter, intracoronary microcatheter, thromboaspiration catheter or over-the- 
wire angioplasty balloon. Careful and gentle distal contrast injection should be 
performed after aspirating some blood to confirm the true lumen position and the 
absence of obstruction due to thrombus or coronary wall at the exit of the catheter. 
Visualization of the distal part of the coronary artery is precious to exclude other 
causes of epicardial obstruction and confirm the no-reflow. Furthermore, microcath-
eters allow distal administration of drugs such as calcium inhibitors or adenosine 
which, by definition, could not reach the microvasculature in the no-reflow area 
from a guiding administration. An example is provided in Fig. 17.3.
17.6.4  No-Reflow Treatment
In no-reflow, microvascular damage is usually confined in the related coronary artery 
territory which constitutes a myocardial necrosis area. Therefore, treating no- reflow 
may not necessarily reduce the infarcted size but might improve blood flow to the 
necrotic area to improve area healing, infarction expansion and prevent left ventricular 
remodelling. Furthermore, restauration of flow will salvage the small vessels which 
may help promote collateral circulation and ensure drug delivery to the necrotic zone. 
To decrease the incidence of this phenomenon, short-term intracoronary and systemic 
drugs were studied to restore coronary flow within the no-reflow area (Table 17.1).
17.6.5  Haemodynamic Stabilization
Before starting dedicated therapeutics to treat no-reflow, it is essential to evaluate 
the patient haemodynamic to maintain optimal aortic blood pressure. Of note, no- 
reflow of the right coronary artery is prone to reflex hypotension or bradycardia 
which needs atropine administration. General supportive measures are usually used 
to maintain stable haemodynamic such as fluid administration and if necessary 
Fig. 17.3 Example of no-reflow management in a 72-year-old patient with anterior MI and no- 
reflow after DES implantation in the mid-left anterior descending artery
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inotrope support such as epinephrine. In rare refractory cases intra-aortic balloon 
pump might be an option to maintain overall coronary perfusion.
17.6.6  Thromboaspiration
One must realize that manipulating the occluded thrombotic vessel with balloons and 
stents often results in distal embolization of the thrombus, which might contribute to 
no-reflow occurrence. To prevent distal embolization, thromboaspiration might help to 
reduce the thrombus burden and therefore the degree of no-reflow. Thromboaspiration 
was widely used in the past years in STEMI patients, but recent study results and meta-
analyses failed to show benefit with an increased risk of stroke. Therefore, actual 
guidelines do not recommend to perform systematic thromboaspiration [23].
17.6.7  Pharmacological Therapeutics
17.6.7.1  Adenosine
Adenosine used in myocardial infarction might have some benefit in terms of pre-
venting extensive microcirculation injury. Intravenous adenosine, given before 
reperfusion therapy, was suggested to reduce infarct size compared with placebo in 
the AMISTAD randomized clinical trial [24]. Similarly, the larger AMISTAD II 
trial demonstrated infarct size reduction in the adenosine group compared with the 
placebo group, but without significant benefit in terms of clinical outcome [25]. 
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When looking at the post hoc analysis of the AMISTAD II trial, in the subgroup 
with successful reperfusion within 3 h, the adjunct of adenosine infusion enhanced 
early and late survival and reduced the composite clinical endpoint of death or con-
gestive heart failure at 6 months [26]. In addition, during reperfusion, the addition 
of intracoronary adenosine after thromboaspiration, through the thrombectomy 
catheter, showed a significant improvement in STR, with better 1-year left ventricu-
lar remodelling and reduction in clinical events compared with saline and nitroprus-
side [27, 28].
17.6.7.2  Statins
Based on STR, TIMI frame count and myocardial blush, Kim et al. showed that a 
high dose of atorvastatin may produce an optimal result in patients with STEMI 
undergoing PCI by improving microvascular myocardial perfusion, without signifi-
cant clinical improvement [29].
17.6.7.3  Calcium Inhibitors and Other Drugs
Finally, intracoronary calcium inhibitors (verapamil, diltiazem and nicardipine) are 
probably the most evaluated and effective drugs available for the prevention and 
treatment of no-reflow phenomenon. In a meta-analysis by Su et al., including 7 
trials involving 539 patients with intracoronary verapamil administration at a dos-
age of 200 μg to 2 mg, the authors showed a significant decrease in no-reflow inci-
dence, a better TIMI grade and frame count and a reduction in major adverse cardiac 
events (MACE), 2 months after PCI (relative risk 0.56, 95% confidence interval 
0.33–0.95) [30]. Another Meta-analysis of 8 randomized controlled trials involving 
494 patients evaluated the efficacy of the combination of verapamil and diltiazem or 
verapamil alone to treat no-reflow which suggested significant clinical benefit over 
standard of care with respect to no-reflow [31].
Nitroprusside is an effective intracoronary drug in the treatment of no-reflow. 
Two meta-analyses showed that intracoronary nitroprusside is beneficial in prevent-
ing no-reflow in reducing TIMI frame count and in improving left ventricular ejec-
tion fraction. It is also likely to reduce MACE [32, 33].
17.7  Outcome
After the procedure, non-invasive indexes are of importance to evaluate the myocar-
dial damage and assess potential poor outcome.
17.7.1  ECG
Among several indices to assess microvascular obstruction with ECG, only the 
residual ST-segment elevation was an independent predictor of microvascular injury 
(odds ratio 19.1, 95% confidence interval 2.4–154; P = 0.005) in multivariable anal-
ysis in a study evaluating ECG in 180 patients with STEMI.  Interestingly, 
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ST-segment resolution was not associated with LV function, infarct size, transmu-
rality indexes or microvascular injury in multivariable analysis [34] (Fig. 17.4a). A 
distortion of the terminal portion of the QRS complex was significantly associated 
with infarct size, impaired myocardial salvage and reperfusion injury in 572 patients 
with reperfused STEMI as assessed by cardiac magnetic resonance imaging (CMR). 
Moreover, this QRS modification was independently associated with MACE [35].
17.7.2  Echocardiography
Myocardial contrast echocardiography (MCE) is a bedside technique that can be 
used to assess microvascular perfusion (Fig. 17.4c). Echo contrast agents are micro-
bubbles of inert gases of sizes and rheology similar to that of red blood cells and can 
be administered intravenously. Myocardial uptake of microbubbles is delayed in 
areas of “no-reflow” and MVO. MCE is able to detect only 1/3 of patients with a 
no-reflow phenomenon after ACS [36, 37]. However, widespread use of MCE has 
been hampered by a long learning curve for image acquisition and reporting, 
a b
dc
Fig. 17.4 Non-invasive tools to assess microvascular obstruction. (a) ST-segment resolution rep-
resents a useful tool of coronary microvascular obstruction after myocardial infarction. Black 
arrows showing absence of ST-segment resolution after artery recanalization. (b) Cardiac magnetic 
resonance. On late gadolinium enhancement, areas of microvascular obstruction are seen, hypoen-
hancement (so-called “dark zones”) within an avidly enhancing site of myocardial infarction. (c) 
Myocardial contrast echocardiography showing lack of intra-myocardial contrast opacification 
(indicated by white arrow). (d) Single-photon emission computed tomography showing absent 
tracer uptake (white arrow, scintigraphic no-reflow phenomenon), as compared to normal uptake 
(left position). Adapted from Adjedj, J., et al. (2018). “Coronary microcirculation in acute myocar-
dial ischaemia: From non-invasive to invasive absolute flow assessment.” Arch Cardiovasc Dis
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uncertain reproducibility, concerns over microbubble contrast safety. Moreover, 
MCE has some limitations such as operator skills, moderate spatial resolution, 
incomplete left ventricular coverage and semi-quantitative assessment of MVO.
17.7.3  Cardiac Magnetic Resonance
CMR is the non-invasive gold standard to assess MVO. It allows multislice imag-
ing with high tissue contrast and high spatial resolution, enabling accurate quan-
tification and localization of MVO and the infarct size relative to the entire left 
ventricle (Fig. 17.4b). CMR-defined MVO has been well correlated with MCE, 
angiographic and invasive indices used for the assessment of MVO [38]. Symons 
et  al. demonstrated that early post-infarction CMR-based MVO was a strong 
independent predictor of MACE in reperfused STEMI patients at long-term fol-
low-up. Remarkably, MVO extent ≥2.6% of LV was the strongest independent 
predictor of death and heart failure hospitalization, overriding the prognostic 
performance of traditional outcome predictors and leading to better long-term 
risk stratification [39].
17.7.4  Nuclear Imaging
Both single-photon emission computed tomography [40] and positron emission 
tomography (PET) [41] demonstrated the “no-reflow” phenomenon in humans 
could be detected by nuclear imaging. Nuclear imaging no-reflow phenomenon can 
occur in a subgroup of patients without angiographic no-reflow phenomenon, that 
the myocardial damage depends on the severity of microvascular damage and that 
prolonged ischemia time may increase the likelihood of “microvascular no-reflow 
phenomenon” (Fig.  17.4d) [42]. However, PET scanning is still underutilized in 
clinical practice, and its clinical use is limited to sites with PET scans and cyclo-
trons or generators.
 Conclusion
Currently, there is still a lack of an optimal treatment for no-reflow phenomenon. 
Prevention is effective to reduce no-reflow occurrence with medical therapy and 
proper use of dedicated techniques such as rotational atherectomy and venous 
graft PCI. The diagnosis of no-reflow remains a challenge and, if not recognized, 
may be treated inadvertently by additional PCI which will only harm the situa-
tion. When no-reflow occurs, the main objective is to diagnose properly, stabilize 
the patient and treat this condition by sub selective administration of vasodilator 
drugs to “open” the microcirculation, avoiding a systemic effect on the blood 
pressure. No-reflow management aims to improve coronary blood flow at the 
level of microcirculation to reduce myocardial damage and improve clinical 
outcome.
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Shock is circulatory failure with inadequate cellular oxygen utilization. Four poten-
tial pathophysiological mechanisms result in shock, including hypovolemic, cardio-
genic, obstructive, and distributive factors. Cardiogenic shock (CS) decreases 
myocardial contractility and is the most common cause of death in patients with 
acute myocardial infarction (AMI). To differentiate the type and cause of shock, 
medical history, physical examination, and clinical investigations are important. 
Focused echocardiography offers advanced information for differentiation and 
should be performed as soon as possible in any shock patient.
AMI with subsequent ventricular dysfunction is the most frequent cause of CS 
accounting for about half of cases, and other causes of CS include end-stage cardio-
myopathy, advanced valvular heart disease, myocarditis, and cardiac arrhythmias. 
Around 5–15% AMI patients complicated with CS. For AMI patient, early revascu-
larization is the most important strategy [1]. In addition to percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG), intra-aortic balloon 
pumping (IABP), active assist devices, inotropes, and vasopressors are widely used 
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for CS management. Resuscitation should be started early and adequately to prevent 
organ dysfunction worsening. The basic resuscitation principles for patients with 
CS are based on the “VIP rule,” including ventilate (oxygen administration), infuse 
(fluid resuscitation), and pump (vasoactive agents). The chapter focused on inotro-
pic support in cardiogenic shock patient.
18.2  Definition and Initial Assessment
CS is a lethal disease and a state of reduced cardiac output and critical end organ 
hypoperfusion. It ranges from mild hypoperfusion to profound shock and multi- 
organ system dysfunction. Established criteria for the diagnosis of CS are (1) sys-
tolic blood pressure (SBP) <90 mmHg for >30 min, vasopressors required to achieve 
SBP ≥90 mmHg, or a reduction of cardiac index (<1.8 L/min/m2 without support 
and less than 2.2 L/min/m2 with support); (2) pulmonary congestion or elevated left 
ventricular filling pressures (pulmonary capillary wedge pressure > 18 mmHg); and 
(3) impaired organ perfusion. Inadequate organ perfusion contains at least one of 
the following criteria: (a) altered mental status; (b) cold, clammy skin; (c) oliguria; 
and (d) increased serum lactate. Clinical signs of tissue hypoperfusion are apparent 
through three “windows” of the body: (1) skin (cold and clammy skin, with vaso-
constriction and cyanosis), (2) kidney (urine output of <0.5 mL per kilogram of 
body weight per hour), (3) and brain (altered mental state, which typically includes 
obtundation, disorientation, and confusion). Hyperlactatemia is typically present, 
indicating abnormal cellular oxygen metabolism. The normal blood lactate level is 
approximately 1 mmol per liter, but the level is increased (>1.5 mmol per liter) in 
acute circulatory failure. A full clinical assessment contains skin color and tempera-
ture, jugular venous distention, and peripheral edema. Point-of-care echocardio-
gram offers advanced information for diagnosis via the evaluations of pericardial 
effusion, left and right ventricular size and function, and respiratory variations in 
vena cava dimensions, the calculation of the aortic velocity–time integral, and a 
measure of stroke volume [1–3].
18.3  Initial Approach to the Patient in Cardiogenic 
Shock (VIP)
Irrespective of early revascularization by PCI or CABG, the basic principle of treat-
ment for CS is “VIP rules” to maintain ventilation, obtain euvolemia with volume 
expansion, and administer vasopressors or inotropes for the prevention or treatment 
of multi-organ dysfunction.
18.3.1  Ventilation
Oxygen should be administered immediately to increase oxygen delivery. Pulse 
oximetry is not reliable due to peripheral vasoconstriction, and blood gas 
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monitoring is required for precise determination of oxygen. For CS patients present-
ing with severe dyspnea, hypoxemia, persistent, or worsening acidemia (pH <7.30), 
symptoms could rapidly progress in respiratory failure and cardiac arrest, which 
prompted physicians to perform endotracheal intubation and invasive mechanical 
ventilation. Invasive mechanical ventilation also reduces the oxygen demand of 
respiratory muscles and decreases left ventricular afterload by increasing intratho-
racic pressure. After the initiation of invasive mechanical ventilation, an abrupt 
decrease in arterial pressure implies hypovolemia, and sedative agents in minimum 
should be kept to avoid further decrease in arterial pressure and cardiac output.
18.3.2  Fluid Resuscitation and Objective Fluid Status Evaluation
The pragmatic endpoints for fluid resuscitation are to achieve the plateau portion of 
the Frank–Starling curve and become preload-independent status. In patients receiv-
ing mechanical ventilation, signs of fluid responsiveness could be identified directly 
from beat-by-beat stroke-volume measurements with the use of cardiac-output 
monitors or indirectly from observed variations in pulse pressure on the arterial- 
pressure tracing during the ventilator cycle. There are several limitations in such 
bedside inferences, including that patients must have no spontaneous breathing 
effort (usually requires the administration of sedatives or muscle relaxants), receive 
ventilation with relatively large tidal volumes, and be free of major arrhythmia and 
right ventricular dysfunction. A passive leg-raising test is an alternative method, but 
the effect is transient and requires a rapid response device.
Four elements are incorporated in fluid challenge, including (1) the type of fluid, 
(2) the rate of fluid administration, (3) the objective of fluid challenge, and (4) the 
safety limit. First, crystalloid solutions are the first choice, and the use of albumin to 
correct severe hypoalbuminemia may be reasonable in some patients. Second, fluids 
should be infused rapidly to achieve a quick response but not fast to develop an 
artificial stress response. (i.e., infuse 300–500  mL of fluid during a period of 
20–30 min). Third, the objective of the fluid challenge contains an increase in SBP, 
a decrease in heart rate, or an increase in urine output. Finally, the safety limit is to 
avoid fluid infusion-associated pulmonary edema, and central venous pressure of a 
few millimeters of mercury above the baseline value is usually set to prevent fluid 
overload, although it is not a perfect guideline. Because hemodynamic management 
depends on optimal filling pressures, pulmonary artery catheters, Pulse Contour 
Cardiac Output (PiCCO), or other measure systems should be used in all compli-
cated patients [4].
18.4  Vasoactive and Inotropic Agents
Catecholamines are used in near 90% CS patients, but there is limited evidence 
from randomized trials to compare different catecholamines. In SOAP II (Sepsis 
Occurrence in Acutely Ill Patients) trial, dopamine was shown to have higher rates 
of arrhythmias and mortality in CS subgroup [5]. Nevertheless, clinical and 
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methodological concerns have raised questions about the external validity and 
applicability of the findings because SOAP II trial did not have an operationalized 
definition of CS. The predefined CS subgroup had lower mortality with norepineph-
rine [5]. Therefore, norepinephrine should be the first choice as vasopressor in 
patients with CS. European STEMI guidelines recommend dopamine (IIa/C recom-
mendation) over norepinephrine (IIb/B recommendation), which are partly confus-
ing and are in contrast to current evidence, but it is also stated that norepinephrine 
is preferred over dopamine when the blood pressure is low.
There are no clear SBP or mean arterial pressure (MAP) recommendations for 
CS patients. MAP targets are often extrapolated from non-CS populations and 
65–70 mm Hg has been considered a reasonable target. However, higher blood pres-
sure is not associated with beneficial outcome [6]. CS is a hemodynamically hetero-
geneous disorder; thus despite improvements in hemodynamic variables, 
microcirculatory dysfunction may persist. Inotropic and vasopressor agents have 
been recommended and used in the treatment of patients with shock. Despite the 
benefit of myocardial contractility, the pharmacodynamics of different inotropic 
agents and associated side effects (arrhythmias and increased myocardial oxygen 
consumption) may increase mortality [7]. The use of catecholamine and vasocon-
strictors should be restricted to the shortest duration and the lowest possible dose. 
The ideal inotrope would increase cardiac output and reduce ventricular filling pres-
sures and mortality without adverse effects. Several studies still continue to develop 
ideal inotrope for the treatment of CS [8]. Omecamtiv mecarbil is a promising new 
drug for stable heart failure that exerts inotropic effects by activating cardiac myo-
sin [9]. Gene therapy is another area and further results of these new approaches are 
awaited [10]. Medications and their characteristics prescribed in CS patients are 
listed in Table 18.1 [11]. Initial vasoactive management strategies in different types 
of CS are presented in Table 18.2.
18.5  Vasoactive Agents
18.5.1  Norepinephrine
Norepinephrine is a naturally occurring catecholamine and acts mainly on 
α-adrenergic receptor but has small effect on beta receptor. Norepinephrine can 
increase blood pressure by constricting small vessels. The increasing blood pressure 
will stimulate the parasympathetic tone, with little change in heart rate or cardiac 
output. The well-known adverse effects are reduced renal and splanchnic blood 
flow, especially in patients needing volume expansion. Norepinephrine is associated 
with fewer arrhythmias and may be the vasopressor of choice in many patients with 
CS. However, in light of SOAP II trial limitations, the optimal first- line vasoactive 
medication in CS remains unclear, but norepinephrine should be considered as the 
vasopressor of first choice.
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Mitral stenosis 1. Phenylephrine or 
vasopressin
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dependent state







Surgical mitral valve 
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2. Inotropic agents


















1. Classic wet and cold 
considerations
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including IABP
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vasopressin
3. Avoid inotropic 
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4. Avoid vasodilating 
agents
5. Esmolol or 
amiodarone
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4. Induce ventricular 
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CI cardiac index, CS cardiogenic shock, HR heart rate, IABP intra-aortic balloon pump, LVEDP 
left ventricular end-diastolic pressure, LVEF left ventricular ejection fraction, LVOT left ventricu-
lar outflow tract, MCS mechanical circulatory support, MI myocardial infarction, PAC pulmonary 
artery catheter, PVR pulmonary vascular resistance, RV right ventricular, SBP systolic blood pres-
sure, SVR systemic vascular resistance
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18.5.2  Epinephrine
Epinephrine is a naturally occurring catecholamine which acts on both α- and 
β-receptor. Epinephrine has predominantly β-adrenergic effects in lower dosage, 
which increases myocardial contraction and heart rate. In higher dosage, it acts on 
α-adrenergic receptor and constricts peripheral small vessels which can increase 
blood pressure. Epinephrine is associated with arrhythmia and decreases splanchnic 
blood flow. It also increases blood lactate levels, probably by increasing cellular 
metabolism. Prospective, randomized studies have not shown any beneficial effects 
of epinephrine over norepinephrine in septic shock. Therefore, epinephrine was 
considered as a second-line agent for severe cardiogenic shock.
18.5.3  Vasopressin
Vasopressin is a hormone that binds to its own receptors. Binding to V1 receptors 
leads to vasoconstriction due to contraction of the vascular smooth muscle, while 
V2 stimulation increases renal free water reabsorption. Norepinephrine is effective 
and safe for treating patients in septic shock and enables tapering down other vaso-
pressors. Vasopressin deficiency can generate in those patients with severe distribu-
tive shock. Administration of low-dose vasopressin may result in substantial 
increases in arterial pressure. Addition of low- dose vasopressin to norepinephrine in 
the treatment of patients with septic shock was safe and may have been associated 
with a survival benefit for patients with forms of shock that were not severe and for 
those who also received glucocorticoids. Vasopressin should not be used at doses 
higher than 0.04 U per minute and should be administered only in patients with a 
high level of cardiac output [12, 13].
18.6  Inotropic Agents
18.6.1  Dopamine
Dopamine is a natural precursor of norepinephrine and epinephrine. Its effects are 
dose-dependent: at low doses (1–2 μg/kg/min), it binds to dopaminergic receptors 
and has a vasodilatory effect, while at higher doses (5–10 μg/kg/min), it acts as a β1 
receptor agonist and thus has inotropic effects. At even higher levels (>10 μg/kg/
min), dopamine stimulates α-adrenergic receptors, leading to vasoconstriction and 
an increase in BP. Previously, dopaminergic effects at very low doses (<3   μg/kg/
min) may selectively dilate the hepatosplanchnic and renal circulations, of which 
the protective effect on renal function was not supported by controlled trials, and 
its routine use for this purpose is no longer recommended [14]. Dopaminergic stim-
ulation may be associated with undesired endocrine effects on the hypothalamic–
pituitary system and reduction of the release of prolactin, resulting in 
immunosuppression.
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18.6.2  Dobutamine
Dobutamine acts on the myocardium by stimulating β1-adrenergic receptors to 
increase heart rate and enhance myocardial contractility, and it also acts on smooth 
muscle via β2 receptors to induce system vasodilation and lower blood pressure. As 
a result, dobutamine can increase cardiac output and reduce LV filling pressures. 
Dobutamine may be given simultaneously with norepinephrine to improve cardiac 
contractility. It may improve capillary perfusion in patients with septic shock, inde-
pendent of its systemic effects. For CS patients, dobutamine is less likely to induce 
tachycardia than isoproterenol. Intravenous doses in excess of 20 μg/kg/min could 
not provide additional benefit. Dobutamine has limited effects on arterial pressure, 
although pressure may increase slightly in patients with myocardial dysfunction or 
decrease slightly in patients with underlying hypovolemia.
18.6.3  Levosimendan
Levosimendan increases the myocardium sensitivity of troponin C to intracellular 
calcium and thus has inotropic and lusitropic properties. It also acts on ATP- 
dependent potassium channels, making the relaxation of vascular smooth muscle 
associated with coronary and peripheral vasodilation. Levosimendan induces vaso-
dilation and improves myocardial contractility without increasing oxygen require-
ments and affecting blood pressure or heart rate. Compared to enoximone, 
levosimendan showed a borderline survival benefit in AMI complicated by cardio-
genic shock or low cardiac output syndrome (hazard ratio 0.33; 95% confidence 
interval 0.11–0.97) and had only small differences in hemodynamics and length of 
hospital stay [15]. This study also showed that there was no difference between 
levosimendan and dobutamine in cardiogenic shock. Furthermore, levosimendan 
has a half-life of several days, which limits the practicality of its use in acute shock 
states.
18.6.4  Phosphodiesterase Inhibitors (Milrinone and Enoximone)
By inhibiting PDE3, milrinone prevents degradation of cyclic adenosine 
monophosphate (cAMP) and increases cAMP levels, which promotes calcium 
uptake by cardiomyocytes and increases myocardial contractility without 
affecting heart rate. In vascular smooth muscle, it reduces the degradation of 
cAMP and accelerates the removal of intracellular calcium, leading to relax-
ation and vasodilation. These agents reinforce the effects of dobutamine by 
decreasing the metabolism of cyclic AMP.  Milrinone may also be useful in 
patients recently treated with beta-blockers or when β-adrenergic receptors 
are downregulated. However, phosphodiesterase type III (PDE III) inhibitors 
have long half-lives (4–6 h) and may complicate with unacceptable adverse 
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effects in patients with hypotension. Thus, intermittent and short-term infu-
sions of small doses of PDE III inhibitors may be preferable to a continuous 
infusion in shock states.
18.7  Outcome
CS remains the leading cause of in-hospital mortality in the setting of an acute 
MI. Most longitudinal studies and registries have reported a decline in MI-associated 
CS mortality. The prevalence of CS from 6 to 10% in the overall population and 
from 7 to 12% among patients >75 years of age presenting with STEMI was reported 
in an analysis of the Nationwide Inpatient Sample Database between 2003 and 2010 
[16]. In-hospital mortality decreased from 45 to 34% over the same time frame, 
although mortality rates remained high (55%) in patients >75 years of age. In the 
IABP-SHOCK II trial, despite inotropic and vasopressor therapy, in addition to the 
benefit of intra-aortic balloon counterpulsation, mortality in patients with CS com-
plicating AMI was still around 40%. Mortality in CS patients occurs mainly in the 
first 3 days. Thus, besides medical therapy, mechanical circulatory support devices 
should be considered as soon as possible in CS patients [2].
18.8  Conclusion
CS decreases myocardial contractility and represents the majority causes of death in 
patients with AMI.  It can result in both acute and subacute derangements to the 
entire circulatory system, including the peripheral vasculature. A full clinical assess-
ment and point-of-care echocardiogram offer more information for differentiation 
of different mechanisms of shock. The initial approach and basic principle of treat-
ment for CS are “VIP rules” to maintain ventilation, obtain euvolemia with volume 
expansion, and administer vasopressors or inotropes for the prevention or treatment 
of multi-organ dysfunction. Stimulation of each type of adrenergic receptor has 
potentially beneficial and harmful effects. For example, β-adrenergic stimulation 
increases blood flow but also increases heart rate and elevates the risk of myocardial 
ischemia; hence, the use of pure β-adrenergic agent (i.e., isoproterenol) is limited 
for patients with severe bradycardia. At the other extreme, α-adrenergic stimulation 
increases vascular tone but decreases cardiac output and impairs tissue blood flow, 
especially in the hepatosplanchnic region. For this reason, phenylephrine is rarely 
indicated. Adrenergic agonists characterize rapid onset of action, high potency, and 
short half-life and thus are the first-line vasopressors. In order to prevent tissue 
hypoperfusion and organ dysfunction, inotropes and vasopressors are essential in 
the management of patients in CS to maintain a mean arterial pressure of 
65–70 mmHg. Physicians should keep in mind to administer vasopressor temporar-
ily while fluid resuscitation is ongoing and discontinue it as soon as possible after 
hypovolemia has been corrected.
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18.9  Case Example: Successful Medical Management 
of Cardiogenic Shock
Cheng Chung Hung and Wei-Chun Huang
18.9.1  Case Example
A 58-year-old male suffered from inferior wall STEMI. His blood pressure was 
low before primary PCI, which was shown as 90/60 mmHg. Fluid challenge was 
provided. During primary PCI, his blood pressure dropped to 80/50 mmHg with 
junctional rhythm, while blood clot was aspirated (Figs.  18.1 and 18.2). 
Therefore, atropine 1 mg was injected immediately, but in vain. Norepinephrine 
100 mcg were injected directly via the coronary artery (Fig. 18.3). After 10 s, 
sinus tachycardia regained, and his blood pressure increased to 120/80 mmHg. 
Norepinephrine 10 mcg/kg/min was used to infuse continuously via the periph-
eral vein, and his vital sign remained stable with inotropic agents support 
(Figs. 18.4 and 18.5).
Fig. 18.1 Coronary image 
before percutaneous 
coronary intervention
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Fig. 18.2 Coronary image 
after thrombus aspiration
Fig. 18.3 Norepinephrine 
was used due to low blood 
pressure
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19Mechanical Circulatory Support in ST-Elevation Myocardial Infarction
Nathan Lo and E. Magnus Ohman
19.1  Introduction
Cardiogenic shock (CS) occurs in approximately 8–10% of patients with 
ST-elevation myocardial infarction (STEMI). While immediate percutaneous coro-
nary intervention (PCI) continues to be the mainline treatment strategy, mortality 
remains as high as 40% before hospital discharge. Even after hospital discharge, 
survivors of cardiogenic shock complicating myocardial infarction (CSMI) often 
suffer from severe heart failure and its consequences, including repeated hospital-
ization and high mortality. Mechanical circulatory support (MCS) devices during 
CSMI PCI can be lifesaving by supporting poor ventricular function while decreas-
ing myocardial wall stress and relieving ischemia. In this chapter, we review the 
definition and pathophysiology of CSMI, the major ventricular support devices, an 
algorithm for MCS use in STEMI, relevant data, and a prototypic case that illus-
trates CSMI management augmented by MCS.
19.2  Definition and Identification of Cardiogenic Shock
Cardiogenic shock is typically defined as a cardiac index <2.2  L/min/m2 and 
systolic blood pressure <90 mmHg with signs of impaired organ perfusion such 
as decreased urine output, altered mental status, or cool extremities. Initial eval-
uation of a patient with STEMI suspected to be in CS should rely on clinical 
bedside evaluation (Table 19.1). Generally, the focused evaluation should deter-
mine clinical stability and whether the patient exhibits signs of low cardiac 
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output and high intravascular volume. The Killip classification score combines 
assessment of cardiac output and intravascular volume and can be helpful to 
quickly assess patients suffering from heart failure after myocardial infarction. 
Killip Class I patients show no signs of heart failure; Class II patients have rales, 
S3 gallop, and venous hypertension; Class III patients have severe heart failure 
with pulmonary edema; and Class IV patients are in cardiogenic shock with 
hypotension and evidence of poor perfusion. Higher Killip score has been shown 
to be an independent predictor of mortality in STEMI patients and may be use-
ful for quick risk stratification in the emergency department in patients present-
ing with acute coronary syndrome. This initial evaluation is vital as it guides 
further therapy and whether vasopressors, inotropes, or MCS need to be started 
concurrent with or even prior to PCI.
19.3  Pathophysiology of Cardiogenic Shock Complicating 
Myocardial Infarction
CS begins with pump failure but soon becomes systemic, multiorgan failure. 
Pump failure begins a “downward spiral” which—if unchecked—potentiates 
itself as worsened ischemia, causing progressive myocardial dysfunction and 
eventually death (Fig.  19.1). Pump failure leads to decreased cardiac output, 
reduced systemic perfusion, fluid retention, elevated cardiac filling pressures, 
decreased coronary perfusion, worsened ischemia, multiorgan failure, worsened 
myocardial dysfunction, and death. Pressure-volume loops provide a useful con-
struct in visualizing the pathophysiology of CS (Fig. 19.2), as well as the effects 
of MCS in CS (Fig. 19.3). The rationale for mechanical support in CSMI is to (1) 
support pump failure and provide increased cardiac output and systemic perfu-
sion, (2) alleviate myocardial ischemia and limit infarct size (after STEMI, a large 
region of myocardium is often stunned, which may regain function after revascu-
larization with PCI, and MCS can serve to decrease myocardial wall stress and 
demand while bridging the time for the myocardium to recover function), and (3) 
delay or halt the “downward spiral.”
Table 19.1 Important 
physical examination findings 
in patients with ST-elevation 
myocardial infarction 
suspected to be in cardiogenic 
shock
Intravascular volume status—“wet” Cardiac output—“cold”
↑ Jugular venous pressure Cool extremities
Rales Hypotension
S3 gallop Narrow pulse pressure
Orthopnea Altered mental status





↓ Systemic Perfusion ↓ Coronary Perfusion
↑ Ischemia
↑ Fluid Retention
Fig. 19.1 “Downward 
spiral” in cardiogenic 
shock complicating 
myocardial infarction. 
STEMI causes left 
ventricular dysfunction 
that begets a “downward 
spiral” that potentiates 
itself. Pump failure leads 
to decreased cardiac output 
and systemic perfusion, 
causing increased fluid 
retention and elevated 
cardiac filling pressures, 
decreasing coronary 
perfusion, and worsening 
existing myocardial 
ischemia, which in turn 



























Fig. 19.2 Pressure-volume loops in normal conditions and in cardiogenic shock complicating 
myocardial infarction. The blue loop represents a pressure-volume loop in normal conditions, and 
the orange loop represents a pressure-volume loop in CSMI. Stroke volume is represented by the 
width of the loop, preload is represented by LVEDV, and myocardial contractility is represented by 
the slope of ESPVR. Compared to normal conditions, CSMI patients have lower stroke volume 
(decreased width of the loop), higher LVEDV, and reduced contractility (decreased ESPVR slope). 
LV left ventricle, LVEDV left ventricular end-diastolic volume, ESPVR end-systolic pressure- 
volume relationship
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19.4  Intra-aortic Balloon Pump
19.4.1  Introduction
The intra-aortic balloon pump (IABP) is the most widely used mechanical support 
device (Fig 19.4). The IABP is usually inserted via the femoral artery through a 
7.5–8.0 French (Fr) sheath (Table 19.2). It is a polyethylene balloon mounted on a 
catheter that is inserted into the descending aorta, with the tip ideally positioned 
~1–2 cm distal to the origin of the left subclavian artery. The catheter itself is con-
nected to a console that controls timed inflation of the balloon during the cardiac 
cycle. Different sizes of the IABP balloon exist and should usually be chosen based 
on patient height:
• 4′10″–5′4″ height should receive 30 mL IABP balloon.
• 5′4″–6′0″ height should receive 40 mL IABP balloon.
• >6′0″ height should receive 50 mL IABP balloon.
19.4.2  Hemodynamic Effect
IABP works by counterpulsation in which the balloon is inflated by helium during 
diastole and deflated during systole. In diastole, inflation of the balloon increases 













Fig. 19.3 Pressure-volume loops in cardiogenic shock and various mechanical ventricular sup-
port devices. The orange loop represents a pressure-volume loop in a patient with CSMI, while the 
other loops represent pressure-volume loops in patients with CSMI supported by various 
MCS. IABP reduces LVEDP and increases stroke volume. Both Impella and TandemHeart reduce 
LVEDP. Notably, VA ECMO increases LVEDP, which increases wall stress and myocardial oxy-
gen demand. LV left ventricle, CSMI cardiogenic shock complicating myocardial infarction, MCS 
mechanical circulatory support, IABP intra-aortic balloon pump, LVEDP left ventricular end- 
diastolic pressure, VA ECMO venoarterial extracorporeal membrane oxygenation
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systole, deflation of the balloon reduces left ventricle (LV) afterload and increases 
cardiac output (Fig. 19.5). The net effect is an increase in mean arterial pressure 
(MAP), reduction of LV end-diastolic volume and LV end-diastolic pressure, and 
decreased myocardial oxygen demand (Fig. 19.3). The hemodynamic support pro-
vided is ~0.5 L/min (Table 19.2).
Fig. 19.4 Intra-aortic 
balloon pump. The 
intra-aortic balloon pump 
consists of a polyethylene 
balloon mounted on a 
catheter that is inserted 
into the descending aorta 
with the tip ~1–2 cm distal 
to the origin of the left 
subclavian artery (Image 
used with permission from 
Getinge)
Table 19.2 Comparison of mechanical circulatory support devices
IABP
Impella 2.5, CP, 
5.0 TandemHeart VA ECMO
Pump mechanism Pneumatic Axial Centrifugal Centrifugal
Sheath size 7.5–8.0 Fr 13 Fr (2.5); 14 Fr 
(CP); 21 Fr (5.0)
15–19 Fr arterial; 
21 Fr venous








Afterload ↓ ↓ ↑ ↑↑↑
Risk of limb 
ischemia and 
bleeding
↑ ↑↑ ↑↑↑ ↑↑↑
Complexity of 
insertion
↑ ↑↑ ↑↑↑↑ ↑↑↑
IABP intra-aortic balloon pump, VA ECMO venoarterial extracorporeal membrane oxygenation, Fr 
French
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19.4.3  Data
Clinical studies have failed to consistently show benefit of IABP in CSMI. While 
some retrospective studies and meta-analyses have shown mortality benefit with 
IABP in CSMI, these studies were often confounded by higher rates of revascular-
ization in patients who received IABP. The most important study of IABP in CSMI 
was the IABP SHOCK II study published in 2012. This was a multicenter, open- 
label trial of 600 patients with CSMI receiving early revascularization who were 
randomized 1:1 to use of IABP or no IABP. There was no difference in the primary 
endpoint of 30-day all-cause mortality (39.7% in IABP group vs. 41.3% in control 
group; p = 0.69), and subsequent studies of the cohort failed to show differences in 
6- and 12-month mortality. Furthermore, no difference was seen in subgroup analy-
sis or secondary safety endpoints such as bleeding, peripheral complications, sepsis, 
and stroke. Critics of the study note that 10% of patients from the control group 
crossed over to the IABP group, some of the control group patients received left 
ventricular assist devices, and the vast majority of the patients received the IABP 
after PCI. Proponents of IABP in CSMI claim that IABP placement may be most 
beneficial prior to PCI to halt the progression of the “downward spiral” and to 
reduce infarct size. However, the CRISP AMI (Counterpulsation to Reduce Infarct 
Size Pre-PCI Acute Myocardial Infarction) multicenter, randomized trial failed to 
show that the use of IABP prior to PCI reduced infarct size measured by MRI in 
patients presenting with anterior STEMI without CS. The secondary endpoint of 















Fig. 19.5 Intra-aortic balloon pump aortic waveform. The IABP inflates at the timing of aortic 
valve closure or the dicrotic notch on the aortic pressure waveform. Inflation results in diastolic 
augmentation that is higher pressure than unassisted systole, which results in increased coronary 
blood flow and MAP. IABP deflates just prior to systole, resulting in a lower assisted aortic EDP 
and lower assisted systolic pressure. This decrease in afterload decreases myocardial demand and 
workload. IABP intra-aortic balloon pump, MAP mean arterial pressure, EDP end-diastolic 
pressure
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19.4.4  Guidelines
The ACC/AHA guidelines give a Class IIa (level of evidence [LOE] B) recommen-
dation for the use of IABP in CSMI who do not stabilize with pharmacologic ther-
apy. ESC guidelines are more stringent in their recommendation for the use of IABP 
in STEMI, giving a Class IIa (LOE C) recommendation only in CSMI patients who 
have a mechanical complication, such as papillary muscle rupture with severe mitral 
regurgitation or ventricular septal defect. Otherwise, ESC guidelines give IABP a 
Class III recommendation (LOE B) for routine use in STEMI patients (Table 19.3).
19.4.5  Contraindications
• Severe aortic regurgitation
• Aortic dissection
• Severe aortic-iliac-femoral vascular disease
• Severe thrombocytopenia
• Abdominal aortic aneurysm
• Sepsis
19.4.6  Complications
The incidence of complications is ~7% based on outcomes data from the Benchmark 
Counterpulsation Outcomes Registry of 16,909 patients undergoing IABP therapy 
between 1996 and 2000. Independent risk factors for major complications of IABP 
Table 19.3 ACC/AHA and ESC guidelines for use of mechanical support in ST-elevation myo-
cardial infarction
Mechanical assist 





CSMI that does not 



























Short-term use may be 
considered in 
refractory CSMI
ACC/AHA American College of Cardiology/American Heart Association, ESC European Society 
of Cardiology, IABP intra-aortic balloon pump, LOE level of evidence, CSMI cardiogenic shock 
complicating myocardial infarction, STEMI ST-elevation myocardial infarction, ECMO extracor-
poreal membrane oxygenation
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were peripheral vascular disease, female sex, body surface area  <  1.65  m2, and 








• Renal artery, mesenteric artery, or left subclavian artery obstruction
• Infection/sepsis
19.5  Axial-Flow Pump (Impella)
19.5.1  Introduction
The Impella consists of a miniature axial-flow pump system that continuously 
pulls blood from the LV into the ascending aorta, thus augmenting cardiac output 
(Fig. 19.6). The pump is mounted on a catheter that is inserted retrograde across 
Pump Motor
Blood Outlet
. Peak Flow up to: 4.3L/min
. Catheter Diameter: 9Fr
Blood Inlet
Pigtail
Fig. 19.6 Impella CP. The 
Impella is placed 
retrograde across the aortic 
valve, with the pigtail and 
inlet area in the left 
ventricle and the outlet 
area in the ascending aorta. 
Blood is continuously 
pulled from the left 
ventricle into the ascending 
aorta. CP cardiac power  
(© 2018 Abiomed, Inc, 
image used with 
permission)
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the aortic valve, usually via the femoral artery. The tip of the catheter is in the 
shape of a pigtail for stabilization and safety of the device in the LV. Near the tip 
of the catheter is an inlet area, from which blood is pulled to be expelled through 
the outlet area into the aorta. While three versions of the device are available, 
Impella 2.5 and the Impella cardiac power (CP) are most commonly used in 
STEMI since they can both be inserted percutaneously. The third version, Impella 
5.0, requires surgical cutdown. Although all three devices have a 9 Fr catheter, the 
size of the femoral artery sheath varies due to different sizes of the pump motor 
(Table 19.2):
• Impella 2.5: 12 Fr pump motor requiring a 13 Fr femoral arterial sheath
• Impella CP: 14 Fr pump motor requiring a 14 Fr femoral arterial sheath
• Impella 5.0: 21 Fr pump motor requiring a 22 Fr femoral arterial sheath
Similar to the IABP, the Impella is connected to a console outside of the body 
that powers and regulates its function.
19.5.2  Hemodynamic Effect
By directly removing blood from the LV, the Impella reduces LV end-diastolic 
volume and end-diastolic pressure. The blood is expelled into the ascending 
aorta, which increases aortic root pressure and increases coronary perfusion 
during diastole. The net effect is an increase in cardiac output, MAP, and coro-
nary perfusion, with a decrease in wall stress. The Impella more markedly 
reduces LV volumes and preload compared with an IABP, thus reducing myo-
cardial oxygen demands of the LV which can be visualized as the area inside the 
loop (Fig. 19.3). It is also important to note that the width of the pressure-vol-
ume loop only shows the stroke volume produced by the heart and not by the 
contributions of the Impella. Hemodynamic support is ~2.5  L/min for the 
Impella 2.5, ~4.0 L/min for the Impella CP, and ~5.0 L/min for the Impella 5.0 
(Table 19.2).
19.5.3  Data
The most important study evaluating the use of Impella in CSMI is the ISAR- SHOCK 
(Efficacy Study of LV Assist Device to Treat Patients with Cardiogenic Shock) trial, 
which tested whether Impella 2.5 provided superior hemodynamic support in CSMI 
compared with IABP. This prospective trial randomized 26 patients presenting with 
CSMI to either IABP or Impella 2.5 implantation after PCI. The primary endpoint of 
hemodynamic improvement after 30 minutes of device implantation was significantly 
better in patients receiving the Impella 2.5 versus IABP (∆cardiac index = 0.49 ± 0.46 L/
min/m2 vs. 0.11 ± 0.31 L/min/m2; p = 0.02). Overall 30-day mortality was 46% in both 
groups. However, the study had a small number of patients and was not powered to 
detect mortality differences between groups. Similar to criticisms of the IABP 
SHOCK II trial, proponents of Impella 2.5  in CSMI note that the patients in 
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ISAR-SHOCK received the mechanical devices only after revascularization, when the 
expected benefit may not be as large. Indeed, an observational study evaluating 154 
consecutive unselected patients from the USpella Registry who received Impella 
2.5 in CSMI found that the patients who received Impella 2.5 prior to PCI had signifi-
cantly better survival to hospital discharge compared with patients who received 
Impella 2.5 after PCI (65.1 vs. 40.7%; p = 0.003). In the interval following the publi-
cation of the ISAR-SHOCK results, the Impella CP became available, which can also 
be placed percutaneously and should provide greater hemodynamic support in 
CSMI. However, no randomized trials have evaluated the Impella CP or 5.0 in CSMI.
19.5.4  Guidelines
Both ACC/AHA and ESC guidelines give Impella a Class IIb (LOE C) indication 
for use in refractory CSMI (Table 19.3).
19.5.5  Contraindications
• Mechanical aortic valve
• Critical severe aortic stenosis
• Moderate to severe aortic regurgitation
• LV thrombus
• Ventricular septal defect
• Severe peripheral arterial disease
• Severe sepsis
19.5.6  Complications
The most common complication of Impella is bleeding, given the need for antico-
agulation and the 13–22 Fr size catheters needed for arterial access. In the Impella- 
EUROSHOCK- registry that retrospectively evaluated 120 patients receiving 
Impella 2.5 for CSMI, bleeding requiring transfusion occurred in 24.2% of patients, 








• Acquired von Willebrand syndrome
• Mitral regurgitation secondary to chordal rupture
• Functional mitral stenosis
N. Lo and E. Magnus Ohman
263
19.6  Extracorporeal Left Heart Bypass (TandemHeart)
19.6.1  Introduction
The TandemHeart is an extracorporeal left atrial to arterial assist device (Fig. 19.7). 
Unlike the IABP and Impella that require only arterial access, the TandemHeart 
requires both venous and arterial access. It is inserted by first creating a transseptal 
puncture from the right atrium into the left atrium. After a guidewire is passed into the 
left atrium and the transseptal opening is sufficiently dilated, a 21 Fr cannula is 
inserted via the femoral vein, up the inferior vena cava, through the right atrium, and 
into the left atrium. The cannula has a large end-hole and multiple side holes that 
Fig. 19.7 TandemHeart. 
The TandemHeart is a left 
atrial to arterial 
extracorporeal device that 
requires atrial transseptal 
puncture. A cannula is 
situated into the left atrium 
and aspirates oxygenated 
blood, which is delivered 
to the body by a femoral 
artery outflow cannula 
(Image used with 
permission from 
CardiacAssist)
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allow for aspiration of oxygenated left atrial blood. The aspirated blood is pulled into 
an extracorporeal centrifugal pump that pumps the blood into a 15 Fr–19 Fr arterial 
outflow cannula in the femoral artery. An external console controls the pump.
19.6.2  Hemodynamic Effect
By taking blood from the left atrium, the TandemHeart directly reduces left atrial 
pressure, which reduces LV end-diastolic volume and LV end-diastolic pressure 
(Fig. 19.3). Afterload is mildly increased due to the blood flow into the large outflow 
cannula in the femoral artery. The net effect is an increase in cardiac output, MAP, 
and coronary perfusion, with a decrease in wall stress. The TandemHeart works in 
“tandem” with the native heart; therefore, the aorta is still perfused via the native LV 
pump as well as the TandemHeart pump. However, due to the decrease in preload 
and increase in afterload associated with the TandemHeart, the contribution to car-
diac output from the native heart usually falls. It is not uncommon to have a flat, 
non-pulsatile arterial waveform on the display console showing little contribution of 
pulsatile blood flow from heart. Hemodynamic support is ~3.5–5.0 L/min, mostly 
depending on the size of the femoral artery outflow cannula (Table 19.2).
19.6.3  Data
The most important study evaluating TandemHeart in CSMI was a prospective, sin-
gle-center, randomized trial published in 2005 comparing IABP to TandemHeart in 
the setting of intended PCI of the infarct artery in 41 patients. The primary outcome 
of improvement in cardiac power index was much greater for the TandemHeart group 
compared with the IABP group (0.22–0.37 W/m2 vs. 0.22–0.28 W/m2; p = 0.004). 
Pulmonary capillary wedge pressure and serum creatinine levels also decreased. 
However, 30-day mortality was similar between the two groups (IABP 45% vs. 
TandemHeart 43%; p = 0.86). Complications such as severe bleeding and limb isch-
emia were seen much more frequently in the TandemHeart patients. Limitations of the 
study included its lack of power to detect mortality differences as well as the lack of 
generalizability since >50% of study patients were excluded from the study.
19.6.4  Guidelines
Both ACC/AHA and ESC guidelines give TandemHeart a Class IIb (LOE C) indica-
tion for use in refractory CSMI (Table 19.3).
19.6.5  Contraindications
• Bleeding diathesis
• Severe peripheral vascular disease
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• Severe right ventricular dysfunction
• Severe aortic regurgitation
• Ventricular septal defect
19.6.6  Complications
The major complications of the TandemHeart are severe bleeding and limb isch-
emia. In the randomized trial in 2005 noted above, 19 of the 21 patients randomized 
to TandemHeart required blood transfusions. Most of the patients had bleeding at 
the arterial access site. Seven of the 21 patients developed limb ischemia that either 





• Infection/sepsis/systemic inflammatory response syndrome
• Stroke
19.7  Extracorporeal Membrane Oxygenation
19.7.1  Introduction
Venoarterial extracorporeal membrane oxygenation (VA ECMO) can be percutane-
ously placed at the bedside or catheterization laboratory table, providing not only 
circulatory support but also gas exchange (Fig. 19.8). An 18–21 Fr inflow cannula 
is placed via the femoral vein into the right atrium. A 15–17 Fr outflow cannula is 
placed via the femoral artery into the aorta (Table 19.2). Deoxygenated blood is 
removed from the right atrium by an extracorporeal centrifugal pump into a mem-
brane oxygenator for gas exchange, and the oxygenated blood is then pumped back 
into the patient via the femoral artery cannula. A perfusionist is needed to assemble 
and manage the circuit.
19.7.2  Hemodynamic Effect
Although VA ECMO directly removes blood from the right atrium, it does not 
decrease LV preload. This is due to pulmonary and bronchial venous return to the 
LV. VA ECMO also increases afterload due to the retrograde flow via the femoral 
artery cannula into the aorta. The combined effect of both increased preload and 
afterload of the LV results in an overloaded LV with elevated LV end-diastolic vol-
ume and LV end-diastolic pressure (Fig. 19.3), causing increased wall stress and 
myocardial oxygen consumption. In CSMI, this increase in wall stress can worsen 
ischemia and LV function, as well as decrease the likelihood of stunned 
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myocardium to recover. Hemodynamic support is ~4.0–6.0 L/min, with significant 
increases in MAP and total cardiac output (Table 19.2).
19.7.3  Data
The data for ECMO in CSMI are from retrospective, small studies. One single- 
center study evaluated 30-day outcomes in patients with STEMI complicated by 
profound CS, defined as systolic blood pressure ≤ 75 mmHg after IABP and ino-
trope agents. This study compared 46 patients with profound CSMI treated with 
primary PCI and ECMO between 2002 and 2009 with a historical control group of 
25 patients with profound CSMI treated with primary PCI without ECMO between 
1993 and 2002. Thirty-day mortality in the group treated with ECMO and PCI was 
significantly lower than the historical group (72 vs. 32%, RRR 46%; p = 0.003). 
However, results may be confounded due to the large temporal differences between 
the groups, as some of the improvement in mortality may be due to improved 
adjunctive pharmacotherapy, equipment, and technique. Other retrospective studies 
have suggested that VA ECMO may be particularly beneficial in CSMI patients with 
cardiac arrest, with improvements in short- and mid-term survival. No randomized 
controlled trials exist for ECMO in CSMI.
Fig. 19.8 Venoarterial extracorporeal membrane oxygenation. Venoarterial extracorporeal mem-
brane oxygenation is a unique MCS device that provides both circulatory support and gas exchange. 
Deoxygenated blood is removed from the right atrium by a large venous cannula and pumped 
through a membrane oxygenator for gas exchange, and the oxygenated blood is delivered to the 
body through a large outflow femoral artery cannula. MCS mechanical circulatory support (Image 
used with permission from Getinge)
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19.7.4  Guidelines
Both ACC/AHA and ESC guidelines give ECMO a Class IIb (LOE C) indication for 
use in refractory CSMI (Table 19.3). The ESC guidelines also recommend consider-
ing ECMO in CSMI patients who continue to deteriorate despite IABP.
19.7.5  Contraindications
• Bleeding diathesis
• Severe peripheral vascular disease
• Prolonged cardiopulmonary resuscitation (CPR)
• Severe aortic regurgitation
19.7.6  Complications
As with TandemHeart, severe bleeding and limb ischemia are major complications 
of ECMO. Unique to ECMO among the mechanical support devices, however, are 
the complications resulting from LV overload. Over time, LV dilatation, LV throm-
bus, pulmonary edema, and pulmonary venous hypertension may occur. Strategies 
to “vent” the LV such as IABP, Impella, atrial septostomy, or direct LV decompres-
sion may decrease complications from LV overload. Other complications of ECMO 
include:
• Acquired von Willebrand deficiency
• Hemolysis
• Thrombocytopenia
• Infection/sepsis/systemic inflammatory response syndrome
• Coronary and cerebral hypoxia
• Renal insufficiency
• Stroke
19.8  Practical Approach to the Use of Mechanical Support 
Devices in STEMI
The main decision points for use of mechanical support in STEMI are (1) when to 
initiate MCS and (2) which device to use. MCS needs to be carefully selected in 
STEMI patients. First, an evaluation based on vital signs, physical examination, and 
available data needs to be conducted. If the patient exhibits no evidence of cardio-
genic shock, then prompt revascularization without planned MCS should be the 
initial strategy. An algorithm for MCS in STEMI is shown in Fig. 19.9.
For patients who initially present in shock, either immediate revascularization or 
early use of MCS with prompt revascularization is the preferred strategy. As 
19 Mechanical Circulatory Support in ST-Elevation Myocardial Infarction
268
discussed earlier in this chapter, there is no clear evidence that MCS should be rou-
tinely used in CSMI.  Despite the benefits of MCS, the use of support devices 
exposes the patient to more complications—especially bleeding—and may also 
delay door-to-device time. Prompt revascularization in CSMI continues to be the 
ultimate goal, with Class I indications from both AHA and ESC. The randomized 
SHOCK trial in 1999 showed that patients presenting with CSMI had statistically 
significant improved survival at 6 months with emergency revascularization com-
pared with initial medical stabilization, despite a high use of IABP in both groups. 
Regardless of the initial strategy chosen, once stabilized in the emergency depart-
ment, patients with CSMI should be immediately rushed to the cardiac catheteriza-
tion laboratory, at which point the operator can proceed with either primary PCI or 
MCS with subsequent PCI.  If the patient cannot be stabilized in the emergency 
department and has refractory cardiac arrest despite high-quality advanced cardio-
vascular life support, then consideration should be given for ECMO.
If the patient with CSMI requires no inotropic or vasopressor therapy, or only 










Reevaluate for MCS initiation or escalation
PCI
IABP Impella VA ECMO
Refractory Cardiac Arrest?
Fig. 19.9 Algorithm for mechanical circulatory support in STEMI. STEMI ST-elevation myocar-
dial infarction, IABP intra-aortic balloon pump, VA ECMO venoarterial extracorporeal membrane 
oxygenation, PCI percutaneous coronary intervention
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then we generally proceed with immediate PCI. However, if the patient is requiring 
either increasing doses of adjunctive pharmacologic therapy or is already on multi-
ple inotropes or vasopressors and has signs of moderate to severe CS (wedge >20, 
altered mental status, cool extremities, elevated serum lactate), then MCS should 
first be initiated prior to PCI in the cardiac catheterization laboratory. Pharmacological 
therapy such as inotropes and vasopressors may be used to stabilize the patient, but 
these agents may actually be harmful over time. Vasopressors increase MAP and 
improve hypotension but at the cost of increased LV afterload, which increases 
myocardial work and demand, leading to worsened myocardial ischemia. Similarly, 
inotropes improve pump function but directly increase myocardial work and 
demand, again leading to worsened myocardial ischemia. Furthermore, these drugs 
are often proarrhythmic and inadequately support a failing heart pump. Thus, while 
a patient may initially be “stable” on vasopressor and inotrope therapy, the increased 
myocardial workload and ischemia with these agents may hasten the “downward 
spiral” of cardiogenic shock. Conversely, mechanical ventricular support devices 
can provide greater circulatory support, reduce filling pressures, reduce myocardial 
wall stress and demand, increase coronary perfusion, and even limit infarct size. 
Therefore, for patients in moderate to severe CS with moderate or high doses of 
inotropes or vasopressors, MCS prior to PCI should be strongly considered to sup-
port the patient and to relieve myocardial demand and ischemia. Similarly, if a 
STEMI patient who initially received planned PCI without MCS deteriorates and 
develops CS, then strong consideration should be given for immediate MCS 
implantation.
Consideration of which mechanical support device to be used is mostly based on 
the amount of hemodynamic support needed, risk of bleeding, ease and rapidity of 
placement, and contraindications (Table 19.2). Immediate measurement of LV end- 
diastolic pressure and the performance of a left ventriculogram should be done to 
help assess the severity of CS, dysfunction of the LV, and any possible mechanical 
complications. Additionally, if concern for peripheral arterial disease exists, ilio-
femoral angiography should be quickly done via a femoral artery sheath to help 
determine whether the femoral artery is suitable for an MCS device. In general, the 
favored MCS devices should be the IABP and Impella CP. While the IABP is rela-
tively inexpensive, generally safe, and straightforward to implant, the tradeoff is 
that it provides only modest hemodynamic support. Impella CP provides much 
greater hemodynamic support and is a better choice for patients in severe CS. It can 
still be inserted percutaneously, and provides greater hemodynamic support than the 
Impella 2.5, with a femoral artery sheath only 1 Fr size larger. It can provide nearly 
the same forward cardiac output as the TandemHeart without the technical chal-
lenges associated with the latter device (the larger femoral artery sheath and the 
need for a transseptal puncture). Finally, while VA ECMO can effectively provide 
complete cardiopulmonary support, it also increases afterload and can worsen myo-
cardial ischemia. Thus, generally patients in mild CS should receive IABP with 
frequent reevaluation for device escalation (replacement with Impella or VA 
ECMO), and those with moderate to severe CS should receive Impella CP.  VA 
ECMO should be reserved for those patients in cardiac arrest.
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19.9  Summary
MCS in STEMI can be useful in carefully selected patients with cardiogenic shock. 
Early identification of CS is paramount, and early initiation of MCS can help sup-
port a failing LV, reduce filling pressures, improve coronary perfusion, relieve myo-
cardial ischemia, and ultimately prevent the “downward spiral” of CS that leads to 
multiorgan failure and death. An algorithm for use of MCS in STEMI patients helps 
select which patients may benefit from MCS and which ventricular support device 
may be optimal. Ultimately, a multidisciplinary team approach to patients with 
CSMI is vital, as quick action and communication from EMS, emergency medicine 
physicians, interventional cardiologists, cardiac surgeons, nurses, and technicians 
can stabilize and identify the patients who are best candidates for mechanical ven-
tricular support devices.
19.10  Case Report: Severe Cardiogenic Shock in Context 
of Cardiac Arrest
Nathan Lo and E. Magnus Ohman
19.10.1  Case Report
A 66-year-old female with history of hypertension, hyperlipidemia, and smoking 
abuse presented with chest pain at home prompting a call to emergency medical 
services (EMS). Upon EMS arrival, she was hypotensive with electrocardiogram 
(ECG) showing sinus bradycardia and ST-elevations in leads II, III, and AVF. On 
arrival to the emergency department, she sustained a pulseless electrical activity 
(PEA) arrest requiring CPR, epinephrine administration, and intubation. She 
regained return of spontaneous circulation (ROSC) after several minutes, but she 
remained hypotensive requiring norepinephrine drip at a low dose. Physical exami-
nation was notable for elevated JVP of ~16 mmHg, S3 gallop, and no rales. She was 
given IV heparin and PO aspirin via an orogastric tube. She was quickly taken to the 
cardiac catheterization laboratory.
On the catheterization laboratory table, she had a bradycardic cardiac arrest 
requiring CPR, atropine, and epinephrine. She regained ROSC after several min-
utes. We obtained access in the right femoral artery with a 6 Fr sheath and per-
formed diagnostic angiograms of the left and right coronary arteries. This revealed 
three-vessel disease with a culprit proximal 95% dominant RCA thrombotic occlu-
sion, 80% mid-LAD lesion, and 90% large ramus lesion (Fig. 19.10). A pigtail cath-
eter was used to cross the aortic valve revealing LVEDP of 19 mmHg and akinetic 
inferior and apical walls with LV ejection fraction ~40% on left ventriculogram. 
Arterial blood gas showed a pH of 7.07, PCO2 of 63, and PO2 of 154, and the tidal 
volume and respiratory rate were increased on the ventilator.
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We decided to proceed directly with PCI of her culprit RCA lesion without 
upfront MCS due to her mild cardiogenic shock and low vasopressor requirements, 
although upfront IABP placement could arguably have been better. Eptifibatide 
bolus and drip was started. On balloon inflation of her RCA occlusion, the patient 
became bradycardic and hypotensive, requiring further brief CPR, atropine, and 
epinephrine administration. Angiography of her RCA showed slow flow. We imme-
diately proceeded to IABP placement via the left femoral artery. She had excellent 
diastolic augmentation with MAP in the 90s. Flow in her RCA improved, and we 
proceeded to stent her RCA with a 3.0  ×  38  mm drug-eluting stent, with distal 
embolization to a posterolateral branch (Fig. 19.11). Her MAP decreased to 70s 
despite the IABP and vasopressor support. A Swan-Ganz catheter was placed via 
her right femoral vein which showed mean RA pressure of 16 mmHg, RV pressure 
of 33/15 mmHg, PA pressure of 33/21 mmHg with mean of 26 mmHg, and wedge 
of 19 mmHg. PA saturations were 52 and 54% in duplicate, and Fick CO was 2.2 L/
min with index of 1.4 L/min-m2. We considered MCS device escalation to Impella 
and further revascularization of her other coronary disease, but given her relative 
stability, we decided to transfer her to the CCU and closely watch her over the next 
several hours. Her right femoral artery sheath was left in place in case ECMO was 
required. Transthoracic echocardiogram showed LVEF of 35% with akinetic infe-
rior and posterior walls and hypokinetic anterior, lateral, and apical walls. RV was 
mildly enlarged with moderate global dysfunction. Over the next 36 h, her vasopres-
sors were weaned off, she was extubated, and the IABP removed. Her Fick CO 
improved to 4.2 L/min with index of 2.6 L/min-m2. She was discharged home in 
stable condition with plan for elective revascularization of her LAD and ramus. This 
case illustrates several important points: (1) MCS can be very effective in conjunc-
tion with PCI in the treatment of CSMI; (2) even in cases where MCS is not placed 
a b
Fig. 19.10 Severe three-vessel disease in a patient with cardiogenic shock complicating 
STEMI. Angiography reveals a dominant RCA with culprit 95% lesion (a), 80% mid-LAD lesion, 
and 90% ostial ramus lesion (b). STEMI ST-elevation myocardial infarction, RCA right coronary 
artery, LAD left anterior descending artery
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upfront prior to PCI, it is important to always reevaluate whether MCS should be 
initiated or whether device escalation is necessary; and (3) a clear algorithm can 
help guide device initiation and selection in CSMI.
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20Mechanical Complications of Acute Myocardial Infraction
Wei Wang and Anson Cheung
20.1  Introduction
With timely reperfusion, myocardial loss following myocardial infarction (MI) can 
be significantly reduced and may limit the incidence of mechanical complications. 
However, with improving treatment of those with larger or delayed presentation MI, 
appropriate management of mechanical complications remains a key consideration 
for those working in heart attack centers.
20.2  Ischemic Ventricular Septal Defect
20.2.1  Incidence and Pathophysiology
The incidence of post-infarction ventricular septal defect (VSD) is reported as 
1–2% after acute myocardial infarction (MI). However, the true incidence may be 
decreasing in modern era with the advancement of early interventions after acute 
myocardial infarction including thrombolytic treatment, early revascularization 
with percutaneous coronary angioplasty, or stenting and coronary bypass grafting. 
Nonetheless, timely and appropriate management of this important complication of 
MI can be lifesaving.
The timing to develop post-infarction VSD is variable, in a few hours and up to 
2 weeks with an average time of 2–4 days after acute MI. It is usually associated 
with complete occlusion of a single coronary artery with poor collateral vessels. 
About 2/3 of post-infarction VSDs are located in the anteroapical septum, while the 
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remaining in the posterior septum, from acute left anterior artery (LAD) and domi-
nant right coronary artery (RCA) or circumflex artery (LCx) occlusions, 
respectively.
The natural history of untreated VSD is extremely poor, carrying a mortality 
rate of 25% within 24 h and 80% within 4 weeks. The early development of con-
gestive heart failure (CHF) leading to cardiogenic shock is the primary cause of 
death. Ventricular dysfunction can be primarily left or right, depending on the ter-
ritory infracted and the location of the septal rupture. Especially in posterior 
infarct, significant mitral valve regurgitation (MR) can play an important role in 
the development of heart failure, resulting in elevated left ventricular end-diastolic 
pressure (LVEDP) and pulmonary edema. The degree of left-to-right shunt 
depends on the size of the VSD and pressure gradient across the septum. If the 
shunt is large, the normally compliant right ventricle (RV) will not tolerate the 
sudden increase in load, and the development of significant RV failure pursues. As 
a result, severe biventricular failure is not uncommon in patients with post-infarc-
tion VSD.
20.2.2  Presentation and Diagnosis
Typical presentation of post-infarction VSD includes the presence of a new holo-
systolic murmur radiating to the axilla a few days post MI. It is often accompanied 
by an abrupt hemodynamic deterioration, i.e., signs of CHF and cardiogenic 
shock.
Electrocardiography (ECG) may show ST elevation and/or Q wave in accor-
dance with location of transmural MI. Chest radiography (CXR) often shows acute 
pulmonary edema. Currently, transthoracic echocardiography (TTE) with color 
Doppler is the quickest and most definitively diagnostic method for post-infarction 
VSD. It can delineate the size, location, presence, and degree of shunt. In addition, 
TTE can identify and quantify the degree of MR and rule out other causes of MR, 
such as secondary to papillary muscle rupture and primary MR.  Other valuable 
information include the presence of other valvular pathology, the degree of ven-
tricular dysfunctions, free wall rupture, cardiac infront of tamponade, pulmonary 
embolism, and aortic dissection/rupture. As many patients now undergo rapid left 
heart catheterization to permit primary percutaneous coronary intervention (PCI)—
even increasingly among late presenters—the finding of a compatible murmur dur-
ing clinical evaluation may prompt left ventriculography which may prove 
diagnostic for VSD. The role of primary PCI or concomitant coronary artery bypass 
grafting in the setting of VSD is debatable as myocardial damage is already trans-
mural and residual viability therefore questionable.
Right heart catheterization is usually not required, but a step-up in the oxygen 
saturation between the right atrium (RA) and pulmonary artery (PA) indicates left- 
to- right shunt. The right heart catheterization can also calculate the pulmonary to 
systemic flow ratio (Qp/Qs).
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20.2.3  Timing of Surgery
The natural history of untreated post-infarction VSD is very poor with a 25% mortal-
ity within 24 h, 50% mortality within 1 week, 80% within 1 month, and 97% at 1 year 
[1]. The presence of post-infarction VSD is therefore an indication for urgent inter-
ventions. Intervention includes definitive surgical correction, mechanical circulatory 
support (MCS), and device closure of VSD. Cardiogenic shock in the setting of post-
infarction VSD is a surgical emergency. In patients with cardiogenic shock, early 
MCS using extracorporeal membrane oxygenation (ECMO) or other short- term 
devices should be initiated to stabilize hemodymics and correct metabolic derange-
ments. Furthermore, it can bridge the patient to decision regarding the best therapeu-
tic option. Percutaneous device closure rarely works in the acute setting as the VSD 
is frequently serpentines, the infarcted and peri-infarct myocardium is necrotic and 
fragile. Given friable myocardium at the rim of the VSD, the use of percutaneous 
closure device can result in significant residual shunt and device embolization.
20.2.4  Preoperative Care
Medical management is aimed to improve cardiac output and reduce the left-to- 
right shunt by reducing systemic vascular resistance and LV pressure. Inotropes and 
diuretics are often used. Placement of an intra-aortic balloon pump (IABP) and 
other short-term MCS device can be helpful.
20.2.5  Surgical Techniques
Surgical principles include elimination of left-to-right shunt, preservation of LV 
function, and revascularization when possible. Small anterior and apical defects can 
be closed by suturing the free wall of the RV and LV, sandwiching the septum. For 
larger defects, generally the two commonly employed surgical techniques are 
infarctectomy and infarct exclusion. Infarctectomy technique involves removal of 
left ventricular infarction area and closure of VSD without tension. Infarct exclu-
sion technique, on the other hand, does not remove any infarct tissue. Principles of 
both techniques include good myocardial protection during the operation, suture 
placement through non-infarcted tissue to maximize suture line integrity, and mini-
mizing tension with the use of large prosthetic patches. Infarct exclusion techniques 
are more popular and thought to have the advantages of preserving left ventricular 
geometry and function. Meticulous medical management intraoperatively is criti-
cal, and intraoperative transesophageal echo (TEE) is mandatory. After the estab-
lishment of cardio-pulmonary bypass (CPB) and arresting the heart, the heart is 
inspected and the infarcted area exposed. In primary infarctectomy repair, the 
infarcted wall is incised (Fig. 20.1). After the resection of necrotic septal myocar-
dium, pledgeted interrupted horizontal mattress sutures are placed around the 
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defect. Subsequently, sutures are then passed through the septum from right to left 
through a felt strip. Closure of the ventriculotomy is reinforced with felt strips. 
Infarctectomy may also be performed with bovine pericardial patch repair 
(Fig. 20.2). As previously described, after the resection of infarcted tissue, pled-
geted interrupted horizontal mattress sutures are placed around the defect. Sutures 
are then passed through a large bovine pericardial patch. All sutures are pledgeted 
once again and then tied down. The edges of the ventriculotomy are reapproximated 
with a double-layer buttressed closure with Teflon felt. Biological glue is often used 
to ensure complete hemostasis.
Fig. 20.1 Infarctectomy technique for anterior VSD repair with primary closure. [Courtesy of 
Miss Christina YS Wong]
Fig. 20.2 Infarctectomy with bovine pericardial patch. [Courtesy of Miss Christina YS Wong]
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Infarct exclusion techniques differ from infarctectomy where no infarcted tissue is 
being removed (Fig. 20.3). A trans-infarct incision is made and the extent of the infarct 
inspected. A large bovine pericardial patch covering is used to exclude defect from LV 
cavity; placements of suture onto healthy septal tissue are crucial in the integrity of the 
repair. Closure of the ventriculotomy is then closed as previously described. Repair of 
posterior ischemic VSD can sometimes be technically more challenging than anterior as 
exposure is less ideal. The infarct exclusion technique can provide a more tension-free 
repair and is believed to be better in preserving LV and RV geometry and function.
A third surgical technique, the right atrium approach, has been described for the 
post-infarction VSD (Fig. 20.4). It is used more commonly in posterior VSD repair. 
It has the benefit of not performing a left ventriculotomy. Repair is done through the 
tricuspid valve as performed in congenital ventricular septal defect patients [2]. 
However, this technique has not gained popularity for a number of reasons. Firstly, 
Fig. 20.3 Infarct exclusion for anterior (left) and posterior (right) post-infarction VSD. [Courtesy 
of Miss Christina YS Wong]
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the exposure of VSD through the right atrium is often suboptimal. Secondly, place-
ment of repair sutures can be difficult requiring detachment of the septal leaflet of 
tricuspid valve and the need for tricuspid valvuloplasty. Thirdly, putting a large 
patch from the right side of the ventricular septum can be difficult, especially in 
acute phase. This technique is best performed in patients 2–4 weeks after presenta-
tion of VSD, where a fibrotic rim will often develop.
20.2.6  Transcatheter Device Closure
Transcatheter device is widely used in patients with congenital VSD. However, the 
role of transcatheter device in post-infarction VSD is unclear. Limited data is available 
and most of the case studies had small number of patients. When device closure is 
Fig. 20.4 Right atrium 
approach for posterior 
VSD repair. [Courtesy of 
Miss Christina YS Wong]
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performed in acute phase of post-infarction VSD, the 30-day mortality can be as high 
as 65% [3]. A study from Mayo Clinic also showed the predictors of adverse events 
from transcatheter device closure of post-infarction VSD included cardiogenic shock 
and acute phase post MI. At present, device closure is limited in selected patients 
4–6 weeks after post-infarction VSD, with the fibrotic rim is well developed.
20.2.7  Mechanical Circulatory Support Involvement 
(ECMO, LVAD)
With the advancement of mechanical circulatory support, patients with severe end- 
organ damage deemed too sick to undergo operative repair may be candidates for a 
delayed repair. Interval treatment which may involve placement of short-term MCS 
devices will help improve end-organ dysfunction and allow for maturation of the 
infarcted tissue. Durable MCS devices can be used, however, not encouraged, due 
to complexity of the implant procedure, the high mortality associated with postin-
farct VSD, and the cost of the device (Fig. 20.5).
20.2.8  Postoperative Management and Surgical Results
Postoperative care centers on ensuring adequate cardiac output for end-organ perfu-
sion and correcting metabolic derangements. Pharmacologic agents such as epi-
nephrine and milrinone may help to augment contractility. After separating from 
CPB, right-sided heart failure is common; inhaled nitric oxide, prostaglandin, and 
milrinone can be helpful in this setting. Some patients may require temporary right 
ventricular assist device postoperatively. The utility and effectiveness of IABP in 























Fig. 20.5 Operative mortality rate stratified by timing of VSD repair [5]
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20.2.9  Outcome
Operative mortality is relatively high which ranges from 30 to 50%. Risk factors for 
early mortality after surgical intervention include persistent low cardiac output state 
and recurrent or residual VSD. While a residual defect with a significant shunt in an 
unstable patient should be imminently addressed, delayed repair is favored in a 
hemodynamically stable patient with a residual VSD.
Arnaoutakis et al. analyzed and reported the outcome of 2876 patients with post- 
infarction VSD who underwent surgical repair from the Society of Thoracic Surgery 
database. The operative mortality was 54.1% when repair occurred within 7 days 
from myocardial infarction, and only 18.4% when repair was performed more than 
7 days from infarction [5]. These results may suggest mechanical circulatory sup-
port could play an important role in delaying surgical repair to achieve much better 
outcome in hemodynamically unstable patients. Alternatively, this finding can be 
explained by selection bias.
20.3  Acute Mitral Valve Regurgitation Secondary to Papillary 
Muscle Rupture
20.3.1  Pathophysiology
Acute mitral valve regurgitation secondary to papillary muscle rupture is a cata-
strophic complication after acute MI. Approximately 1–5% of death after acute MI 
is due to acute mitral valve regurgitation as a result of papillary muscle rupture. As 
in post-infarction VSD, the incidence of acute papillary muscle rupture is decreas-
ing with early reperfusion interventions. Typically, the anterolateral papillary mus-
cle has dual blood supply by the LAD and LCx, whereas the posteromedial papillary 
muscle has single blood supply by either the dominant RCA or the circumflex artery 
in a left dominant circulation. Hence the posteromedial papillary muscle is more 
susceptible to ischemia and consequent rupture accounting for 2/3 of all cases and 
are more commonly associated with an acute inferior STEMI.
20.3.2  Presentation and Diagnosis
Post-infarction acute MR usually occurs 2–7 days after MI. It carries a very high 
mortality of 50–75% without surgical intervention and 20–25% with surgical inter-
vention. A new holosystolic murmur in conjunction with cardiovascular collapse 
several days after MI should raise the suspicion of papillary muscle rupture. The 
major differential is post-infarction VSD. Unlike an acute VSD, MR is best heard at 
the apex rather than the left sternal border and does not have an associated thrill. 
Papillary muscle rupture results in mitral valve flail leaflet and severe mitral valve 
regurgitation. In a normal left atrium (LA) with a relatively low compliance, acute 
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mitral regurgitation results in sudden elevation of LA pressure leading to rapid 
development of pulmonary edema and cardiogenic shock.
EKG may show signs of an inferior MI, and chest radiography may demon-
strate severe pulmonary edema. TTE with color Doppler is the golden standard for 
diagnosis. It can confirm mitral valve prolapse with flailing chordae or papillary 
muscle, quantify the degree of MR and ventricular function, and rule out post-
infarction VSD. Development of multi-organ failure is common in patients with 
acute MR.
20.3.3  Preoperative Considerations
Acute MR often results in rapid hemodynamic collapse. Intubation and mechanical 
ventilation may be required for respiratory failure. Inotropes and diuretics can sta-
bilize some patients; however, in unstable patients with evidence of cardiogenic 
shock or severe end-organ failure, early MCS with short-term devices can be 
lifesaving.
20.3.4  Operative Techniques
Emergent mitral valve replacement (MVR) is most commonly undertaken with con-
comitant coronary revascularization. Even in patients who received satisfactory per-
cutaneous coronary interventions, isolated MVR should be performed emergently 
in papillary muscle rupture cases. Successful MV repair cases have been reported 
with reimplantation of papillary muscle, chordal transfer, and artificial chord 
implantation; however, repair is not recommended as the early failure rate is very 
high in the acute setting.
Surgical technique emphasizes on a swift operation with good myocardial pro-
tection, and MVR is generally performed via a median sternotomy. Arterial and vein 
graft conduits are harvested if concomitant CABG is needed. Routine cardiopulmo-
nary bypass cannulation and antegrade and retrograde cardioplegia are routinely 
used. For patients with concomitant CABG, distal coronary anastomoses are per-
formed first. Mitral valve exposure can be difficult in acute setting as the LA is often 
small and not dilated. Both mechanical and tissue valve may be used. It is important 
to preserve the chordae and leaflets (especially posterior leaflet) as much as possible 
to better preserve the left ventricular geometry.
20.3.5  Results
The surgical mortality of MVR in patients with acute MR secondary to papillary 
muscle rupture can be as high as 30%. Literature-supported concomitant CABG 
with MVR has an improved long-term survival compared to MVR alone [6].
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20.4  Left Ventricular Free Wall Rupture
20.4.1  Pathophysiology
Free wall ventricular rupture occurs in 2–4% of patients presenting with an acute 
MI. Autopsy data showed the incidence could be as high as 11% [1]. Like ventricu-
lar septal defect, patients with LV free wall rupture commonly have transmural ST 
elevation MI. Rupture tends to occur at the junction of viable and necrotic myocar-
dium when the infarction expands. Early thrombolytic therapy is associated with 
decreased incidence of free wall rupture after acute MI.
LV free wall rupture can be classified as acute, subacute, and chronic. Acute LV 
free wall rupture may cause severe hemodynamic compromise secondary to cardiac 
tamponade, often leading to sudden death. Subacute rupture indicates a small tear 
on LV free wall that may be temporarily clotted, contained, and not leading to 
immediate death. Chronic LV free wall ruptures commonly occur in the posterior 
wall. It is associated with very small leakage of blood that is walled-off by pericar-
dium and the subsequent formation of a false aneurysm. Surgical interventions are 
indicated in subacute and chronic LV free wall ruptures.
20.4.2  Presentation and Diagnosis
Cardiac tamponade and cardiogenic shock are the most common presentations in 
patients with LV free wall rupture. Patients can have signs of tamponade including 
increased in jugular venous pressure and pulsus paradoxus. An urgent echocardiog-
raphy is the choice for diagnosis in unstable patient. In stable and chronic patients, 
cardiac CT with contrast can provide better anatomical information and may aid 
surgical planning.
20.4.3  Surgical Techniques for Repair
Subacute LV free wall rupture requires emergency surgical repair. 
Pericardiocentesis might be helpful to stabilize patient’s hemodynamic status 
while preparing an operating room. An IABP or other short-term MCS device is 
commonly necessary for preoperative stabilization. A variety of repair techniques 
have been described. Rupture closure with horizontal mattress sutures buttressed 
with Teflon felts is widely used. An additional bovine pericardial, Dacron, or 
PTFE patch can also be used to reinforce the suture line. Simple placement of a 
large pericardial patch on the ruptured surface with Bio-glue can be an option in 
cases where the myocardial tissue is too fragile to be repaired safely.
Chronic LV free wall rupture with false aneurysm does not require emergency 
surgery. Cardiac CT and MRI can better delineate the anatomical defect. The 
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aneurysm neck can be identified readily and contains fibrotic scar tissue; primary 
closure can be performed on an elective basis. Reconstruction with Dacron or 
bovine pericardial patch can also be used.
20.4.4  Results
LV free wall rupture is usually lethal, and many diagnoses are only established by 
postmortem. Thus only small series studies have been reported in patients with LV 
free wall rupture who were able to undergo surgery. Operative mortality can be as 
high as 30% in patients with contained rupture. Haddadin et al. showed the simple 
glued patch covering technique is superior than direct suture closure technique (hos-
pital mortality 12% vs. 36%) [7].
20.5  Case Reports: Mechanical Complications of Acute 
Myocardial Infraction
Wei Wang and Anson Cheung
20.5.1  Clinical Case 1
A 55-year-old male with no previous cardiac history presented late with an infe-
rior STEMI.  The patient developed acute heart failure and cardiogenic shock 
requiring intubation in emergency department. TTE showed a large posterior VSD 
involving the base of mitral valve and extending downward toward the apex. The 
patient had moderate to severe left ventricular dysfunction with an ejection frac-
tion of 35%.
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Coronary angiography showed an occluded RCA with no visible vessels distally, 
a small and diffusely diseased LAD, and LCx without any critical lesions. IABP 
was inserted in coronary suite. Despite escalating dosage of vasopressor and inotro-
pes, the patient developed persistent cardiogenic shock with severe metabolic acido-
sis with a pH of 6.85. Short-term MCS was initiated percutaneously in the form of 
VA ECMO via femoral vessels.
Metabolic derangement and hemodynamic was corrected with ECMO support in 
the next 3 days. Subsequently, the patient was taken to the operating theatre for VSD 
repair. Intraoperative findings include infarction of the entire inferior wall with 
involvement of the RV and an extensive VSD extending from the base of mitral 
annulus to the apex. A successful VSD repair using infarct exclusion technique with 
large bovine pericardial patches was carried out. There was no residual shunt 
detected post repair, and only mild MR was seen by transesophageal echocardio-
gram (TEE) postoperatively. Unfortunately, the patient was unable to be weaned 
from cardiopulmonary bypass due to moderate to severe RV dysfunction and pul-
monary dysfunction. VA ECMO was reinitiated, and further support was required 
for another 8 days with eventual successful wean from ECMO.
20.5.2  Clinic Case 2
A 62-year-old female, who had missed acute STEMI 5 days previously, presented 
with cardiogenic shock and was brought to catheter laboratory. The coronary angio-
gram showed occluded LAD and left circumflex with LVEF 15%. Balloon angio-
plasty was performed, but it was unable to restore LAD flow. The patient was 
hemodynamically unstable despite intubation, IABP, and high dose of norepineph-
rine and dobutamine. Echocardiogram showed severe MR and signs of tamponade 
secondary to large amount of pericardial fluid. Cardiac surgery was emergently con-
sulted, and the patient was brought to the operating room for emergency ECMO. The 
patient had a cardiac arrest before cutting the skin. Stat cardiopulmonary bypass 
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was established via median sternotomy. There was a lot of blood found in the peri-
cardial cavity and LV free wall rupture was identified. The LV tissue around rupture 
area was necrotic, which made it impossible to sew on the fragile tissue. A large 
bovine pericardium patch was glued on the LV free wall. The patient was then 
placed on central ECMO and chest left open and was listed for high status heart 
transplant candidate. Fortunately, 3 days later a donor heart became available, and 
the patient received orthotopic heart transplant successfully. Posttransplant course 
was uneventful and she was discharged from hospital 3 weeks later.
References
 1. Lawrence HC. Cardiac surgery in the adult. NY: McGraw-Hill Education; 2011.
 2. Massetti M, et al. Postinfarction ventricular septal rupture: early repair through the right atrial 
approach. J Thorac Cardiovasc Surg. 2000;119(4 Pt 1):784–9.
 3. Thiele H, et al. Immediate primary transcatheter closure of postinfarction ventricular septal 
defects. Eur Heart J. 2009;30(1):81–8.
 4. Thiele H, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N 
Engl J Med. 2012;367(14):1287–96.
 5. Arnaoutakis GJ, et  al. Surgical repair of ventricular septal defect after myocardial infarc-
tion: outcomes from the Society of Thoracic Surgeons National Database. Ann Thorac Surg. 
2012;94(2):436–43.
 6. Lorusso R, Gelsomino S, De Cicco G, et al. Mitral valve surgery in emergency for severe acute 
regurgitation: analysis of postoperative results from a multicentre study. Eur J Cardiothorac 
Surg. 2008;33(4):573–82.
 7. Haddadin S, et al. Surgical treatment of postinfarction left ventricular free wall rupture. J Card 
Surg. 2009;24(6):624–31.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter’s Creative Commons license and your intended use is not permitted by 
 statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
20 Mechanical Complications of Acute Myocardial Infraction
289© The Author(s) 2018
T. J. Watson et al. (eds.), Primary Angioplasty, 
https://doi.org/10.1007/978-981-13-1114-7_21
M. M. Sherman Jollis 
Department of Biology, Denison University, Granville, OH, USA 
J. G. Jollis (*) 
Department of Medicine, Duke University, Durham, NC, USA
e-mail: james.jollis@duke.edu
21Time to Reperfusion, Door-to-Balloon Times, and How to Reduce Them
Margot M. Sherman Jollis and James G. Jollis
21.1  Introduction
Time to reperfusion and first-medical-contact-to-balloon times are key parameters 
in assessing efficiency of the primary PCI pathway while also being powerful pre-
dictors of outcome. This chapter discusses the role of these measures and how 
improvements may impact clinical outcomes.
21.2  Does Time Matter?
The time-dependent nature of myocardial injury following coronary artery  occlusion 
has been consistently documented in the literature and runs congruent with clinical 
experience. Reimer and Jennings first documented an “ischemic wavefront” after 
transient ligation of the circumflex coronary artery in open-chested dogs, followed 
by reperfusion for 2–4 days (Fig. 21.1) [1]. Examining transmural slices of the pos-
terior papillary muscle, they identified a subepicardial zone of ischemic but viable 
myocardium which is available for salvage for at least 3 and perhaps 6 h following 
circumflex occlusion in the dog. Thus, the time-critical nature of coronary artery 
reperfusion was established.
Numerous observational studies have concurred with this relationship. 
Combining data from 22 fibrinolysis trials involving 50,246 patients, Boersma 
and colleagues found the number of lives saved per 1000 patients treated to be 
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greatest for patients presenting within the first hour, with an inflection point for 
less benefit for patients presenting beyond 2 h (Fig. 21.2) [2]. This relationship 
between time and treatment has been documented in additional studies, with the 
greatest time benefit seen among patients with the highest-risk clinical presenta-
tions such as cardiogenic shock [3–5]. One notable exception to this relationship 
involved a manuscript by Menses et al. that showed no change in 30-day mortal-
ity for Medicare (over age 65) patients recorded in the CathPCI Registry, despite 
a fall in door-to-balloon (D2B) time from 83 to 67 min [6]. However, the finding 
was refuted in a subsequent publication that used the same data and shared two 
co-authors, showing that shorter patient-specific D2B times were consistently 
associated with lower mortality over time [7].
Most recently, data involving the coordination of ST-elevation myocardial infarc-
tion (STEMI) care in 12 regions across the United States in the Accelerator-2 proj-
ect resulted in modest improvement in treatment times for patients transported by 
ambulance, with an increase from 67 to 74% of patients meeting the goal of first 
medical contact (FMC) to device within 90 min. This improvement in treatment 
time was associated with a relatively large and statistically significant decline in 
mortality compared to patients treated at the same time without such coordination 
[8] (Fig.  21.3). This finding suggests that time serves as a process measure that 
reflects coordination of care. Likely activities involved in such coordination lead to 
improved mortality beyond that is expected by time metrics alone such as better 
paramedic training and enhanced ability of emergency physicians to move the sick-




Fig. 21.1 Progression of the 
wavefront of ischemic cell death 
[1]. All shaded areas, necrosis; 
dotted areas, necrotic muscle; 
horizontal cross hatching, 
microvascular injury; dashed 
line, anatomic border between 
ischemic circumflex coronary 
and nonischemic left anterior 
descending coronary arteries
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21.3  How to Reduce Time
The overall goal of efforts to expedite coronary reperfusion is to shorten the time 
from artery occlusion to resumption of normal flow. Initial efforts in the United 
States concentrated on a “door-to-needle” time of less than 30 min for patients 
treated with fibrinolysis and a “door-to-balloon” time of less than 90  min. 
Recognizing that treatment times could be accelerated with involvement of emer-
gency medical services (EMS) and transferring hospitals, the standard was moved 
to an earlier starting point, “first medical contact,” maintaining the same overall 
goal of 90 min. In the case of EMS-transported patients, FMC represents the time 
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Fig. 21.2 A 35-day mortality reduction versus treatment delay [2]. Small closed dots, information 
from trials included in FTT analysis; open dots, information from additional trials; small squares, 
data beyond scale of x/y cross. The linear (34·7–1·6x) and nonlinear (19·4–0·6x + 29·3x1) regres-
sion lines are fitted within these data, weighted by inverse of the variance of the absolute benefit in 
each datapoint. Black squares, average effects in six time-to-treatment groups (areas of squares 
inversely proportional to variance of absolute benefit described)
Not in Accelerator-2
N = 22,651; P = 0.7*
Accelerator-2


















Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017
*Adjusted P-value for trend
Fig. 21.3 In-hospital 
mortality according to 
hospital participation in 
Accelerator-2 with overall 
improvements in timely 
treatment versus hospitals 
not involved in the project 
without significant 
improvement in treatment 
times [8]
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inter-hospital transfer, FMC is the time the patient arrives at the first hospital. To 
further encompass emergency response and treat patients sooner, the Los Angeles 
STEMI system starts the reperfusion clock at EMS dispatch time, and Dallas 
starts with symptom onset to arterial reperfusion (SOAR) time. The earlier pro-
cesses are included in systematic measurements, the greater opportunity for pro-
cess improvement.
In order to expedite coronary reperfusion, one needs to take a systemic survey 
of existing patterns of care, ideally considered separately according to the point of 
entry of the patient. Generally, patients present by one of four scenarios: walking 
into an emergency department, arriving by ambulance, transferring from another 
hospital emergency department, or experiencing a STEMI while hospitalized for 
some other condition. The latter group represents one of the most challenging 
with the highest mortality. Below, we will discuss approaches to accelerating cor-
onary reperfusion according to each of these four presentation scenarios. Other 
tenets to improving care include data collection and feedback on a prompt and 
ongoing basis; establishing treatment plans agreed upon by all participating pro-
viders; establishing and maintaining treatment systems with the aid of dedicated 
coordinators; working across all disciplines involved in the diagnosis and treat-
ment of acute myocardial infarction; developing as broad of a network as possible 
with the inclusion of competing hospitals, physician groups, and EMS agencies 
within a region; and recognizing that most opportunities, barriers, and solutions 
vary by region and can be overcome with local expertise and solutions. Our 
approach to organizing and transforming myocardial infarction care is summa-
rized in Fig. 21.4. We first develop leadership, establish funding, and implement a 
data system. Leadership is best composed of passionate healthcare providers that 
span multiple disciplines and institutions. Funding is reserved to support regional 
coordinators, data analyses and feedback, and local and regional meetings. Once 




    funding, data collection
   and feedback structure
2) Strategic site visits / barrier / gap analyses
Regional coordinator External faculty mentorship
3) Establish Regional 24/7 PCI Centers
    (activation plans, data registry)
4) Develop and ratify regional EMS and





Fig. 21.4 Approach to organizing regional emergency cardiovascular care system [8]
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these are established, our leadership team assesses the current system for diagnos-
ing and treating STEMI with particular attention to existing barriers that delay 
care. Primary PCI centers within a region are identified according to the following 
criteria: provide full-time primary coronary intervention, allow for single-call 
catheterization laboratory activation by trained paramedics or emergency physi-
cians, accept all patients regardless of bed availability, and participate in regional 
data collection and reporting (Fig. 21.5). These regional PCI centers and associ-
ated medical professionals including those who refer patients to these institutions 
establish regional treatment protocols that are disseminating in training sessions 
and supported by ongoing measurement and regular meetings. An example of a 
common protocol or “operations manual” can be viewed at https://duke.box.
com/s/ks6ipcc262illo8jyethbst8bblqybcj. We have found that systems develop-
ment can be expedited through assistance from experienced colleagues from other 
institutions who do not have any direct relationships with the local healthcare 




EMS First Medical Contact to Device
Distribution of Times (minutes)






Project goal: Regional 75th%
below 90 min
2nd goal: All hospitals 75th%
below 90 min
Median











Transferred from outside facility = No; Means transport to first facility = Ambulance; First EKG obtained = Pre-hospital or after arrival*32
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25th Percentile
Fig. 21.5 Mission: lifeline regional report example. De-identified example of quarterly mission: 
Lifeline regional report used in system measurement and feedback to hospitals and emergency 
medical services. Bar and whisker plots. Whiskers represent ranges; bars represent interquartile 
range. Left hand bar is summary for region. Bars to right represent individual letter-coded hospi-
tals. Goal of system is for each hospital to have 75% of EMS-transported patient treated within 
90 min, depicted by the top of the bar graph lying at or below the 90 min red line goal [8]
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21.4  Expediting Care According to Point of Entry
Each of the four entry scenarios described above requires solutions specific to each 
setting. While each system and setting has unique challenges and opportunities, 
there are a number of common approaches that have been identified and are listed 
below, organized by point of entry (Table 21.1). Many of these approaches have 
been demonstrated to expedite treatment. For example, Fordyce showed signifi-
cantly faster treatment times for hospitals that adopted paramedic catheterization 
lab pre- activation, single-call hospital transfer protocols, and emergency depart-
ment bypass when the lab was prepared to accept an anticipated patient on hospital 
arrival [9]. In related work, Glickman demonstrated sequentially faster “door-in, 
door-out” times according to the number of eight recommended processes imple-
mented by transferring hospitals [10]. Our work has associated paramedic prehos-
pital activation with both faster treatment times and substantially lower  mortality 
[10] (Fig. 21.6).
Table 21.1 Processes and protocols to expedite coronary artery reperfusion according to point of 
patient entry [8, 10]
Walk-in
Key process measures:
Door to ECG time
ECG to cath lab activation time
Measures efficiency of identifying patients 
with STEMI and initiating reperfusion
Door-to-ECG target of 10 min
“Nurse first” Asking patients about possible cardiac 
symptoms prior to registration
Dedicated area for ECG
Standard rules for ECG performance ECG for all patients over age 30 with 
typical cardiac symptoms and for patients 
over age 50 with atypical cardiac symptoms 
such as shortness of breath or nausea
Hand ECG to emergency physician
Standard plan for ST-elevation myocardial 
infarction reperfusion
Emergency physician activates reperfusion plan
Reperfusion inclusion and contraindication 
checklist
If part of treatment plan, fibrinolytic medication 
stored in emergency department
Imaging the infarct-suspected infarct-related 
artery first using a guide catheter and opening 
the vessel if appropriate prior to imaging the 




Emergency department dwell time
Systems with shorter times (less than 
20 min) have successful pre-activation 
protocols





Standard plan for ST-elevation myocardial 
infarction reperfusion
This plan should include symptom, ECG, 
and exclusion criteria for catheterization 
lab activation by paramedics. Activation 
should have a regionally recognized 
designated term such as “code STEMI” or 
“level 1 heart alert”
Dispatch of 12-lead ECG and personnel trained 
to diagnose STEMI to patients with cardiac 
symptoms
Standard rules for ECG performance
EMS personnel perform and read ECG
Single-call catheterization lab activation
15 min scene time
Diversion of STEMI patients directly to full-time 
PCI hospitals if additional transport time less 
than 30–45 min.
Emergency department bypass when possible Proceed directly to the catheterization 
laboratory if staffed and ready
Training of paramedics on diagnosis and 
treatment of STEMI
Feedback within 24 h to all involved personnel 
including treatment times, catheterization 
findings, and patient outcomes
Health information privacy rules in the 
United States allow for exchange of 
patient-identified data between entities 
caring for the same patients and accrediting 
organizations requiring such 
communication




Door-in door-out time from first hospital
Systems with shorter times (less than 
40 min) have successful protocols for 
diagnosis and transfer of patients
Similar emergency department processes to 
those described for “walk-in” patients above
Nurse first, ECG area, ECG rules, 
immediate availability of technician, 
handing tracing to emergency physician, 
emergency physician activating reperfusion 
system
Standard plan for ST-elevation myocardial 
infarction reperfusion
120 min from first hospital door threshold
PCI reliably available within 120 min, 
transfer to PCI hospital
PCI not reliably available within 120 min 
fibrinolysis preferred
Nursing-led reperfusion protocols
Use local ambulance for transfer when available
Identify a primary and backup method of transfer
Leave the patient on the stretcher Patients with likely STEMI should be 
evaluated on the stretcher and rapidly 
moved back to the ambulance for transfer 
when appropriate
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Table 21.1 (continued)
Avoid intravenous drips Aspirin, heparin bolus, and topical nitrates 
should be sufficient. Platelet inhibitors such 
as ticagrelor or cangrelor can be added 
according to local and regional preferences
Do not delay transfer for copying of medical 
records
Records can be transmitted by facsimile to 
the receiving hospital after patient 
departure
Single-call catheterization lab activation
Feedback within 24 h to all involved personnel 
including treatment times, catheterization 
findings, and patient outcomes
Regular interdisciplinary meetings to review 
STEMI cases
STEMI in patient already hospitalized for another condition
Key process measure:
Rapid response team can diagnose STEMI and 
activate reperfusion protocol
Standard plan for ST-elevation myocardial 
infarction reperfusion
Rapid-response team responds to patients with 
acute cardiac symptoms and trained to recognize 
and diagnose
Nurse leader or hospitalist authorized to activate 
reperfusion plan
In hospitals without full-time PCI facilities, 
transfer to PCI hospital for patients with 
contraindications to fibrinolysis such as recent 
surgery, gastrointestinal bleeding, or recent 
non-compressible arterial access site
Feedback within 24 h to all involved personnel 
including treatment times, catheterization 
findings, and patient outcomes
Regular interdisciplinary meetings to review 
STEMI cases
0.0%



























contact time to 
catheterization-activation 
time and in-hospital 
mortality [8]
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21.5  Walk-In
Identifying and treating STEMI patients in the emergency department has been 
the focus of coordinated care efforts for decades, starting with the “door-to-nee-
dle” focus of the National Registry of Myocardial Infarction and culminating in 
the “door-to-balloon” projects of the last decade [11]. Approximately 2  in 100 
patients presenting to an emergency department with chest pain are having an 
acute myocardial infarction, and the process mirrors that of “finding a needle in a 
haystack” in often crowded emergency departments. Successful approaches have 
included a target door-to-electrocardiogram (ECG) time of 10 min, asking patients 
about possible cardiac symptoms prior to registration, maintaining a dedicated 
area for rapid ECG performance, having standard rules for when to obtain an 
ECG, handing the ECG to the emergency physician, maintaining a standard 
approach to urgent coronary reperfusion most suitable to local resources and 
expertise, and allowing emergency physicians to activate the reperfusion plan, 
sometimes described as pressing the “easy button.” In the catheterization labora-
tory, reperfusion can be accelerated by imaging the infarct-suspected infarct-
related artery first using a guide catheter and opening the vessel if appropriate 
prior to imaging the other coronary arteries or performing ventriculography. The 
trade-off of treating the infarct artery first is that important lesions in other vessels 
may not be taken into account prior to intervention, and the rare patient with a 
mechanical complication such as ventricular septal rupture may undergo coronary 
intervention prior to urgent surgery. Using these approaches, most patients can be 
treated within 30 min of hospital arrival with fibrinolysis and within 60 min with 
primary angioplasty.
21.6  Arrival by Ambulance
Likely the ideal and most expedient process for rapid diagnosis and treatment of 
STEMI involves patient transport by ambulance. This process includes EMS dis-
patch, diagnosis at the patient location by symptoms and ECG, and pre-activation 
of the cardiac catheterization laboratory prior to hospital arrival. In the United 
States, most major systems dispatch emergency technicians with advanced levels 
of training termed “paramedics” to patients with cardiac symptoms. These para-
medics perform a 12-lead ECG on scene, interpret the tracings, and activate car-
diac catheterization labs prior to the hospital using prespecified terminology such 
as “STEMI alert,” “code STEMI,” or “level 1 heart alert.” The process expedites 
care, and in ideal instances, infarct-related arteries are opened within 1 h of activat-
ing the emergency medical system, “aborting” a myocardial infarction before sig-
nificant damage ensues. The implementation of pre-activation involves a number 
of supporting processes. Most importantly, strong medical leadership from emer-
gency medicine or interventional cardiology is required to support paramedics and 
maintain a system of accurate diagnoses. Prior to initiation of prehospital 
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activation, cardiologists and emergency medical leadership should agree to a com-
mon threshold of symptoms, ECG findings, and exclusions to activate. A reason-
able approach differentiates a “definite” from a “possible” STEMI, reserving the 
former for activation and the latter for additional consultation with emergency 
medicine and cardiology, ideally supported with ECG transmission. Systems vary 
in ECG criteria for activation, from 1 mm of ST elevation in two contiguous leads 
to requiring 2 mm of ST elevation in precordial leads. Some systems include addi-
tional support from machine interpretation, with vendor-specific statements like 
“meets STEMI criteria” or “acute MI suspected” resulting in lab activation. In 
well-performing systems, cancellation rates of 20% are reasonable and can be low-
ered to 10–15% with focused paramedic training and ongoing feedback. Additional 
processes include standard rules for ECG performance similar to the emergency 
department, limiting “ambulance scene time” to 15 min with a “load and go” focus, 
the ability of medics to direct patients to hospitals that perform percutaneous coro-
nary intervention (PCI) on a 24-h basis, an expectation that catheterization labora-
tories will be ready to begin procedures within 30 min or less of activation, and 
feedback to all involved personnel within 24  h and at regular multidisciplinary 
meetings to review cases. In the best situation, when a catheterization laboratory is 
fully staffed and ready to accept patients on hospital arrival, the emergency depart-
ment is bypassed rather than required to partake in patient registration as they pass 
quickly through the area. Similar to patients with major trauma going directly to an 
awaiting operating room or women in childbirth proceeding directly to labor and 
delivery, there is no mandate for STEMI patients to be evaluated in the emergency 
department if they can be treated immediately in the catheterization lab. The emer-
gency department remains an important component of rapid reperfusion systems, 
holding patients who arrive before the lab is ready and assisting in triage of ques-
tionable cases. Bagai found that emergency department bypass significantly low-
ered FMC- to- device times by 20 min [12].
21.7  Inter-Hospital Transfer
Timely treatment of patients requiring inter-hospital transfer remains one of the 
most challenging scenarios, with almost half of patients treated beyond 2 h of first 
hospital arrival. The delays are attributable to geographic challenges and the diffi-
culty of coordinating patient care in referring hospitals that are often small, rural, 
and challenged with busy emergency departments. The same tenets that assist the 
treatment of patients who walk into PCI hospitals apply to emergency departments 
that must transfer patients for treatment including a “nurse first” query of symptoms 
before registration and a dedicated ECG area and personnel who are immediately 
available to obtain ECGs, handing the tracing to the emergency physician and rely-
ing on the emergency physician to activate the coronary reperfusion plan without 
cardiology consultation for obvious cases. As smaller hospitals may staff their 
emergency departments with itinerant emergency physicians, the system and plan 
for treatment should heavily rely on nursing leadership and guidance. Prespecified 
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reperfusion plans should be developed with the input of local experts and be guided 
by available resources and geography. For locations where patients can be reliably 
transferred for PCI within 120 min to the hospital, transferring all patients for PCI 
is a reasonable approach. In our experience in published data, on average, ground 
transport by local ambulance is as fast as helicopter transport at any distance, and 
ground transport is not subject to weather restrictions often faced in air travel. 
Effective ground transport requires the willingness of local emergency medical or 
critical-care transport services to convey patients to PCI hospitals, a system for 
rapid dispatch of transport such as the use of terms “code STEMI patient” to priori-
tize ambulance resources, avoiding intravenous drips with a reliance on aspirin, 
heparin bolus, and topical nitrates during transfer, obtaining “mutual aid” from 
neighboring EMS when patient transport will leave large geographies without emer-
gency responders, and transferring patients before records and Emergency Medical 
Treatment and Active Labor Act (EMTALA) forms are copied with routine fac-
simile of records to the receiving cath lab after the patient leaves the first hospital. 
Having two transport alternatives for transfer patients avoids unanticipated delays. 
For patients arriving at the first hospital by ambulance who appear likely to have a 
STEMI, leaving the patient on the stretcher for ED evaluation will preclude poten-
tially long delays in procuring a second ambulance. Transfer systems are aided by 
EMS that will transport STEMI patients directly to PCI hospitals from the field 
when geographically feasible, avoiding the delays of inter-hospital transfer.
For emergency departments that cannot reliably transfer patients to PCI hospitals 
for device activation within 120 min of first hospital arrival, fibrinolysis remains an 
important and timely intervention. Again, protocols should be designed to provide 
lytics within 30 min of arrival to include standard criteria for STEMI diagnosis, 
systematic exclusion of contraindications, and the availability for fibrinolytic drugs 
in the emergency department. For the 20% of patients who are ineligible for fibrino-
lysis, and the 25% of patients who do not show signs of clinical reperfusion accord-
ing to symptom relief and ST-segment elevation resolution, protocols for rapid 
transfer to PCI hospitals still need to be established.
21.8  STEMI in Patients Already Hospitalized  
for Another Condition
The highest-risk STEMI involves those that occur in patients who are already hos-
pitalized for another condition. In California discharge data, Kaul and colleagues 
identified a threefold higher mortality for patients with inpatient-onset STEMI [13]. 
While some of the higher mortality may be attributed to age and comorbid illness, 
significant delays in the identification and treatment of these patients likely lead to 
worse outcomes. Recent efforts have focused on the systematic identification and 
treatment of these patients. Similar to other settings, a prespecified, in-hospital 
STEMI plan can increase treatment rates and reduce delays. In the hospital setting, 
“rapid-response teams” should be dispatched to patients who are possibly experi-
encing an acute coronary syndrome, and these teams should be trained in the 
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recognition and diagnosis of STEMI.  Nursing leadership or hospitalists who 
 routinely respond to these patients should be authorized to activate the cardiac cath-
eterization laboratory according to standard criteria and protocols. For hospitals 
lacking full- time PCI facilities, a plan should be in place for rapid transfer to a PCI 
hospital. Hospitalized patients with recent surgery, gastrointestinal bleeding, or 
non- compressible arterial access sites are not eligible for fibrinolysis and merit 
rapid transfer. In-hospital STEMI patients should be included in reporting and qual-
ity review efforts involving other STEMI settings.
21.9  Case Reports: Time to Reperfusion, Door-to-Balloon 
Times, and How to Reduce Them
Margot M. Sherman Jollis and James G. Jollis
21.9.1  Case Study
A 66-year-old man with the onset of chest pain while walking his dog in the  evening. 
He called 911, paramedics were dispatched, and an anterior ST-elevation myocar-
dial infarction was diagnosed at his house. The catheterization laboratory was acti-
vated while he was being transported to the hospital.
21.9.2  EMS Narrative
“A 66-year-old male lying on his couch. The patient stated he was out walking with 
his family dog and started to feel pressure across his chest. The patient was pale in 
color but not diaphoretic. He had already taken 325 mg of aspirin prior to EMS 
arrival. A 12-lead ECG showed anterior-septal STEMI.  The patient was given 
0.4  mg of nitroglycerine sublingually and moved to a stretcher and secured for 
transport to local ED per patient’s choice. IV access was established, and the patient 
was placed on 3L O2 due to room air saturation of 94%. STEMI alert to local ED 
and 12-lead ECG was transmitted. Upon arrival at ED, the patient had two 5–8 s 
runs of V-Tach that were self-corrective. Patient care was transferred to ED nursing 
staff and physician by verbal report, and EMS went with patient to cath lab. 100% 
LAD blockage noted in cath. END OF REPORT”
21.9.3  Cardiac Catheterization Report and Images
Once radial access was obtained with a Glidesheath Slender 6f radial introducer 
sheath, heparin 70 units per kilogram was administered. Verapamil 3 mg intra- arterial 
was infused through the sheath. A VL 3.5 guide catheter was advanced to the left 
main and a guiding angiogram was performed. Ticagrelor 180 mg was administered. 
A 0.014, 180-cm Extra Floppy Runthrough guidewire was advanced across the left 
anterior descending occlusion, and TIMI 1 flow was restored. The stenosis was 
M. M. Sherman Jollis and J. G. Jollis
301
pre-dilated with a 2.5 × 15-mm monorail balloon. The lesion was at the bifurcation 
of the first diagonal. A Forte Xsupport, 185-cm wire was placed into the diagonal to 
protect the side branch. A Synergy, 3.5 × 16-mm coronary stent was advance across 
the lesion. Angiography confirmed adequate coverage of the stenosis. The stent was 
deployed at 16 ATM and post-dilated with the same balloon to 17 ATM. An angio-
gram showed the proximal portion stent was slightly undersized. The stent was post-
dilated with a Quantum 3.75-mm balloon to 16 ATM. A final angiogram showed no 
residual stenosis and TIMI 3 flow into the distal vessel. Ventriculography performed 
after coronary angiography showed anterior and apical hypokinesis and ejection 
fraction of 45% (Figs. 21.7, 21.8, 21.9, 21.10, 21.11, 21.12, 21.13, and 21.14).
Date of Service: 12/27/1   22:09
Time Code STEMI Activated: 22:01
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Fig. 21.7 STEMI Feedback Report. Returned to all involved providers including EMS, emer-
gency department, catheterization laboratory, critical care transport, and STEMI team 1 day after 
catheterization. Case is also reviewed in biweekly multidisciplinary team review
Fig. 21.8 Initial image, 
AP cranial view, radial 
access, guide catheter VL 
3.5, 100% proximal LAD, 
TIMI 0 flow
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Fig. 21.9 Crossed with 
0.014 guidewire and 
pre-dilated with a 2.5-mm 
balloon
Fig. 21.10 Post initial 
dilation, residual filling 
defects, TIMI 3 flow
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Fig. 21.11 Forte wire 
placed in diagonal branch 
for protection. 
3.5 × 16-mm Synergy 
drug- eluting stent 
advanced across lesion
Fig. 21.12 Final images 
before wire pull. Stent 
deployed 16 ATM, 
post-dilated 17 
ATM. Proximal portion 
post-dilated with Quantum 
3.75-mm balloon to 16 
ATM
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Fig. 21.13 RCA imaged 
after LAD opened. No 
stenosis
Fig. 21.14 Fluoroscopy report and camera angles
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21.9.4  Summary
This patient was found to have total occlusion of the left anterior descending artery 
with TIMI 0 flow. This was opened with a 3.5-mm stent, and the first balloon infla-
tion happened 63 min after the paramedics were “on scene” or arrived to the loca-
tion of the patient. This case demonstrates how an ideal system for prehospital 
diagnosis and coordination between emergency medical services and hospitals 
serves to rapidly treat patients and thus how this translates into optimal outcomes.
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In the context of ST-segment elevation myocardial infarction (STEMI), early and 
successful myocardial reperfusion by primary percutaneous coronary intervention 
(PPCI) is the most powerful intervention for reducing myocardial infarct (MI) size, 
preserving left ventricular (LV) systolic function and preventing the onset of heart 
failure. However, despite continual improvements in acute care, the mortality and 
morbidity rates following STEMI remain significant, with 7% death and 22% 
rehospitalisation for heart failure, at 1 year. Although timely reperfusion of the 
occluded vessel by PPCI is essential to minimise the acute ischaemic time (a major 
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determinant of MI size) and salvage viable myocardium, the process of reperfusion 
itself, paradoxically, induces additional myocardial injury and cardiomyocyte death, 
a phenomenon which has been termed ‘myocardial reperfusion injury’. This has 
been shown to contribute to up to 50% of the final MI size, making it an important 
therapeutic target to reduce MI size in STEMI patients reperfused by PPCI. However, 
the translation of novel cardioprotective strategies for targeting myocardial reperfu-
sion injury to reduce MI size following STEMI has been both challenging and dis-
appointing. In this chapter, we provide an overview of myocardial reperfusion 
injury, discuss the challenges facing the investigation of treatment strategies for 
reducing MI size following STEMI and highlight future cardioprotective therapies 
for potentially improving clinical outcomes in STEMI patients.
22.2  Myocardial Reperfusion Injury: A Residual Target 
for Cardioprotection in STEMI
There is currently no effective therapy for reducing myocardial reperfusion injury, 
making it an important therapeutic target for reducing MI size following PPCI in 
STEMI patients. It is characterised by:
 1. Reperfusion arrhythmias—these are often short-lived and easily treated.
 2. Myocardial stunning—this is reversible impairment in myocardial contractile 
function and is due to oxidative stress and calcium dysregulation.
 3. Microvascular obstruction (MVO)—this manifests as coronary no-reflow at the 
time of PPCI and refers to the inability to perfuse the myocardium at the level of 
the coronary microvasculature, despite a patent epicardial coronary artery. It has 
a multifactorial aetiology which includes coronary microembolisation, platelet 
activation and external compression of coronary microvasculature by swollen 
endothelial cells and cardiomyocytes. In severe cases of MVO, damage to the 
endothelium allows the extravasation of red blood cells into the myocardium 
(termed ‘intramyocardial haemorrhage’ or IMH). Both MVO and IMH have 
been shown to be independent predictors of adverse LV remodelling and clinical 
outcomes following STEMI.
 4. Cardiomyocyte death—this lethal form of myocardial reperfusion injury con-
tributes to the final MI size and is due to several factors including abrupt changes 
in intracellular pH, ATP depletion, oxidative stress, mitochondrial and cytosolic 
calcium overload, cardiomyocyte hypercontracture and mitochondrial 
dysfunction.
A number of other proponents also contribute to the pathophysiology of myocar-
dial reperfusion injury, and these include endothelial dysfunction, platelet activation 
and inflammation. The strongest evidence for the existence and importance of myo-
cardial reperfusion injury is the demonstration that acute MI size can be reduced by 
applying an intervention solely at the onset of reperfusion. However, given the com-
plex pathophysiology underlying myocardial reperfusion injury, and the fact it man-
ifests in the first few minutes of reperfusion, it is probably no surprise that it has 
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been challenging to target reperfusion injury to reduce MI size following STEMI 
(see later section).
22.3  Strategies for Targeting Reperfusion Injury to Reduce 
MI Size Following STEMI
A large number of treatment strategies, shown to be effective in the experimental 
setting, have been tested in the clinical setting of STEMI over the years, and many 
have failed to show any benefit in terms of reducing MI size and/or improving clini-
cal outcomes (Table 22.1), and the reasons for this are discussed in a later section. 
In this section, we review the most recent interventions which have been tested as 
cardioprotective strategies for reducing MI size in STEMI patients (Table  22.1). 
These can be divided into mechanical interventions and pharmacological thera-
pies—the signalling pathways these cardioprotective therapies target in the cardio-
myocyte are depicted in Fig. 22.1.
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Fig. 22.1 Some of the major signalling pathways underlying ischaemic conditioning and the 
potential targets of cardioprotective therapies to reduce myocardial infarct size in ST-segment 
elevation myocardial infarction (STEMI) patients are depicted. The signalling cascade underlying 
cardioprotection begins at the cardiomyocyte plasma membrane with the activation of G-protein- 
coupled or cytokine receptors by autocoids such as adenosine, bradykinin or opioids (released in 
response to the ischaemic postconditioning [IPost] or remote ischaemic conditioning [RIC] stimu-
lus). As a consequence, the reperfusion injury salvage kinase (phosphatidylinositol 3-kinase-Akt 
(PI3K-Akt) and mitogen-activated protein kinase 1/2-extracellular signal-regulated kinase 1/2 
(MEK1/2-Erk1/2)), survivor activator factor enhancement (SAFE), Janus kinase and signal trans-
ducer and activator of transcription (JAK-STAT) and the PKG pathways are recruited. These pro- 
survival signalling pathways activate mediators such as endothelial nitric oxide synthase (eNOS), 
glycogen synthase kinase (GSK)-3, protein kinase C-ε (PKC-ε) and the mitochondrial ATP- 
dependent potassium channel (KATP), which then mediate an inhibitory effect on mitochondrial 
permeability transition pore (MPTP) opening
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22.3.1  Ischaemic Postconditioning: Interrupting Reperfusion 
to Reduce MI Size Following STEMI
Experimental studies have demonstrated that following a sustained coronary artery 
occlusion, interrupting myocardial reperfusion with short-lived episodes of alternat-
ing coronary artery occlusion and reflow (four 30-s cycles) in the first few minutes 
of reflow reduced MI size in small and large animal models of acute myocardial 
infarction, a phenomenon which has been termed ischaemic postconditioning 
(IPost). The signalling pathways which mediate the cardioprotective effects of IPost 
in the cardiomyocyte are depicted in Fig. 22.1.
In the STEMI patient, IPost has been applied at the onset of reperfusion by 
PPCI using alternating low-pressure inflations and deflations of an angioplasty 
balloon (four 60-s  cycles) positioned upstream of the directly deployed stent 
within the infarct-related artery, a manoeuvre which has been shown to reduce MI 
size by 30–40% and preserve LV systolic function. However, the results of the 
clinical studies have been mixed with positive, neutral and even negative studies 
in terms of MI size. Furthermore, two large clinical trials of IPost in STEMI 
patients were neutral. IPost (four 1-min inflations/deflations of coronary angio-
plasty balloon following PPCI) failed to improve ST-segment resolution when 
compared to control in a 700 STEMI patient study, and in the 460 STEMI patient 
LIPSIA trial, no difference was found between IPost (four 1-min inflations/defla-
tions of coronary angioplasty balloon following PPCI) and control with respect to 
MRI-determined MI size and clinical outcomes at 6 months (death, re-infarction 
and new congestive heart failure).
The reasons for the discordant results of IPost in STEMI remain unclear, but 
they may be due to key factors: patient selection (STEMI patients most likely to 
benefit are those presenting with a fully occluded coronary artery and treated by 
direct stenting) and delivery of the IPost protocol (the most effective protocol 
should be four 60-s angioplasty inflations/deflations, delivered upstream of the 
deployed stent to avoid potential coronary thromboembolism). The largest clini-
cal study of IPost to date, the multicentre DANAMI 3-iPOST trial, tested the 
effect of IPost on major clinical endpoints in 1234 STEMI patients treated by 
PPCI, and it found no difference between IPost (four 30-s inflations/deflations of 
coronary angioplasty balloon following PPCI) and control with respect to clinical 
outcomes (all-cause death, re- infarction and hospitalisation for heart failure), 
after an extended median follow-up of 3.8 years. However, this trial was likely 
underpowered (the primary event rate was lower than expected), may have used a 
suboptimal IPost stimulus (four 30-s angioplasty balloon inflations/deflations 
instead of standard four 60-s protocol) and included patients who were reperfused 
not using direct stenting.
In summary, IPost in the setting of STEMI is an invasive cardioprotective strat-
egy which requires stringent patient selection and careful delivery of the IPost pro-
tocol to be effective. Whether IPost can improve clinical outcomes following 
STEMI remains unclear.
V. Paradies et al.
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22.3.2  Remote Ischaemic Conditioning: Transient Arm Ischaemia 
to Reduce MI Size Following STEMI
IPost requires an invasive intervention to be administered directly to the heart thereby 
hampering its application in STEMI patients. Therefore, the phenomenon of remote 
ischaemic conditioning (RIC), which allows the cardioprotective intervention to be 
applied away from the heart, has greatly facilitated the translation of ischaemic con-
ditioning into the clinical setting. Experimental studies have shown that RIC could 
be applied to the hindlimb of animals (using a tourniquet to induce cycles of brief 
ischaemia and reperfusion), and clinical studies have gone on to show that RIC could 
be non-invasively applied to human volunteers and patients by simply inflating a 
standard blood pressure cuff placed on the upper arm or thigh to induce cycles of 
brief ischaemia and reperfusion. The signalling pathways which mediate the cardio-
protective effect of RIC in the cardiomyocyte are depicted in Fig. 22.1.
In patients presenting with a STEMI, the application of limb RIC to either the arm 
or leg prior to or even at the onset of PPCI has been shown in several proof-of- 
concept clinical studies to reduce MI size (assessed by serum cardiac biomarkers, 
myocardial nuclear imaging or cardiac MRI) and preserve LV ejection fraction. Only 
one recent study has been neutral, but this may have been due to the non- standardised 
and unorthodox limb RIC protocol used in this study, which comprised variable 
numbers of cycles of RIC (5 to 11 5-min cycles of lower limb cuff inflations/defla-
tions), initiated prior to PPCI and continued to the end of the PCI procedure. Extended 
follow-up of a cohort of STEMI patients treated by limb RIC reported a 51% reduc-
tion in the combined clinical endpoint of all-cause mortality, non-fatal MI, transient 
ischaemic attack or stroke and hospitalisation for heart failure, when compared to 
control, although this study was not originally designed to test the effect of limb RIC 
on these clinical endpoints. In this regard, the 5200 STEMI CONDI2/ERIC-PPCI 
patient prospective study is currently investigating whether limb RIC (four 5-min 
inflations and deflations of a cuff placed on the upper arm administered prior to 
PPCI) can reduce cardiac death and hospitalisation for heart failure at 12 months—
the results for this study are expected in the summer of 2019.
In summary, limb RIC provides a non-invasive, low-cost strategy for reducing 
MI size and has the therapeutic potential to improve clinical outcomes in STEMI 
patients.
22.3.3  Therapeutic Hypothermia: Cooling the Heart to Reduce  
MI Size Following STEMI
Therapeutic hypothermia has been shown to reduce MI size in preclinical studies by 
reducing myocardial metabolic demands, preventing platelet aggregation and limit-
ing the inflammatory response. Large animal studies have shown that hypothermia 
to 32  °C is cardioprotective if initiated during ischaemia but not at reperfusion. 
Early clinical studies (ICE-IT, COOL-MI) failed to demonstrate a benefit of 
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hypothermia, possibly due to slow cooling. The combination of cold saline and 
endovascular cooling induced a faster temperature decline and reduced MI size in a 
20-patient pilot trial (RAPID MI-ICE). However, the larger CHILL-MI trial failed 
to demonstrate a significant reduction in MI size, although patients presenting 
within 4 h with an anterior STEMI had a reduction in MI size and there was also a 
significant reduction in heart failure. It was hypothesised, therefore, that faster cool-
ing may be beneficial in anterior STEMI patients. However, the recently published 
COOL AMI EU Pilot Trial which recruited anterior STEMI patients only (N = 50), 
and used the ZOLL Proteus Intravascular Temperature Management System device 
to achieve rapid hypothermia (33.6 °C at the time of PPCI), failed to significantly 
reduce MI size, and the intervention resulted in a 17-min delay in reperfusion and 
increased the rates of paroxysmal atrial fibrillation.
As such, the role of therapeutic hypothermia to reduce MI size following STEMI 
remains unproven, and it is associated with logistical challenges to implement into 
the clinical pathway and has side effects.
22.3.4  Thrombus Aspiration to Improve Microvascular 
Reperfusion Following STEMI
Whether routine manual thrombus aspiration at the time of PPCI can reduce distal 
embolisation and improve microvascular perfusion in STEMI patients has been 
heavily debated in recent years following positive results in the TAPAS trial 
(Thrombus Aspiration During Percutaneous Coronary Intervention in Acute 
Myocardial Infarction Study) which showed that routine thrombus aspiration 
improved microvascular perfusion and reduced mortality at 1 year. However, two 
major randomised multicentre trials, TASTE (Thrombus Aspiration in ST-Elevation 
Myocardial Infarction in Scandinavia) and TOTAL (Trial of Routine Aspiration 
Thrombectomy with PCI vs. PCI Alone in Patients with STEMI), failed to confirm 
any beneficial effects of routine thrombus aspiration use during PPCI and found that 
it may increase the risk of stroke. As a result, the routine use of thrombus aspiration 
has been changed from a IIa to III recommendation in the latest 2017 ESC STEMI 
guidelines. Whether selective use of thrombus aspiration in STEMI patients with 
high thrombus burden is beneficial in terms of improving coronary microvascular 
perfusion and clinical outcomes remains to be elucidated. Further in-depth discus-
sion of this chapter is available in Chap. 10.
22.3.5  GLP-1 Agonists to Reduce MI Size Following STEMI
The anti-diabetic agent, glucagon-like peptide-1 (GLP-1), has been demonstrated in 
experimental animal studies to reduce MI size when administered at the onset of 
reperfusion by mechanisms independent of increased insulin levels. As a therapeu-
tic strategy, the GLP-1 analogue, exenatide, has also been shown to protect against 
myocardial reperfusion injury in small and large animal MI models. In the clinical 
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setting, an intravenous infusion of exenatide initiated prior to PPCI has been shown 
to reduce MI size in patients presenting with an acute STEMI, especially in those 
patients presenting with short ischaemic times from symptom onset (<132 min). 
Another GLP-1 analogue, liraglutide, when administered prior to PPCI and contin-
ued for 7 days, has been shown in a study of 85 STEMI patients to improve LV 
systolic function. However, not all studies have been favourable with neutral effects 
on MI size in two recently published using exenatide in STEMI patients.
On the basis of these conflicting results, further clinical studies are required to 
determine whether this therapeutic approach is beneficial as adjunctive therapy to 
PPCI to reduce MI size in STEMI patients.
22.3.6  Adenosine to Reduce MI Size Following STEMI
Experimental studies have demonstrated that adenosine administered prior to index 
ischaemia can reduce MI size—however, whether it can also reduce MI size when 
administered at the time of reperfusion has been contentious. Unsurprisingly then, 
the results of clinical studies investigating adenosine as an adjunct to PPCI have 
been inconsistent, and this may in part relate to patient selection, the different doses 
used and the route of administration (intravenous versus intracoronary). Some stud-
ies have reported reductions in MI size with high-dose intravenous adenosine 
administered as a 3-h infusion initiated prior to reperfusion in STEMI patients pre-
senting within 3 h of chest pain onset, with other studies using lower doses of IV 
adenosine or boluses of intracoronary adenosine being less successful at reducing 
MI size. The recently published REFLO-STEMI trial has recently shown that high- 
dose intracoronary adenosine during PPCI did not reduce MI size or MVO mea-
sured by cardiac magnetic resonance imaging (CMR) in 247 STEMI patients when 
compared to conventional treatment. Furthermore, the investigators reported that 
adenosine may adversely affect mid- term clinical outcomes.
On the basis of these conflicting results, the role of adenosine as adjunctive ther-
apy to PPCI to reduce MI size in STEMI patients remains unclear.
22.4  Anti-platelet and Anti-thrombotic Strategies to Reduce 
MI Size Following STEMI
Anti-platelet and anti-thrombotic agents form the cornerstone of therapy for STEMI 
patients treated by PPCI. A number of studies have investigated new approaches to 
optimise anti-platelets and anti-thrombotic therapy to reduce MI size following 
STEMI.
It has been shown that current oral P2Y12 platelet inhibitors, such as prasugrel 
and ticagrelor, administered to STEMI patients prior to PPCI, can take 4–6 h to 
achieve maximal platelet inhibition, meaning that at the time of reperfusion, the 
platelets are not maximally inhibited—this may be expected to result in an 
increased risk of MVO and worsened clinical outcomes following STEMI. The 
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intravenous (IV) P2Y12 platelet inhibitor, cangrelor, which has a rapid onset of 
action and induces maximal platelet inhibition within 1–2 min of administration, 
has been shown in the CHAMPION studies to reduce stent thrombosis and prevent 
MACE in ACS patients when administered at the time of PCI, when compared to 
oral clopidogrel. The administration of cangrelor prior to PPCI might be expected 
to offer complete platelet inhibition at the time of reperfusion, thereby reducing the 
risk of developing MVO following STEMI. Moreover, a number of experimental 
small and large animal studies have demonstrated that administrating cangrelor 
prior to reperfusion has the ability to reduce MI size through a direct cardioprotec-
tive effect on the cardiomyocyte involving the activation of established pro-sur-
vival signalling cascades. These findings suggest that administering cangrelor prior 
to reperfusion in STEMI patients has the therapeutic potential to target myocardial 
reperfusion injury through two distinct mechanisms—maximal platelet inhibition 
at time of PPCI, thereby preventing MVO, and a direct cardioprotective effect on 
the cardiomyocyte, thereby reducing MI size. The ongoing multicentre randomised 
controlled trial “Platelet Inhibition to Target Reperfusion Injury” (PITRI) 
(ClinicalTrials.gov NCT03102723) is currently investigating whether initiating a 
cangrelor infusion prior to PPCI can reduce MI size and prevent MVO in STEMI 
patients treated by PPCI.
The INFUSE-AMI trial demonstrated that an intracoronary bolus of the GPIIb/
IIIa inhibitor, abciximab, reduced MI size on cardiac MRI at 30 days in anterior 
STEMI patients when compared to placebo, suggesting that potent platelet inhibi-
tion delivered locally to the infarct lesion site may be beneficial. Whether admin-
istering an intracoronary bolus of abciximab is more effective at reducing MI size 
and preventing MVO, when compared to using an intravenous bolus, had been 
unclear. However, the large randomised AIDA-STEMI trial failed to demonstrate 
significant differences in the primary composite outcome of all-cause mortality, 
re-infarction and new congestive heart failure between intracoronary and intrave-
nous administration of abciximab. Current European guidelines recommend 
GPIIb/IIIa inhibitor administration only for bailout, evidence of no-reflow or 
thrombotic complications.
In order to target the thrombus within the infarct-related coronary artery follow-
ing PPCI, the ongoing T-TIME trial (Trial of Low-dose Adjunctive alTeplase During 
prIMary PCI) is currently investigating the effect of low-dose intracoronary alteplase 
infusion initiated after reperfusion with aspiration thrombectomy ± angioplasty but 
before stenting, on the extent MVO on cardiac MRI in STEMI patients treated by 
PPCI.
22.5  Targeted Mitochondria to Reduce MI Size  
Following STEMI
The immunosuppressant, cyclosporin-A (CsA), has been shown to have a protective 
effect on mitochondrial function and reduce MI size when administered at the onset 
of reperfusion in a number of small and large animal experimental studies. Although 
V. Paradies et al.
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an initial small proof-of-concept studies found that administering an IV bolus of 
CsA prior to PPCI reduced MI size in STEMI patients treated by PPCI, two subse-
quent large clinical trials (CYLCE and CIRCUS) failed to find any benefit with this 
therapeutic approach in terms of ST-segment resolution, enzymatic infarct size and 
clinical endpoints.
The mitochondria-targeting peptide, MTP-131, which optimises mitochondrial 
energetics and attenuates the production of ROS by selectively targeting cardiolipin 
in the inner mitochondrial membrane, has been reported in small and large animal 
experimental studies to reduce MI size when administered at the onset of reperfu-
sion and prevent adverse LV remodelling following MI. However, in the 117-patient 
EMBRACE-STEMI clinical trial, intravenous MTP-131 administered prior to PPCI 
failed to reduce enzymatic MI size in a carefully selected population of anterior 
STEMI patients with ischaemic time < 4 h, no collaterals and fully occluded coro-
nary artery.
Finally, the mitochondrial targeting drug, TRO40303, which binds to the translo-
cator protein in the outer mitochondrial membrane, has been reported in small ani-
mal experimental studies to reduce MI size when administered at time of reperfusion. 
However, in a clinically relevant large animal MI model, it failed to reduce MI size 
in the porcine heart. In the 163 STEMI patient MITOCARE study, this agent failed 
to reduce MI size despite careful patient selection (completely occluded infarct- 
related artery, large area-at-risk). Prior experimental studies had revealed ambigu-
ous cardioprotective capacity, and the formulation and dosage of TRO40303 used in 
the clinical study differed from experimental studies, which may in part explain the 
neutral findings of the MITOCARE study. Finally, more adverse events were 
reported in patients receiving TRO40303 when compared to the placebo arm, 
thereby limiting the clinical application of this therapeutic approach.
As such, the current evidence does not support a role for these three mitoprotec-
tive agents as an adjunct to PPCI to reduce MI size following STEMI.
22.6  Metoprolol: Beta-Blocker Therapy to Reduce MI Size 
Following STEMI
Intravenous metoprolol administered prior to reperfusion has been shown to reduce 
MI size and preserve LV systolic function in the porcine heart. The mechanisms 
underlying this cardioprotective effect are currently being investigated and appear 
to extend beyond their effects on haemodynamics and myocardial oxygen consump-
tion. In the 270 anterior STEMI patient METOCARD-CNIC trial, intravenous 
metoprolol administered in the ambulance prior to PPCI reduced MI size, prevented 
LV adverse remodelling, preserved LV systolic function and lowered hospital read-
missions for heart failure. However, the larger EARLY BAMI trial failed to show 
any benefit with IV metoprolol on MI size by cardiac MRI or clinical outcomes in a 
non-selected cohort of 683 STEMI patients.
As such, the current evidence does not support a role for IV metoprolol as an 
adjunct to PPCI to reduce MI size following STEMI.
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22.7  Nitric Oxide Donors to Reduce MI Size Following STEMI
Although there have been experimental studies demonstrating reduced MI size with 
intravenous nitrite administered at the onset of reperfusion to release nitric oxide, 
the National Heart, Lung, and Blood Institute (NHLBI) Consortium for preclinicAl 
assESsment of cARdioprotective therapies (CESAR) Network failed to demon-
strate MI size reduction with nitrite using a multicentre approach in small and large 
animal MI models. Two recent clinical studies have failed to demonstrate a signifi-
cant reduction in MI size with nitrite administered by either the intravenous or intra-
coronary routes in STEMI patients treated by PPCI. However, there was a borderline 
increase in myocardial salvage index and reduced MI size in a subgroup of patients 
presenting with a fully occluded coronary artery. The 250-patient NOMI study 
investigated the role of inhaled nitric oxide (vasoKINOX 450) as an adjunct to PPCI 
to target myocardial reperfusion injury in STEMI patients also failed to reduce MI 
size (day 3 cardiac MRI), although a post-hoc subgroup analysis revealed that there 
was a significant reduction in MI size in those patients who had not received nitrates 
in the ambulance. Recently, the NACIAM trial demonstrated that the co- 
administration of two old drugs, the nitric oxide donor, nitroglycerin, and the anti- 
oxidant, N-acetylcysteine (NAC), reduced MI size on cardiac MRI, but had no 
beneficial effects on LV remodelling in 112 all-comers STEMI patients.
As such, the current evidence is mixed over whether there is a role for nitric 
oxide donors as an adjunct to PPCI to reduce MI size following STEMI.
22.8  Optimising the Translation of Cardioprotection into 
the Clinical Setting
Given the numerous examples of failed translation of cardioprotective therapies to 
reduce MI size and improve clinical outcomes following STEMI, new approaches 
are required to optimise the preclinical and clinical testing of future cardioprotective 
therapies—these include the following.
22.8.1  More Rigorous Preclinical Evaluation 
of the Cardioprotective Strategy Before Clinical Testing
A number of clinical trials may have failed to demonstrate benefit with some car-
dioprotective therapies due to inconsistent and/or insufficient experimental data. In 
general, most treatment strategies have only been studied in healthy, young ani-
mals, and preclinical studies in adult or older animals, with comorbidities and con-
comitant medication usually received by patients with STEMI, have been lacking. 
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Thus, clinical testing of novel cardioprotective strategies should only be performed 
after consistent demonstration of efficacy and absence of safety concerns obtained 
in adequate small and large animal models in different laboratories using stan-
dardised methods.
22.8.2  Optimising Clinical Study Design
 (a) Patient selection: It is important to select those STEMI patients who are more 
likely to benefit from a strategy applied at the onset of reperfusion to reduce 
MI—this includes those STEMI patients presenting with:
• Short ischaemic time (<2–3 h)
• Large area-at-risk (>30–40% of LV) such as proximal LAD STEMI
• Fully occluded coronary artery prior to PPCI (TIMI flow <1)
• No significant coronary collaterals
 (b) Dosing the intervention: A failure to ascertain the most efficacious dose of the 
cardioprotective strategy, whether it be a mechanical or pharmacological one, 
may have contributed to the failure to translate cardioprotection in some of the 
clinical STEMI studies.
 (c) Timing the intervention: There is consistent preclinical evidence that the inter-
vention to target myocardial reperfusion injury might reduce final MI size when 
administered prior or at the onset of reperfusion, and it has achieved sufficient 
concentrations in the blood in the first few minutes of reperfusion.
22.9  Future Perspectives
Translating cardioprotective therapies for targeting myocardial reperfusion injury 
to reduce MI size following STEMI has been extremely challenging. The failure 
to find an effective agent for preventing myocardial reperfusion injury thus far, 
however, does not question the existence of myocardial reperfusion injury as a 
valid target for cardioprotection—rather it underscores the need to better under-
stand the mechanisms underlying myocardial reperfusion injury and investigate 
novel strategies for cardioprotection. These should include combination therapy 
to (1) target different cardioprotective signalling pathways within the cardiomyo-
cyte in order to provide additive cardioprotection and (2) target the different play-
ers involved in myocardial reperfusion injury (cardiomyocyte, microvasculature, 
inflammatory cells, and platelets). These experimental and clinical studies are 
currently under way and should allow more effective targeting of myocardial 
reperfusion injury, thereby reducing MI size in reperfused STEMI and preventing 
the onset of heart failure.
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22.10  Case Report: Strategies for Reducing Myocardial Infarct 
Size Following STEMI
Valeria Paradies, Mervyn Huan Hao Chan,  and Derek J. Hausenloy
22.10.1  Case Report
This 41-year-old male with diabetes was referred to our hospital for primary 
 percutaneous coronary intervention (PPCI) for acute onset of chest pain and 
anterolateral ST-segment elevation myocardial infarction (STEMI) on ECG. He 
was recruited into the PITRI trial which is currently investigating the effect of an 
intravenous infusion of the P2Y12 inhibitor, cangrelor, initiated prior to PPCI, on 
myocardial infarct size and microvascular obstruction (MVO), in STEMI patients 
treated by PPCI. Right coronary angiography demonstrated the absence of both 
atherosclerotic lesions and collaterals towards the left coronary artery. Left coro-
nary angiography revealed a critical lesion in the proximal left descending artery 
(LAD) with evidence of acute thrombus. Distal coronary embolisation and abrupt 
occlusion of a big septal branch, apical LAD and first marginal branch were 
detected (Fig. 22.2a). Thrombus aspiration of the septal branch was initially per-
formed with restoration of the flow. The procedure continued with PPCI of the 
culprit lesion and drug-eluting stent implantation in the proximal LAD. The pro-
cedure was completed with thrombectomy of the marginal branch and this 
achieved good final angiographic result (Fig. 22.2b). Cardiac MRI performed at 
day 4 after PPCI revealed normal left ventricular (LV) size with severely impaired 
LV systolic function with akinesia of the LAD territory and mid lateral segment 
with a dyskinetic apical cap. Late gadolinium enhancement (LGE) images showed 
transmural infarction in the LAD territory in the basal to mid septum, mid 
* 
* 
  a b
Fig 22.2 Coronary angiogram in acute LAD STEMI patient. (a) Left coronary angiography 
showing culprit lesion in proximal LAD and distal embolisation in septal branch (arrow), distal 
LAD and marginal branch (asterisk). (b) Angiographic result after PPCI with proximal LAD, 
thrombectomy of septal and marginal branches
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anterior, mid lateral and apical segments. MVO was detected at the mid septum 
and mid lateral LV segments (Fig. 22.3a, b).
This case demonstrates aptly that even with effective and timely reperfusion with 
PPCI for STEMI, the insult to the myocardium is often substantial, and effective 
interventions to protect the myocardium from myocardial reperfusion injury (which 
can contribute up to 50% of final infarct size) are urgently needed.
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23Primary PCI: Outcomes and Quality Assessment
John S. Douglas
23.1  Introduction
ST-segment elevation myocardial infarction (STEMI) and patients with equivalent 
findings (true posterior MI, hyper-acute T-wave changes, anterior ST depression 
with ST elevation in lead aVR, and new left bundle branch block with Sgarbossa 
concordance criteria or hemodynamic instability) account for 30–50% of myocar-
dial infarctions (MI) and are associated with substantial short- and long-term mor-
bidity and mortality [1, 2]. Reperfusion of ischemic myocardium is the primary 
therapeutic goal and can be accomplished by primary angioplasty with stent implan-
tation or intravenous fibrinolytic therapy. Timely PCI (≤90 min from first medical 
contact) is the preferred approach in PCI-capable hospitals (ACC/AHA class I rec-
ommendation, level of evidence A) resulting in more complete reperfusion and 
lower rates of early death, reinfarction, and bleeding, including intracranial hemor-
rhage, compared to fibrinolysis.
When hospital transfer for primary PCI involves a delay of more than 120 min, 
fibrinolytic therapy, if not contraindicated, is an ACC/AHA class I recommenda-
tion, level of evidence A. Following fibrinolytic therapy, subsequent transfer to a 
PCI-capable hospital is recommended. This reperfusion strategy (Fig.  23.1) has 
resulted in reductions in in-hospital mortality from over 20% to less than 5% in 
patients treated without significant delays due to need for non-cardiac diagnostic 
testing or other nonsystem delays. Evaluation of the care received by the STEMI 
patient requires an assessment of events extending from initial symptom onset to 
reperfusion to hospital discharge and return home [3]. Outcome data must be 
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risk- stratified as complications of death, acute kidney injury, and bleeding are 
highly influenced by baseline patient characteristics as well as subsequent clinical 
events. ACC/AHA STEMI guidelines give a class I recommendation for an active 
quality assessment and improvement program which is judged to be essential to 
optimize application of evidence-based reperfusion strategies and improve out-
comes in all STEMI patients irrespective of gender, age, race, education, insurance 
status, and income.
23.2  Quality Assessment
Three components of quality assessment (QA) in healthcare have been conceptual-
ized: (1) structure, (2) processes of care, and (3) outcomes (Table  23.1). In the 
STEMI patient, structural components include prehospital emergency medical ser-
vices (EMS), emergency rooms, cardiac catheterization laboratories, inpatient 
STEMI patient who is a
candidate for reperfusion
DIDO time ≤30 min













time as soon as
possible and
≤120 min
(Class I, LOE: B)


















(Class IIa, LOE: B)
Administer fibrinolytic




(Class I, LOE: B)
Fig. 23.1 Reperfusion therapy for patients with STEMI. The bold arrows and boxes are the pre-
ferred strategies. Performance of PCI is dictated by an anatomically appropriate culprit stenosis. 
*Patients with cardiogenic shock or severe heart failure initially seen in a non-PCI-capable hospi-
tal should be transported for cardiac catheterization and revascularization as soon as possible, 
DIDO, door-in-door-out. Source: O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA 
guideline for the management of ST-elevation myocardial infarction: a report of the American 
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
J Am Coll Cardiol 2013; 61(4):e78-e140
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hospital facilities, and medical personnel. Cath lab QA committees perform surveil-
lance of times to treatment and initiate improvement activities needed to provide 
optimal STEMI care. Process measures include those actions performed by provid-
ers in the delivery of care to STEMI patients ideally using proven diagnostic and 
therapeutic strategies advocated by clinical guideline statements and appropriate 
use criteria. Writing committees of the ACC/AHA have established specific mea-
sures that assess essential aspects of care in STEMI patients [4, 5]. The AHA/ACC 
Task Force on Performance Measures was charged with updating performance and 
quality measures in patients hospitalized with STEMI in order to benchmark and 
improve the care of these patients. In 2017, this committee published a comprehen-
sive measure set that included 22 total measures related to STEMI patients 
(Table 23.2). Seventeen were performance measures (those with the strongest sup-
porting evidence such as administration of aspirin) and five quality measures (strong 
but less robust supporting evidence such as inappropriate in-hospital use of nonste-
roidal anti- inflammatory drugs). The chair of the writing committee stated, 
“Implementation of this measure set by health care providers, physician practices 
and hospital systems will enhance the quality of care and likely improve outcomes 
of patients hospitalized with a heart attack.” Important in-hospital outcomes of 
patients with STEMI are substantially less favorable than with non-STEMI 
(Fig. 23.2) and include procedural success and complications, death, reinfarction, 
heart failure, shock, and stroke (Table 23.3).
Table 23.1 Quality domains 
in primary angioplasty
Structural components
STEMI/cath lab QA committee: chairman and staff, 
regular meeting
Analysis of times to treatment including EMS, 
emergency department, and cath lab
Monthly-quarterly-annual reporting
Credentialing














Hospital- and physician-specific data
NCDR and AHA registries, comparative results
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Table 23.2 2017 AHA/ACC STEMI clinical performance and quality measures
Measure title Measure region
Performance measures
Aspirin at arrival Effective clinical care
Aspirin prescribed at discharge Effective clinical care
Beta blocker prescribed at discharge Effective clinical care
High-intensity statin prescribed at discharge Effective clinical care
Evaluation of LVEF Effective clinical care
ACEI or ARB prescribed for LVSD Effective clinical care
Time to fibrinolytic therapy Communication and care 
coordination
Time to primary PCI Communication and care 
coordination
Reperfusion therapy Effective clinical care
Time from ED arrival at STEMI referral facility to ED 
discharge from STEMI referral facility in patients 
transferred for primary PCI
Communication and care 
coordination
Time from FMC (at or before ED arrival at STEMI referral 
facility) to primary PCI at STEMI receiving facility among 
transferred patients
Communication and care 
coordination
Cardiac rehabilitation patient referral from an inpatient 
setting
Communication and care 
coordination
P2Y12 receptor inhibitor prescribed at discharge Effective clinical care
Immediate angiography for resuscitated out-of-hospital 
cardiac arrest in STEMI patients
Effective clinical care
Noninvasive stress testing before discharge in conservatively 
treated patients
Efficiency and cost reduction
Early cardiac troponin measurement (within 6 h of arrival) Efficiency and cost reduction
Participation in ≥1 regional or national registries that 
include Patients with Acute Myocardial Infarction Registry
Community, population, and 
public health
Quality measures
Therapeutic hypothermia for comatose STEMI patients with 
out-of-hospital cardiac arrest
Effective clinical care
Aldosterone antagonist prescribed at discharge Effective clinical care
Inappropriate in-hospital use of NSAIDs Patient safety
Inappropriate prescription of prasugrel at discharge in 
patients with history of prior stroke or TIA
Patient safety
Inappropriate prescription of high-dose aspirin with 
ticagrelor at discharge
Patient safety
Abbreviations: ACC American College of Cardiology, ACEI angiotensin-converting enzyme inhib-
itor, AHA American Heart Association, ARB angiotensin receptor blocker, ED emergency depart-
ment, FMC first medical contact, LVEF left ventricular ejection fraction, NSAIDs nonsteroidal 
anti-inflammatory drugs, PCI percutaneous coronary intervention, PM performance measures, 
QM quality measures, LVSD left ventricular systolic dysfunction, STEMI ST-elevation myocardial 
infarction, TIA transient ischemic attack





















STEMI (N=71,368) NSTEMI (N=111,535)
Cardiogenic Shock Stroke Bleeding Events
Fig. 23.2 In-hospital outcomes of the ACTION-GWTG Program 2014. Rates of death, reinfarc-
tion, heart failure, cardiogenic shock, stroke, or bleeding during hospitalization for patients with 
STEMI and NSTEMI.  Source: Masoudi MD, Ponirakis A, de Lemos JA et  al. Trends of US 
Cardiovascular Care. J Am Coll Cardiol 2017; 69:1427–50
Table 23.3 Characteristics 
and in-hospital outcomes of 
10,730 patients with STEMI 
transported by EMS to 132 








Symptoms to FMC 50 min










Source: Data from Jollis et al. [3]
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23.3  Risk Assessment and Adjustment
The risk associated with STEMI is highly dependent on demographic features such 
as age, acuity of presentation, baseline comorbidities (diabetes, peripheral vascular 
and chronic lung disease), left ventricular function, and findings at coronary angi-
ography. High-risk angiographic findings include large culprit vessel size and distri-
bution (left main, LAD). A number of risk scores have been developed to estimate 
the threat to life that STEMI poses to the individual patient. Although the majority 
of high-risk patients survive primary PCI without a complication, risk assessment 
models such as the NCDR CathPCI Registry Bedside Risk Scoring System 
(Table 23.4) allow the physician to estimate the risk of primary PCI, counsel the 
patient and family, and correlate clinical features and in-hospital mortality. In addi-
tion to the risk of ischemic complications, bleeding risk can be estimated. Bleeding 
risk has a different temporal pattern than ischemic risk (Fig. 23.3). Among patients 
presenting with STEMI to US hospitals and captured in the NCDR ACTION 
Registry between 2007 and 2009, the CRUSADE bleeding risk score predicted a 
fivefold difference in the risk of bleeding based on eight criteria (hematocrit, creati-
nine, heart rate, sex, heart failure, systolic blood pressure, prior vascular disease, 
and diabetes) (Fig.  23.4). Although the bleeding risk associated with the use of 
bivalirudin is lower than unfractionated heparin, fewer stent thromboses and lower 
costs favored the frequent use of unfractionated heparin which is documented in this 
figure and supported by the VALIDATE-SWEDEHEART randomized comparison 
of these two agents in 25 Swedish PCI centers and reported in 2017. The most 
important bleeding avoidance strategy, the use of radial artery access, is described 
below.
Among the highest risk patients are those experiencing out-of-hospital cardiac 
arrest. Only a small minority survive to reach the hospital. Those reaching the hos-
pital have a significant risk of failure to recover neurologically. In a study of out-of- 
hospital cardiac arrest in North Carolina during 2012–2014, among 1507 patients 
with prehospital return of circulation, survival to discharge was approximately 
threefold higher in those transported to a PCI center even if the transport time 
exceeded 30 min [6]. However, survival to discharge in both groups was quite low 
(33% and 14.6%, respectively).
Cardiogenic shock is the most common cause of in-hospital death in patients 
with STEMI, and, disappointingly, mortality rates still approach 50% and are not 
decreasing in spite of early invasive strategies, better technology, and the avail-
ability of improved mechanical circulatory support devices [7, 8]. Risk scores 
have been proposed which allow early risk stratification (Fig. 23.5). In an ade-
quately powered randomized trial, the use of intra-aortic balloon pump (IABP) 
compared to control showed no benefit with respect to mortality or hemody-
namic parameters [9]. These findings led to downgrading of recommendations 
for the use of IABP in guideline statements (class III in the European STEMI 
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rapidly than ischemic risk
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Fig. 23.3 Conceptualizing the temporal risk of ischemic and bleeding risk of PCI in 
STEMI. Ischemic risk is influenced by culprit and non-culprit lesion characteristics, antithrom-
botic therapy, and extent of coronary disease. Bleeding risk is affected by bleeding risk of the 
patient, access site, antithrombotic pharmacology, duration of antithrombotic therapy, and need 


























Overall Bleeding Rate 8.3% 11.6% 16.3%9.6% 8.9%
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Fig. 23.4 Rates of major bleeding according to anticoagulation regimen and the CRUSADE 
BLEEDING RISK SCORE in patients with STEMI. Source: Kadakia MB, Desai NR, Alexander 
KP et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocar-
dial infarction J Am Coll Cardiol 2010; 3:1166–77
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support device compared to IABP improved hemodynamics but was associated 
with more  complications, and there was no difference in mortality. In a recently 
published randomized comparison of the Impella CP left ventricular support 
device (maximum output of about 3.7 L/min) and IABP in 48 STEMI patients 
with cardiogenic shock, there was no difference in mortality at 30  days or in 
serum lactate [11]. This study was underpowered but there was no signal, sug-
gesting benefit with Impella CP use. It has been estimated that a trial of approxi-
mately 2500 cardiogenic shock patients would be required to confirm a significant 
mortality benefit of 4% with a strategy such as left ventricular support. In a ran-
domized trial of patients with cardiogenic shock due to acute myocardial infarc-
tion and multivessel disease [7], the guideline-supported strategy of progressing 
to PCI of non-culprit arteries in patients with persisting shock resulted in worse 
outcomes than culprit-only PCI, suggesting that a change in the guideline state-
ment may be needed. A recent AHA scientific statement reviewed efforts to study 














Glucose >10.6 mmol/l (191 mg/dl)*
Arterial Lactate >5 mmol/l*
TIMI flow grade <3 after PCI
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3/4 vs. 0-2 p<0.0001


















Fig. 23.5 Cardiogenic shock complicating acute myocardial infarction: IABP-SHOCK II RISK 
SCORE. The scoring system attributed one or two points per variable. Source: Pöss J, Köster J, 
Fuervan G, et al. J Am Coll Cardiol 2017; 69:1913–20
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23.4  Procedural Outcomes
In patients undergoing primary PCI for treatment of STEMI, complete reperfusion 
with development of TIMI 3 flow is achieved in over 90% of patients compared to 
50–60% of patients treated with fibrinolytic therapy. Patients who achieve less than 
TIMI 3 flow with PCI are frequently late presenters, have large thrombus burden, 
and have poorer outcomes. No reflow due to microcirculation injury and/or distal 
embolization is a particularly unfavorable prognostic finding. With the advent of 
intracoronary stents, the need for emergency coronary bypass surgery has plum-
meted to 6% of STEMI patients according to the NCDR CathPCI Registry, but 
surgery may be required in advanced triple vessel or left main coronary artery dis-
ease that does not appear treatable with PCI. Surgery may be needed as the initial 
emergency revascularization (3% of STEMI patients) or at a later time after percu-
taneous treatment of the culprit coronary artery lesion (2% of STEMI patients).
There is an ongoing controversy regarding whether non-culprit coronary artery 
stenoses should be treated at the time of primary PCI in the absence of ongoing 
ischemia (ACC/AHA class IIb indication, level of evidence B). Although the pres-
ence of multivessel disease in the STEMI patient is an independent risk factor asso-
ciated with a threefold increase in MACE on follow-up, recent studies indicate that 
immediate multivessel PCI is not necessary and favor staged PCI of non-culprit 
lesions (more in-depth discussion in Chap. 13). Also, routine manual thrombus aspi-
ration which was supported by early studies was not shown to be beneficial in recent 
reports and was associated with a small increase in the risk of stroke (more in-depth 
discussion in Chap. 10). However, thrombus aspiration may be indicated in patients 
with large thrombus burden or thrombotic complications. Bleeding complications, 
most commonly access site bleeding, occur in 5–10% of patients and are a major 
source of morbidity and occasionally mortality. Increased use of radial artery access 
has occurred, especially in Europe (Fig. 23.6), and the use of fibrinolytic therapy 
has diminished dramatically both in Europe and the United States. Randomized tri-
als have demonstrated that compared to femoral access, the use of radial artery 
access in STEMI patients leads to lower rates of bleeding, major adverse cardiac 
events, and in-hospital mortality (more in-depth discussion in Chap. 7). Recent 
studies indicate that, in experienced hands, radial artery access does not result in the 
use of more contrast media or increased radiation exposure of patients or operators. 
In spite of these advantages, the use of radial artery access in the United States 
remained less than 50% in early 2017 as reported by the NCDR CathPCI Registry. 
The failure to use radial artery access in higher-risk patients (e.g., elderly female 
patients) has been described as a “risk-treatment paradox.” Although the 2013 
ACCF/AHA guideline statement supports implantation of either drug-eluting or 
bare-metal stents in patients with STEMI, the 2017 European guideline statement 
endorses the use of drug-eluting stents (more in-depth discussion in Chap. 11). The 
use of second-generation drug-eluting stents has become the standard practice in 
most US centers. The critical role of antithrombotic therapy in treatment of STEMI 
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has been recognized. In addition to aspirin, an oral P2Y12 inhibitor (clopidogrel, 
prasugrel, or ticagrelor) is recommended pre-procedure and to be taken for 1 year 
(more in-depth discussion in Chap. 8). Ticagrelor and prasugrel are more effective 
antiplatelet agents than clopidogrel but are associated with more bleeding necessi-
tating a risk-benefit analysis and are more expensive, which becomes a factor in the 
uninsured patient. Glycoprotein IIb/IIIa platelet receptor inhibitors currently have a 
limited role in primary PCI being primarily reserved for treatment of thrombotic 
complications. Following primary PCI, STEMI patients have an increased risk of 
thrombotic events such as deep vein thrombosis and/or pulmonary embolism. 
Although anticoagulation with unfractionated heparin has been frequently used for 
several days post-PCI, data from HORIZONS-AMI and EUROMAX trials indicate 
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Fig. 23.6 Temporal trends in the thrombolytic and PCI activity and the use of radial access in 
STEMI in the United Kingdom. (a) Decrease in the use of fibrinolytic therapy and increase in 
radial artery access. (b) The use of radial access from 2007 to 2014. Source: Rashid et al. J Am 
Coll Cardiol Interv 2017; 22;2258–65
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thrombotic events (more in-depth discussion in Chap. 9). Consequently, routine 
post-PCI anticoagulation should be avoided unless there is a clear indication for its 
use. With early reperfusion and better techniques, the results of primary PCI have 
improved substantially. In stented patients with early reperfusion and preserved left 
ventricular function, hospitalizations as short as 3 days are possible. In less fortu-
nate patients, more prolonged hospitalizations are required to allow recovery of left 
ventricular function and monitor for complications and for titration of medical ther-
apy. Treatment of heart failure symptoms may be required in large myocardial 
infarctions. Warfarin anticoagulation is needed when left ventricular aneurysms or 
mural thrombus is detected. Importantly, in all STEMI patients, education is pro-
vided regarding risk factor modification, activity, smoking cessation, medications, 
and follow-up planning, and referral to cardiac rehabilitation is accomplished.
23.5  Audit
There is a wide variation in treatment of patients with STEMI around the world. To 
improve quality of care, the US and European STEMI guideline statements indicate 
that measurable quality indicators be established (see Table 23.2), that routine data 
collection be carried out, and that routine audits be performed. The American 
College of Cardiology and American Heart Association have established registries, 
the NCDR CathPCI and ACTION Registries by the ACC, and the Mission: Lifeline 
program by the AHA. These registries provide parallel opportunities for collection 
of the important data relating to the STEMI patient and quarterly update on the 
performance of healthcare providers and systems aimed at reducing time to reperfu-
sion and improving outcomes. In an analysis of quarterly AHA Mission: Lifeline 
reports in over 10,000 patients [3], it was shown that enhanced regional efforts can 
significantly reduce time to reperfusion and lead to a significant reduction in in- 
hospital mortality. Inpatient death was reduced from 4.4 to 2.3% (p  =  0.001), a 
remarkable and encouraging outcome.
23.6  Conclusion
Primary PCI is the preferred reperfusion strategy in STEMI. Timely delivery of this 
strategy requires well-honed local and regional networks of dedicated professionals 
and institutions aimed at achieving the earliest possible reperfusion which has been 
shown to save lives in a significant number of patients presenting with STEMI.
23.7  Case Presentation
A 62-year-old female with a history of hypertension developed crushing chest pain 
and called emergency medical services. About 15 min before the ambulance reached 
the emergency room (ER), ventricular fibrillation occurred that was effectively 
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terminated with a shock. As the ambulance was nearing the hospital, ventricular 
fibrillation recurred which did not immediately respond to cardioversion, and the 
patient entered the ER with ongoing cardiopulmonary resuscitation (CPR). Tracheal 
intubation was performed and CPR continued. Amiodarone bolus plus infusion was 
initiated, but ventricular fibrillation recurred repetitively requiring over 20 shocks. 
Abnormal lab results included arterial blood pH 6.91 and serum lactate 
18.9 mmol/L. Blood pressure was 70–80/30–40 mm Hg in spite of norepinephrine 
infusion. The ECG is shown (Fig. 23.7).
After 90 min of CPR, the rhythm stabilized long enough to rush the patient to the 
cardiac catheterization laboratory where ventricular fibrillation recurred twice. An 
intra-aortic balloon pump was inserted. Coronary angiography revealed moderate 
diffuse left coronary artery disease (Fig. 23.8a) and total occlusion of the proximal 
right coronary artery (Fig. 23.8b). Following placement of two drug-eluting stents 
in the right coronary artery, flow was restored (Fig. 23.8c). Cardiac rhythm stabi-
lized and blood pressure increased to 100/60 mm Hg. The patient was treated with 
hypothermia and mechanical ventilation for 48 h and made a complete recovery.
Although the presence of refractory ventricular fibrillation, shock, and markedly 
elevated serum lactate are poor prognostic signs, observed cardiac arrest and even 
prolonged resuscitation can result in complete recovery. While the use of the intra- 
aortic balloon pump has not been shown to improve outcomes, its use is not contra-
indicated in ACCF/AHA guidelines, is thought by some experienced operators to 
provide assistance, and can be performed in a few minutes. Mechanical left ven-
tricular assist devices provide more hemodynamic support but require longer times 
to insert and also have not been shown to save lives in randomized studies of shock 
in patients with STEMI [11].
Fig. 23.7 Electrocardiogram following multiple cardioversions suggests diffuse subendocardial 
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